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Experiments were carried out using 1igand-binding techniques to
investigate extensively a variety of aspects of the LHRH receptor,
both in situ in the cell membrane and in a solubilised state.
The possibility of the close involvement of a K+ channel with
the LHRH receptor protein gained no support from results presented
in this Thesis. However, the possible role for a G-protein in the
LHRH receptor in primary transducing system is supported by these
studies. A direct interaction between ligand binding to the LHRH
receptor and a G-protein has not been demonstrated previously.
Solubilisation of the LHRH-receptor has been achieved with a
very high efficiency for the first time, using the combination of a
zwitterionic detergent (CHAPS) and high ionic strength. Experiments
with CHAPS and a broad range of other detergents, with varying NaCl
concentrations and protein: detergent ratios were not able to reveal
another method capable of giving comparable results.
The conditions required for maximal solubilisation of the
LHRH-receptor were found to inhibit the binding of LHRH to the
receptor protein. A polyethylene glycol (PEG) precipitation step
was sufficient to remove the CHAPS/NaCl solution and allow optimal
binding of LHRH and its analogues. Ligand binding experiments to
such PEG- precipitated preparations revealed that the solubilised
LHRH-receptor had very similar binding properties to that of the
membrane bound receptor. These results strongly suggest that the
entity solubilised by the CHAPS/NaCl method was an undenatured
LHRH-receptor.
To try to investigate further the solubilised LHRH-receptor
using ligand binding techniques conditions were sought that would
maintain hot.h the solubility of the protein and its affinity for
(vi)
LHRH analogues. Many possible solutions to this problem were
investigated, but no such condition has been found.
In order to overcome this obstacle, a new approach was devised.
LHRH-biotin analogues were designed that would allow the interaction
of both the LHRH and the biotin moieties. Chemical crosslinking and
photoaffinity techniques were investigated to optimise the specific
crosslinking of these bi-functional ligands to the anterior
pituitary membrane preparation. Optimal results were obtained using
the homo-bifunctional chemical crosslinker ethylene glycolbis
(succinimidylsuccinate)(EGS). Whilst further refinement of this
method of covalently labelling the membrane bound LHRH-receptor
protein with a biotin molecule is necessary, preliminary results
using a streptavidin-affinity column suggest that it is a viable
approach to the purification of specifically covalently-1abelled
membrane proteins.
Further characterisation of the solubilised LHRH-receptor was
achieved using the technique of gel filtration. As this is a
non-denaturing technique under the conditions utilised in this
study, the results may be interpreted as revealing the apparent
molecular size of the non-denatured LHRH-receptor. A molecular
weight of approximately 100,000-160,000 was revealed. Whilst this
is approximately twice that shown by other workers using the
denaturing technique of sodium dodecyl sulphate polyacrylamide gel
electrophoresis, (SDS PAGE) it is of a similar magnitude to that
revealed in situ by the radiation inactivation technique.
These results suggest that the LHRH-binding protein solubilised
with high efficiency from anterior pituitary membranes is the
LHRH-receptor and that this is maintained in solution as the same
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1.1 The identification of a hypothalamic factor influencing pituitary
gonadotrophin secretion.
The culmination of many years of investigation into the brain's
influence on reproduction (see Sawyer, 1969; Harris, 1972 for
reviews) was the discovery of an unidentified factor extracted from
the median eminence of the hypothalamus which, on infusion into the
anterior pituitary gland, induced an ovulatory response (Campbell,
Feurer, Garcia and Harris, 1961; Campbell, Feurer and Harris, 1964;
McCann, 1962). For many years previously, it had been clear that
somatosensory stimuli and many other environmental factors such as
day length, light, temperature and olfactory stimuli could modify
reproductive function (Sawyer, 1969). The association of
hypothalamic lesions and tumours with many gonadal and other sexual
disorders, such as precocious puberty or amenorrhea, led early
workers to suggest that a neural mechanism within the hypothalamus
may have a role in regulating the reproductive status of man and
other mammals (for reviews see Riddoch, 1938; Sawyer, 1969). The
influence of the hypothalamus over the pituitary (pars nervosa, pars
intermedia and pars distalis or anterior pituitary) was initially
thought to be exerted via a neural link (Le Gros Clark, 1938;
Beattie, 1938). However, experiments revealed that the anterior
pituitary was insensitive to direct electrical stimulation (Markee,
Sawyer and Hollinshead, 1946; Harris, 1948). Identification (Popa
and Fielding, 1930) and further investigation of (Wislocki and King,
1936) a system of fine capillaries in the pituitary stalk connecting
two capillary networks (one in the hypothalamus and one in the
anterior pituitary gland) revealed a flow of blood from the
hypothalamus to the pituitary gland. In the hypothalamus the
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capillary plexus was in the median eminence, the area found to be
most sensitive for an electrically stimulated ovulatory response
(Saul and Sawyer, 1957). Severence of the pituitary stalk had been
found to block irreversibly the ovulatory response to electrical
stimulation (Westman and Jacobsohn, 1936; Brooks, 1938) and result
in gonadal atrophy (Westman and Jacobsohn, 1938; Westman and
Jacobsohn, 1940). Experiments involving the transplantation of the
pituitary from its position under the hypothalamus resulted in an
abolition of gonadotrophs secretion (Harris and Jacobsohn, 1952;
Harris, 1964), except when the pituitaries were reimplanted in situ
when normal functioning was subsequently observed (Greep, 1936;
Harris and Jacobsohn, 1952), a phenomenon that was coincident with
the regeneration of the portal vessels (Harris and Jacobsohn,
1952). In a series of experiments, Nikitovitch-Winer and Everett
(1957, 1958, 1959) demonstrated that the retransplantation of a
pituitary from a site under the kidney capsule back to its original
position resulted in the restoration of all pituitary functions,
including the release of gonadotrophins. Taken together these
results led to the hypothesis of a neurosecretory mechanism for the
hypothalamic control of the anterior pituitary (Harris, 1969). That
is the release of substances from nerve terminals in the median
eminence into the portal plexus which, on reaching the anterior
pituitary via the portal system, affected the activity of the
pituitary gland.
The effect of various neurotransmitters on the gland was
investigated by Markee, Sawyer and Hollinshead (1946). No classical
neurotransmitter could be shown to exert a direct effect on the
anterior pituitary and it was not until its extraction in 1961
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(Campbell, Feurer and Harris) that the hypothalamic factor mediating
neural control over anterior pituitary gonadotrophes was identified
(Sawyer, 1969; Harris, 1972).
In subsequent years, the median eminence ovulatory factor was
partially purified, being identified as a polypeptide, distinct from
other known hypothalamic factors (such as corticotrophin releasing
factors and thyrotrophin releasing factors) which could be extracted
from the median eminence but not the cerebral cortex (Mittler and
Meites, 1964; Endroczi and Hilliard, 1965). Porcine hypothalami
were the source of the first isolated homogenous preparation of this
factor (named luteinizing hormone releasing hormone, LHRH: Schally,
Arimura, Baba, Nair, Matsuo, Redding and Debeljuk, 1971) and it was
subsequently sequenced (Matsuo, Baba, Nair, Arimura and Schally,
1971). A similar peptide could be purified from ovine hypothalami
(Amoss, Burgus, Blackwell, Vale, Fellows and Guillemin, 1971). Very
rapidly, chemical synthesis of the decapeptide (pGlu, His, Trp, Ser,
Tyr, Gly, Leu, Arg, Pro, Gly-NH^) was achieved (Matsuo, Arimura,
Nair and Schally, 1971). This product was shown to have effects
identical to those of the isolated peptide, that is inducing
ovulation in rabbits and causing LH release from the anterior
pituitary gland, confirming its authenticity as the hypothalamic
factor for gonadotrophin release.
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1.2 The physiological role of LHRH and its clinical applications
LHRH (or an LHRH-like substance) has been found to occur in the
CNS, predominantly in hypothalamic regions but also to a lesser
extent in other brain areas such as cortex (Sternberger and Hoffman,
1978; Krey and Silverman, 1983)?and in non-neural tissues such as
the placenta (Lee, Seppala and Chard, 1981; Tan and Rousseau 1982;
Hseuh and Jones 1983),, the gonads (Paull, Turkelson, Thomas and
Arimura, 1981; Hseuh and Jones, 1983; Sharpe, 1984) and the
lactating mammary gland (Sardar and Nair, 1981; Smith-White and
Ojeda, 1983). It acts at the level of the pituitary to stimulate
the release of the gonadotrophins, luteinizing hormone (LH) and
follicle-stimulating hormone (FSH) (Schally, Arimura, Kastin,
Matsuo, Baba, Redding, Nair, Debeljuk and White, 1971).
Radioimmunoassay techniques have been used to determine LHRH levels
in portal blood (Carmal, Araki and Ferin, 1976; Fink and Jamieson,
1976; Sarkar and Fink, 1980) and the results of such studies suggest
that changes in LHRH secretion can account for most alterations in
LH and FSH secretion. In this way LHRH appears to exert a
controlling influence on reproduction (see Fink, 1979, for review).
An array of additional LHRH actions have been suggested, not all
of which are fully elucidated as yet. One seemingly well
established role of LHRH in the CNS is that of facilitating mating
behaviour. LHRH facilitates the lordosis response in
ovariectomised, oestrogen-treated female rats when given
systemically or by intracerebral infusions into medial preoptic
area, arcuate area and mesencephalic central gray (McCann and Moss,
1975; Moss, 1977; 1979). Conversely, intracerebral infusions of
anti-serum to LHRH abolishes the lordosis response in these
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animals (Sakuma and Pfaff, 1983). Iontophoresis of LHRH or its
analogues results in an increase in electrical activity of up to 50%
of neurones in the arcuate ventromedial complex (Moss 1977) and
mesencephalic central gray (Samson, McCann, Chud, Dudley and Moss,
1980), and electrical stimulation of mesencephalic central gray in
oestrogen treated, ovariectomised rats results in a facilitation of
the lordosis response (Sakuma and Pfaff, 1979). In the medial
preoptic area the membrane responses to iontophoresis of LHRH and
its analogues have been shown to be modulated by ovarian hormone
pretreatment (Moss and Dudley, 1978). These results all suggest a
physiological role of LHRH in the brain in determining sexual
responsiveness, according to hormonal status. There is also some
evidence of an ultra-short feedback mechanism of LHRH on LHRH
release into portal blood (De Paulo, King and Carrillo, 1987).
In the gonads LHRH (or an LHRH-like substance: Ying and
Guillemin, 1980) has been found to inhibit gonadotrophin-stimulated
steroidogenesis (Arimura, Serafini, Talbot and Schally, 1979;
Clayton, Harwood and Catt, 1979; Hseuh and Erickson, 1979(a);
1979(b); Hseuh and Ling, 1979; Ying and Guillemin, 1979; Bambino,
Schreiber and Hseuh, 1980; Hseuh, Wang and Erickson, 1980). Less
well established actions of LHRH include its role in the
differentiation of various pituitary cell types. (Begeot, Hemming,
Martinet, Dubois and Dubois, 1983; Aubert, Begeot, Winiger, Morel,
Sigoneako and Dubois, 1985) and in the early, post natal sexual
differentiation of the brain (Charlton, 1986). At puberty a change
in the pulse frequency of LHRH release into the hypophysial portal
blood system is thought to be the key factor in controlling the
increased gonadotrophic hormone output required for sexual
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maturation (Yen, Tsai, Naftolin, Vanden Berg and Ajabor, 1972;
Carmel, Arai and Ferin, 1976; Brook, Jacobs, Stanhope, Adams and
Hindmarsh, 1987). Evidence of this pivotal role of the LHRH gene in
the postnatal development and functioning of the reproductive system
has been provided by experiments using the hypogonadal (hpg) mouse.
Homozygous hpg mice have a deletional mutation of 33.5 kilobases in
the gene encoding for pre-pro LHRH, including the third and fourth
exon of the gene (Mason, Hayflick, Zoeller, Young, Phillips,
Nikolics and Seeburg, 1986). Although they produced a shortened
version of LHRH mRNA, they are unable to generate any functional
LHRH (Mason, Hayflick, Zoeller, Young, Phillips, Nikolics and
Seeburg, 1986). Such hpg mice show normal foetal development but
postnatally their reproductive system fails to develop further
(Cattanach, Iddon, Charlton, Chiappa and Fink, 1977). Using
techniques of genetic engineering a 13.5 kilobase gene encoding for
LHRH and its flanking sequences have been introduced into ova from
heterozygous hpg mice. Selective breeding resulted in offspring
that were homozygous hpg but transgenic for the LHRH gene (Seeburg,
Mason, Stewart and Nikolics, 1987). These offspring exhibited
normal reproductive development and function (Seeburg, Mason,
Stewart and Nikolics, 1987), apparently confirming the central role
of LHRH in coordinating both sexual maturation .and the processes
involved in maintaining reproductive capacity.
Clinically LHRH and its analogues appear to have wide
application (Ziporyn, 1985). Initially it was thought that long
acting agonist analogues would be useful in treating
hypogonadal states (Schally, 1973). However repeated administration
of LHRH analogues was found to result in a paradoxical
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desensitisation and inhibition of gonadotrophin release (see Ziporyn
1985; McLachlan, Healy and Burger, 1986; Fraser and Baird, 1987 for
reviews). As this inhibition of the pituitary-gonadal axis was
induced by peptides of high potency with no apparent metabolic side
effects and which were rapidly metabolised (Sandow, Jerabek-Sandow,
Kraus and Stoll, 1982),the clinical application of this
antigonadotrophic action was rapidly investigated. The successful
clinical uses of LHRH analogues include the treatment of precocious
puberty (Sandow, 1983; Ziporyn, 1985; Fraser and Baird, 1987) and
many steroid-dependent disorders. These include hormone-dependent
tumours such as prostatic and some mammary carcinomas (Sandow, 1983;
McLachlan, Healy and Burger, 1986; Fraser and Baird, 1987) and many
other oestrogen-dependent gynaecological diseases such as
endometriosis, fibriomyomata and menstrual disorders (Sandow, 1983;
McLachlan, Healy and Burger, 1986; Fraser and Baird, 1987). Much
research has also been directed towards the use of LHRH analogues
for contraception, both in males and females (Sandow, 1983; Ziporyn,
1985; McLachlan, Healy and Burger, 1986; Fraser and Baird, 1987).
As yet it appears unlikely that LHRH analogues offer significant
overall advantages, but their use is indicated in certain cases
(such as in lactating women or older women for whom steroids are
contra-indicated: McLachlan, Healy and Burger, 1986; Fraser and
Baird, 1987).
When LHRH, or its analogues, are administered in frequent but
small pulses (such as by a pulsatile infusion pump) a
pro-gonadotrophic action can be achieved without the paradoxical
desensitisation. This type of regime has been successfully used to
treat conditions such cryptorchidism (Sandow, 1983; Ziporyn, 1985;
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Fraser and Baird, 1987) and hypogonadotrophic hypogonadism, in both
men and women (Sandow, 1983). In infertility in women due to a
disturbance of rather than deficiency of gonadotrophins, LHRH
agonists have been used to induce a hypogonadal state, facilitating
induction of follicular development and ovulation by exogenous
gonadotrophins (Fraser and Baird, 1987). Such regimes have been
applied to induce multiple follicular development for in vitro
fertilisation techniques.
The actions of LHRH are all thought to be mediated via specific
membrane-bound receptor proteins (Conn, Marian, McMillan, Stern,
Rogers, Hamby, Penna and Grant, 1981). Gonadal and pituitary gland
LHRH binding sites have been shown to exhibit similar
pharmacological characteristics (Clayton, Katikineni, Chan, Dufau
and Catt, 1980; Reeves, Seguin, Lefebvre, Kelly and Labrie, 1980),
whereas those in placental tissue have a lower affinity for LHRH
analogues (Currie, Fraser and Sharpe, 1981) and the potency ratios
of analogues for behavioural and electrophysiological responses in
the CNS differ from those in the pituitary gland (Moss and Dudley,
1978; Sakuma and Pfaff, 1983). Possibly different but related
receptors for LHRH (or an LHRH-like substance) may be involved in
the placental and central actions of the peptide; however, there is
no evidence of a heterogeneous LHRH receptor population in the
anterior pituitary gland (see Chapter 3). The clinical responses to
LHRH administration are therefore all likely to be receptor mediated
- by one or possibly two related receptors. Certain aspects of the
paradoxical clinical effects of LHRH and its analogues can be
explained in terms of known properties of these receptors and their
signal tranduction mechanisms. For example, using an in vitro
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superfusion system, Badger, Loughlin and Naddaff (1983) demonstrated
that whilst continuous exposure of dispersed anterior pituitary
cells to LHRH at a high dose rapidly produces a desensitisation of
LHRH induced LH release, administration in pulses of a few minutes
at hourly intervals was able to prevent this effect. Such a result
may in part explain the paradoxical inhibitory action of LHRH
agonists used clinically at high doses (although extrapituitary
actions of LHRH have also been suggested to be involved in this
effect; Fink, 1986) and the pro-gonadotrophic action of a pulsatile
LHRH dose regime. The way in which this desensitisation is brought
about has not yet been elucidated, although it is not thought to be
directly linked to a reduction in the number of receptors available
for interaction, but possibly the result of a change in the coupling
of the LHRH receptor to its effector mechanisms (Conn, McArdle,
Andrews and Huckle, 1987).
The structure of the LHRH-receptor protein and the way in which
this affects the release of LH and FSH from gonadotrophes are
largely unknown, although some progress towards understanding its
transducing mechanism has been made (see 1.4 and Chapter 3).
Further insights into these aspects of the LHRH receptor may well
facilitate understanding of its functioning in vivo. This could in
turn lead to the design of improved analogues, .or enable
manipulation of cellular processes regulating the receptor and its
responses, so improving and/or extending the clinical applications
of LHRH analogues.
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1.3 Analysis of membrane receptor proteins by biochemical and
molecular biological techniques
The first membrane receptor to be biochemically and structurally
characterised in depth was the nicotinic acetylcholine receptor
(nAChR) from the electric organ of rays (Torpedo species) or eels
(Electrophorus species). The availability of the receptor in such a
concentrated form, making up as much as 30-45% (by mass) of Torpedo
electric organ preparations (Changeux, Giraudat and Dennis, 1987),
was fundamental to its successful molecular characterisation.
Biochemical techniques were initially used to isolate and physically
characterise the nAChR (Karlin, 1980), revealing a complex of four
different glycosylated polypeptide subunits, each relatively
hydrophobic in nature (Vandlen, Wu, Eisenach and Raftery, 1979).
Each complex was found to consist of five subunits: a^, 6, y, 6,
with the one complex containing both the ligand binding sites and
the Na+ channel (Anholt, 1981). The integral nature of the nAChR
and Na+ channel greatly facilitated the study of functional
aspects of the receptor complex. Some understanding of the
structural basis of the receptor complex has been achieved by the
application of molecular biological techniques. Cloning and
sequencing of the cDNA for the four different subunits (Noda,
Takahashi, Tanabe, Toyosata, Kikyotani, Furutan.i, Hirose, Takashima,
Inayama, Miyata and Numa, 1983; Changeux, Devi 1lers-Thiery and
Chemoulli, 1984) revealed a high degree of homology (both of
amino-acid sequence and hydropathicity profiles) between them,
leading to the suggestion that they all arose from a common
ancestral protein (Changeux, Giraudat and Dennis, 1987). Previous
biophysical techniques - such as measurement of the Stokes radius
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(Meunier, Olsen and Changeux, 1972), neutron scattering of the
solubilised receptor complex (Wise, Schoenborn and Karl in, 1979) and
electron microscopy (McCarthy, Earnest, Young, Chloe and Stroud,
1986; Changeux, Giraudat and Dennis, 1987) had resulted in a
detailed model of the overall shape of the nAChR complex. The
sequence homology between the four subunits led to the suggestion of
a similar arrangement across the membrane for all subunits and
several models of the tertiary and quaternary configuration of the
nAChR complex with respect to the membrane have been put forward
(Guy and Hucho, 1987).
Affinity labelling studies of isolated nAChRs or subunit cDNA
expressed in oocytes (Gurdon, Lane and Woodland, 1971), had shown
that the two a subunits of the complex were involved in ligand
binding, the two sites apparently not being equivalent (McCarthy,
Earnest, Young, Chloe and Stroud, 1986; Changeux, Giraudat and
Dennis, 1987). As both ex subunits were thought to be derived from a
single gene, differential post-translational modifications (such as
glycosylation) or an influence of neighbouring subunits was
suggested as being responsible for these differences (McCarthy,
Earnest, Young, Choe and Stroud, 1986; Changeux, Giraudat and
Dennis, 1987). Site directed mutagenesis techniques (Mishina,
Kurosaki, Tobimatsu, Marimoto, Noda et al., 198.4) revealed
components of the a helix essential for ligand binding, and others
involved in mediating the agonist induced ion flux, possibly in
forming the wall of the ion channel. Molecular biological
techniques would appear to have contributed significantly to
understanding certain aspects of the functional operation of the
nAChR (Changeux, Giraudat and Dennis, 1987). In addition to this,
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molecular biological techniques have revealed the existence of
several different nAChR-subunit-1ike polypeptides. A novel e
subunit, thought to be involved in the functional alteration of
nAChR during muscle development (Mishina, Takai, Imoto, Noda,
Takahashi, Numa, Methfessel and Sakmann, 1986) was identified by
cloning and sequencing cDNA from calf muscle (Takai, Noda, Mishina,
Schimizu, Furutani, Kayano, Ikeda, Kubo et al. 1985). In neural
tissue two putative a subunit species have been identified (Goldman,
Deneris, Luyten, Kochhar, Patrick and Heineman, 1987). The
implication of different nAChR complexes predominating at different
developmental stages or in different tissues gives rise to the
possibility of the development of selective drugs as well as
contributing to the understanding of the function and mechanisms of
nAChR under these different conditions.
Whilst the nAChR complex was the first, and probably the most
extensively studied receptor to be investigated using molecular
biological techniques, such procedures have recently been applied to
many different membrane receptors and other proteins (Strosberg,
1987). This has led to the identification of different families of
membrane proteins, exhibiting homologies of amino-acid sequence,
hydropathicity, glycosylation sites and hypothesised topography.
For example the bovine brain GABA^ receptor complex (Schofield,
Darlison, Fujita, Burt, Stephenson, Rodriguez, Rhee, Ramachandran,
Reale, Glencorse, Seeburg and Barnard, 1987) and rat glycine
receptor strychnine binding subunit (Grenningloh, Rienitz, Schmitt,
Methfessel, Zensen, Beyreuther, Gundelfinger and Betz, 1987) have
both been recognised to share features with the nAChR. These
include the existence of four hydrophobic a helices in similar
positions, similar postulated ion channel charge distribution and a
highly conserved Cys domain in the extracellular region (the
presumptive ligand binding regions). The similarities are thought
to be coincident with the related functions of the three receptors -
that is, as ligand gated ion channels (Grenningloh, Rienitz,
Schmitt, Methfessel, Zensen, Beyreuther, Gundelfinger and Betz,
1987; Schofield, Darlison, Fujita, Burt, Stephenson, Rodriguez,
Rhee, Ramachandran, Reale, Glencorse, Seeburg, and Barnard, 1987).
Similarly homologies can be seen with other ion channel-type
proteins (for review see Unwin, 1986) such as the gap junction
polypeptide (Paul, 1986; Kumar and Gilula, 1986), the voltage
sensitive sodium channel (Noda, Shimizu, Tanabe, Takai, Kayano, et
al., 1984),the potassium channel (Schwarz, Tempel, Papazian, Jan
and Jan, 1988) and the postulated voltage-sensitive calcium channel
(Tanabe, Takeshima, Mikami, Flockerzi, Takahashi, Kangawa, Kojima,
Matsuo, Hirose and Numa, 1987).
Membrane receptors not associated with ion channels have also
been recognised as belonging to families by virtue of their sequence
homologies and functional similarities. One such family is that of
the growth-stimulating peptide receptors, all of which appear to be
substrates for tyrosine specific protein kinase (Ullrich, Coussens,
Hayflick, Dull, Gray, Tarn, Lee, Yarden et al., 1984; Ullrich, Bell
Chen, Herrera, Petruzzelli, Dull, Gray, Coussens et al., 1985;
Caoussens, Van Beveren, Smith, Chen, Mitchell, Isacke, Verma and
Ullrich, 1986; Yarden, Escobedo, Kuang, Yang-Feng, Daniel, Tremble,
Chen et al., 1986). Another group of membrane receptor proteins for
which functional similarities appear to be reflected in sequence and
probable structural homologies are those known to interact with
G-proteins. Indeed, it is this superfamily of receptors acting
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through a G-protein mediated production of diffusible second
messengers to which the LHRH receptor is likely to belong (Conn,
McArdle, Andrews and Huckle, 1987; Chapter 3). Examples of such
receptors that have been sequenced include rhodopsin (Ovichinnikov,
1982), e^-adrenergic (Frielle, Collins, Daniel, Caron and
Lefkowitz, 1987),e^-adrenergic (Dixon, Kobilka, Strader, Behovic,
Dohlman, Frielle, Volanowski et al., 1986), and muscarinic
cholinergic receptors (Kubo, Fukuda, Mikami, Maeda, Takahashi,
Mishina, Haga, Haga et al., 1986; Bonner, Buckley, Young and Brann,
1987), (Kubo, Maeda, Sugimoto, Akiba, Mikamim Takahashi, Haga,
Haga et al., 1986; Peralta, Winslow, Peterson, Smith, Ashkenazi,
Ramachandran, Schimerlik and Capon, 1987; Gocayne, Robinson,
Fitzgerald, Chung, Kerlavage, Lentes, Lai, Wang, Fraser and Venter,
1988) and two pharmacologically uncharacterised muscarinic
receptors, m^ and m^ (Bonner, Buckley, Young and Brann, 1987).
In all cases the receptors are members of families of related
proteins, non-identical in either pharmacological profile or type of
second messenger activated (Hall, 1987). However, high sequence
identity (20-30%) exists between the three families (that is the
rhodopsin, 3 adrenergic and muscarinic receptor protein families)
which also exhibit very similar hydropathicity profiles. Two other
G-protein associated receptors recently cloned and shown to exhibit
sequence and hydropathicity homologies with the three above families
are the 5HT^ receptor (Julius, McDermott, Axel and Jessell, 1988)
and the substance K receptor (Masu, Nakayama, Tamaki, Harada, Kuno
and Nakanishi, 1987). This has resulted in the suggestion that
these G-protein linked receptors all exhibit a similar transmembrane
topography with seven membrane spanning hydrophobic sequences (Hall,
1987; Kerlavage, Fraser and Venter, 1987). Homologous glycosylation
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sites and putative positions of the ligand binding site of the
different receptors types have also been suggested (Hall, 1987;
Kerlavage, Fraser and Venter, 1987). The coincidence of sequence
and functional similarities (that is the interaction of the proteins
with G-protein of one type or another) might suggest that the
G-protein binding site is also conserved in all such receptors. One
suggestion is that the cytoplasmic loop between hydrophobic segments
I and II (a highly conserved region in all known sequences for
G-protein-1inked receptors) is a likely site for the G-protein
interaction (Hall, 1987). Deletion experiments on the hamster b
adrenergic receptor amino acid sequence suggest that the cytoplasmic
loop from segment V to VI may be involved in the receptor
interaction with G-proteins (Dixon, Sigal, Rands, Register,
Candelore, Blake and Strader, 1987). The idea of a conserved site
of interaction is further supported by the finding that all known
G-proteins, although capable of interacting with different second
messenger systems, (Stryler and Bourne, 1986) have a topologically
conserved amphipathic a helix at their carboxy-terminal thought to
be involved in their interaction with receptor proteins (Sullivan,
Miller, Masters, Beiderman, Heideman and Bourne, 1987).
One obvious conclusion that can be drawn from these findings is
that the function of a protein is closely related to its primary
structure. Knowledge of the primary structure of a membrane
receptor may therefore provide some insight into its function. Even
when its mechanism of action is not known and its primary structure
shows no homologies with other known receptor proteins - as in the
case of the growth hormone receptor (Leung, Spencer, Cachianes,
Hammonds, Collins, Henzel, Barnard, Waters and Wood, 1987) - the
application of other molecular biological techniques (such as site
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directed mutagenesis) may be fruitful for its elucidation.
Knowledge of the mechanism of action of a receptor may in turn be
used to isolate the cDNA encoding for it. For example the screening
of the human genome with a full length adrenergic probe (under
conditions of low stringency) revealed a putative protein,
differentially expressed in several tissues, with the structural
features of a G-protein coupled receptor (Kobilka, Frielle, Collins,
Yang-Feng, Kobilka, Francke, Lefkowitz and Caron, 1987). A similar
technique has been used to identify possible cDNA clones of proteins
related to steroid receptors (Giguera, Yang, Segui and Evans,
1988). So, in these ways, molecular biological techniques can be
used not only to directly determine primary sequences but also to
help in the elucidation of the function and tertiary structure of a
receptor protein (as in the case of the nAChR) and even in the
identification of other receptors utilising similar mechanisms.
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1.4 Cellular signalling by LHRH as a clue to its possible receptor
structure.
The mechanism of action of the LHRH receptor has not yet been
fully elucidated. Whilst a role for calcium in LHRH-induced
gonadotrophs secretion appears to have been established (Conn,
McArdle, Andrews and Huckle, 1987)?an increase in intracellular
calcium levels seems to be a virtually ubiquitous signal for
exocytosis in many cell types (Baker and Knight, 1986) and may not
necessarily be a very direct consequence of LHRH receptor
activation. Nevertheless, recent results (see Chapter 3) suggest
that this increase in intracellular calcium, in response to LHRH,
may be derived from non-mitochondrial intracellular stores. In
other cell types where agonist binding results in the release of
calcium from such non-mitochondrial intracellular stores, inositol
1,4,5-trisphosphate has been implicated as the second messenger
(Berridge, 1984; Irvine, 1986).
Inositol 1,4,5-trisphosphate has been shown to act in a specific
and concentration-dependent manner over a pM range - which is
considered capable of being reached physiologically (Streb, Irvine,
Berridge and Schulz, 1983; Joseph, Thomas, Williams, Irvine and
Williamson, 1984). It is thought to be derived from membrane
inositol phospholipids; phosphatidyl inositol and the 4-phosphate
and 1,4-bisphosphate derivatives, by an enzymic hydrolysis that is
regulated by receptor:G-protein interaction (see reviews, Michel!,
1975; Hawthorne, 1983; Berridge, 1984; Putney, 1987). A membrane
bound phospholipase C, specific for the polyphosphatidyl inositols,
inactive under normal cell conditions but activated by a G-protein
at unstimulated intracellular calcium concentrations has been
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described (Cockcroft, 1987). The concomitant production of
diacylgiycerol by the action of this enzyme may also subserve a
regulatory role in cellular signalling by means of its activation of
protein kinase C (Nishizuka, 1984).
In support of such a mechanism for the LHRH receptor, rapid,
agonist-specific, concentration dependent stimulation of inositol
phospholipid hydrolysis has been shown in response to LHRH (Schrey,
1985; Andrews and Conn, 1986; Huckle and Conn, 1987). This effect
has been found to be largely independent of calcium ion
concentration (Andrews and Conn, 1986; Huckle and Conn, 1987).
32
Experiments using P labelling of membrane phospholipids show
that LHRH increases the labelling of phosphatidyl inositols whereas
labelling of other phospholipids is unchanged (Naor, Molcho, Zakut
and Yavin, 1985). Analysis of the inositol phosphates produced as a
result of LHRH stimulation of pituitary cells has confirmed the
increased production of inositol 1,4,5 trisphosphate (Morgan, Chang
and Catt, 1987). The implication from all this evidence is that the
LHRH receptor belongs to the same superfamily as the muscarinic
cholinergic, p adrenergic and rhodopsin families, 5HT^ and
substance K receptors (see 1.3). That is, receptor proteins that
interact with G-proteins on activation by an agonist. Consistent
with this idea is recent evidence that introduction of GTP analogues
into permeabi1ised gonadotrophes can facilitate LHRH-induced LH
secretion (Andrews, Staley, Huckle and Conn, 1986).
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1.5 Strategy of this study
In order to investigate further the transducing mechanisms of
the LHRH receptor-including the possible involvement of a G-protein,
experiments were carried out to assess any (previously undescribed)
influence of guanine nucleotides on ligand binding to the LHRH
receptor. Together with extensive pharmacological characterisation
of the native binding site in pituitary membranes for LHRH
analogues, these experiments are described in Chapter 3.
The success of molecular biological techniques in helping to
determine functional and topological aspects of other membrane
receptors (1.3) suggests that this would be a fruitful approach to
understanding the structure and function of the LHRH receptor. One
of the most commonly used strategies for molecular biological
characterisation of membrane proteins involves their solubi1isation
with detergents. Purification and isolation of the solubilised
protein can be followed by partial protein sequencing to produce
oligonucleotide probes (Strosberg, 1987) for the screening of cDNA
libraries for long stretches of receptor sequence. This approach
was adopted in these studies of the LHRH receptor.
In Chapter 4, various detergents were investigated in order to
optimise conditions for the solubilisation of the rat anterior
pituitary LHRH receptor. The high yielding non-denaturing
solubilisation enabled several biochemical and pharmacological
properties of the solubilised receptor to be determined (Chapter
5). In order to overcome the inhibition of specific LHRH analogue
binding in the presence of solubilisation solution, an affinity
labelling strategy to incorporate a biotin moiety onto the LHRH
receptor was developed (Chapter 6). This approach allows for
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subsequent purification and isolation of the LHRH receptor protein
utilising a biotin-avidin affinity column.
Biochemical techniques have been used both to further the
understanding of the way in which the LHRH receptor functions in
situ and reveal aspects of the detergent-solubi1ised receptor.
Although the strategy of receptor solubilisation and isolation did
not provide sequencable amounts of the LHRH receptor (due in part to
the low tissue concentration of the LHRH receptor)^the results
obtained should facilitate future attempts to isolate and sequence





Animals used for the majority of experiments were male Wistar
rats (200-250g) supplied by Edinburgh University (Department of
Occupational Medicine) or purchased from Charles River, UK Ltd
(Margate, Kent). They were maintained under controlled lighting
(lights on 05.00-19.OOh) and temperature (22°C) and had free access
to tap water and diet 41B (Oxoid, Basingstoke, Hants).
Bovine pituitaries (obtained from slaughter house steers) were
purchased from Imperial Labs (Europe) Ltd (Andover, Hampshire).
These had been plunged into liquid nitrogen immediately after
dissection and shipped on dry ice. On arrival they were stored at
-20°C. The porcine pituitaries were generously supplied by Dr R
Jones (Department of Pharmacology, Edinburgh University), from
farmyard reared young boars.
2.2. Dissection of tissues
Rats were stunned, decapitated and their brains removed. The
pituitary gland was then removed from the base of the skull and the
neurointermediate lobe separated from the anterior pituitary with
fine forceps. The hippocampus was dissected from the posterior
portion of the brain after making a midline sagittal section. The
bovine pituitaries were dissected into anterior and
neurointermediate lobes using blunt dissection, after removal of the
surrounding connective tissue. The porcine pituitaries whose
morphology were similar to that of the bovine pituitaries (Cummings
and Habel, 1965) were dealt with in a similar manner.
2.3. Peptide Iodination
Iodination was carried out by the chloramine-T method (Hunter
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and Greenwood, 1962) as described for LHRH (Niemann and Sandow,
1973) and buserelin ([D-Ser(Bu^)^, des Gly^]-LHRH
ethylamide; Sandow and Konig, 1979) with modifications. The
125
procedure is detailed in Appendix 1. Briefly 37 MBq Na I was
added to 5v«g of peptide in a 0.5M phosphate buffer pH 7.5. On
125
addition of chloramine-T the Na I is oxidised and the
radioiodine incorporated into the tyrosyl residue (Hunter and
Greenwood, 1962). After 20 sees the remaining chloramine-T was then
reduced by the addition of excess sodium metabisulphite. In the
case of LHRH the reaction yield is > 90% (Niemann and Sandow,
1973), the ratio of di-iodo- to mono-iodo-LHRH increasing with the
degree of iodination. Chromatography on a Sephadex G-25 fine
(Pharmacia Fine Chemicals, Milton Keynes, Bucks) column separated
125
free I from the iodinated peptide and the mono-iodo- from the
di-iodo-peptide (as shown by Niemann and Sandow, 1973). The free
125
I was initially eluted using 0.01M acetic acid and the
iodinated peptide with 3% BSA/0.01M acetic acid in the case of
125
I-buserelin, 6% BSA/0.01M acetic acid for the other LHRH
125
analogues. For use in the cross!inking reactions I-XBAL was
125
separated from free I using HPLC, as detailed in Appendix 1,
the 125I-XBAL eluting in 60% MeOH/O.2% TFA.
2.4. LHRH-Receptor Binding
LHRH exerts its gonadotrophs (LH and FSH)-releasing and
regulatory actions on gonadotrophes via interaction with a membrane
bound receptor (Vale, Rivier, Brown, Leppaluoto, Ling, Monahan and
Rivier, 1976; Hopkins and Gregory, 1977). Whilst initial studies
using radiolabelled native LHRH suggested the existence of two
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populations of receptors, one of high affinity but low capacity and
one of low affinity and high capacity, further experiments using
degradation-resistant analogues of LHRH labelled to a high specific
125
activity with I confirmed the existence of a single class of
specific high affinity LHRH receptors (reviews - Clayton and Catt,
1981; Conn, Marian, McMillian, Stern, Rogers, Hamby, Penna and
Grant, 1981; Chapter 3). In the majority of the ligand binding
experiments in this thesis the radiolabelled analogue used was the
LHRH superagonist buserelin, generously donated by Hoechst AG
(Frankfurt, FRG).
2.4.1. Rat Equilibrium Binding Assay
The method is outlined in Fig.2.1.
2.4.1.1. Membrane preparation
Dissected anterior pituitaries (or hippocampus) were placed in
100 volumes ice-cold Tris-HCl (25mM, pH 7.4) and homogenised using a
high frequency homogeniser (Ystral X1020) for 5 seconds at setting 3
followed by centrifugation at 60,000g for 15 minutes at 4°C (MSE
Superspeed 65). The supernatant was then discarded and the washed
membranes resuspended into 20 volumes of Tris-HCl (25mM, pH
7.4)/0.1 % BSA (Tris/BSA).
2.4.1.2. Ligand binding
Assays were usually carried out in triplicate, in a volume of
using
500y 1 containing 10-60 yg proteineither a membrane or solubilised
preparation. Iodinated analogue diluted in Tris/BSA was added to
give ~50,000cpm per tube and unlabelled LHRH analogue was present in
the appropriate concentrations. In all cases non-specific binding
was determined in the presence of 1 yM LHRH. After incubation for
90 minutes at 4°C, equilibrium had been reached (Fig.2.2). The
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bound radioiodinated ligand was then separated from the free by
centrifugation at l,600g, 6°C for 20 minutes (MSE Coolspin) followed
by careful aspiration of the supernatant, or by a polyethylene
glycol 8000 (PEG) precipitation (see below). The resulting pellet
was counted by ^-spectrometry (Berthold Mag 310 Gamma counter) to
125
determine the amount of I-LHRH analogue bound.
A linear relationship was found between the amount of tissue
used in the binding assay and the specific binding seen (Fig.2.3).
In all cases the total binding was 20.8 ± 1.2% (± SEM, n = 8) of the
total radioligand added, and non-specific binding 28 ± 3% (± SEM,
n = 8) of total binding, similar to values previously reported for
iodinated LHRH analogues (Marshall and Odell, 1975). Specific
125
activity of the I-buserelin was determined by self-displacement
(Clayton and Catt, 1980; Millar, Garritsen and Hazum, 1982; Loumaye,
Wynn, Coy and Catt, 1984) to be approximately 40,700 GBq
(1100 Ci/mmol).
2.4.1.3. PEG precipitation
To ensure consistent precipitation of the membrane preparation
and the solubilised preparation (2.6.) a PEG precipitation step was
included. PEG was found by Poison, Potgieter, Largier, Mears and
Joubert (1964) to be the most suitable of a number of linear
polymers tested for protein precipitation. It has been shown to
have little tendency to denature, or otherwise interact with
proteins (Ingham, 1984). The rapid precipitation is thought to be a
result of the proteins becoming concentrated in the extrapolymer
space until their solubility limit is exceeded. This effect is
relatively insensitive to temperature, pH or ionic strength and
dependent both on the proteins' molecular weight and solubility
Figure 2.2
125
I-Buserelin binding to rat anterior pituitary gland
tissue. Each point is the mean ± SEM for assays carried out in
125
triplicate. 50,000cpm I-buserelin was added to each tube,
non-specific binding was determined in the presence of lpM LHRH, in
a total volume of 500p1 25mM Tris-HCl, pH7.4/0.1% BSA. Free
radioligand was separated from that bound to the tissue preparation
at various time intervals by a PEG precipitation step.
a) Binding to membrane preparation. Tissue equivalent to one
eighth of an anterior pituitary gland was present in each assay
tube.
b) Binding to membrane preparation solubilised with 5mM CHAPS, 1.5M
NaCl (shaken in 30 vols for 90' at 4°C, then centrifuged 2 hrs
at 60,000g, 4°C). Aliquots of the supernatant (equivalent to
one sixth of an anterior pituitary gland) were used in each
assay tube. 0.25mM CHAPS, 75mM NaCl were present in the assay
mixture.
Figure 2.3
Relationship between amount of tissue (membrane preparation) and
125
specific I-buserelin binding detected. Each point is the mean
value from four determinations. Assays were carried out as
described (2.4.1.2) in a total volume of 500pl 25mM Tris-HCl
125
pH7.4/0.1% BSA with 50,000cpm I-buserelin; non-specific binding
was determined in the presence of lpM LHRH. After incubation for
90' at 4°C samples were subjected to a PEG precipitation to separate
125
free I-buserelin from that bound.
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(Ingham, 1984). Small soluble peptides (such as free LHRH
analogues) would therefore be expected to have little or no tendency
to precipitate under conditions where membrane proteins would. PEG
precipitation therefore represented a simple, reproducible and quick
method of protein precipitation, allowing both for separation of
bound and free radioligand and also the solubilised preparation from
the detergent solution. Other methods of protein precipitation
(ammonium sulphate and trichloroacetic acid, Ratcliffe, 1974) tend
to denature proteins, therefore subsequent binding assay of the
precipitated protein may not have been possible. Separation of
bound from free ligand by charcoal absorption would not be of
similar use for removal of the detergent solution prior to binding
assay, and is said to be adversely affected by high ionic strength
(Ratcliffe, 1974). These two factors suggest it to be less suitable
than the PEG precipitation technique. Another method that has been
used to separate free and bound radiolabel is gel chromatography,
but its relatively low sample capacity and therefore unsuitabi1ity
for large numbers of samples (Ratcliffe, 1974) again suggests PEG
precipitation to have advantages over it here.
Using PEG, effective precipitation of LHRH binding sites has
been shown without any change in their binding characteristics
(Winiger, Birabeau, Lang, Capponi, Sizonenko and Aubert, 1983;Hazum,
1983; Perrin, Haas, Rivier and Vale, 1983). Briefly PEG was added
here to a final concentration of 15% and bovine y-g^obulin to
0.035%, both in Tris-HCl (25mM, pH 7.4), to give a total volume of
1.5ml. This was left on ice for 20 minutes and then centrifuged for
15 minutes at l,600g, 6°C. After careful aspiration the resulting




I-Buserelin binding to membrane and solubilised
preparations both with and without the inclusion of a PEG
precipitation step before the ligand binding assay. All values are
shown as mean ± SEM of three determinations. Ligand binding assay
was carried out as described (2.4.1.2) with 50,000cpm
125
I-buserelin in a total volume of 500pl 25mM Tris-HCl pH7.4/0.1%
BSA and 50pg/ml soybean trypsin inhibitor, 400KIU/ml aprotinin,
non-specific binding being determined in the presence of lpM LHRH.
After reaching binding equilibrium (90' at 4°C), samples were
subjected to a PEG precipitation step to separate free
125
I-buserelin from the tissue preparation. Tissue equivalent to
one eighth of an anterior pituitary gland was used in the membrane
binding experiments, tissue equivalent to one quarter of an anterior
pituitary gland for the solubilised preparation. Membranes were
solubilised in 20 vols of the 5mM CHAPS, 1.5M NaCl solubi1isation
solution (agitated for 90' at 4°C, centrifuged for 2hrs at 60,000g,
4°C) and both pellet and supernatant (either with or without an
initial PEG precipitation step) were used in the binding assays.
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Initial experiments in which membrane preparations were used in
ligand binding experiment both before and after a PEG precipitation
step suggested that no change in binding of LHRH-analogues resulted
from inclusion of this technique (Fig.2.4). Similar results were
obtained usinq the pellet obtained after solubi1isation of the
(3-((3-cholamidopropyl)-dimethylammonio)-1-propanesulphonate)
membrane preparation with 5mM£CHAPS/l .5M NaCl, see Chapter 4
(Fig.2.4).
2.4.1.4. Use of fresh rat anterior pituitary tissue versus frozen,
for ligand binding assays and solubi1isation
Initial experiments comparing the displacement of
125
I-buserelin by cold buserelin from freshly prepared rat
anterior pituitary membranes and membranes that had been frozen
overnight at -20°C showed there was no difference in the binding
characteristics of the two preparations (Fig.2.5). Hofstee analysis
revealed a binding constant (K^) of 0.31nM in both cases (single
experiment, triplicate samples). In initial experiments on LHRH
receptor solubilisation (Chapter 4),fresh and frozen membrane
preparations did not give similar results. Whilst fresh membrane
preparations treated with 20 volumes of 5mM CHAPS/1.5M NaCl solution
as described (4.2.2.1) resulted in 56% of LHRH binding sites being
found in the supernatant, only 34% were solubilised from frozen
tissue using similar conditions (single experiment, triplicate
samples). Freezing the tissue had also resulted in an apparent
overall 33% loss of LHRH binding sites (as determined by combining
125
binding of I-buserelin seen in both the pellet and supernatant
of the solubilised preparation). It was therefore decided that
fresh rat anterior pituitary preparations should be used in all
experiments, in case the reduction in LHRH binding sites and amount
Figure 2.5
125
Comparison of I-buserelin binding to anterior pituitary
gland membranes prepared from fresh or frozen tissue. Ligand
binding assay was carried out as previously described (2.4.1.2) in a
total volume of 500yl 25mM Tris-HCl pH7.4/0.1% BSA with 50,000cpm
125
I-buserelin and various concentrations of unlabelled
buserelin. Non-specific binding was determined in the presence of
lyM LHRH. Tissue equivalent to one eighth of an anterior pituitary
gland was used in each sample. Points are means of triplicate
samples. Data was analysed according to the Eadie-Hofstee method
using an error weighted programme (see 2.5). A best-fitted of
approximately 0.31nM was found for both preparations.
Figure2,5
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solubilised reflected an adverse affect of freezing on the LHRH
receptor.
2.4.2. Bovine Equilibrium Binding Assay
2.4.2.1. Membrane preparation
Bovine anterior pituitaries were weighed and homogenised in 100
volumes of Tris-HCl (25mM, pH 7.4) with 10 strokes in a glass-teflon
homogeniser. The homogenised tissue preparation was carefully
decanted to remove any remaining pieces of connective tissue.
Following centrifugation (as for the rat tissue, 15 minutes at
60,000g, 4°C) the anterior pituitary gland membranes were
resuspended in to 20 volumes Tris/BSA containing 50yg/ml soybean
trypsin inhibitor and 400 KlU/ml aprotinin (Tris/BSA.peptidase
inhibitors).
2.4.2.2. Binding assay
Assays were carried out in triplicate in a total volume of 500yl
containing 50yl of the washed membrane preparation. Unlabelled
analogue and 50,000cpm of radio-iodinated analogue, both in
Tris/BSA/peptidase inhibitors, were added as appropriate.
Non-specific binding was determined in the presence of lyM LHRH.
Equilibrium was reached after incubation at 4°C for 16 hrs, an
incubation period considered to be optimal in earlier studies by
Winiger, Birabeau, Lang, Capponi, Sizonenko and Aubert (1983)
(Fig.2.6). After this, free radioligand was separated from the
membrane preparation by centrifugation, 20 minutes at l,600g, 6°C.
Bound radioligand was counted by ^-spectrometry. Of the
radiolabeled buserelin added, 12 ± 3% (± SEM, n = 6) was bound,


















I-Buserelin binding to bovine anterior pituitary gland
membranes. Assays were carried out as described (2.4.2) using
125
~2.5mg of tissue per sample, 50,000cpm I-buserelin in a total
volume of 500pl 25mM Tris-HCl pH7.4/0.1% BSA/50yg/ml soybean trypsin
inhibitor/400KIU/ml aprotinin. Non-specific binding was determined
in the presence of lpM LHRH. Points are mean ± SEM of four
125determinations. At various time intervals free I-buserelin was
separated from that bound to the membrane sample by centrifugation
(15' at 1,600g, 9°C).
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2.5. Analysis of Binding Data
Displacement data were analysed according to the Eadie-Hofstee
method (Eadie, 1942; Hofstee, 1952). The saturation data were
analysed after graphical transformation according to Scatchard
(1949) using an error-weighted programme (Zivin and Waud, 1982) on a
Texas TI58C calculator or by linear regression using a Casio
fx-5200P calculator.
2.6. Affinity Chromatography
Once membrane constituents have successfully been solubilised a
method of protein purification is required. Ideally this method
should be based on a property that is specific to the protein of
interest - in this case the LHRH receptor. The usual method of
choice for membrane protein purification is affinity chromatography
(Strosberg, 1984). Ligands specific for the desired protein are
covalently linked to inert supports - such as agarose or sephadex.
On passing a solubilised membrane preparation down a column of the
ligand-gel complex, specific interaction between the ligand and
membrane protein result it in being retained whilst other membrane
constituents are washed out. Addition of excess free ligand to the
gel will in turn elute the membrane protein.
The first use of this technique was for the-separation of
antibodies from other serum constituents using a cellulose-antigen
complex (Lerman, 1953). Basically unchanged, except for the
development of improved inert gels (Cuatrecasas, Wilchek and
Anfinsen, 1968),the method has been used for the purification of
many different proteins and other molecules exhibiting specific and
selective binding (Wilchek, Miron and Kohn, 1984).
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Essential to the technique is the retention of specific binding
under the conditions used. For solubilised proteins these
conditions should be such that the protein is retained in solution.
In the case of the LHRH receptor, extensive surveying of detergent
conditions (Chapter 4) showed the two requirements apparently to be
incompatible for high yielding solubilisation conditions. An
alternative approach was therefore needed. Hofmann and Finn (1985)
and Kohanski and Lane (1985) described a method using the
biotin-streptavidin interaction for affinity chromatography of
insulin receptors bound with biotin-containing analogues of
insulin. Using LHRH analogues incorporating a biotin molecule and
crosslinking the analogue to the receptor site, the method could be
adapted for the LHRH receptor protein. Solubilised LHRH receptors
could then be purified using the biotin-streptavidin interaction
down a biotin affinity column.
2.6.1. Biotin-Avidin affinity column matrix and characterisation of
binding both in the absence and presence of 5mM CHAPS/1.5M NaCl
Affinity columns were constructed using streptavidin-agarose
(streptavidin attached via a 6 carbon spacer to 4% cross-linked
beaded agarose; Sigma Chemical Co. Ltd., Poole, Dorset) or
avidin-Sepharose CL-4B.
The method used for coupling the avidin to the Sepharose CL-4B
was that of Beaty and Lane (1982) and is detailed in Appendix V.
Briefly, the Sepharose CL-4B was activated by cyanogen bromide
(March, Parikh and Cuatrecasas, 1974), washed with 0.1M NaHCO^
pH 8.5, water and 0.1M Na/PO^ buffer, pH 7.0 and then mixed with
avidin for 24 hours. After this time, uncoupled avidin was removed




Binding of [ H]-biotin to the avidin-Sepharose CL-4B was
studied both in the presence and absence of the detergent solution
containing 5mM CHAPS/1.5M NaCl in order to determine the effect of
the detergent solution on the biotin-avidin interaction.
[^H]-Biotin (10-®M, 155 GBq/mmol purchased from Amersham
International pic, Bucks) and 50yl of the avidin-Sepharose CL-4B
preparation in a total volume of 500yl of 0.01M Na/PO^ pH 7.0,
0.1% BSA (or 5mM CHAPS/1.5M NaCl in Tris-HCl 25mM pH 7.4) with
various concentrations of unlabelled biotin, were incubated for 60
minutes at 4°C (Kohanski and Lane, 1985(b)). Non-specific binding
was determined in the presence of O.lmM biotin. Following a wash
step (by centrifugation l,600g, 10 minutes at 6°C, and resuspension
in fresh buffer) the [ H]-biotin bound to the pelleted
avidin-Sepharose CL-4B was determined by liquid scintillation
counting in lOmls NE-265 (Nuclear Enterprises, Edinburgh).
Similarly, the displacement of [ H]-biotin by the biotinylated
LHRH analogue PBL* (2.9) in the CHAPS/NaCl solution was determined.
Displacement of [ H]-biotin by unlabelled biotin from the
avidin-Sepharose CL-4B revealed an IC^q value of 7yM in the
Na/PO^ buffer and 3yM in the CHAPS/NaCl solution (Fig. 2.7).
These results are of a similar order to those found by Kohanski and
Lane, (1985(b)) of a Kp = 0.2yM. The biotinylated LHRH analogue,
PBL, displaced [ H]-biotin from the avidin-Sepharose CL-4B in the
presence of CHAPS/NaCl with an IC^q of llyM. These results
suggest that the binding of biotin to avidin-Sepharose CL-4B is of
an affinity suitable for use in affinity chromotography (Kohanski
and Lane, 1985(b)), is not affected by the high NaCl/detergent
solution used in LHRH binding site solubi1isation (Chapter 4) and is
*
[b Lys6 £l\l&-biot Phe(N^)]] -LHRH
Figure 2.7
Binding of biotin and PBL to the avidin-Sepharose CL-4B. Assays
were carried out as described (2.6.1) using 50yl of the
avidin-Sepharose CL-4B preparation, 10~^M ^H-biotin and various
concentrations of unlabelled biotin or PBL in a total volume of
500y1. Non-specific binding was determined in the presence of O.lmM
biotin. After 60' at 4°C samples were washed (centrifuged for 10'
at l,600g 6°C, resuspended in 500yl fresh buffer, recentrifuged) and
3
the bound H-biotin determined by liquid scintillation.
(#) Biotin binding in 0.01M Na/PO^ pH7/0.1% BSA.
IC50 7yM"
(♦) Biotin binding in 5mM CHAPS, 1.5M NaCl/25mM
Tris-HCl pH7.4. IC5Q 3yM.
(A) PBL binding in 5mM CHAPS, 1.5M NaCl/25mM Tris-HCl
pH7.4. IC5Q llyM.
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not adversely affected by covalent attachment to an LHRH analogue.
2.6.2. Method of affinity chromatography
The method is outlined in Fig.2.8.
Anterior pituitary membranes covalently labelled (6.2.2) with a
radioiodinated, biotin-containing LHRH analogue (2.9) were
solubilised as described (4.2.2) using 5mM CHAPS/1.5M NaCl. The
method for biotin/streptavidin affinity chromatography used was
based on that described by Kohanski and Lane, 1985(b). The labelled
solubilised preparation was preincubated (1 hr at room termperature)
with 1ml streptavidin-agarose in the CHAPS/NaCl solubilisation
solution. After this time, the column, (in a 1ml syringe plugged
with glass wool) was constructed and washed through for an hour with
the 5mM CHAPS/1.5M NaCl solubi1isation solution at 4°C. A constant
head reservoir was used, and the columns ran under gravity at
8mls/hr. Two minute fractions were collected. After 1 hr the
eluting solution was changed to the CHAPS/NaCl solution containing
2mM biotin. Two minute fractions were again collected. lOOyl
aliquots of the fractions were then counted using y-spectrometry.
Two affinity columns were run in parallel. One was loaded with
solubilised membranes labelled with the iodinated biotin-LHRH
analogue, one with solubilised membranes that had been bound and
cross-linked in the presence of lyM LHRH (non-specific binding
conditions). Comparison of the two patterns of eluted radiolabel
indicated the specificity of the method for LHRH receptor protein
purification.
2.7. Estimate of the Molecular Weight of the LHRH receptor protein
by Gel filtration.





(total and non-specific binding samples run in parallel)
I
Solubilised in 30 vol.s 5mM CHAPS/1.5M NaCI
I








EIute(1hr with CHAPS/NaCI solution)
Collect 2min fractions
I
Elute with 2mM Biotin
(in CHAPS /NaCI solution)
Collect 2min fractions
I
Count aliquots of fractions
(y-spectrometry )
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molecular size was first described by Lathe and Ruthven (1956) using
a column of starch. Methods have since been improved with the
development of more suitable inert gels such as the crosslinked
dextran (Sephadex: Porath and Flodin, 1959) and beaded agarose
(Sepharose: Hjerten, 1964). The separation depends on the ability
of the molecule to move out of the solution into the stationary
phase of the gel (Ackers, 1975). Smaller molecules may spend a high
proportion of their time in the stationary phase and therefore move
slowly through the gel. Larger molecules unable to enter the gel
stationary phase move much more rapidly. Assuming a similar
relationship between molecular weight and molecular size for all
molecules, there is a constant relationship between molecular weight
and elution volume.
Kav = Ve - Vo
Vt - Vo
where Ve = elution volume for the molecule
Vt = total bed volume of column
Vo = void volume of column
and the calculated Kav = the fraction of the stationary gel volume
available for diffusion of the molecule.
A plot of Kav against log (molecular weight) for several
standard substances of known molecular weight, provides a
calibration curve for a particular column (Ackers, 1975). This can
be used to determine unknown molecular weights using the calculated
Kav values. The molecular weight value is, however, only an
apparent value, for whilst denatured proteins (and to some extent
soluble proteins) may have good correlation between their molecular
radius (Stokes radius) and molecular weight, this does not
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necessarily hold for solubilised membrane proteins (Ackers, 1975;
Tanford and Reynolds, 1976).
Gel filtration has the advantage over other forms of molecular
weight determination in the wide range of conditions under which it
can be used. It does not require pure samples of the protein (as is
needed for the more accurate methods of sedimentation equilibrium
and velocity determination, Tanford and Reynolds, 1976). Denaturing
of proteins is not essential (Fischer, 1980) as is the case for SDS
PAGE techniques (2.10). This means that bioassays - such as ligand
binding - can be used in the construction of an elution profile for
the protein of interest. Gel filtration under mild conditions has
been used to help characterise many proteins, including the
muscarinic acetylcholine receptor (Peterson, Rosenbaum, Broderick
and Schimerlik, 1986) and has in some instances revealed or
confirmed the existance of receptor binding sites in high molecular
weight complexes, for example the insulin receptor complexes found
by Sepharose CL-6B gel filtration to have apparent molecular weights
of 370K and 140K, which under denaturing SDS PAGE conditions
dissociate into 130K/82K and 47K subunits respectively (Im, Fraugakis,
Meezau, DiBona and Kim, 1982). Gel filtration of CHAPS solubilised
GABA receptors have revealed the benzodiazepine binding site to
exist on the same protein complex (Stephenson, .Watkins and Olsen,
1982). High molecular weight complexes of porcine LH/hCG receptors
(Wimalasena, Moore, Wiebe, Abel and Chen, 1985) and bovine mammary
gland prolactin receptors (Ashkenazi, Madar and Gertler, 1987) have
been demonstrated using gel filtration. In several cases a putative
receptor-G-protein complex has been identified using this technique
(Nissenson, Mann, Winer, Teitelbaum and Arnaud, 1986;
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Dattatreyamurtyl, Figgs and Reichert, 1987; Kamada, Rondon, Frohlich
and Cole, 1987; Paul and Said, 1987) as has the apparent
dissociation of a multimeric mineralocorticoid receptor complex as a
result of receptor activation (Eisen and Harmon, 1986). Gel
filtration therefore appears to be a suitable technique for partial
characterisation (giving an apparent molecular weight estimate) of
non-denatured, solubilised proteins under mild conditions.
In this case it has been used to determine the apparent
molecular weight of the solubilised LHRH receptor protein. Gel
filtration has been shown not to be adversely affected by the
presence of detergents (Tanford, Nozaki, Reynolds and Makino, 1974)
or high salt concentrations (Petrovic, Petrovic, Markovic and
Knezevic, 1974). The LHRH receptor protein molecular weight can
therefore be determined whilst held in solution in the 5mM
CHAPS/1.5M NaCl.
2.7.1. Method
A gel filtration column (70cm x 2.6cm) was prepared using
Sepharose 6B (Pharmacia Fine Chemicals Ltd., Uppsala, Sweden) and
kept at 4°C. After packing for 3 column volumes at 25ml/hr the
column was run at 19.5ml/hr. The eluting solution used was the 5mM
CHAPS/1.5M NaCl solubilisation solution. Void volume was determined
using Dextran 2000 (lmg/ml) and a calibration curve constructed
using high and low Molecular Weight Gel Filtration Calibration Kits
(Pharmacia) (Fig.2.8). Eluted proteins were detected using an LKB
Uvicord II 8300 and UV absorbtiometer 8303A detector unit and
recorded on a LKB Chopper Bar Recorder 6520-4 (LKB Instruments,
Stockholm, Sweden). Sucrose (50yg/ml) was added to the samples





Calibration curve for Sepharose 6B (70cm x 2.6cm) gel filtration
column. Kav values, calculated as described (2.7) are means of two
determinations. Void volume was determined using Dextran 2000
(lmg/ml) before each sample run. The column was run as described
(2.7.1) at 19.5ml/hr with the eluting solution (5mM CHAPS, 1.5M
NaCl, 25mM Tris-HCl pH7.4, 50yg/ml soybean trypsin inhibitor,
400KIU/ml aprotinin) and eluted proteins detected using an LKB
Uvicord II 8300 and UV absorbtiometer 8303A detector unit.
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the gel bed as a compact band and therefore improve the resolution
of the separation.
The supernatant of anterior pituitary membranes solubilised as
previously described (Chapter 4) using 5mM CHAPS/1.5M NaCI were
applied to the calibrated column and eluted (19.5ml/hr) using the
CHAPS/NaCl solution. Fifteen minute fractions were collected using
a LKB Ultrorac 7000 fraction collector. From these 1.3ml aliquots
were taken for PEG precipitation (as previously described but scaled
up proportionally to a total volume of 35mls). After standing for
20 minutes on ice the precipitated proteins were separated from the
detergent solution by centrifugation for 30 minutes at 15,000 g 4°C,
and then resuspended in 1.8 ml Tris-HCl (25mM, pH 7.4). Aliquots of
125
300 pi were used in I-buserelin binding assays (2.4) to
determine the elution volume (Ve) of the proteins responsible for
specific binding of LHRH ligands. Using the calibration curve
(Fig.2.9) and the calculated Kav for the protein its apparent
molecular weight could be estimated.
2.8. SDS Polyacrylamide gel electrophoresis (PAGE)
Whereas gel filtration (2.7) can be used to give an estimate of
the apparent molecular weight of the solubilised LHRH binding
protein, any contribution to this by individual, polypeptides or
subunits may not be revealed. Dissociation of the receptor protein
into its constituent polypeptides (if more than one) may not occur
under the mild conditions used for solubilisation and gel
filtration, more extreme conditions may be required to reveal
these. The anionic detergent sodium dodecyl sulphate has been shown
(Nielsen and Reynolds, 1978) to dissociate many water soluble
proteins into their constituent polypeptide chains (in the presence
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of a reducing agent). Approximately 1.4g SDS is found to bind per
gram of protein (Nielsen and Reynolds, 1978) which is said to be a
number of SDS molecules approximately equal to half the number of
amino-acid residues (Weber and Osborn, 1975). This is thought to
result in an almost constant negative charge per unit mass of
protein (for proteins not initially possessing a high overall
charge; Weber and Osborn, 1975). The binding of SDS to the proteins
was also shown to induce a conformational change, resulting in
rod-like complexes of constant width but of length proportional to
their molecular weight (Reynolds and Tanford, 1970).
This denaturing of proteins by SDS has enabled electrophoretic
techniques to be used to estimate their molecular weights (Weber and
Osborn, 1975; Nielsen and Reynolds, 1978). Whilst the
electrophoretic mobility of proteins is dependent on their molecular
charge and size, no rigorous relationship exists between
electrophoretic mobility and molecular weight (Nielsen and Reynolds,
1978). For protein-SDS complexes in polyacrylamide gel
electrophoresis (PAGE, first introduced by Raymond and Weintraus,
1959), the high degree of SDS binding and conformational changes
result in an apparent relationship between the logarithm of the
molecular weight of protein and its electrophoretic mobility
(Shapiro, Vinuela and Maizel, 1967; Weber and Osborn, 1969). The
empirically established relationship has not however been shown to
have any theoretical basis (Nielsen and Reynolds, 1978) and
exceptions exist, such as proteins of high intrinsic charge, for
example histones (Weber and Osborn, 1975) or glycoproteins (Pitt
Rivers and Impiombato, 1968). Grefrati and Reynolds (1974) found
that the erythrocyte glycoprotein (a transmembrane protein
consisting of 55% carbohydrate) whilst dissociating into monomers in
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the presence of SDS, binds an abnormally high amount of SDS (5 — 7g
of SDS/g protein, or 2.5 - 3.4g SDS/g glycoprotein). Similarly the
hydrophobic region of the intrinsic mitochondrial membrane protein
cytochrome b^ has been shown to bind ~3g SDS/g protein whereas the
hydrophilic, extramembrane portion of the protein binds only ~0.7g
SDS/g protein (Robinson and Tanford, 1975). In both cases these
proteins might be expected to show non-standard mobilities in
SDS-PAGE, and this is thought to be the case for many intrinsic
membrane proteins (Nielsen and Reynolds, 1978).
The technique of SDS-PAGE has however been used both to show the
existence of polypeptide subunits making up a membrane associated
complex, and to determine the approximate molecular weights of the
constituents. For example the mitochondrial membrane cytochrome C
oxidase complex has been shown to contain six polypeptide subunits
(Briggs, Kamp, Robinson and Capaldi, 1975) or seven in the case of
the yeast complex (Rubin and Tzagoloff, 1973). The acetylcholine
receptor (Lindstrom, Merlie and Vogeeswaran, 1979), insulin receptor
(Im, Frangakis, Meezan, DiBona and Kim, 1982) prolactin receptor
(Yamada and Donner, 1985; Mitani and Dufau, 1986; Haldosen and
Gustafsson, 1987) and the LH/hCG receptor (Wimalasena, Moore, Wiebe,
Abel and Chen, 1985) have all been shown by SDS-PAGE to be complexes
of more than one polypeptide subunit. Electrophoresis of samples
containing many different proteins, such as a sample of rat anterior
pituitary membranes, requires some method of identifying specific
proteins. In the case of several receptor-types including the
somatostatin (Lewis and Williams, 1987; Zeggari, Viguerie, Susini,
Gamier, Esteve and Ribet, 1987) TSH (Furmaniak, Haskim, Buckland,
Petersen, Beever, Howells and Rees Smith, 1987) angiotensin II
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(Guillemette, Guillon, Marie, Balestre, Escher and Ward, 1987;
Laribi, Allard, Vincent and Simonnet, 1987) and adenosine receptors
(Stiles and Jacobson, 1987), this has been achieved by the covalent
labelling of radioiodinated analogues of specific ligands to the
receptor proteins prior to electrophoresis. This method has
previously be used in the identification of LHRH receptors on
SDS-PAGE (Hazum, 1981(b); Iwashita and Catt, 1985). Ligand binding
to the LHRH protein after electrophoresis has also been used (Eidne,
Hendricks and Millar, 1985), but the technique of covalently
labelling with a radioiodinated specific ligand was that used in
this thesis (Chapter 6).
The method of SDS-PAGE used here was that of discontinuous gel
electrophoresis first described by Laemmli (1970). Estimation of
the unknown molecular weights of proteins is by calculation of
relative mobilities (R^r) - the migration distance of protein
divided by that of dye front - and consulting a standard curve of
R^r values for proteins of known molecular weight against the log
of their molecular weight (Weber and Osborn, 1969).
2.8.1. Method
Separating gels of 7% acrylamide were used. The solutions used
are listed in Appendix II. Slab gels (20cm x 20cm x 0.7mm) were
poured by hand. After polymerisation was complete (~1 hr at room
temperature) a stacking gel (4.75% acrylamide) was applied, using
well formers of lOOpl capacity.
Samples dissolved in sample buffer (see Appendix II) were heated
at 90-100°C for five minutes and 5pl of 1% bromo-phenol blue
solution added to each. ^C-labelled molecular weight standards





Representative calibration curve for an SDS 7% polyacrylamide
gel with a stacking gel of 4.75% acrylamide. ^C-Labelled
standards (Amersham International pic) dissolved in sample buffer as
described (2.8.1 and Appendix II) were applied and run at 40mA for
10-12hr at 10°C. The gel was then fixed and dried and exposed to
X-Omat S film for 4 weeks at -70°C (see Appendix II). The resulting
autoradiograph was used to calculate Rf values (the migration
distance of protein divided by that of the dye front) and so
construct a standard curve.
-47-
2,350-200,000) were run with each set of samples and could be used
to construct a standard curve, as above (Fig.2.10). Electrophoresis
was carried out for 10-12 hr at 40 mA (constant current) using the
GE-214 LS vertical electrophoresis apparatus (Pharmacia Fine
Chemicals, Ltd) and LKB 2197 power supply. The running buffer (see
Appendix II) was continuously circulated and cooled to 10°C with the
LKB 2219 Multitemp II thermostatic circulator.
2.9. Design and Synthesis of LHRH Analogues
For the affinity chromatography of the LHRH receptor using
biotin affinity columns (2.6) analogues of LHRH containing a biotin
molecule and some means of covalently attaching the peptide to the
receptor site are required. It is also necessary for efficient
affinity labelling of the LHRH receptor, that the analogues have a
high specific:non-specific binding ratio, a slow rate of
dissociation from the LHRH receptor site and resistance to enzymatic
degradation. In order to try and satisfy these requirements, a
literature survey of the conformational and binding characteristics
of LHRH and its analogues was undertaken (2.9.1). Similarly,
information in the literature was used to try to optimise the
structure of the biotin containing groups chosen (2.9.2).
2.9.1. Choice of Peptide Backbone
Conformational studies of LHRH (Momany, 1976(a)) and analogues
of LHRH (Momany, 1976(b)) have shown the lowest energy confirmation
of the decapeptide to be hinged, forming a e turn at the Gly®
residue (Fig.2.11). Generally it was shown that changes in the
amino-acids of LHRH which resulted in a change in the backbone shape
(in order to maintain a lowest energy conformation) lead to a loss
Figure 2.11
Conformation of LHRH as proposed by Momany-(1976(a),(b)).
Positions of hydrogen atoms are not shown for clarity. Structure
modelled using "Interchem" by Dr P Bladon (Strathclyde University).
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of biological activity. Some changes which did not involve a change
in backbone shape also resulted in decreased biological activity and
these have been suggested to indicate the moieties important for
receptor-peptide interaction. Those residues required for
12 9
biological activity would appear to be the Glu , His and Pro
3 5
residues, with aromatic residues at Trp , Tyr positions. The
amino-acid in position 6, as long as it retained the e turn
formation, was unimportant. A D-isomer in this position however
stabilises the e turn of the molecule (Momany, 1976(b)) and such
analogues are more active than the native LHRH (Coy,
Vi1chez-Martinez, Coy and Schally, 1976).
As position 6 is some distance away from the part of the LHRH
molecule considered to interact with the receptor it may be a good
candidate as the position on which to substitute bulky groups - such
as the biotin molecule. Replacement of Gly^ with D-Lys® would
not only stabilise the low energy e turn conformation but provide a
free amino group at position 6 for substitution.
Arimura, Vilchez-Martinez, Coy, Coy, Hirotsu and Schally (1974),
Fujino, Fukunda, Shinagawa, Kobayashi, Yamazaki, Nakayama, Seely,
White and Rippel (1974) and Dericks-Tan, Hammer and Taubert (1977)
showed that LHRH analogues altered not only by a D-amino acid
substitution at position 6 but also at their C-terminal to des
Gly^ ethylamide were far more potent, biologically, than either
native LHRH or the D(x)^ LHRH analogue. Binding experiments using
iodinated analogues (Clayton, Shakespear, Duncan and Marshall,
1979a) showed that these [D(x)^ des Gly^]-LHRH ethylamine
analogues bound largely to one high affinity site, non-specific and
low affinity site binding being much less than that seen for native
LHRH. However, the increase in biological activity over native LHRH
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observed could not be accounted for entirely by the increase in
affinity.
Marks and Stern (1974) using whole brain extracts and Koch,
Baram and Chobsieng (1974) using hypothalamic and cerebrocortical
extracts showed that native LHRH was rapidly degraded, largely by
the cleavage of the Gly^-Leu'' peptide bond. Clayton,
Shakespear, Duncan and Marshall (1979(b)) showed also that an LHRH
degradation enzyme (of an unspecified type) was associated with
purified pituitary plasma membranes. Further studies by Elkabes,
Fridkin and Koch (1981) suggested that the main cleavage sites for
the plasma membrane bound enzymes were the Gly^-Leu'7 and
3 4
Trp -Ser bonds of LHRH. However, LHRH analogues with a D-amino
acid at position 6 were shown to be resistant to degradation by
these enzymes (Marks and Stern, 1974; Koch, Boram, Hazum and
Fridkin, 1977; Clayton and Shakespear, 1978; Clayton, Shakespear,
Duncan and Marshall, 1979(b)), with the increase in potency of these
analogues of a similar order to their resistance to enzymatic
degradation. A slower, C-terminal inactivation of LHRH was seen by
whole brain extracts (Marks and Stern, 1974) and this was blocked by
the modification of the C-terminal to des Gly^-ethylamide. The
higher biological activity of LHRH analogues [D(x)^, des
Gly^]-LHRH ethylamide therefore could possibly be explained in
terms of both an increased affinity and a resistance to enzymatic
degradation. Such analogues have been shown in vivo to bind to
specific sites in the pituitary to a greater degree and for a longer
time than native LHRH (Reeves, Tarnavsky, Becker, Coy and Schally,
1976). As the half-lives of the analogues in serum were found to be
similar to that of LHRH (Reeves, Tarnavsky, Becker, Coy and Schally,
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1976), this has been suggested (Clayton and Catt, 1981) to be due to
the slower dissociation of these analogues from the LHRH receptor
than native LHRH. This is in agreement with in vitro data on the
dissociation of radiolabelled LHRH and its analogues from rat
anterior pituitary tissue (Clayton and Catt, 1981).
In summary, LHRH altered to a D-amino acid at position 6, on to
which the biotin containing group can be added, and with a
C-terminal alteration to des Gly"^ N-ethylamide should optimise
all the conditions required for the peptide backbone for a biotin
containing affinity ligand for the LHRH receptor. That is:-
(1) a high affinity LHRH analogue with a high
specific:non-specific binding ratio,
(2) resistance to enzymatic degradation,
(3) and slow dissociation from the LHRH receptor site.
A D-Lys residue, as mentioned above, provides a free amino
group onto which the biotin containing molecule can be reacted.
2.9.2. Choice of Biotin containing group
As the biotin-streptavidin interaction was to be used in the
affinity purification of the covalently labelled LHRH receptors it
was important that the biotin group binding was not sterically
impeded. The 4-carbon chain, between the part of the biotin
molecule important in streptavidin binding and its attachment to
the rest of the side chain (Fig. 2.12), was thought to be
sufficient to ensure this.
Two methods of covalent labelling of the receptor site were to
be used - photoaffinity and Afunctional chemical crosslinkers.
2.9.2.1. Choice of Photoaffinity Moiety
A photoaffinity ligand may in theory enable a high specificity
Figure 2.12
Chemical structure of a) Biotin, and the novel,
biotin-containing reagents prepared by Dr C M Bladon for coupling
LHRH analogues -
b) the aryl azide, photoaffinity compound























of labelling in the region of the receptor site (Bayley and Knowles,
1977; Das and Fox, 1979; Ji, 1979). This is thought to be dependent
on the specificity of the ligand binding at equilibrium with the
membrane preparation, the close proximity of the photoaffinity group
to the receptor and the rapid and non-selective reactivity of the
photoactivated group (Das and Fox, 1979; Ji, 1979).
Criteria have been proposed that a suitable photo-reactive group
should fulfil (Baley and Knowles, 1977), they are:-
1) a readily synthesised precursor that is chemically stable
in an aqueous solution for at least the time required to
reach a binding equilibrium.
2) a group susceptible to photolysis at wavelengths that will
not result in photo-oxidative or other photochemical damage
to the membrane constituents.
3) a group which on exposure to light gives rise to a highly
reactive species of short half-life.
Early experiments using photoreactive ligands were attempts to
map the active site of the enzyme chymotrypsin and utilised diazo
compounds (Singh, Thornton and Westheimer, 1962). Photoactivation
of the diazo group generates a carbene which is capable of reacting
very rapidly and non-selectively (Bayley and Knowles, 1977).
Unfortunately diazo compounds are susceptible to rearrangements
(Bayley and Knowles, 1977; Das and Fox, 1979) resulting in a loss of
photoreactivity or a loss in the non-selective, rapid reactivity of
the photogenerated group (Bayley and Knowles, 1977; Das and Fox,
1979). They therefore would not appear to be ideal photoreactive
compounds. A second group of photoreactive compounds are the aryl
azides. Aryl azides are very stable in aqueous solution (in the
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dark) but have a low activation energy and are activated by light of
the long wavelength UV/visible range ~300-400nm (Ji, 1979; Das and
Fox, 1979). On activation an aryl nitrene is formed which is a
highly reactive species capable of reacting with primary, secondary
and tertiary carbon-hydrogen bonds or with an oxygen-hydrogen bond.
Only the amino-acid glycine has been suggested to be resistant to
reaction with them (Ji, 1979). The half-life of the reactive
species has been found to be of the order of 10~^sec, the actual
value dependent on substituents on the group (Das and Fox, 1979).
Aryl azides would appear to comply with the criteria suggested for
useful photoreactive groups, and have been used in preference to
diazos in many studies (Bayley and Knowles, 1977).
Early photoaffinity ligands incorporating aryl azide groups
included acetylcholine receptor and esterase ligands (Kiefer,
Lindstrom, Lennox and Singer, 1970; Ruoho, Kiefer, Roeder and
Singer, 1973) and derivatives of opioids (Winter and Goldstein,
1972) insulin (Levy, 1973) and gastrin (Galardy, Craig, Jamieson and
Caron, 1974). Whilst initial studies revealed high non-specific
labelling with the photoaffinity ligands (Ruoho, Kiefer, Roeder and
Singer, 1973; Winter and Goldstein, 1972)?their use in combination
with histochemical (Rostene, Mazella, Dussaillant and Vincent, 1986)
and SDS-PAGE techniques (Furmaniak, Hashim, Buckland, Petersen,
Beaver, Howells and Rees Smith, 1987; Stiles and Jacobson, 1987;
Amlaiky, Berger, Chang, McQuade and Caron, 1987; Robichon, Kuks and
Besson, 1987) have shown specific covalent labelling of the receptor
site. Efficiencies as high as 40% of all receptors covalently
labelled have been reported (Gui1lenette, Guillon, Marie, Balestre,
Escher and Jard, 1987). Aryl azide compounds were therefore chosen
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as the photoreactive group in photoaffinity LHRH analogues used in
this Thesis.
2.9.2.2. Choice of the Substrate for Chemical Crosslinker Affinity
Label 1ing
Another method for covalently linking a ligand to its receptor
site is that of chemical crossiinking. Bifunctional reagents are
used to introduce a chemical bridge between the two molecules (Ji,
1979). The first attempts to crosslink ligands to their receptors
used glutaraldehyde to covalently bind insulin and epidermal growth
factor to their respective binding sites on liver membranes
(Sahyoun, Hook and Hollenberg, 1978). The bond formed by the
glutaraldehyde was unstable and required reducing before the
resultant complex could be further examined. More suitable chemical
crosslinkers for ligands and receptors were found in the bisimidates
(Dutton, Adams and Singer, 1966 ; Hartman and Wold, 1966). These
react (with high specificity) with primary and secondary amino
groups to form stable amide bonds. Unfortunately they have been
found to be unstable in water and hydrolyse rapidly to their free
acid, particularly below pH 8 and low temperatures (0-4°C) where
these side reactions are said to occur at a far greater rate than
the amide bond formation (Ji, 1979; Pilch and Czech, 1984). Lomant
and Fairbanks (1976) suggested that bis(succinimidyl) esters would
prove more useful as chemical crosslinkers in biological systems.
They showed them to be reactive with primary and secondary amino
groups with the amide bond reaction proceeding at a far higher rate
than hydrolysis at pH7, 23°C. Homobifunctional succinimidyl esters
have been widely used in the crossiinking of ligands to their
receptors, for example receptors for insulin (Pilch and Czech, 1979)
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M.S.A. (Massague, Guillette and Czech, 1981) human chorionic
gonadotropin (Rebois, Omedeo-Sale, Brady and Fishman, 1981) platelet
derived growth factor (Glenn, Bowen-Popeand Ross, 1982) growth
hormone releasing hormone (Zysk, Cronin, Anderson and Thorner, 1986)
and angiotensin II (Laribi, Allard, Vincent and Simonnet, 1987).
An alternative to the homobifunctional crosslinkers are
heterobifunctional crosslinkers. These are often constructed to
contain a succinimidyl ester and a photoreactive group (such as an
aryl azide: Ji, 1976; Ji, 1979). These have the advantage over
homobifunctional N-hydroxy succinimidyl esters of being able to
react with the ligand by amide bond formation prior to binding with
the receptor and then, after ligand binding equlibrium has been
reached, undergo photoactivation to crosslink the ligand to the
receptor (Ji, 1979). Again many ligands and receptors have been
crosslinked using these types of reagent including LHRH (Hazum,
1981; Iwashita and Catt, 1985), somatostatin (Lewis and Williaks,
1987; Zeggari, Viguerie, Susini, Gamier, Esteve and Ribet, 1987),
thyroid stimulating hormone (Furmaniak, Hashim, Buckland, Petersen,
Beever, Howells and Rees-Smith, 1987), adenosine (Stiles and
Jacobson, 1987), dopamine receptors (Amlaiky, Berger, Chang,
McQuade and Caron, 1987) and vasoactive intestinal peptide (VIP:
Robichon, Kuks and Besson, 1987). In the case of VIP the
derivatisation of the ligand was carried out whilst it was bound to
the receptor in order to protect those parts of the ligand required
for binding affinity.
Comparison of studies of insulin receptors using chemical
crosslinkers, photoaffinity ligands and specific antibodies reveal
no major differences in the apparent structure of the receptor found
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(Czech, Massague and Pilch, 1981). This suggests that, at least in
the case of the insulin receptor, neither photoaffinity nor chemical
crosslinking techniques results in significant crosslinking of
non-related membrane proteins, supporting the hypothesis that they
are valid techniques for the identification of receptors for
specific ligands.
All of the chemical crosslinkers used in this Thesis, both
homobifunctional and heterobifunctional, contained an
N-hydroxysuccinimide ester group. This is reactive with free amino
groups (see above) and so the biotin-containing group of LHRH
analogues used in the chemical crosslinking experiments were
required to have a free amino group. In order to increase the
chance of this free amino group being available for reaction with
the chemical crosslinker and not subject to excessive steric
hinderance by the 1igand-receptor complex a 2-carbon spacer arm was
incorporated (Fig.2.12).
2.9.3. Biotin containing LHRH-analogues
The biotin-LHRH-analogues chosen to be synthesised were
[biotinyl-p-azidophenylalanine-D-Lys®]-LHRH (PBL),
[biotinyl-p-azidophenylalanine-D-Lys^, des Gly^]-LHRH
ethylamide (PBAL) and [4-amino-2-biotinyl-D-Lys^, des
Gly^]-LHRH ethylamide (XBAL) (Fig.2.13(a,b,c)).
2.9.4. Method of Synthesis of Biotin-containing LHRH-analogues
All peptide synthesis was undertaken by Dr C.M. Bladon of the
MRC Brain Metabolism Unit. [D-Lys^, des Gly^]-LHRH ethylamide
was synthesised by the solid-phase method using Sheppard's
Fmoc-t-butyl-polyamide chemistry (Eberle, Atherton, Dryland and
Sheppard, 1986). Details of the techniques and methods appear in
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Figure 2.13














PheN3* But Leu Arg Pro Gly
PBL 1.07 1.00 0.81 1.07 1.01 0.30 - 1 1.00 0.96 1.04
PBAL 1.05 0.96 0.83 0.95 1.02 0.20 - 1 0.89 0.91 -
XBAL 1.09 1.01 0.91 1.01 1.07 - 0.94 1 0.96 0.99 -
* largely decomposed on hydrolysis.
Table 2.1
Ami no-acid analysis of LHRH analogues (performed by Dr C M
Bladon). Samples were hydrolysed in distilled, constant boiling
hydrochloric acid containing a trace of phenol for 18hr at 110°C.
The hydrolysate was evaporated and the residue was partitioned
between citrate buffer (pH2.20) and methylene chloride. The aqueous
layer was filtered through a nylon-66 membrane and an aliquot
subjected to amino-acid analysis (LKB LH50 Alpha amino acid
analyser).
Each conjugate gave an amino acid analysis consistent with the
expected sequence, though tryptophan was not determined due to its
normal degrading under these conditions.
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Appendix III. [D-Lys^]-LHRH was purchased from Peninsula
Laboratories Europe Ltd (Merseyside).
The novel ligands (Fig.2.12) were prepared in several steps (see
Appendix III) from biotin and either p-nitrophenylalanine or
2,4-diaminobutyric acid. These ligands were converted to their
N-hydroxysuccinimide esters prior to coupling to the e-amino group
of the D-Lys of the peptide backbone. The coupling reactions
were performed in demethylformamide in the presence of triethylamine
and the conjugated products were purified by reverse-phase hplc.
Details of the reactions are shown in Appendix III. Each conjugate
gave an amino acid analysis (Table 1) consistent with the expected
sequence, though tryptophan was not determined due to the expected
degeneration during analysis.
2.10. Protein Assay
All protein assays in this Thesis were carried out according to
the method of Geiger and Bessman (1972). Samples in Tris or Hepes
buffers were first precipitated using TCA and then resuspended into
0.03M NaOH. Aliquots of samples or bovine serum albumin standards
(range 4-20pg) were made up to 200yl with distilled water in 3ml
polystyrene (LP^) tubes and 500^1 alkaline copper reagent was
added. After 20 minutes 1ml of diluted Folin-Ciocalteau reagent was
added. Absorbance of the solution was measured, at 725nm using a
Gil son model 250 spectrophotometer, after 20 minutes when the colour
formation had gone to completion. Details of the method are given
in Appendix IV. Values for samples were read off from the standard
curve, which showed linear absorbance against protein concentration
over the range used (Fig.2.14).
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Representative protein assay standard curve. Aliquots (0-50ul)
of a standard solution (BSA; 500yg/ml) made up to 200^1 in 25mM
Tris-HCl pH7.4 were precipitated using TCA and resuspended into
0.03M NaOH (50yl) and made up to 200^1 with distilled water for use
in the protein assay (see Appendix IV). Absorbance (at 725nm
measured using a Gilson model 250 spectrophotometer) plotted against
amount of protein revealed a linear standard curve.
Chapter 3
Characterisation of ligand binding to LHRH receptors in situ:
relation to post-receptor events
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3.1 Introduction
In common with other neurotransmitters and neuropeptides LHRH is
thought to exert its actions on gonadotrophes by interacting with
specific receptors (Vale, Rivier, Brown, Leppaluoto, Ling, Monahan
and Rivier, 1976). Morphological studies using a ferritin conjugate
of an LHRH analogue and electron microscopy (Hopkins and Gregory,
1977) and a fluorescent LHRH analogue with video-intensified
fluorescence microscopy (Naor, Atlas, Clayton, Forman, Amsterdam and
Catt, 1981) have localised these receptors to the plasma membrane.
Initial ligand binding studies to investigate these receptors used
radiolabelled native LHRH, either ^H-labelled (Grant, Vale and
Rivier, 1973; Theoleyre, Berault, Gamier and Jutisz, 1976) or
1 ?5
I-labelled (Spona, 1973; Marshall, Shakespear and Odell,
1976). These revealed two specific binding sites, one of high
affinity (nM) but low capacity - only 30% of the total - and one low
affinity (pM) high capacity site. Since the concentration of LHRH
in portal blood is less than nM the physiological significance of
the low affinity site is dubious. The possibility that it may
represent interaction with the recognition site of an degradative
enzyme has been widely suggested (Clayton, Shakespear, Duncan and
Marshall, 1979(b); Clayton and Catt, 1981; Conn, Marian, McMillian,
Stern, Rogers, Hamby, Penna and Grant, 1981). .Saturation
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experiments using I-LHRH revealed only one class of sites; that
125
is high affinity receptors, whereas displacement of I-LHRH by
unlabelled LHRH showed only the low affinity site (Braumann and
Kuhl, 1979; Wagner, Adams and Nett, 1979). This is in contrast to
the multiple-binding sites seen using H-LHRH (Clayton,
Shakespear, Duncan and Marshall, 1979(b)). The inconsistency of
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these results highlights the three major difficulties encountered by
the early LHRH ligand binding experiments:-
1) Low specific binding of the radiolabels
2) Rapid dissociation of radiolabelled native LHRH (Clayton
and Catt, 1981)
3) Susceptibility of the native LHRH (radiolabelled and
unlabelled) to protease degradation (Kochman, Kerdelhue,
Zor and Jutisz, 1975; Benuck and Marks, 1976; Clayton,
Shakespear, Duncan and Marshall, 1979(b); Griffiths and
Kelly, 1979).
As described previously (2.11.1), the principal degradation
5 6
sites of native LHRH are said to be the Tyr -Gly and
fi 7
Gly -Leu bonds, (cleaved by an endopeptidase) and the
9 10
Pro -Gly NH£ bond (cleaved by a carboxyamide peptidase)
(Marks, 1970; Koch, Baram, Chobsieng and Fridkin, 1974). The
synthesis of LHRH analogues altered to a D-amino-acid at position 6
10 9
or desGly with an ethylamide at Pro not only resulted in
analogues resistant to degradation but also with increased potency
(Arimura, Vilchez-Martinez, Coy, Hirotsu and Schally, 1974; Fujino,
Fukuna, Shinagawa, Kobayashi, Yamazaki, Nakayama, Seely, White and
Rippel, 1974; Kochman, Kerdelhue, Zopr and Jutisz, 1975; Schally,
Kastin and Coy, 1976; Vale, Rivier, Brown, Lappaluoto, Ling, Monahan
and Rivier, 1976; Koch, Baram, Hazum and Fridkin, 1977; Clayton and
Shakespear, 1978; Clayton, Shakespear, Duncan and Marshall, 1979(b);
Sandow, Kuhl and Krauss, 1979; Swift and Crighton, 1979; Perrin,
Rivier and Vale, 1980). The increase in potency of the analogues
has been suggested to be due not only to their resistance to
degradation but also to the stabilisation of the peptide bond (6-7)
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in the lowest energy conformation by the presence of a D-amino acid
in position 6 (Monahan, Amass, Anderson and Vale, 1973; Fujino,
Fukuna, Shinagawa, Kobayashi, Yamazaki, Nakayama, Seely, White and
Rippel, 1974; Momany, 1976(b)) and the slower dissociation of the
analogues from the LHRH receptor (Reeves, Tarnavsky, Becker, Coy and
Schally, 1977; Clayton and Catt, 1981). Use of analogues with both
an ethylamide in lieu of Gly^ and a D-amino-acid at position 6 as
radioiodinated labels in binding studies has been a successful
approach in experiments using dispersed anterior pituitary cells
(Meidan and Koch, 1981), gonadotrophes in culture (Berault, Jansem
de Almeida Catanho, Theoleyre and Jutisz, 1983) and membrane
preparations (Conne, Aubert and Sizonenko, 1979). As regards tissue
preparations, identical binding characteristics have been shown for
sucrose density gradient-enriched pituitary plasma membranes,
partially purified pituitary membrane particles and a crude rat
anterior pituitary homogenate preparation (Clayton and Catt, 1981).
In all cases whilst the degradation-resistant analogue displaced
radiolabeled native LHRH from both the low and high affinity sites,
126
the I-analogue,which bound exclusively to a high affinity site,
\
was completely displaceable by native LHRH and by various LHRH
analogues.
[D-Ser(tBu)®,des Gly^] LHRH ethylamide (buserelin) has been
extensively used in ligand binding studies (Sandow and Konig, 1979;
Reeves, Seguin, Lefebvre, Kelly and Labrie, 1980; Clayton and Catt,
1981; Hazum, 1981; Meidan and Koch, 1981; Berault, Jansem de Almeida
Catanho, Theoleyre and Jutisz, 1983; Eidne, Hendricks and Millar,
1985). Buserelin is an ideal choice for use as an iodinated label
for LHRH-receptor binding assays as it is easily iodinated to a high
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specific activity of ~ llOOyCi/pg and the mono-iodinated buserelin
125
readily purified (Chapter 2.3). I-Buserelin has been found to
retain its specific binding activity for 2-4 weeks when stored at
4°C (playton and Catt, 1981), the affinity constant shown to be the
same as that of unlabelled buserelin, with up to 60% of the total
binding to rat anterior pituitary membrane preparation being
specific (Clayton, Shakespear, Duncan and Marshall, 1979(b)).
Buserelin - generously donated by Hoechst A.G. (Frankfurt, F.R.G.)
has been used in the majority of the 1igand binding experiments in
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this Thesis as the radiolabel. I-Buserelin binding has been
shown to maximal at 4°C to both dispersed rat pituitary cells
(Meidan and Koch, 1981) and to rat anterior pituitary membranes
(Clayton and Catt, 1981), reaching an equilibrium after about 90
minutes (Chapter 2.4.1.2). During this time there is no significant
degradation of either the radiolabelled or unlabelled buserelin
(Clayton, Shakespear, Duncan and Marshall, 1979(b)). Since a
9+ 9+ + +
variety of cations Ca , Mg , Na and K (Clayton,
Shakespear and Marshall, 1978; Marian and Conn, 1980; Mitchell,
Ogier, Johnson, Cleland, Bennie and Fink, 1985) reduce the specific
125
binding of I-buserelin, assays here (as by other workers) were
routinely carried out in 25mM Tris-HCl buffer, pH 7.4 with 0.1% BSA
to reduce nonspecific binding of the peptides to the plastic tubes
(Clayton, Shakespear, Duncan and Marshall, 1979(a)).
The second messenger systems mediating the action of LHRH on
gonadotrophes have been extensively investigated. Early studies of
the responsiveness of anterior pituitary tissue to crude
hypothalamic extract showed a requirement for extracellular calcium
for LH release from gonadotrophes (Samli and Geshwind, 1968;
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Wakabayashi, Kamberi and McCann, 1969). A role for cyclic AMP was
suggested but,whilst some groups found an increase in cyclic AMP
levels after LHRH stimulation (Borgeat, Chevaney, Dupont, labrie,
Arimura and Schally, 1972; Labrie, Borgeat, Lemay, Lamarie, Barden,
Drouin, Lemaire, Jolicoeur and Belanger, 1974; Adams, Wagner, Sawyer
and Nett, 1979),there were inconsistencies. In some cases no
changes in the levels of cyclic AMP were seen (Sundberg, Fawcett and
McCann, 1976; Conn, Dufau and Catt, 1979; Conn, Morrell, Dufau and
Catt, 1979) or no activation of adenylate cyclase was observed
(Theoleyre, Berautt, Gamier and Justisz, 1976; Clayton, Shakespear
and Marshall, 1978). Naor, Zor, Meidan and Koch (1978) found that
whilst male anterior pituitaries showed an increase in cyclic AMP in
response to LHRH, this was not seen in tissue from either female or
castrated male. A possible role for cyclic GMP was also
suggested (Naor, Clayton and Catt, 1980) with increases in guanylate
cyclase activity demonstrated (Vesely, 1985). However both cyclic
AMP and cyclic GMP changes can be experimentally dissociated from
the LH response to LHRH (Cronin, Evans, Hewlett, Rogol and Thorner,
1983; Naor and Catt, 1980).
Whilst a direct role for the cyclic nucleotides in LHRH-induced
LH release seems rather unlikely, the role of calcium appears to be
more certain. Conn, Marian, McMillian and Rogers (1980) put forward
three basic criteria to be fulfilled by calcium if its role in
mediating LHRH stimulated LH release was to be correct. These were:
a) Blockade of LHRH-stimulated LH release in the absence of calcium
b) Release of LH in response to an increase in intracellular
calcium levels
c) An increase in intracellular calcium levels in response to LHRH.
-67-
LH responses to LHRH are inhibited by the removal of calcium
from the extracellular medium (Bourne and Baldwin, 1980; Stern and
Conn, 1981; Borger, Scott, Kaiser, Evans and Thorner, 1983) or by
the presence of calcium channel blockers (Pickering and Fink, 1979;
Marian and Conn, 1979; Stern and Conn, 1981; Bates and Conn, 1984),
and calcium ionophores give rise to a concentration-dependent LH
release that is blocked by the presence of calcium chelators such as
EGTA (Conn, Kilpatrick and Kirshner, 1980; Conn and Rogers, 1980).
These results would seem to fulfil the first two criteria for the
role of calcium in mediating the LHRH response. Experiments using
the calcium fluorophore Quin 2 (Tsien, Pozzan and Rink, 1982) show
an increase in fluorescence levels when pituitary cells (enriched
for gonadotrophes) are exposed to LHRH (Clapper and Conn, 1985)
indicating increases in free intracellular calcium. This would
appear to fulfil the third criteron. Although many of these studies
indicate that extracellular calcium is required for LHRH action, it
is possible that other (cellular) stores of calcium may play a
role. Some studies have shown that there is a delay (of a few
minutes) between the removal or block of the extracellular calcium
supply and inhibition of LHRH stimulated LH release (Borger, Scott,
Kaiser, Evans and Thorner, 1983; Bates and Conn, 1984). Efflux of
45 2+
Ca in response to LHRH is inhibited but not abolished by the
removal of extracellular calcium (Williams, 1976) and a calcium
ionophore able to cross cell membranes, X537A, was able to cause LH
release independent of extracellular calcium (Conn, Rogers and
Sandhu, 1979). These initial studies, suggesting a component of
LHRH induced LH release results from the liberation of intracellular
calcium stores, have been substantiated by more recent work. Chang,
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McCoy, Graeter, Tasaka and Catt (1986) showed that nitrendipine (a
voltage-sensitive calcium channel blocker) could fully block the
potentiation of submaximal responses to LHRH that was caused by BAY
K8644 (a voltage-sensitive calcium channel activator) but it could
only partially inhibit the LHRH-induced LH release or increase in
Quin 2 fluorescence. This could be due to a role for intracellular
calcium or alternatively, the presence of
non-dihydropyridine-sensitive calcium channels in gonadotrophes, for
which there is not yet evidence. In a calcium free, EGTA medium,
LHRH gives rise to an initial spike of Quin 2 fluorescence, but is
unable to maintain a plateau of increased fluorescence as seen in
the presence of extracellular calcium (Limor, Ayalon, Capponi,
Childs and Naor, 1987). Another (related) voltage-sensitive calcium
channel blocker, nimodipine, was found to block LHRH induced
45 2+
Ca influx in anterior pituitary tissue whereas the transient
efflux of ^Ca^+ in response to LHRH was blocked by stabilisers
or depletors of non-mitochondrial intracellular calcium stores
(Mitchell, Johnson, Ogier and Fink, 1988). LHRH would therefore
seem to utilise two sources of calcium in the mediation of its
response in anterior pituitary cells:-
i) Intracellular calcium from non-mitochondrial stores.
ii) Extracellular calcium via voltage-sensitive calcium channels.
Electrophysiological studies on gonadotrophs confirm the idea
that LHRH results in the activation of voltage-dependent calcium
channels (Mason, Bicknell, Cobbett, Waring and Ingram, 1986). The
activation of a large conductance calcium-dependent K channel as
a result of LHRH application to gonadotrophs was also seen, whilst
action potentials did not occur even in response to depolarisation
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of the cell membrane. Effects of LHRH on K channels have also
been seen using intracellular recording techniques in bullfrog
sympathetic ganglia (Jan, Jan and Kuffler, 1979; Adams and Brown,
1980; Smith and Zidichouski, 1985). Here the channels involved
appear to be those of the voltage-sensitive M-current. The
activation by acetylcholine, histamine and dopamine of similar K+
channels in Aplysia ganglion cells (recorded using voltage clamp
techniques) was shown to be blocked by intracellular injections of
Pertussis toxin. Furthermore, GTPyS caused a slow and irreversible
opening of the channel at a rate dependent on the level of agonist
activation (Sasaki and Sato, 1987). These results suggest a
receptor modulation of the K channel mediated by the direct
interaction of a G-protein. In embryonic atrial cells, using a
whole cell voltage clamp method, activation by cholinergic agonists
of inward rectifying, voltage sensitive K+ channels was shown to
be independent of a diffusible second messenger, have a delay of
30-100 msecs, require GTP and be blocked by Pertussis toxin
(Pfaffinger, Martin, Hunter, Nathanson and Hi lie, 1985). Perfusion
of purified G-protein subunits revealed that the subunit was
the direct activator of the K+ channel (Yatani, Cordina, Brown and
Birnbaumer, 1987). Studies showing the &y complex of G-protein
subunits to be the activators (Logothetis, Kurachi, Galper, Neer and
Clapham, 1987) have been questioned and suggested to be a result of
a subunit contamination (Rosenthal and Schultz, 1987).
In addition to an apparent direct role in the receptor mediated
activation of K+ channels in some tissues, results of work by
Gomperts (1983) suggest a role for guanine nucleotides in the
mechanism of action of calcium-mobilizing receptors. Introduction
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of non-hydrolysable GTP analogues (such as GTPyS) into permeabi1ized
mast cells and increasing extracellular calcium concentrations
resulted in exocytosis dependent upon GTP analogue concentration.
This GTP-specific exocytosis was not observed when the mast cells
were metabolically inhibited. Evidence for a role of guanine
nucleotides in LHRH actions has been found in primary cultures of
enriched gonadotrophes where GTP analogues result in a time and
concentration-
dependent stimulation of LH release and inositol phosphate
accumulation. Since this can be blocked by LHRH antagonists, a
close association between the LHRH receptor and a G-protein has been
suggested (Andrews, Staley, Huckle and Conn, 1986). However no
effect of guanine nucleotide on agonist binding affinity (as
characterises receptors linked via a G-protein to adenylate cyclase;
Blume, 1978; Glossman and Presek, 1979; Tsai and Lefkowitz, 1979;
Shane, Gammon and Bilzeikian, 1981) has been demonstrated to confirm
the interaction between LHRH receptors and G-proteins (Hazum,
1981(a); Perrin, Haas, Rivier and Vale 1983(a)).
As well as anterior pituitary gonadotrophes, early studies using
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I-LHRH suggested that a low affinity receptor could be found in
other tissues such as liver, spleen, lung and gonads (Heber,
Marshall and Odell, 1978). Using the more reliable LHRH analogues
however, high affinity binding sites could be detected only in the
gonads (Reeves, Seguin, Lefebvre, Kelly and Labrie, 1980; Clayton
and Catt, 1981; Pieper, Richards and Marshall, 1981). Binding of
LHRH analogues suggested that these sites were similar to those
found in anterior pituitary (Reeves, Seguin, Lefebvre, Kelly and
Labrie, 1980) and physiological actions of LHRH at the gonads have
been shown (Sharpe, 1980).
In the brain immunohistochemical techniques have been used to
detect LHRH containing cell bodies and axons (Barry, 1979; Moss,
1979; McCann, 1982). Most LHRH immunoreactivity is found in the
hypophysiotropic area - that is the medial basal hypothalamus and
preoptic area - with rather small amounts seen in some
extrahypothalamic tracts such as the hypothalamo-mesencephalic,
preopticosupraoptic and rostral limbic tracts (see Krey and
Silverman, 1983, for review) . The projections are largely to
regions thought to be involved in inducing mating behaviour (McCann
and Moss, 1975; Samson, McCann, Chud, Dudley and Moss, 1980). Both
behavioural (McCann and Moss, 1975; Moss, 1977; Moss, 1979) and
electrophysiological (Moss 1977; Moss and Dudley, 1978; Sakuma and
Pfaff, 1979; Samson, McCann, Chud, Dudley and Moss, 1980) data
suggest a physiological role for LHRH in the brain in determining
sexual responsiveness.
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Autoradiography using I—[DAIa , Na Me Leu , des
Gly^j-LHRH ethylamide has revealed high levels of specific LHRH
receptors in CAp and CA^ of rat hippocampus (Reubi and
Maurer, 1984). These receptors were shown to have a similar rank
order of affinity for several LHRH analogues to that seen in
anterior pituitary tissue (Reubi, Palacios and Maurer, 1987) whereas
those in the preoptic and mesencephalic grey areas show potency
ratios for analogues that are at variance with those in anterior
pituitary (Moss and Dudley, 1978; Sakuma and Pfaff, 1983). These
results may suggest that whilst the receptors seen in hippocampal
areas are similar to those found in the anterior pituitary, those
involved in mediating the role of LHRH in sexual responsiveness in
forebrain areas are different.
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In situ hybridization has revealed LHRH-like mRNA in cell bodies
in rat forebrain which contain LHRH immunoreactivity (Shivers,
Harlan, Jentmancik, Conn and Pfaff, 1986). The pre-pro-LHRH protein
(encoded for by the LHRH mRNA) has been found using recombinant DNA
techniques to be 92 amino-acids in length (Seeburg and Adelman,
1984; Fig 3.13). The presence in the sequence of one signal peptide
and two possible enzymatic cleavage sites is said to be indicative
of a poly-protein precursor (Douglass, Civelli and Herbert, 1984).
That is the 56-amino-acid C-terminal extension of the pre-pro-LHRH
following the LHRH sequence and its cleavage site (gonadotroph!"n-
associated-peptide, GAP) may have a functional role. This has been
said to be further implicated by the finding that immunoreactive GAP
and LHRH coexist in secretory granules (Nikolics, Mason, Szonyi,
Ramachandran and Seeburg, 1985). The same group have demonstrated
an LH- and FSH-releasing and prolactin release-inhibiting action of
GAP (1-56) on cultured rat anterior pituitary cells (Nikolics,
Mason, Szonyi, Ramachandran and Seeburg 1985). Whilst the
dose-response relationship for LH and FSH release by GAP was similar
to that of LHRH and inclusion of both GAP and LHRH did not result in
additive responses (suggesting that the same post-receptor
mechanisms are used by both peptides),the effect of an LHRH
antagonist on GAP actions was not shown. Whether or not GAP is
acting through specific LHRH receptors has therefore not been
demonstrated.
In this Thesis, several aspects of the membrane bound LHRH
receptor have been investigated using ligand binding techniques.
Initial studies on analogue binding have been used to validate the
binding assay used. A possible involvement of potassium channels
and G-proteins in mediating gonadotrophe responses to LHRH binding
and the interaction between the receptor and second messenger has
been investigated. Extrapituitary binding of LHRH in hippocampal
tissue was examined along with the binding of a fragment of GAP (GAP
27-41, prepared by Dr. C.M. Bladon for use in immunological studies
and kindly made available for these experiments). In particular the
possibility that GAP may be binding to LHRH receptors was
investigated. Finally, as the number of high affinity, specific
LHRH receptors found in rat anterior pituitary tissue is low,
206fmol/mg protein (Conne, Aubert and Sizonenko, 1979) or about
90fmol per gland, anterior pituitary tissue from other species have
been examined as a potential source of larger quantities of the
receptor protein.
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3.2 Materials and Methods
3.2.1 Materi al s
Buserelin ([D-Ser (Bu^)® des Gly^]-LHRH-ethyl amide) was a
generous gift from Hoechst A.G. (Frankfurt, F.R.G.). LHRH and its
analogues [des pGlu^j-LHRH and [D-pGlu^",D-Phe2,
q
D-Trp ' ]—LHRH were obtained from Sigma Chemical Company Ltd
(Dorset, England) 4-AP., (4-aminopyridine) and 3,4-DAP
(3,4-diaminopyridine) were also from Sigma, as were GTPyS (guanosine
5'-0-(3-thiotriphosphate)), ATP (adenosine triphosphate), EGTA
(ethylene glycol bis (B-aminoethylether)N,N,N',N'-tetraacetic acid),
EDTA (ethylenediaminetetraacetic acid), diamide and dithiothreitol
(DTT). The LHRH antagonist ([DpGlu1,DPhe2,DTrp3'6,desGly10]
-LHRH-ethylamide) and the GAP (27-41) fragment (gonadotropin-
associated peptide, H-Cys-Thr-Thr-Hi s-Glu-Pro-Arg-Ser-Pro-Lev-Arg-
Asp-Lev-Lys-Gly-OH) were synthesised by Dr C M Bladon (MRC Brain
Metabolism Unit, Edinburgh).
3.2.2 Methods
3.2.2.1 LHRH analogue binding to rat anterior pituitary membrane
preparations.
Details of the rat anterior pituitary dissection and equilibrium
binding assay are given in Chapter 2 (2.2 and 2.4). Briefly male
Wistar rats(200-250g) were stunned, decapitated and their anterior
pituitary glands rapidly removed. These were placed in 100 volumes
ice-cold 25mM Tris-HCl pH 7.4 and sonicated, followed by
centrifugation at 60,000g for 15 minutes at 4°C. The washed
membranes were then resuspended into 20 volumes of 25mM Tris-HCl
pH 7.4, 0.1% bovine serum albumin (Tris/BSA).
Assays were carried out in a total volume of 500yl containing
-75-
1 ? 5
10-60pg protein, ~ 50,000 cpm (approx 25pM) I-buserelin
(iodinated by the chloramine-T method, see Chapter 2.3 for details)
and LHRH analogues as appropriate in Tris/BSA. Non-specific binding
was determined in the presence of lyM LHRH. Incubation for 90
minutes at 4°C was followed by PEG precipitation (Chapter 2.4.1.3).
The resultant pellet containing bound ligand was counted.
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Displacement of specific I-buserelin binding by LHRH and
buserelin (agonists), [des pGlu^]-LHRH (partial agonist) and
[D-pGlu\D-Phe2,D-Trp^'6]-LHRH (antagonist) was determined.
3.2.2.2 Effect on LHRH receptor affinity of K+ channel manipulation
To determine whether or not the LHRH receptor interacted with
potassium channels directly, the effect of K+ ions and several
blockers of K+ channels on the affinity of the LHRH receptor for
buserelin was investigated.
Any close relationship between the LHRH receptor and K+
channels may possibly be revealed by a change in the affinity state
of the receptor in the presence of high concentrations of K+
ions. Hazum (1981(a)) showed that for female rat anterior pituitary
tissue, K+ ion concentrations (> 50mM) reduced agonist specific
binding whilst the effect on antagonist binding was much less. This
suggests that there may be an allosteric interaction between K+
channels and LHRH receptors. As such the affinity of the agonist
125
buserelin was here determined by displacement of I-buserelin as
described above (3.2.2.1) but with the addition of a high
concentration of K+ ions to the assay buffer. The assay was
carried out in triplicate or presence of various concentrations of
either 4-AP or 3,4-DAP.
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3.2.2.3 The effect of guanine nucleotides on LHRH receptor affinity
In order to try and reveal an effect on LHRH agonist binding
affinity by activation of G-proteins;the binding of LHRH analogues
in the absence and presence of a guanine nucleotide analogue, GTPyS,
was investigated. An effect might be expected if the LHRH receptor
and a G-protein are in close association, as was suggested by the
inhibition of guanine nucleotide-stimulated LH release by an LHRH
antagonist (Andrews, Staley, Huckle and Conn, 1986). Receptors
linked to adenylate cyclase via a G-protein show just such a
modulation of agonist affinity by guanine nucleotides (Blume 1978;
Glossman and Presek, 1979; Tsai and Lefkowitz, 1979; Shane, Gammon
and Bilzeikian, 1981) and conditions revealing this interaction have
been used to try to reveal it in the case of the LHRH receptor.
Consistently,experiments to show guanine nucleotide effects on
binding affinity to different receptors have been carried out at
room temperature (Blume, 1978; Tsai and Lefkowitz, 1979) 30°C
(Glossman and Presek, 1979; Hulme, Berrie, Birdsall, Jameson and
Stockton, 1983) or 37°C (Shane, Gammon and Bilzeikian, 1981). This
series of experiments were therefore carried out at room temperature
(typically found to be 25°C). Equilibrium at this temperature has
been shown (Clayton and Catt, 1981) for LHRH analogue binding, to be
reached by 30 minutes, and this was the time course chosen for the
binding assays here. Peptidase inhibitors (soybean trypsin
inhibitor, 50mg/ml; aprotinin, 400KIU/ml) were included in the
Tris/BSA assay buffer to prevent enzymatic degradation of either the
LHRH receptor or peptide analogues. Otherwise the binding assays
125
were carried as described above (3.2.2.1),and free I-buserelin was
125
separated from the membranes and bound I-buserelin by a PEG
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precipitation (2.4.1.3), in the presence or absence of a
nonhydrolysable GTP analogue, GTP-yS. This particular analogue was
chosen as it has been found to be the most potent in the activation
of G-proteins linked to calcium-mobilizing receptors in mast cells
(Gomperts, 1983).
Experiments on the nucleotide effects on adenylate cyclase
2+
linked receptors had shown that Mg (> ImM) was essential for GTP
analogue induced changes in agonist binding affinity (Tsai and
Lefkowitz, 1979; Glossmann and Presek, 1979). Concentrations of
9+
Mg of ImM have been shown to reduce LHRH receptor binding by ~
30% (Marian and Conn, 1980) but have no effect on LHRH-stimulated LH
release. Higher concentrations do also inhibit LHRH-stimulated LH
release (Conn, Marian, McMillian, Stern, Rogers, Hamby, Penna and
2+
Grant 1981). For these reasons ImM Mg was the highest
2+
concentration included in the binding assays. The effect of Mg
on nucleotide actions has been shown to be further enhanced by the
presence of calcium chelators (Glossmann and Presek, 1979), so the
additional effect of ImM EGTA was investigated. The GTP-activated
phospholipid breakdown and LH release were only seen in gonadotrophs
permeabi1ized with ATP (Andrews, Staley, Huckle and Conn 1986).
Whilst permeabi1ization is required to give intracellular access to
the GTP analogues, ATP permeabi1ization is thought to be mediated by
a specific receptor peculiar to mast cells, on which the technique
was developed (S. Cockcroft, personal communication to
Dr. R. Mitchell). Therefore the possibility exists that ATP may be
involved in helping to mediate the GTP effect in gonadotrophes. To
test this hypothesis ATP (10yM) was included in one set of binding
assays.
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The susceptibility of muscarinic receptor sites to guanine
nucleotide actions is apparently increased by pretreatment of the
membrane preparation with high concentrations of the
calcium-chelator EDTA (Hulme, Berrie, Birdsall, Jameson and
Stockton, 1983). A similar EDTA pretreatment has been used in some
experiments here. Washed male rat anterior pituitary membranes
were resuspended into 200 volumes of 25mM Tris/HCl pH 7.4 containing
50pg/ml soybean trypsin inhibitor, 400 KlU/ml aprotinin and lOmM
EDTA (Tris/lOmM EDTA). After 15 minutes at 37°C the membranes were
centrifuged (15 minutes at 60,000g, 4°C) and washed once in
Tris/O.lmM EDTA (200 volumes), then resuspended into 60 volumes
Tris/O.lmM EDTA/lmM Mg . Specific I-buserelin binding was
2+
then determined in the presence of O.lmM EDTA/lmM Mg with or
without GTPyS as described above. Parallel controls (membranes
?+
similarly treated in the absence of EDTA and Mg ) were also
assayed.
However, for and e adrenergic receptors, GTP modulation of
affinity has been best demonstrated by changes in full agonist
displacement of labelled antagonist (Tsai and Lefkowitz, 1979; De
Lean, Stadel and Lefkowitz, 1980). The effect of GTPyS on LHRH
125
displacement of an iodinated LHRH-antagonist ( I-LHRH-ant) from
EDTA pretreated membranes was therefore examined. Again binding was
2+
carried out in the EDTA/Mg medium, both with and without GTPyS,
at room temperature for 30 minutes. Various concentrations of LHRH
were added to reveal any shift in its binding affinity as a result
of the inclusion of GTPyS. The LHRH-antagonist was iodinated by the
chloramine-T method (2.3 and Appendix 1).
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3.2.2.4 The effect of sulphydryl group-oxidising (diamide) and
reducing (dithiothreitol, DTT) agents on buserelin binding
to anterior pituitary membranes
Gurwitz, Baron and Sokolovsky (1984) have shown that the
presence of sulphydryl oxidising agents (such as cupric ions or
diamide) abolishesthe sensitivity of muscarinic agonist binding to
guanine nucleotides. Subsequent exposure to a reducing agent (DTT)
was found to restore the guanine nucleotide-sensitivity (in the case
of the diamide treated membranes). They concluded from these
studies that sulphydryls (in a reduced state) are involved in the
G-protein and muscarinic receptor interaction. In the case of the
LHRH receptor Hazum (1981(a)) has shown that,on female rat anterior
pituitary membraneSjDTT has no effect on either agonist or
antagonist specific binding. However, sulphydryl reagents were
found to increase agonist binding but have no effectson antagonist
binding. As it seems likely that the LHRH receptor interacts with a
G-protein (3.1 and 3.2.2.3) the effect of oxidising and reducing
agents (diamide and DTT respectively) have been examined using
membranes from male rat anterior pituitaries.
Washed membranes were resuspended into 50 volumes of 25mM Tris
HC1 pH 7.4 containing either 4mM diamide or lOOmM DTT. After
incubating at 22°C for 30 minutes the membranes were used in a
125
buserelin displacement of I-buserelin binding assay. The
binding assay was carried out as previously described (2.4) at 4°C
125
with ~ 50,000 cpm I-buserelin in a total volume of 500ylsexcept
that either diamide (2.4mM) or DTT (60mM) was present. In some
cases GTPyS was added to see if the specific binding of
125
I-buserelin in the presence of diamide or DTT was affected by
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guanine nucleotides. Non-specific binding was determined in the
presence of lpM LHRH. Parallel controls (membranes similarly
treated but in the absence of either DTT or diamide) were included and
the assay was carried out in triplicate. After 90 minutes at 4°C
125
the unbound and bound I-buserelin were separated by a PEG
precipitation step (2.4.1.3) and the aspirated pellet counted by y
spectrometry.
125
3.2.2.5 I-Buserelin binding to rat hippocampal tissue
Whilst autoradiographic studies have shown specific LHRH binding
sites in the male rat hippocampus which were similar to those in the
anterior pituitary (Reubi and Maurer, 1984; Reubi, Palacios and
Maurer, 1987),no studies have been reported on the characterisation
of these binding sites using conventional ligand binding
125
techniques. Here the binding of I-buserelin to hippocampal
tissue from both male and female rats has been examined.
Electrophysiological and behavioural responses to LHRH in rat
forebrain have been shown to be affected by the hormonal status of
female rats (McCann and Moss, 1975; Moss, 1977; Moss and Dudley,
1978; Moss, 1979). Therefore female rats at different stages of the
oestrous cycle were used in case the hormonal status influenced the
LHRH receptor in hippocampus.
Hippocampal tissue, dissected as in Chapter 2.2 from male or
125
female Wistar rats, was prepared and used in I-buserelin ligand
binding assays as described (Chapter 2.4.1). Total and non-specific
levels of binding were determined.
3.2.2.6 GAP (gonadotropin associated peptide) binding to rat anterior
pituitary and hippocampal tissue
The 56 amino-acid peptide GAP has been suggested to be a
-81-
prolactin-inhibitory factor (Nikolics, Mason, Szonyi, Ramachandran
and Seeburg, 1985). However it was also shown to have a stimulatory
action on LH and FSH release. The site of this action was not fully
elucidated, although it was suggested that the same post-receptor
mechanisms may be utilised by the two peptides. Here we have
of
investigated the binding^a fragment of GAP (GAP(27-41)), both
radioiodinated and unlabelled to rat anterior pituitary and
125
hippocampal membranes. Displacement of specific I-buserelin by
unlabelled GAP (27-41) was examined to determine whether or not LHRH
and GAP (27-41) bind to the same receptor site in either the
anterior pituitary or hippocampus.
125
Binding assays were carried out using I-buserelin or
125
I-GAP(27-41) on rat anterior pituitary and hippocampal
membranes as previously described (3.2.2.1 and 3.2.2.5).
Non-specific binding was determined in the presence of lpM LHRH or
luM GAP (27-41). GAP(27-41) was iodinated by the chloramine-T
method (2.3 and Appendix I).
3.2.2.7 Assay of LHRH receptor binding in anterior pituitary tissue
of other species
Current methods of protein microsequencing (the ultimate goal of
the receptor purification programme) require relatively large
amounts of protein (10-100pmol: Hunkapiller, Strickler and Wilson,
1984). The rat anterior pituitary gland contains only approximately
90fmol of LHRH receptors. A rather more abundant source of
receptors would therefore be desirable. Anterior pituitary glands
from other (larger) animal species have therefore been examined as
possible sources of high affinity LHRH receptors.
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125
3.2.2.7.1 I-Buserelin binding to bovine anterior pituitary LHRH
receptors
As described in Chapter 2.4.2 bovine anterior pituitary tissue
displacement
was used in I-buserel in^by unlabelled buserelin. Incubations
were for 16 hrs. at 4°C. Separation of non-bound label was by
centrifugation for 15 minutes at 1,600 g 6°C and the resultant
pellet was counted after aspiration of the supernatant.
125
3.2.2.7.2 I-Buserelin binding to porcine anterior pituitary
LHRH receptors
Porcine anterior pituitary tissue was prepared as described for
125
bovine (Chapter 2.4.2.). I-buserelin ligand binding assays
were set up as described above for both rat and bovine tissue, with
total binding, non-specific (lyM LHRH) and various concentrations of
unlabelled buserelin (O.OlnM - lOnM). The assays were incubated for
either 90 minutes, 150 minutes or 16 hrs at 4°C. After this the
membranes were centrifuged (15 minutes at 1,600 g, 6°C) to separate
125




3.3.1 Analogue binding to rat anterior pituitary membrane
preparations
i.e.
All four of the LHRH analogues,^native LHRH, buserelin (a
superagonist), [des pGlu^J-LHRH (a partial agonist) and [DpGlu^,
DPhe^, DTrp^'^]-LHRH (an antagonist)>displaced specific
125
I-buserelin binding in a concentration dependent manner
(Fig. 3.1). Analysis of the displacement data by an error weighted
computer programme (Zivin and Waud, 1982; 2.5) revealed their
dissociation
apparent^yalues (Table 3.1; Fig. 3.2). This suggests that the
methods of membrane preparation, peptide iodination and ligand
binding assay used here are valid for the investigation of LHRH
receptor binding characteristics.
3.3.2 Effects of K+ and K+ channel modulators on LHRH
receptor binding.
+ 125
Inclusion of 150mM K in a I-buserelin displacement assay
apparently did not affect the affinity of buserelin for the
LHRH-receptor (Fig.3.3). Total specific binding was 3655 ± 298 cpm
and 3512 ± 128 cpm in the absence or presence of 150mM K+
respectively (58% of total binding being specific in both cases).
Calculated K. values for this experiment were 1.05 ± 0.23nM
(± SEM, n = 3) in control displacements and 1.5 ± 0.6nM (± SEM,
n = 3) in the presence of 150mM K+. Whilst the trend was for a
higher in the presence of 150mM K+ there was no significant
difference in these two values (Mann Whitney U-test). Previous
+ 125
studies, using 50mM K on total I-buserelin binding to male
and female anterior pituitary membranes (Mitchell, Ogier, Johnson,
Cleland, Bennie and Fink, 1986) had shown a reduction of 44 ± 6% of
Figure 3.1




Displacement of specific I-buserelin binding to rat





Each point is the mean ± SEM from 3-10 separate determinations.
Assays were carried out as described (2.4.1.2); non-specific binding
being determined in the presence of lyM LHRH and free
125








[D-pGlu1 ,D-Phe2 ,D-Trp3,<j LHRH
[Des-pGlu ] LHRH
2.20 + 0.72 nM
0.47 +0.14 nM
0.15 + 0.01 nM
1.52 + 0.26 jjyl
Table 3.1
Dissociation constants of LHRH analogues for the rat anterior
1 pc
pituitary membrane preparation. I-Buserelin displacement data
was analysed according to the Eadie-Hofstee method by an
error-weighted programme (see 2.5). Values are given as mean ± SEM
of 3-6 separate determinations.
Figure 3.2
125
Hofstee analysis of LHRH displacement of I-buserelin from
rat anterior pituitary gland membranes. Points are mean values from
four separate determinations. Data was analysed using an
error-weighted programme (see 2.5). K. = 2.2 ± 0.72nM (mean ±






Buserelin displacement of I-buserelin binding from rat
anterior pituitary gland membranes in the absence and presence of
150mM K+. Points are means ± SEM of triplicate samples. Analysis
by an error-weighted programme (see 2.5) revealed values of
1.05 ± 0.23nM for control conditions and 1.5 ± 0.6nM in the presence















total specific binding for male anterior pituitary membranes,
whereas specific binding in membranes from female rats had been
largely unaffected. In a separate study by Hazum (Hazum 1981(a))
concentrations of K+ ions above lOmM were found to reduce specific
125
I-buserelin binding in female anterior membranes. The results
from the present experiments, whilst not confirming the clear
inhibition of LHRH agonist binding by high concentrations of K+
ions, do follow the trend for a reduced affinity under such
conditions.
125
Total specific I-buserelin binding to rat anterior
pituitary membranes was also found to be unaffected by the inclusion
of 0.01 - ImM 3,4-DAP (Fig. 3.4). The channel blocker 4-AP had no
effect on the binding except at the highest concentration used, lOmM.
4-AP has previously been shown to block K+ A-current channels
effectively with an ICgQ of about l-2mM (Thompson, 1977; Yen,
Oxford, Wu and Narahashi, 1976). The 3,4-DAP analogue has been
suggested to be a more selective and potent K+ channel blocker,
with a yM ICgQ (Kirsch and Toshino, 1978). The apparent lack of
effect by the more potent of the two blockers and the inability of
125
4-AP to affect I-buserelin specific binding except at lOmM
concentrations, suggests that the block of A-current K+ channels
does not have any effect on the affinity of the male rat anterior
pituitary LHRH receptor.
3.3.3. Effect of G-protein activation on LHRH receptor affinity.
125
Specific I-buserelin binding to rat anterior pituitary
membranes was not affected by GTP^S (at concentrations in the range
(3-300yM) shown previously to result in polyphosphoinositide
phosphodiesterase activation: Cockcroft and Gomperts, 1985; and
Figure 3.4
125
I-Buserelin binding to rat anterior pituitary gland
membranes in the presence of various concentrations of the K+
A-current channel blockers 4-AP and 3,4-DAP. Points are means ± SEM
of four determinations, non-specific binding was determined in the
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activation of K+ channels linked directly to a G-protein: Sasaki
and Sato, 1987) under any of the three conditions tested. That is:
?+
i) In the presence of ImM Mg (Fig. 3.5(a))
ii) ImM Mg^+ and 20yM ATP (Fig. 3.5(b))
iii) ImM Mg^+ and ImM EGTA (Fig. 3.5.(c))
In view of this lack of effect and since in other receptor
systems G-protein-receptor interactions had been observed (as a
change in agonist affinity) more clearly after pretreatment of the
membrane preparation to EDTA (Hulme, Berrie, Birdsall, Jameson and
Stockton, 1983), the effect of EDTA pretreatment was examined. It
125
was found that total specific I-buserelin binding, whilst
reduced both by the preincubation treatment and the exposure to EDTA
(Fig. 3.6), was not further changed by the presence of 300pM GTPyS.
It is possible that any change in agonist binding affinity by
guanine nucleotides would be revealed more clearly in agonist
displacement of a radiolabeled antagonist rather than agonist.
This has been previously demonstrated in the case of adenylate
cyclase linked receptors and may relate to receptor uncoupling by
high affinity agonist ligands (Tsai and Lefkowitz, 1979; De Lean,
Stadel and Lefkowitz, 1980). This possibi1ity was investigated.
125
LHRH displacement of the I-LHRH-antagonist was affected by
the presence of GTPyS (300yM). The displacement curve was shifted
to the right (Fig. 3.7.(a)), suggesting that the affinity of the
LHRH-receptor for LHRH was reduced (about 10 fold) by the presence
125
of GTPyS. Unfortunately the binding of the I-LHRH antagonist
prepared was only about 10% specific (Fig. 3.7.(b)). The large
amount of background "noise" that this entailed meant that the LHRH
displacement values were not easily calculated. So whilst
Figure 3.5
125
I-Buserelin binding to rat anterior pituitary gland
membranes in the presence of various concentrations of GTP S and
Y
under different conditions. All binding assays were carried out at
25°C in 500vil Tris-HCl 25mM, pH7.4/0.1% BSA/50yg/ml soybean trypsin
apro tinin
inhibitor/400KIUvml, non-specific binding was determined in the
presence of lpM LHRH. All points are means ± SEM of 3-6
determinations.
i or
a) I-buserelin binding in the presence of ImM Mg
IOC p_|_
b) I-buserelin binding in the presence of ImM Mg and
20yM ATP.
1 p c p+
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I-Buserelin binding to rat anterior pituitary gland
membranes at 25°C under control conditions or after a preincubation
(15' at 37°C) either in the absence (control) or presence of lOmM
EDTA, which was then present at a concentration of O.lmM with ImM
2+
Mg during the binding assay. Inclusion of 300pM GTP S had no
125
effect on I-buserelin binding after EDTA preincubation. All
values are mean ± SEM of three determinations, non-specific binding
















a) Displacement of specific I-LHRH Antagonist binding to
rat anterior pituitary gland membranes by LHRH, at 25°C, in the
absence or presence of 300yM GTP^S. Points are mean values of
triplicate samples.
1
b) Total and non-specific binding of I-LHRH Antagonist to
rat anterior pituitary at 25°C. Values are means of triplicate






















indications of the reduced affinity of the LHRH receptor in the
presence of 300wM GTPyS have been observed, reliable values for
125
the LHRH displacement of I-LHRH-antagonist could not be
determined. The results are however consistent with the hypothesis
that the LHRH receptor in male rat anterior pituitary interacts with
a G-protein on activation by LHRH agonists.
3.3.4 The effects of oxidising (diamide) and reducing (DTT) agents
on buserelin binding to anterior pituitary membranes.
125
Assay of buserelin displacement of I-buserelin specific binding
in the presence of 2.6mM diamide on membranes pretreated with 4mM
diamide (concentrations found to be effective in previous studies:
Gurwitz, Baron and Sokolovsky, 1984) showed a small reduction in
total specific binding (89 ± 5% of control values). This was seen
as a reduction in both the total binding value (7177 ± 292 cpm
compared to 8203 ± 178 cpm for controls) and also a small reduction
in non-specific binding (1750 * 16 cpm compared to 2093 ± 72 cpm,
mean ± SEM n = 3 for all values). IC^q values for both controls
and diamide treated membranes were very similar, 0.4mM and 0.5mM
respectively.
Pretreatment of the membrane preparation with DTT resulted in an
125
abolition of virtually all specific I-buserelin binding. Total
binding value using DTT was 746 ± 28 cpm and the non-specific
binding value 644 ± 42 cpm (other conditions were identical to those
in the diamide treated and control membrane assays). This is in
contrast to the results of Hazum (1981(a)) who found DTT had no
125
effect on specific I-buserelin binding. However, the
concentrations of DTT used in that study were lower than those used
here (0.1 and 2mM compared to lOOmM pretreatment and 60mM in the
-95-
binding assay in these experiments). It is possible that the high
concentrations used in this study (concentrations 10 fold higher
than those that had no effect alone but reversed diamide effects on
3
H-acetylcholine binding to muscarinic receptors: Gurwitz, Baron
and Sokolovsky, 1984) have resulted in a denaturing of the LHRH
receptor protein, or buserelin, or both.
The diamide results suggest a slight trend to a lower affinity
of the LHRH receptor than controls. Diamide treatment of cerebral
cortex membranes has been shown to increase specific
3
H-acetylcholine binding and abolish its sensitivity to guanine
1 ?5
nucleotides. Whilst 300yM GTPyS had no effect on I-buserelin
binding to diami de-treated membranes here, no effect on control
membrane binding was seen either. The conditions used for the
binding assay were very different to those that have revealed an
effect on LHRH agonist binding of guanine nucleotides, so this
result is not unexpected.
The results of this study neither confirm or deny conclusively
the involvement of sulphydryl groups in the interaction between the
LHRH receptor and its second messenger system (possibly a G-protein)
maintaining the LHRH-receptors1 high affinity conformation.
125
3.3.5. I-Buserelin binding to rat hippocampal tissue
125
No specific I-buserelin binding could be detected in rat
hippocampal membranes (Fig. 3.8) either in male or female (either
pro-oestrous or met/dioestrous rats). Rat anterior pituitary tissue
125
in the same experiment bound I-buserelin with 58% specificity
(Mean total binding 7667 cpm, mean non-specific binding 3235 cpm).














showed rather higher levels of non-specific binding (mean value of
4446cpm). The amount of tissue (wet weight) used in the hippocampal
binding assay was three times that in the anterior pituitary binding
assay. Therefore a higher level of non-specific binding would be
expected. More tissue had been used in the hippocampal assay as the
autoradiographic study had shown specific LHRH binding sites to be
125
less dense in the hippocampus than the pituitary. I-buserelin
ligand binding in this study has failed to confirm the presence of
specific LHRH receptors in hippocampal tissue.
3.3.6 GAP (27-41) binding to rat anterior pituitary and
hippocampal tissue
In neither anterior pituitary or hippocampal tissue was the
125
peptide GAP (27-41) able to displace specific I-buserelin
binding (Fig. 3.9). This suggests that any specific binding of this
peptide is not to LHRH receptors. This result was confirmed by the
125
inability of 1„M LHRH to displace lc°I-GAP (27-41) from either
125
tissue preparation. I-GAP (27-41) binding was not displaced by
unlabelled GAP (27-41) either. This suggests that specific binding
sites for this peptide (or at least the fragment investigated) are
not found in either male rat anterior pituitary tissue or male or
female (prooestrous) rat hippocampal tissue.
3.3.7 Assay of LHRH receptor binding in anterior pituitary tissue of
other species.
125
3.3.7.1 I-Buserelin binding to bovine anterior pituitary tissue
125
Displacement of I-buserelin by unlabelled buserelin from
bovine anterior pituitary membranes was found to be dose-dependent
(Fig. 3.10). Binding was 22% specific under standard conditions.
Figure 3.9
GAP(27-41) binding to rat hippocampal and anterior pituitary
gland membranes. lpM GAP(27-41) was used to try to displace total
125
I-buserelin binding to these tissues and lyM LHRH and luM
GAP(27-41) to displace *25I-GAP(27-41) total binding to these
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Displacement of I-buserelin binding to bovine anterior
pituitary gland tissue by buserelin and lyM LHRH. Binding assays
were carried out as described (2.4.2) with 50,000cpm
125
I-buserelin and ~2.5mg of tissue in 500yl of 25mM Tris-HCl
pH7.4; 50yg/ml soybean trypsin inhibitor; 400 KlU/ml aprotinin,
reaching binding equilibrium after 16hrs at 4°C. Values are means ±
SEM (n = 4).
-100-
Analysis of the data (Fig. 3.11) revealed a for buserelin of
0.84 ± 0.17 nM (± SEM, n = 3), similar to that seen in rat anterior
pituitary tissue. Tissue (wet weight) equivalent to half a male rat
anterior pituitary gland was used in each assay tube. Average
specific binding for this amount of tissue was 1024cpm, compared to
which was binding by
5025cpm for anterior pituitary tissue,Equivalent to/.a quarter of a
male rat gland (2.4.1). That is the density of specific
125
I-buserelin binding sites in bovine anterior pituitary is
approximately one-tenth of that found in rat anterior pituitary
125
tissue. The calculated total number of specific I-buserelin
binding sites (cpm equivalent) in a bovine anterior pituitary gland
is approximately 350,000 cpm, compared to 20,100 for a rat gland.
125
Despite the reduced density of I-buserelin binding sites,
bovine anterior pituitaries do contain nearly 18 times the number of
195
sites, which have a similar affinity for I-buserelin as the
LHRH receptors found in rat anterior pituitary tissue.
1253.3.7.2 I-Buserelin binding to porcine anterior pituitary
tissue.
125
No specific I-buserelin binding could be detected after 90
minutes incubation with porcine anterior pituitary membranes. After
125
150 minutes, 14% of the total I-buserelin binding was specific
and could be displaced by unlabelled buserelin.in a concentration
dependent manner (Fig. 3.12). 50% displacement occurred at a
-10 -9
concentration of unlabelled buserelin between 10 and 10 M,
giving an IC^q value of approximately 0.4nM. Increasing the
incubation time to 16 hours increased the level of specific
125 anci
I-buserelin binding to 26%,^displacement by unlabelled
buserelin was similar to that seen after 150 minutes with an
Figure3.11
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Buserelin displacement of I-buserelin binding to porcine
anterior pituitary gland tissue. Ligand binding was carried out
125
with 50,000cpm I-buserelin and ~2.5mg tissue in a total volume
of 500jil 25mM Tris-HCl pH7.4; 50yg/ml soybean trypsin ibhibitor; 400
KIU aprotinin; 0.1% BSA with various concentrations of unlabelled
o 125
buserelin. After 150' at 4 C free I-buserelin was separated
from that bound to the tissue preparation by centrifugation (15' at
1,600g, 6°C).
-103-
apparent IC^q value of 0.6nM. The average specific binding (after
an incubation period of 150 minutes) was 570 cpm per (rat anterior
pituitary gland) tissue equivalent. Porcine anterior pituitary
125
glands appear therefore to contain specific I-buserelin binding
sites at only one-fortieth the density of male rat glands. Total
1 pc
I-buserelin specific binding (cpm) expected under these
conditions for a whole porcine gland would be 15,200 cpm, or rather
less than that found in one male rat anterior pituitary gland.
-104-
3.4 Discussion
3.4.1 LHRH analogue binding to LHRH receptors on rat anterior
pituitary membranes
Binding of the analogues to the rat anterior pituitary membranes
125
and displacement of I-buserelin gave values very similar
in all cases (native LHRH, superagonist, antagonist and partial
agonist) to those obtained by other workers (Clayton and Catt,
1980). These results not only validate the techniques used in this
Thesis, but also provide reference values for the affinity of the
LHRH receptor in situ in the rat anterior pituitary membrane
preparation. A series of further experiments to investigate whether
any allosteric influences on these binding characteristics of the
LHRH receptor could be revealed, were undertaken. Any influences
may reflect receptor interactions with its transducing (second
messenger) system (De Lean, Stadel and Lefkowitz, 1980).
Potassium channels have been implicated as being involved in the
transducing system of LHRH receptors (Mitchell, Ogier, Johnson,
Cleland, Bennie and Fink, 1986). In experiments using high K+
concentrations and K+ channel blockers (A-current) no obvious
effect on the LHRH receptor's affinity could be observed. However
the highest concentration of 4-AP (lOmM, far higher than its
published for A-current channels of 1.5mM) did result in a 43%
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reduction in specific I-buserelin binding, and the trend of the
binding affinity in the presence of 150mM K+ was for a reduction.
As well as blocking K+ A-currents, 4-AP has been found to promote
calcium-dependent transmitter release from neurons by a direct
facilitation of calcium entry through voltage sensitive channels
(4-AP at ImM; Rogawski and Barker, 1983). It has also been
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suggested to block calcium activated K+ channels (Zhand and
Krnjevic, 1986) although higher concentrations (above 5mM) are found
to facilitate these channels (Hermann and Gorman, 1981). The
implication from these results is that LHRH receptors do not
interact directly with A-current channels. The role of K+ channel
activation in response to LHRH is not however disproven, since
indirect influences would not be demonstrable in the present
2+
experiments. Previous results had suggested that Ca activated
K+ channels were not involved in LHRH-stimulation of LH release
(Mitchell, Ogier, Johnson, Cleland, Bennie and Fink, 1986).
However, the finding that 4-AP at concentrations higher than those
effective at blocking K+ A-current channels or activating
2+
voltage-sensitive Ca channels, but in the range found to
2+ +
facilitate Ca activated K channels, reduce specific
125
I-buserelin binding (by 43%), might be consistent with
involvement of these channels with the LHRH receptor protein. This
would be in agreement with electrophysiological studies which have
revealed such channels (of the large conductance type, sensitive to
TEA and quinine; Cook, 1988) to be activated by LHRH (Mason,
Bicknell, Cobbett, Waring and Ingram, 1986). Non-specific effects
of high 4-AP concentrations cannot of course be excluded. However,
since the results from electrophysiological and superfusion
experiments are at variance, it would be interesting to investigate
2+ . +
the effect of other Ca activated K channel blockers TEA
(large conductance channel) and apamin (low conductance, voltage
insensitive channel: Cook, 1988), to resolve whether there is really
any direct association between such K+ channels and the LHRH
receptor.
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Some K+ channels have been suggested to be directly activated
by subunits of a G-protein (Pfaffinger, Martin, Hunter, Nathanson
and Hille, 1985; Sasaki and Sato, 1987) in particular the a subunit
of the G-protein (Yatani, Cordina, Brown and Birnbaumer, 1987).
Results of a series of experiments to try to reveal the involvement
of a G-protein in LHRH receptor activation and a consequential
effect of guanine nucleotides on LHRH receptor affinity suggest that
indeed G-protein activation probably results from LHRH agonist
binding to the receptor. However, there is no evidence that the
LHRH activated G-protein interacts with a K+ channel. It appears
that LHRH (Andrews, Staley, Huckle and Conn, 1986) and other calcium
activiting receptors (Gomperts, 1983; Cockcroft and Gomperts, 1985)
interact with a G-protein which in turn stimulates the activity of a
polyphosphoinositide phosphodiesterase. Previous attempts to use
ligand binding techniques to show a guanosine nucleotide effect on
LHRH receptor have not been successful. In order to show it here,
LHRH displacement of an iodinated antagonist from membranes,
pretreated with high concentrations of EDTA, in the presence of EDTA
2+
and Mg at room temperature was required. These were conditions
that have been shown previously to optimise the effects of guanine
nucleotides on receptors linked to adenylate cyclase via a G-protein
(3.2.2.3). The attempt by Hazum (1981(a)) to show an effect of GTP
on LHRH receptor affinity used conditions similar to the normal
binding conditions used for rat membranes in this Thesis, that is
incubation for 90 minutes at 4°C in lOmM Tris-HCl pH 7.4/0.1% BSA.
Similarly, the experiments by Perrin, Haas, Rivier and Vale (1983)
used a binding assay in lOmM Hepes-KOH pH 7.6, 0.2% BSA and 0°C for
120 minutes.
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Whereas the binding of agonists to receptors linked to adenylate
cyclase via a G-protein have been widely reported to be inhibited by
guanosine nucleotides, for example a^-receptors (Glossman and
Presek, 1979; Tsai and Lefkowitz, 1979), g adrenergic receptors
(Shane, Gammon and Bilezikian, 1981), opiate receptors (Blume, 1978)
and muscarinic receptors (Hulme, Berrie, Birdsall, Jameson and
Stockton, 1983), this does not appear to be the case for
calcium-activating receptors, although the evidence does suggest
that they interact with a G-protein (Graziano and Gilman, 1987;
Putney, 1987). The demonstration here of a reduction in affinity of
LHRH in the presence of GTPyS appears to be the first such report
for a receptor linked to polyphosphoinositide phosphodiesterase
activation. A several-fold right shift in the displacement curve
was seen, but the change in affinity could not be accurately
measured. This may have been due to several factors, including the
fact that the binding assay was carried out at room temperature. At
room temperature total specific LHRH receptor binding is greatly
reduced (Clayton and Catt, 1981). Another factor is the very low
specific/non-specific binding ratio seen with the iodinated
antagonist used, a problem not helped by the high temperature used.
Clearer changes in LHRH receptor affinity may be seen if the assay
is repeated using improved LHRH antagonists as.the iodinated
ligand. Highly potent antagonists have been described (Folkers,
Bowers, Shao-bo, Tang and Kubota, 1986) and further antagonist
analogues are being prepared (by Dr. C.M. Bladon) in an attempt to
optimise specific binding and high affinity for the LHRH receptor
site.
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Sulphydryl groups have been implicated in the interaction of
G-proteins and some muscarinic receptors (Gurwitz, Baron and
Sokolovsky, 1984). They have also been found to be important in
conformational transformations of nicotinic acetylcholine receptors
from Torpedo californica, responsible for the appearance of
different affinity states of this receptor (Moore and Raftery, 1979)*
and in the modulation of opiate receptor function (Marzullo and
Hine, 1980). Treatment of rat anterior pituitary membranes with the
sulphydryl oxidising agent diamide resulted in an 11% reduction of
125
specific I-buserelin binding. The effect of diamide on the
GTPyS mediated change in LHRH receptor affinity would be interesting
to investigate, as it might reveal the involvement of disulphide
bonds in the interaction between the LHRH receptor and G-protein.
Use of lower concentrations (l-10mM) of DTT may also be informative.
In summary, these experiments have revealed several aspects of
the LHRH receptor protein. It does not appear to interact directly
with A-current K+ channels, but may possisbly have an effect on
2+ . +
Ca -activated K channels. Overall however, any evidence for
direct association with K+ channels is tenuous. An effect of
GTPyS on the LHRH receptors' affinity for agonists has been shown
under carefully controlled conditions, suggesting that the LHRH
receptor protein may interact with a G-protein.- No conclusive
evidence of a role for sulphydryl residues in either the maintenance
of the LHRH receptor conformation or its interaction with its second
messenger system was found.
3.4.2. Studies on LHRH receptors in rat hippocampal tissue and on the
binding of GAP(27-41) in rat anterior pituitary and
hippocampal tissue
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It had been reported in autoradiography studies that LHRH
1P^ f\ 7
analogues displaced the specific I-[DAla , NctMeLeu , des
Gly^]-LHRH labelling of CAp CA^ and CA^ areas of male rat
hippocampus with the same rank order of potency as their binding
affinities to anterior pituitary tissue (Reubi, Palacios and Maurer,
1987). Whilst there does not appear to be any evidence of a
physiological role for LHRH in the hippocampus,these findings
suggested that it would be interesting to examine the binding of
125
I-buserelin to this tissue. Receptors for LHRH in other brain
areas, in particular the preoptic and mesencephalic grey areas,
appear (from both electrophysiological and behavioural responses) to
have different characteristics to those found in the anterior
pituitary (Moss and Dudley, 1978; Sakuma and Pfaff, 1983). The
discrepancies in localisation of immunoreactive LHRH and LHRH
specific binding sites found between immunohistochemical studies and
autoradiography (Barry, 1979; Moss, 1979; McCann, 1982 and Reubi and
Maurer, 1984) arenot unique. The so-called 'mismatch' of receptors
and neurotransmitter has been observed for other systems in the
brain (Kuhar, 1985). However autoradiography has been suggested to
be a less sensitive technique than immunohistochemistry (Kuhar,
1987) so the inability to find neurons immunoreactive to LHRH in the
hippocampus where autoradiography reveals LHRH -receptors is
puzzling. Barry (1979) has suggested that such discrepancies may be
explained by LHRH reaching its receptors via local vascular systems
or the cerebrospinal fluid. It therefore seemed reasonable to look,
using ligand binding techniques, for LHRH binding sites in rat
hippocampal tissue.
in which no receptors for LHRH were demonstrated in the hippocampus
The results of these studies^do not substantiate the findings of
Reubi and co-workers (1984 and 1987). One possible reason for that
is the different susceptibility of the ligands used in the two
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studies to enzymatic degradation. I-buserelin, containing a
D-amino acid at position 6 and C-terminal alteration to des Gly^
ethylamide, is a degradation-resistant LHRH analogue (Koch, Boram,
Hazum and Fridkin, 1977). However, the analogue used in the
1 p C C ~J
autoradiographical study I—[DAIa , N^MeLeu , des
Gly^]-LHRH ethylamide has been found to be even more resistant to
enzymatic degradation (Koch, Baram, Hazum and Fridkin, 1977). If
the hippocampal tissue preparation has a higher enzyme activity than
anterior pituitary tissue preparations under the binding conditions
used (90 minutes at 4°C, pH 7.4) then degradation of the
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I-buserelin may be responsible for the lack of specific binding
seen. However, the enzymatic activity of the hippocampal
preparation would have to be much higher than that of anterior
pituitary gland tissue, as in this preparation under the binding
conditions used, no significant degradation of LHRH analogues such
as buserelin has been observed (Clayton, Shakespear, Duncan and
Marshall, 1979(b)).
It is also possible that the binding sites detected in
hippocampal tissue are not LHRH receptors, but .receptors for a
related peptide that show some affinity for the LHRH analogues used
in the autoradiography studies. Such a peptide may be GAP. GAP has
been shown to act in a similar manner to LHRH on anterior pituitary
cells to release LH and FSH, but also to inhibit prolactin release
(Nicolics, Mason, Szonyi, Ramachandran and Seeburg, 1985). In order
to investigate the possibility of GAP binding specifically to LHRH
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receptors in the anterior pituitary, or to specific receptors in
hippocampai tissue, the peptide GAP (27-41) was used in ligand
binding assays (Fig 3.13). Unfortunately no specific binding, to
either LHRH receptors or specific GAP receptors could be detected
using this fragment. Subsequent to the present experiments, Milton,
Wormald, Brandt and Millar (1986) have isolated the LH and FSH
releasing activity of the peptide GAP to a fragment consisting of
the amino-acid-residues 4-13. This has been shown to be a
calcium-dependent effect independent of LHRH receptors. No effect
of GAP (4-13) on prolactin release was observed. The binding of
this peptide to brain tissue was not reported, and it would be
interesting to see if any specific binding sites for GAP (4-13)
could be demonstrated either in hippocampus (where no physiological
role for LHRH but specific binding sites have been demonstrated) or
forebrain areas (where LHRH does appear to have a physiological
role, Sakuma and Pfaff, 1983).
3.4.3 Binding affinities and abundance of LHRH receptors in anterior
pituitary glands of other species.
As the rat anterior pituitary gland is only approximately 5mg
(wet weight) of tissue, despite the high density of receptors in
this tissue, the total number per gland is very low, about 90fmol
(3.1). Other anterior pituitary glands have therefore been
investigated as possible sources of larger quantities of high
affinity LHRH receptors. Other pituitary glands were chosen in
preference to other organs, as extrapituitary LHRH receptors (with
the exception of those found in the gonads) have been shown to be
only low affinity binding sites (Reeves, Segiun, Lefebvre, Kelly and





Signal peptide (23 aa) -Gln-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-










(Seeburg and Adelman, 1984)
Figure 3.13
Pre-pro-GnRH showing the amlno-acid sequence of pro-GnRH and the
positions of GnRH and GAP. The fragment GAP(27-41) is delineated.
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yMolar affinity for analogues of LHRH that have nMolar affinities
for the pituitary binding site (Iwashita, Evans and Catt, 1986).
Another possible source of larger quantities of the LHRH receptor
protein are cell lines. Unfortunately no stable cell lines
expressing high affinity specific LHRH receptors exist. MCF-7 cells
do express a low affinity LHRH binding site (Miller, Scott, Morris,
Fraser and Sharpe, 1985) but its relationship to functional LHRH
receptors is unclear.
Of the tissues tested bovine anterior pituitary glands would
appear to be the most suitable source of LHRH receptors in
relatively large numbers. Previously, purified bovine pituitary
plasma membranes have been used in LHRH ligand binding assays
(Clayton, Shakespear and Marshall, 1978; Conne, Aubert and
Sizonenko, 1979). In the present study ligand binding was
successfully shown in a crude membrane fraction of the tissue. The
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affinity of the site for I-buserelin is very similar to that
found in anterior pituitary tissue from male rats (0.84nM compared
to 0.47nM). Calculations suggest that each bovine gland contains an
equivalent number of receptors to 18 male rat glands. Therefore
bovine anterior pituitary tissue was used in subsequent studies in
attempts to isolate large amounts of LHRH receptors, sufficient for
protein microsequencing.
Chapter 4
Solubilisation of the LHRH binding protein
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4.1. Introduction
As the results of Chapter 3 show, membrane bound receptors can
be characterised in situ by ligand binding methods. Extensive
studies with analogues of native ligands can supply information
about the structural requirements of the ligands (Momany, 1976(b))
and pharmacological manipulations may reveal components on the
receptor (or adjacent to it) important in maintaining its
conformation (and therefore its affinity for specific ligands, see
Chapter 3). For example, the reduction in binding of LHRH analogues
seen after treatment of rat pituitary membranes with neuroaminidase
and wheatgerm agglutinin has led to the suggestion that the LHRH
receptor is a glycoprotein, containing sialic acid residues (Hazum,
1982). Comparison of information from such experiments and the
structural requirements of ligands for the receptor site can lead to
an hypothesised model of the ligand binding site (Keinan and Hazum,
1985). These methods however are rather imprecise and can provide
very little detailed information about the structure of the receptor
in terms of its amino-acid sequence and their tertiary (or
3-dimensional) structure. One suggestion that has been put forward
is that the binding site of peptide receptors is encoded by the
complementary DNA to that of its ligands (Bost, Smith and Blalock,
1985). Antibodies to peptides derived from RNA complementary to
LHRH mRNA have been shown to bind to gonadotrophes in culture
(Mulchahey, Neill, Dion, Bost and Blalock, 1986) suggesting that
these peptides do resemble a protein found in gonadotrophe cell
membranes. However as peptides derived from complementary DNA
transcribed in either the 5' to 3' or 3' to 5' direction are equally
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as good at binding to their native peptide "ligands (Blalock and
Bost, 1986) it seems most likely that this is a fortuitous,
non-specific finding. In fact studies by Ramussen and Hesch (1987)
have shown that random sequences of amino-acids are just as good as
"complementary-peptides" at providing possible binding sites for the
native peptides. In the ultimate test of the hypothesis, cloning of
the receptor for the peptide substance K, was unable to reveal the
binding site predicted from the complementary DNA to the ligand
(Hanley and Jackson, 1987).
More information about the structure of the receptor molecule
can be obtained by characterising it as a molecular entity, isolated
from its membrane environment. This can be achieved on two levels:-
1. its physical characteristics, such as its molecular weight, the
number of subunits making up the receptor complex etc. These
are aspects of its secondary and tertiary structure.
2. Its primary structure, that is the sequence of amino-acids that
make up the receptor protein (its molecular characteristics).
The essential initial step for physical characterisation and the
common route in determining molecular characteristics (Strosberg,
1987) is the removal of the receptor from its membrane environment.
Ideally the method used to remove the receptor from the membrane
would be non-denaturing, so that the unique characteristics (such as
specific ligand binding) can still be used to identify the receptor
protein.
Membrane proteins, such as receptors, have been recognised as
containing both hydrophilic and hydrophobic regions. This has led
to the hypothesis that they are positioned (partly) within the
membrane lipid bilayer (ie they are integral membrane proteins), and
-116-
that the hydrophilic regions on the surface of the bilayer can
interact with other components of the aqueous phase, such as
adjacent proteins and lipid head groups (Lenard and Singer, 1966;
Wallach and Zahler, 1966). Disruption of the lipid matrix is
therefore required to dissociate the receptor protein from the
membrane. Several approaches have been described. One is the use
of organic solvents (Boyan and Clement-Cornier, 1984). This method
however has been found to extract complexes of membrane proteins and
phospholipids (Boyan and Clement-Cornier, 1984) and tends to result
in some degree of protein denaturation. As such, the method has
been suggested to be useful where the retention of a membrane
protein's biological activity is not required (Van Renswoude and
Kempf, 1984). A more widely used method of extraction for integral
membrane proteins is detergent solubi1isation (Helenius and Simons,
1975).
Detergents, being amphiphilic, are able to disrupt the
hydrophobic interactions between the membrane phospholipids around
the protein and so remove it from the membrane and into solution.
In order to maintain the protein in an active form,the detergent
should simulate its membrane environment but not interfere with the
molecular interactions maintaining the protein's tertiary
structure. Many different detergents have been used in membrane
protein solubilisation. Ionic detergents such as sodium dodecyl
sulphate have been found to bind extensively to proteins tending to
denature them (Reynolds and Tanford, 1970). Other classes (such as
detergents
the nonionic/, the bile salts and their derivatives) have generally
less deleterious effects on a protein's tertiary structure, but
their solubilising ability is often lower (Helenius and Simons,
1975).
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The way in which detergents act to solubilise cell membranes has
previously been investigated using the detergent Triton X-100 and
the Semliki Forest virus (Helenius and Soderlund, 1973). It was
found that at very low concentrations the Triton X-100 molecules
appear to become incorporated into the membrane, binding to it and
resulting in a reduction of its density. This occurs well below its
critical micellar concentration (cmc, the concentration above which
detergent molecules aggregate in an ordered manner to form micelles)
suggesting that it was the detergent monomer that was binding rather
than micelles. Increasing the detergent concentration results in
the disruption of the virus membrane, and this is apparently
enhanced by further increases in the detergent concentration,
resulting eventually in a disintegration of the membranes into
protein:lipid:detergent complexes. Finally by further increasing
the detergent concentration^homogeneous protein:detergent and
1ipidrdetergent complexes are said to be formed. All these stages
(appearing as a continuum with increasing detergent concentration)
have been observed whilst the free Triton X-100 concentration is
below the its cmc. The suggestion therefore was that micelles do
not play an important role in membrane protein solubi1isation.
Tanford (1972) has shown by both theoretical and experimental means
that as long as the change in negative free energy was greater for
the binding of amphipathic molecules (in that case alkylsulphates
and sulphonates) to proteins and membranes than for forming
micelles, then micelles were unlikely to be formed. Again the role
of micelle formation as a prerequisite for detergent solubilization
of membrane proteins was questioned.
Lipophilic proteins - such as membrane proteins - have been
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shown on delipidation to bind large quantities of detergent (Simons,
Helenius and Garoff, 1973; Meunier, Olsen and Changeux, 1972), up to
60% of the protein's weight. In the case of cytochrome bg (an
integral protein of mitochondrial membranes) detergent binding is
highly cooperative at detergent concentrations near their cmc
(Robinson, Nozaki and Tanford, 1974). No detergent however, appears
to bind to the hydrophilic domain of the protein which has been said
to be conformationally unchanged by the presence of the detergent
(Robinson, Nozaki and Tanford, 1974). It was suggested that the
lipophilic region of the protein acts as non-specific nucleus for
the formation of a micelle-like complex of detergent molecules
(Helenius and Simons, 1975). This may act to protect the lipophilic
region of the protein from the ionic forces of the aqueous
solution. Solubilisation of membrane proteins by mild detergents
would appear from these results to occur by a process whereby the
detergent molecules, first become incorporated into the lipid
membrane. The lipophilic portion of an integral protein may act as
a nucleus for the binding of detergent molecules resulting
eventually in its release into solution. Finding a detergent that
will solubilise a particular protein without denaturing it may be
difficult to predict as it would appear to be dependent on the (as
yet unknown) physicochemical properties of that, protein.
The leading detergents currently in use for receptor
solubilisation are synthetic and often derived from natural
compounds. One such series is the sulphobetaine derivatives of the
bile salts -sodium cholate and sodium deoxycholate (Hjelmeland,
Nebert and Osborne, 1983). These have been designed specifically
for non-denaturing solubilisation of membrane constituents. One of
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these, 3-((3-cholamidopropyl)-dimethylammino)-l-propanesulphonate
(CHAPS) has previously been used in studies of LHRH-receptor
solubilisation. Generally however, only low yields have been
achieved, for example 8% of available sites from bovine pituitaries
(Perrin, Haas, Rivier and Vale, 1983) and 20% from rat ovaries
(Capponi, Aubert and Clayton, 1984).
Increasing the ionic strength of a deoxycholate solution has
previously been shown to increase the efficiency of protein
solubilisation (Meissner, Connor and Fleischer, 1973). Similar
results were seen using the related detergent cholate (Carson, 1982;
Hall, Frankham and Strange, 1983; Hooper, 1986) in the
solubilisation of bovine striatum dopamine receptor. As a
cholate derivative, a CHAPS solution of high ionic strength might
also be expected to give higher yields of membrane protein
solubilisation. Alone, CHAPS has been found to solubilise either no
receptors (Wheatley, Hall, Frankham and Strange, 1984) or only
a small proportion (14%) of available receptors (Hooper,
1986). The addition of NaCl to a concentration of 0.72M increased
the solubilisation yield to 26% (Kuno, Saijoh and Tanaka, 1983), or
in the case of 1.5M NaCl to 47% (Hooper, 1986). Results from
studies on the solubilisation of rat brain serotonin S£ receptor
also show a dramatic increase in the amount of
receptor protein solubilised on addition of high NaCl concentrations
(1-1.5M NaCl; Wouters, van Dun, Leysen and Laduron, 1985). In all
cases CHAPS has been used at or about its cmc, 8mM (Hjelmeland,
Nebert and Osborne, 1983). In fact Womack, Kendall and MacDonald,
(1983) have suggested that for maximum solubilisation with minimum
damage to proteins (the aim of most receptor protein solubilisation
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studies) all detergents should be used at concentrations equal to or
slightly below their cmc values. Increasing the concentration of
CHAPS much above its cmc has not been shown to increase yields and
apparently may even decrease them (Hooper, 1986; Perrin, Haas,
Rivier and Vale, 1983; Winiger, Birabeau, Lang, Capponi, Sizonenko
and Aubert, 1983; Hjelmeland and Chramback, 1984).
Once solubilised, some receptor proteins have been found to
rapidly loose their binding activity, for example FSH receptors
(Dias, Huston and Reichert, 1981)?gonadotrophin (LH/hCG) receptors
(Ascoli, 1983) and TSH receptors (Iida, Amin and Ingbar, 1987). The
presence of 30% glycerol during solubi1isation (Dias, Huston and
Reichert, 1981; Ascoli, 1983) or 40-50% either during or immediately
after solubi 1 isation (Iida, Amin and Ingbar, 1987) appears to retain
the binding activity of the solubilised preparation, so enabling
further characterisation of the receptors. Hazum, Schwartz, Waksman
and Keinan, (1986) have used a protocol that includes the addition
of 10% glycerol to a preparation of solubilised LHRH receptors
before attempting to purify them. Although there does not appear to
be any direct evidence that this stabilises or improves the binding
activity of the solubilised LHRH receptors,this possibility does
exist.
In all the studies described above, and most other attempts to
solubilise receptor proteins, the solubilised membrane components
have been separated from the remaining unsolubilised portion by
centrifugation. The rigorous definition of criteria for solubilised
material is of major importance in such studies. Razin (1972) has
suggested three criteria to use in the definition of solubilised
membrane components:
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1) Solubilised material is not sedimentable after 1 hr
centrifugation at 100,000g,
2) Solubilised material should not be excluded from the void
volume of a sepharose 4B column.
3) No membranous structures should be detectable under
electron microscopy.
The criterion used in most studies has been the centrifugation
one. Some caution may be required when only this one criterion is
used as it is said to be dependent on both the temperature and
density of the solution (Hjelmeland and Chramback, 1984).
The series of experiments described here have been carried out
in order to try and optimise the solubilisation of LHRH receptors
from rat anterior pituitaries. Initial experiments have been
carried out using CHAPS, as this has previously been shown to
successfully solubilised LHRH receptors (Perrin, Haas, Rivier and
Vale, 1983; Capponi, Aubert and Clayton, 1984; Hazum, Schwartz,
Waksman and Keinan, 1986). Other detergents have also been tried,
as well as various additions to the solubilisation solution which
have been reported to improve receptor solubi1isation or stability
in solution. In all cases the ability not only to solubilise the
LHRH receptor protein but also to retain its affinity for LHRH
analogues has been determined. The aim was not only to optimise
solubilisation yields but to also find conditions under which the
LHRH receptor was held in solution and retained affinity for its
specific ligands.
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4.2. Materials and Methods
4.2.1. Materials
Digitonin, sodium deoxycholate, polyoxyethylene sorbitan
mono-oleate (Tween 80), (iso-octyl phenoxy)deca-ethoxyethanol
(Triton X-100) and CHAPS were purchased from Sigma Chemical Co Ltd,
Poole, as were the peptidase inhibitors aprotinin and soybean
trypsin inhibitor. Other detergents were obtained from the
following sources:
N,N,-di-(propylamido(2,3,4,5,6-pentahydroxyhexanoyl)) cholamide
(deoxyBIGCHAP; Pierce Chemical Co., Chester,), nonanoyl-N-
methylglucamide (MEGA-9; Cambridge Research Biochemicals,
Cambridge), (N-dodecyl)-sulphobetaine (Zwittergent 3-12; Calbiochem
Brand Biochemicals, Cambridge) Lauryl maltoside (Boehringer
Mannheim, Lewes.)
4.2.2. Methods
4.2.2.1. General solubilsation method for rat anterior pituitary
membranes.
Rat anterior pituitary membranes were prepared as described
(2.4.1.1.). The washed membranes were resuspended into the
solubi1isation buffer (detergent; ± 1.5M NaC1; soybean trypsin
inhibitor 50pg/ml; aprotinin 400KIU/ml, in 25mM Tris/HCl pH 7.4).
All detergents were used at concentrations approximately equal to
their published critical micellar concentrations and in some cases
at various other concentrations as well. Samples were then agitated
for 90 minutes at 4°C using a Stuart Flask Shaker (speed 5).
Centrifugation for 2 hours at 60,000g at 4°C (MSE Superspeed 65) was
used to remove all non-solubi1ised membrane constituents from those
solubilised. Aliquots (typically 50pl) of the solubilised
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preparation (the supernatant) were then subjected to a PEG
precipitation (2.4.1.3.) after increasing their volume to 500yl with
25mM Tris-HCl, pH 7.4/0/1% BSA (Tris/BSA) and used in
125
I-buserelin binding assays (2.4.1.1.). In some cases the
pellet was also resuspended into Tris/BSA (20 volumes) for ligand
binding. The PEG precipitation step was included for the
solubilised preparation to remove the solubilised proteins from the
detergent solution. Detergent solutions have previously been shown
to inhibit the binding of LHRH analogues to their receptor, (Perrin,
Haas, Rivier and Vale, 1983).
4.2.2.2. Investigation into the effect of glycerol on the
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solubi1isation of I-buserelin binding sites with CHAPS.
As the addition of glycerol to the solubi1isation solution had
been shown to improve the stability of FSH, LH and TSH receptors,
(Dias, Huston and Reichert, 1981; Ascoli, 1983; Iida, Amir and
Ingvar, 1987) the possibility existed that it might also improve the
amount of LHRH binding activity detectable in the solubilised
preparation from rat anterior pituitaries. Inclusion of glycerol in
the solubi1isation step for pancreatic somatostatin receptors was
found to improve the solubilisation yield of receptor complexes
(Zeggari, Viguerie, Susini, Gamier, Esteve and Ribet, 1987). This
possibility has been investigated here for the 1HRH receptor.
Winiger, Birabeau, Lang, Capponi, Sizonenko and Aubert (1983) have
reported a high yielding method of LHRH receptor solubilisation from
bovine anterior pituitaries using a CHAPS solution containing 30%
glycerol, 0.32M sucrose. Solubilisation was determined by
centrifugation for 1 hour at 45,000g, rather slower than the usual
centrifugation criterion for solubilisation (Razin, 1972; Hjelmeland
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and Chrambach, 1984). The viscous solubi1isation solution may have
given rise to artifactual solubilization and this possibility has
been examined here.
Washed rat anterior pituitary membranes were resuspended into
5mM CHAPS with various concentrations of glycerol (0-30%), or the
solubi1isation solution used by Winiger, Birabeau, Lang, Capponi,
Sizonenko and Aubert (1983; lOmM CHAPS, 0.32M sucrose, 30% glycerol,
ImM phenylmethylsulphonyl fluoride (PMSF), 0.01% dimethylsulphoxide
(DMSO), 50yg/ml soybean trypsin inhibitor in 50mM Tris/HCl pH 7.5).
In all cases the membranes were shaken (90' at 4°C, speed 5) and
then centrifuged to separate solubilised from non-solubilised
constituents. As an alternative to 2 hrs at 60,000 g, samples of
membranes solubilised using the 30% glycerol/0.32M sucrose solution
were centrifuged at 45,000g for lhr. Membranes suspended in the 30%
glycerol/0.32M sucrose solution in the absence of lOmM CHAPS were
also centrifuged at 45,000 g for 1 hr.
125
4.2.2.3 I-Buserelin binding to rat anterior pituitary membranes
in the presence of detergent solutions.
The aim of this series of experiments was to not only optimise
solubilisation conditions for LHRH receptors but also to find
conditions under which the solubilised receptor retains its affinity
for LHRH ligands. Previous studies have shown that CHAPS reduces
specific binding of LHRH analogues to solubilised receptors (Perrin,
Haas, Rivier and Vale, 1983). In order to try and find conditions
where the deleterious effects of CHAPS on LHRH analogue binding was
minimal, initial experiments were carried out on rat anterior
pituitary membrane preparations.
Washed membranes resuspended into detergent solutions (CHAPS ±
-125-
125NaC1 ± glycerol) were subjected to I-buserelin binding
(2.4.1.1.) in the presence of these various detergent solutions.
Bound and non-bound ligand were separated by a PEG precipitation
(2.4.1.3.) so that both membrane bound receptors and any solubilised
as a result of the 90 minute incubation with the detergent solution
could be assayed.
125
4.2.2.4. The effect on solubilised I-buserelin binding sites of
reducing the detergent solution concentration after
solubi1isation.
Hazum, Schwartz, Waksman and Keinan (1986) reduced the detergent
concentration and added glycerol to the solubilised preparation
after it has been separated from the non-solubi1ised membrane
constituents. No evidence of what happens to the solubilised
proteins as a result of this strategy was presented. This, and the
following set of experiments were designed to reveal whether or not
reducing the detergent concentration after solubi1isation retains
125
the I-buserelin binding sites in solution. Also the ability of
125
I-buserelin to bind to the solubilised sites in the presence of
the reduced detergent concentration has been investigated. In the
first set of experiments the only change in conditions was to reduce
the detergent solution concentration. In the following set, as well
as reducing the detergent solution concentration, glycerol has been
added to the solubilised preparation.
Aliquots of supernatant from membranes solubilised using 20
volumes of either 5mM CHAPS/1.5M NaCl or 5mM CHAPS alone were
diluted 10 fold with CHAPS or CHAPS/NaCl solutions of various
concentrations.
-126-
Samples from each condition were then either:
1 OC
a) subjected to I buserelin binding in an assay adjusted to
the appropriate CHAPS/NaCl concentration to determine the effect
of the various detergent solution concentrations on specific
125
I-buserelin binding. PEG precipitation was used to
separated bound from non-bound ligand after binding had reached
equi1ibriurn.
b) subjected to a PEG precipitation step followed by a) in the
absence of CHAPS/NaCl. This allowed the total number of
125
specific I-buserelin binding sites to be determined and
125
would reveal any direct effects on the I-buserelin binding
site by the reduction in detergent solution concentration.
c) centrifuged (2 hrs at 60,000g, 4°C) and then subjected to a PEG
precipitation (for the supernatant) or resuspended directly into
Tris/BSA (the pellet) followed by a) in the absence of
CHAPS/NaCl. The proportion of available specific
125
I-buserelin binding sites retained in solution after
reducing the detergent concentration could therefore be
determined (by comparison with the results from (b)).
125
4.2.2.5. The effect on solubilised I-buserelin binding sites of
reducing the detergent concentration and adding glycerol
after solubilisation
Aliquots of supernatant from membranes solubilised with 30
volumes of 5mM CHAPS/1.5M NaCl were diluted 10 fold into a glycerol-
containing Tris-HCl solution (25mM, pH 7.4 containing peptidase
inhibitors as present in the solubilisation solution). Samples were
then treated as above (a,b, or c) except that the CHAPS/NaCl
solution with anappropriate concentration of glycerol was used.
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Whilst these experiments were designed to examine the effect on
125
the solubilised I-buserelin binding site of a protocol
described by Hazum, Schwartz, Waksman and Keinan (1986), small
differences between their methods and those used here do exist. In
case these had a great effect on the result obtained, the protocol
described by Hazum and colleagues (1986) was also followed.
Solubilisation was carried out in 20 volumes of 25mM Tris-HCl
pH 7.4, 5mM CHAPS by shaking for 60 minutes at 4°C. Centrifugation
(1 hr at 100,000 g) was followed by a 5 fold dilution into a
Tris-HCl/glycerol solution, giving final concentrations of 10%
glycerol, ImM CHAPS, ImM PMSF. Aliquots of this solution were then
treated as above (a, b, c).
125
4.2.2.6 The effect on solubilised I-buserelin binding sites of
using other detergents to replace the CHAPS/NaCl solution
after solubilisation.
It has been suggested (Tanford and Reynolds, 1976) that whilst
one detergent solution may be most efficient at solubilising a
particular membrane protein, another may be better able to keep it
in solution in a non-denatured state. This has been investigated
125
for I-buserelin binding sites, solubilised with 5mM CHAPS, 1.5M
NaCl, in an attempt to find conditions under which the sites are
125
both retained in solution and show affinity for I-buserelin.
Anterior pituitary membranes were solubilised in 5mM CHAPS/1.5M
NaCl as above (4.2.2.1). Aliquots subjected to a PEG precipitation
were then resuspended into 25mM Tris-HCl pH 7.4 containing various
detergents (at concentrations approximately equal to their cmc )
with or without 1.5M NaCl (and 50yg/ml soybean trypsin inhibitor and
400 KlU/ml aprotinin). After a further centrifugation (2 hrs at
-128-
60,000 g, 40°C) the pellets and supernatants were separated. After
PEG precipitation of the supernatants or resuspension of the pellets
125
into Tris/BSA, I-buserelin binding assays were carried out.
The proportion of total available (supernatant plus pellet) specific
125
I-buserelin binding sites retained in solution (ie found in the
supernatant) could therefore be determined.
-129-
4.3. Results
In all cases results are expressed ± SEM, with values being the
mean of 3-6 separate determinations except where otherwise stated.
125
4.3.1 Optimisation of conditions for solubilisation of I-
buserelin binding sites from rat anterior pituitaries
4.3.1.1 Determination of optimal NaCI concentrations
The absence of NaCI and detergent from the solubilisation
125
solution resulted in the retention of all specific I-buserelin
binding in the pellet and none being found in the supernatant of the
solubilised preparation (Fig. 4.1). Addition of 5mM CHAPS led to
the appearance of a small amount (19 * 3%) of the specific binding
in the supernatant. This was marginally increased by the addition
of 0.2M or 0.6M NaCI to the 5mM CHAPS. The combination of 5mM
CHAPS/1.5M NaCI however, extracted 73 ± 5% of the specific binding
125
sites for I-buserelin into the supernatant. These results were
obtained using 30 volumes (compared to wet tissue weight) of the
solubilisation solution. The routine method of separating
solubilised from non-solubi1ised membrane constituents was
centrifugation for 2 hrs at 60,000g, 4°C. However, centrifugation
of the anterior pituitary membrane preparation solubilised with 5mM
CHAPS/1.5M NaCI for 1 hr at over 230,000 g, 4°C gave identical
125
results. This confirms that the specific I-buserelin binding
sites seen in the supernatant after 2 hrs at 60,000 g are truly
solubi1ised.
125
4.3.1.2 Determination of I-buserelin binding site
solubilisation by various detergents in the presence or
absence of 1.5M NaCI.
Various detergents (as listed in 4.2.1), in the presence and
Figure 4.1
Effects of increasing concentrations of NaCl on solubi1isation
125
of specific I-buserelin binding sites from rat anterior
pituitary gland membranes. Membranes were solubilised as described
(4.2.2.1) in 30 volumes of solubi1isation solution containing 5mM
CHAPS and various concentrations of NaCl. After separation of
non-solubilised components by centrifugation (2hrs at 60,000g, 4°C)
aliquots of the solubilised supernatant (equivalent to the volume of
suspension for one quarter pituitary gland before solubi1isation)
125
were subjected to a PEG precipitation step before I-buserelin
ligand binding. Non-specific binding was determined in the presence
125
of lyM LHRH. Comparison of specific I-buserelin binding to the
PEG-precipitated solubilised samples with that to equivalent amounts
of membrane tissue (one quarter anterior pituitary gland) gave
125
values for % specific I-buserelin binding solubilised.
125
Specific I-buserelin binding to PEG precipitated, 5mM
CHAPS, 1.5M NaCl-solubi1ised preparation was around 6,000cpm, with












absence of 1.5M NaCI (shown above, 4.3.1.1., to be a concentration
125
of NaCI giving optimal yields of solubilised I-buserelin
binding sites with 5mM CHAPS),were screened for their ability to
solubilise the LHRH receptor in an undenatured form (as indicated by
the ability of the supernatant, after PEG precipitation, to bind
125
I-buserelin). Twenty volumes (compared to wet tissue weight)
of the solubilisation solutions were used. The results are shown in
Table 4.1.
In the absence of 1.5M NaCI, Zwittergent 3-12 and sodium
deoxycholate were as efficient as CHAPS in protein solubilisation
(protein assayed according to the method of Geiger and Bessmann
(1972), detailed in Appendix IV). However, no specific
125
I-buserelin binding was detectable in the supernatant, whilst
that seen in the pellet was much reduced (< 10% of that seen in
control pellets not treated with detergent). This suggests that the
LHRH receptor was being denatured in some way. Similar results of
minimal recovery of functional binding sites and only small fraction
of these being found in the supernatant were obtained using
digitonin, lauryl maltoside (1.8mM), Triton X-100 (1%) and MEGA-9
(5%). Other conditions, 0.18mM lauryl maltoside, 0.16% Triton
X-100, 0.5% MEGA-9, 0.13% and 1.3% Tween-80, appear to result in no
deleterious effects on binding site recovery but little
solubilisation of the LHRH receptor. Only CHAPS produced a marked
solubilisation together with only modest losses in recovery. Whilst
this efficiency of solubilisation was also seen with deoxyBIGCHAP,
125
the recovery of I-buserelin binding sites with this detergent
was further reduced, suggesting it was in some way denaturing them.
The addition of 1.5M NaCI to the detergent solutions was
Table 4.1
Rat anterior pituitary membranes were solubilised as described
(4.2.2.1) in 20 volumes of the solubilisation solution containing
detergent ± NaCl (1.5M) as shown. After centrifugation (2hrs at
60,000g, 4°C) to separate non-solubilised components, the
supernatant was subjected to a PEG precipitation step before
121
determination of I-buserelin specific binding. Values for the
recovery of binding sites are the binding recovered (in the
supernatant plus pellet) as a % of initial membrane binding. All
values are mean ± SEM for 3 separate determinations.
Table4.1
Recoveryofbinding

























































































































































generally seen to cause a small increase in the amount of protein
solubilised (Table 4.1). Percentage recovery of binding sites
(supernatant and pellet combined) was found to be rather less than
corresponding values without NaCl present for most of the
detergents. Prominent reductions in recovery were seen with Triton
X-100 (0.16%), digitonin, sodium deoxycholate and MEGA-9 (0.5%).
These results suggest that, for the majority of the detergents
tested, the presence of 1.5M NaCl increases their denaturing action
125
on the I-buserelin binding site. The efficiency of
solubilisation of this protein was however generally similar to that
of the detergents in the absence of NaCl. Only in the case of CHAPS
did the presence of 1.5M NaCl effect a two- to four-fold increase in
solubilisation of the receptor.
4.3.1.3. Investigatiion of the effects of the detergent: protein
ratio on the efficiency of solubilisation using 5mM CHAPS,
1.5M NaCl
It had been observed in the previous two studies that both the
percentage recovery of binding sites and the percentage of binding
sites solubilised by 5mM CHAPS, 1.5M NaCl were dependent on the
detergent: protein ratio used for solubilisation. Further
investigations varying the amount of solubilisation solution used
per mg of tissue wet weight were carried out. Optimal conditions
for solubi1isation were found at a ratio of 30 volumes solubilising
solution to tissue weight (Fig 4.2). Under these conditions there
was full recovery of binding sites and maximal solubi1isation of
about 70% of these sites. This-corresponds to a detergent: protein
ratio of 1.6 (w/w).
This survey of solubilisation conditions therefore revealed that
-134-
Fiaure 4.2
Volumes of CHAPS/Salt for solubilisation
Figure 4.2
Effect of detergent/protein ratio on receptor recovery and
efficiency of solubilisation: Receptor solubilisation was carried
out as described (4.2.2.1) using CHAPS 5mM, NaCl 1.5M, but at a
varying ratio of volumes of solubilising solution to initial tissue
volume (as indicated). Solubilised and residual sites were again
separated by centrifugation prior to polyethylene glycol
125
precipitation and I-labelled buserelin binding.
■ total recovery of binding (values for supernatant plus
pellet as a percentage of initial membrane binding).
• solubilised binding (values for supernatant as a percentage
of initial membrane binding).
Values are the mean ± SEM for three separate determination.
-135-
125
an optimal yield of solubilised I-buserelin binding sites can
be obtained using the detergent CHAPS at a concentration of 5mM,
with 1.5M NaCl at a ratio of 30 volumes to tissue wet weight. These
conditions result in no apparent denaturing of the binding site and
over 70% solubi1isation.
4.3.2. Investigation into the effect of glycerol on the
125
solubilisation of I-buserelin binding sites with CHAPS
Using a solubi1isation volume of 20, the effect of adding
various concentrations of glycerol to the 5mM CHAPS solution was
investigated. 10% glycerol resulted in a slight increase in the
125
percentage of I-buserelin binding sites solubilised compared to
that found using 5mM CHAPS alone (19 ± 3% to 27 ± 2%: Fig 4.3). The
amount of binding detectable in the solubilised preparation (assayed
in the presence of 5mM CHAPS, 10% glycerol and without a previous
PEG step) was no different from that seen in the absence of glycerol
(22 ± 3% compared to 20 ± 2% of control membrane binding). Both the
amount of protein solubilised and the % binding site recovery were
higher than that for CHAPS alone (66 ± 2% and 66 ± 4% respectively
compared to 53 ± 6% and 46 ± 1% for 5mM CHAPS alone under similar
conditions). These results suggest that whilst 10% glycerol may
125
protect the I-binding site from denaturation by 5mM CHAPS under
the conditions used (20 volumes solubilisation -solution) it does not
increase the solubilisation yield greatly, or enable all the
125
solubilised sites to exhibit specific I-buserelin binding in
the presence of the solubilisation solution.
Increasing the glycerol concentration to 30% resulted in a
further increase in % binding site recovery (77 ± 5%) but had no
125
effect on the amount of I-buserelin binding solubilised, whilst
Figure 4.3
Effects of increasing concentrations of glycerol on
125
solubilisation by 5mM CHAPS of I-buserelin specific binding
sites from rat anterior pituitary gland membranes. Solubi1isation
was carried out as described (4.2.2.1) in 20 volumes of the 5mM
125
CHAPS, glycerol solution. I-Buserelin specific binding was
determined on the supernatant (after centrifugation) both with or
without the inclusion of a PEG precipitation step before the binding
assay. The binding assay in the absence of a PEG precipitation step
was carried out in the presence of 5mM CHAPS and the appropriate
glycerol concentrations. Total recovery of specific binding sites
was assessed from the binding found in supernatant (after a previous
PEG precipitation) plus that in the pellet. Values for protein
solubilised are given as a % of total membrane protein and
















that detectable in the presence of the solubilization solution was
reduced (13 ± 3%). These apparently contradictory results can be
explained by the hypothesis that 30% glycerol acts to protect the
125
membrane bound receptor ( I-buserelin binding site) from any
denaturing influence of the detergent (5mM CHAPS) but seems itself
125
to inhibit specific I-buserelin binding to the solubilised
protein. Unlike the pancreatic somatostatin receptor (Zeggari,
Viguerie, Susini, Gamier, Esteve and Ribet, 1987) the yield of
125
solubilised I-buserelin binding sites was not increased by the
presence of either 10% or 30% glycerol.
Using the 30% glycerol/0.32M sucrose solution described by
Winiger, Birabeau, Lang, Capponi, Sizonenko and Aubert (1983) and
centrifugation at 45,000g for lhr, artifactually high results for
the percentage solubilisation were found. That is, after
solubi1isation in the presence of lOmM CHAPS and the low speed
125
centrifugation, 42 ± 3% of the I-buserelin binding sites were
found in the supernatant. However, centrifugation of an anterior
pituitary membrane for lhr under the same conditions, that is at
45,000g, 4°C in the 0.32M sucrose/30% glycerol but in the absence of
lOmM CHAPS?an apparent solubilisation of 19 ± 2% of control
125
I-buserelin binding sites was seen. These solubilisation
criteria (as used by Winiger, Birabeau, Lang, C.apponi, Sizonenko and
Aubert, 1983) would appear not to be stringent enough. The viscous
solubi1isation medium has been shown here to be able to maintain
small membrane particles in solution in the absence of detergent
treatment. It is unlikely that these are truly solubilised
125
I-buserelin binding sites as no time interval between membrane




4.3.3. I-Buserelin binding to Membranes in the presence of
detergent solutions
125
The addition of 5mM CHAPS to the I-buserelin binding assay
on rat anterior pituitary membranes resulted in a 37 ± 4% reduction
in the specific binding seen. A further dramatic reduction - to
only 31 ± 4% of control membrane specific binding was seen when 0.2M
NaCl was included in the assay. This was not significantly altered
on increasing the NaCl concentration up to 1.5M (Fig 4.4). It would
appear therefore that whilst 5mM CHAPS has a deleterious effect on
125
specific I-buserelin binding, of the two solubi1isation
solution constituents, CHAPS and NaCl, the NaCl has the greatest
125
effect in reducing I-buserelin binding.
When glycerol (10%) alone was included in the binding assay
84 ± 3% control binding to membrane was detectable (Fig 4.5).
Inclusion of an additional 0.5mM CHAPS (one-tenth of the
concentration used in solubilisation) only slightly reduced this
value, but it was decreased to 56 ± 1% of control on increasing the
CHAPS to ImM. Inclusion of an additional 150mM NaCl (again
one-tenth of the concentrations found in the solubilisation
solution) with the 0.5mM CHAPS/10% glycerol greatly decreased the
125
amount of specific I-buserelin binding seen to 29 ± 2% of
control values. In the absence of detergent, 150mM NaCl and 10%
glycerol together resulted in an intermediate reduction of control
specific binding (to 46 ± 1%). Again the greatest deleterious
125
effects on specific I-buserelin binding to the membrane
preparation occur in the presence of NaCl. Glycerol (at 10%) did
125
not appear to improve the specific I-buserelin binding and may

























Effects of the presence of detergent/salt on'the ligand binding
125
assay. % of control membrane specific I-buserelin binding
detectable in the presence of 5mM CHAPS and various concentration of
NaCI. Points are mean ± SEM of four determinations.
Figure 4.5
Effects of detergent/salt on the ligand binding assay in the
presence of glycerol. % of control membrane specific
125
I-buserelin binding detectable in the presence of 10% glycerol
and various CHAPS and NaCl concentrations, as indicated. Values are
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4.3.4. The effect on solubilised I-buserelin binding sites of
reducing the detergent solution concentration after
solubi1isation.
These experiments were carried out in order to try to find
conditions under which the solubilised preparation is maintained in
a solubilised state and also retains its affinity for
125
I-buserelin. In this and the following set of experiments
125
I-buserelin specific binding has been determined both in the
presence of the detergent solution (a) and after its removal by a
PEG precipitation step (b). The binding detectable in the presence
of the detergent solution has therefore been expressed as a
percentage of that seen after its removal. The amount of specific
binding detectable (after a PEG precipitation step) in the
supernatant following a second centrifugation (c) (in the
appropriate detergent solution) has also been assayed. The
expression of this (c) as a percentage of the initial specific
binding found in the initial supernatant PEG precipitate (b),
indicates the degree to which the LHRH receptor is still maintained
in solution under conditions of reduced detergent concentration.
In the presence of 5mM CHAPS alone only 16 ± 0.5% of the total
125
specific I-buserelin binding sites found in the membrane were
125
solubilised. I-buserelin binding in this 5mM CHAPS solution
folloiijing
revealed only 20 ± 2% of these sites (Fig 4.6). However,/(the
reduction of the CHAPS concentration to 1.5mM?the specific binding
sites detectable in the presence of CHAPS were increased to 62 ± 10%,
and to 75 ± 7% on further reducing the CHAPS concentration to 0.5M.
On centrifugation all the CHAPS concentrations retained at least 50%













































Effects of various concentrations of CHAPS and NaCI on specific
125
I-buserelin binding to solubilised rat anterior pituitary
gland. After solubilisation as described (4.2.2.1) in 20 volumes of
5mM CHAPS ( ■ ),of CHAPS 5mM, NaCI 1.5M ( • ), and centrifugation,
125
supernatant samples were assayed for binding of I-buserelin.
Assays were adjusted to the detergent and salt concentrations
indicated and parallel determinations of identical aliquots after
PEG precipitation, were always carried out. The binding detectable
in the presence of CHAPS/NaCl is expressed as percentage of that
detected after removal of CHAPS/NaCl by PEG precipitation. Values

























50 1-5 0-5 CHAPS (mM)
1-5 0-45 0-15 NaCI (M)
Figure 4.7
Ability of reduced CHAPS/NaCl concentrations to retain
solubilised receptors in solution: Receptors were solubilised in 20
volumes of CHAPS 5mM or CHAPS 5mM, NaCI 1.5M solubi1isation solution
as described (4.2.2.1). The supernatant fraction was adjusted to
the CHAPS/NaCl concentration indicated, vortexed, then subjected to
further centrifugation (2hrs at 60,000, 4°C) to pellet any proteins
that had precipitated under the new conditions. The specific
125
I-buserelin binding in PEG precipitates of the supernatant from
such a second centrifugation was determined and expressed as a
percentage of that in PEG precipitates of the first supernatant.
This value indicates what proportion of the sites remain in solution
after reduction of the CHAPS/NaCl concentrations. ( • ) CHAPS/NaCl,
( ■ ) CHAPS alone. Values are mean ± SEM for three separate
determinations.
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Solubilisation in 20 volumes of 5mM CHAPS, 1.5M NaCl resulted in
125
54 ± 1% of the specific I-buserelin binding sites found
originally in the preparation appearing in the supernatant (lower
than the maximum ~70% as the amount of detergent solution used was
20 volumes rather than the ideal 30, see 4.3.1.3). Binding of
l
I-buserelin in the presence of 5mM CHAPS, 1.5M NaCl (Fig 4.6)
revealed only 15 ± 7% of these solubilised binding sites, which was
increased slightly to 22 ± 4% in the presence of 1.5mM CHAPS, 0.45M
NaCl. Further reducing the detergent solution concentration to
0.5mM CHAPS, 0.15M NaCl increased the amount of binding detectable
in the CHAPS/NaCl solution to 50 ± 8%. Centrifugation in the 0.5mM
CHAPS, 0.15M NaCl solution however resulted in all but 9 ± 6% of the
specific binding sites being precipitated (Fig 4.7). That is, in
order to detect appreciable amounts of the solubilised
125
I-buserelin binding sites by specific binding, the
concentration of the CHAPS/NaCl solution has to be reduced to levels
where it is no longer capable of maintaining these proteins in
solution.
125
4.3.5. The effect on solubilised I-buserelin binding sites of
reducing the detergent solution concentration and adding
glycerol after solubi1isation.
In an attempt to create conditions where solubilised receptors
were maintained in solution and able to specifically bind
125
I-buserelin, glycerol was added to the solubilised
preparation. As above the concentration of the detergent solution
was also reduced, to give final concentrations of 30% glycerol,
0.5mM CHAPS, 150mM NaCl. In this case the initial solubilisation



























Specific I-buserelin binding to rat anterior pitutary
membranes solubilised in 30 volumes of 5mM CHAPS, 1.5M NaCI
solubilisation solution. Binding was assayed both in the presence
of 30% glycerol, 0.5mM CHAPS, 150mM NaCI and after a PEG
precipitation step. Subjecting the 5mM CHAPS," 1.5M NaCl-solubi 1 ised
supernatant to a second centrifugation (2hrs at 60,000g) in the 30%
glycerol, 0.5mM CHAPS, 150mM NaCI and subsequently binding to this
second supernatant (after a PEG precipitation step) reveals the
125
amount of specific I-buserelin binding sites retained in
125
solution. Control membrane specific I-buserelin binding was
4930 ± 260cpm. All values are mean ± SEM for three separate
determinations.
-146-
control membrane binding appearing in the supernatant. Whilst 43 ±
2% of the binding in the 30% glycerol, 0.5mM CHAPS, 150mM NaCl
dilution was found in the supernatant after a second high speed
125
centrifugation (c), only 6 ± 1% was detectable by I-buserelin
binding in the presence of the glycerol/CHAPS/NaCl solution
(Fig 4.8). Compared to a similar assay in the presence of 0.5mM
CHAPS, 150mM NaCl alone (4.3.4.) the detectable specific binding had
been greatly reduced by the inclusion of 30% glycerol.
Using the protocol described by Hazum, Schwartz, Waksman and
Keinan (1986), 20 ± 1% of the initial membrane specific binding
appeared in the solubilised preparation. A five fold reduction of
detergent concentration and addition of glycerol to give ImM CHAPS,
10% glycerol resulted in an apparent loss of 19 ± 3% of this
specific binding. That is the amount of specific binding detectable
after a PEG precipitation of the solubilised preparation from the
glycerol/low CHAPS solution was only 81 ± 3% of that found in the
solubilised preparation before adding glycerol and reducing the
CHAPS concentration. 55 ± 6% of this remaining specific binding was
detectable in the presence of ImM CHAPS,10% glycerol (Fig 4.9) and
67 ± 7% of it was retained in solution after a second high speed
centrifugation. This is a higher percentage value for retention in
solution than the previous case, but the lower initial
solubilisation (20 ± 1% of initial membrane specific binding
compared with 75 ± 4%) means that the actual amount of
125
I-buserelin specific binding retained in solution after
reducing the CHAPS concentration and adding glycerol is lower




















Specific I-buserelin binding detectable in rat anterior
pituitary gland preparation solubilised with 20 volumes of 5rrM CHAPS
as described (4.2.2.5) and diluted in Tris-glycerol to give 10%
glycerol, ImM CHAPS, ImM PMSF. Binding was assayed both in the
presence of this ImM CHAPS, 10% glycerol solution and after removal
of the solution by a PEG precipitation step. The amount of specific
125
I-buserelin binding in the initial solubilised supernatant
(detected after a PEG precipitation step) was 905 ± lOcpm. After a
second centrifugation (2hrs at 60,000g) of the solubilised
preparation, this time in the 10% glycerol, ImM CHAPS solution, and
following a PEG precipitation of the second supernatant obtained,
125
the amount of specific I-buserelin binding retained in a
solubilised state in the 10% glycerol, ImM CHAPS solution was
determined. All values are mean ± SEM of six determinations.
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one-eighth of a rat anterior pituitary). The presence of 10%
glycerol did however appear to have a far less deleterious effect on
the specific binding sites than glycerol at a concentration of 30%.
This was similar to the result found on the membrane preparation
where 10% glycerol gave only a slight (~ 16%) reduction in the
125
amount of specific I-buserelin binding detectable.
125
4.3.6. The effect on solubilised I-buserelin binding sites of
using other detergents to replace the CHAPS/NaCl solution
after solubilisation.
Further investigations, to try to find conditions under which
125
the solubilised I-buserelin binding site from rat anterior
125
pituitary membranes both retain their affinity for I-buserelin
and are maintained to a large degree in solution, have been carried
out using a protocol that enables the solubilising detergent
solution to be replaced with another detergent solution.
The detergents chosen for the resuspension in these experiments
were those which gave a high recovery of binding sites in the
initial experiments on detergent solubilisation of rat anterior
pituitary membranes (4.3.1.2, Table 4.1). That is, those that
appeared not to denature the binding site to any great extent.
These included lauryl maltoside (0.18mM) Tween-80 (0.13%) and MEGA-9
1 P^\
(0.5%). The proportion of the solubilised specific I-buserelin
binding sites retained in solution by these detergents (in both the
absence and presence of 1.5M NaCl) was determined.
The initial solubilisation (in 20 volumes of 5mM CHAPS, 1.5M
NaCl) resulted in 62 ± 5% of the initial specific binding of
membrane preparation appearing in the supernatant. After a PEG
precipitation and resuspension into the Tris-HCl, peptidase
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inhibitor solution, 72 ± 12% of this specific binding was still
detectable on assaying the precipitate from a second PEG step. That
is, subjecting the solubilised preparation to the protocol of a PEG
precipitation, resuspension,centrifugation and a second PEG
precipitation appears to result in a loss of 28 ± 12% of the
solubilised specific binding activity(Table 4.2). Recovery from the
detergent resuspensions was found to be either similar or further
reduced. Lauryl maltoside (0.18mM) both with or without 1.5M NaCl
gave approximately 72% recovery; the presence of lauryl maltoside
did not have
either with or without NaCl ^ any further denaturing effect
on the binding sites. However, on subjecting the lauryl maltoside
solutions of CHAPS/NaCl solubilised binding sites to a
centrifugation (2 hours at 60,000g) none of the specific
125
I-buserelin binding could be detected in the supernatant.
There was no apparent retention of the binding sites in solution.
MEGA-9 (5%) alone and Tween-80 (0.13%, with or without 1.5M NaCl)
were also unable to retain the binding sites in solution. MEGA-9
(5%) with 1.5M NaCl resulted in some retention in solution up to 52
± 22%, but this was found to be very variable. Recovery of the
binding sites was also found to be variable, ranging from 45% to 63%




Specific I-buserelin binding found in the supernatant (snt)
or pellet (pit) after resuspension of the PEG precipitate from the
supernatant of a preparation solubilised in 20 volumes of 5mM CHAPS,
125
1.5M NaCl. The specific I-buserelin binding initially
solubilised was 533 ± 46cpm (assayed in an aliquot equivalent to one
tenth of an anterior pituitary gland). All supernatant preparations
were PEG-precipitated prior to ligand binding. Pellet preparations
were resuspended into 25mM Tris-HCl pH7.4/0.1% BSA for binding
assay. Concentrations of detergents used for resuspension were
lauryl maltoside 0.18mM, MEGA-9 5% and Tween-80 0.13%. The snt/plt
ratio indicates the efficiency of "re-solubilisation" for each of
the conditions used for the resuspension step. All values are mean




_ ... 125 ......
Specific l-buserelin binding
(cpm) (+SEM)
resuspenskDn No NaCI 1.5 M NaCI
None
Pit 366 + 86 225 + 65
Snt 58 j- 64 118 j- 77
Lauryl
maltoside
Pit 374 + 63 345 + 82
Snt 49 +93 -6 ±71
MEGA -9
Pit 207 1110 163 +52
Snt -12 +57 249 ± 106
Tween-80
Pit 215 +53 98 +54
Snt -19 ± 70 79 ±49
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4.4 Discussion
The detergent chosen for the first attempts to solubilise the
LHRH-receptor in this study was CHAPS. A synthetic detergent
designed specifically to be of use in membrane biochemistry
(Hjelmeland, Nebert and Osborne, 1983), CHAPS has been used to
successfully solubilise several membrane receptors in previous
studies, including the LHRH receptor, (Perrin, Haas, Rivier and
Vale, 1983; Winiger, Birabeau, Lang, Capponi, Sizonenko and Aubert,
1983; Capponi, Aubert and Clayton, 1984; Capponi, Birabeau and
Vallotton, 1983; Kuno, Saijoh and Tanaka, 1983; Katoh, Djiane and
Kelly, 1985; Wouters, Van Dun, Leysen and Laduron, 1985).
Results, both of these studies and others involving detergent-
solubilisation of membrane protein (Womack, Kendall and MacDonald,
1983), suggested that best yields of non-denatured solubilised
proteins would be achieved using the detergent at or just below its
critical micellar concentration (cmc). Therefore CHAPS was used in
all the experiments at 5mM, just below its reported cmc of 8mM
(Hjelmland, Nebert and Osborne, 1983).
As in previously reported experiments using CHAPS (Wouters, van
Dun, Leysen and Laduron, 1985) and cholate (Hooper, 1986) the
addition of NaCl to the 5mM CHAPS solution was found to dramatically
increase the yield of solubilised receptor. As in the above two
studies, maximum solubilisation was achieved using 1.5M NaCl with
the 5mM CHAPS. This increase in yield was not seen with any of the
other detergents tested (Table 4.1). The other sulphobetaine
derivative tested, deoxyBIGCHAP gave the next best yield for
detergents alone but this was not improved by the inclusion of 1.5M
NaCl. Sodium deoxycholate, although efficient at protein
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solubilisation appeared to have a denaturing effect on the
125
I-buserelin binding site. The other detergent that had been
reported previously as successfully solubilising the LHRH receptor -
Triton X-100 (Jansen de Almeida Catanho, Berault, Theoleyre and
Jutisz, 1983) at 1% was found under our solubilisation conditions to
denature the LHRH receptor without appearing to achieve its
solubilisation.
How was the increase in ionic strength of the detergent (5mM
CHAPS) solution by the addition of 1.5mM NaCl able to improve the
efficiency of membrane protein solubilisation? From the literature
it appears that this high ionic strength may have been having an
effect in two ways:
1) A reduction in the detergent cmc.
2) Interacting with the hydrophilic part of the integral protein.
Ray and Nemethy (1971) showed that for non-ionic detergents,
increasing the salt concentration leads to a linear reduction in the
critical micellar concentration. Similar results were seen with
zwitterionic detergents (Ray and Nemethy, 1971). In terms of
membrane protein solubilisation this may mean that at a given
detergent concentration (below the normal cmc) the protein-detergent
complex is more readily formed in a solution of high ionic strength.
It also has been suggested (Hjelmeland and.Chramback, 1985) that
the external portion of integral proteins may interact (via ionic or
hydrogen bonds ) with the polar heads of the lipids making up the
membrane bilayer. Increasing the ionic concentration of the aqueous
solution containing a membrane preparation may to some extent act to
disrupt these van der Waals interactions and so help in the removal
of the protein from the lipid environment.
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One condition that was found from these experiments to be
important in obtaining maximum yields of LHRH receptors from the
solubilisation procedure was the ratio of detergent:protein.
Optimum conditions were found to occur when 30 volumes (c.f. tissue
weight) of the 5mM CHAPS, 1.5M NaCl solution were used. This
corresponds to an optimal detergentrprotein ratio of 1.6(w/w), very
similar to the value of 2 reported by Hazum, Schwartz, Waksman and
Keinan (1986). Tanford and Reynolds (1976) also suggested that a
detergent:protein ratio of about 2 would reduce the probability of
protein molecules in the detergent solution aggregating and
therefore reduce the probability of artifactual protein-protein
complexes occuring. Regarding the membrane phospholipid component
Womack, Kendall and MacDonald (1983) have suggested that,for
efficient solubi1isation?the detergent concentration should not be
exceeded by the concentration of the lipids.
1 9C
The efficiency of solubilisation of the I-buserelin binding
protein found using the optimal solubilising conditions as
determined in this study (that is 30 volumes of 5rrfl CHAPS, 1.5M NaCl
solubi1isation solution per mg of tissue initial wet weight,
agitating for 90 minutes at 4°C) suggest that the criteria for both
membrane phospholipid and membrane protein solubi1isation have been
fulfilled.
In some cases membrane receptors have been shown to be
stabilised in solution by the presence of > 30% glycerol either in
the solubi1isation solution, or added after solubilisation (Dias,
Huston and Reichert, 1981; Ascoli, 1983; Iida, Amir and Ingbar,
1987). The way in which this occurs has been proposed to be by
enhancing hydrophobic interactions within the solubilised proteins
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possibly resulting in an increased association between adjacent
protein subunits (Timasheff, Lee, Pittz and Tweedy, 1976). In the
125
case of the I-buserelin binding site glycerol (at 10% and 30%)
appears to protect to some extent the membrane bound site from any
denaturing influence of the detergent solution (4.3.2) but was not
found to increase the proportion of binding sites solubilised. The
125
presence of glycerol during I-buserelin binding assays of
either the rat anterior pituitary membrane or solubilised
preparation apparently reduced the amount of specific binding
detectable, this effect being far greater for 30% glycerol than the
lower concentration of 10% tried (4.3.5). These results suggest
that in terms of the retention of the specific affinity of the
125
solubilised I-buserelin binding site no benefit would be gained
by the inclusion of glycerol either in the solubilisation step or
subsequently. This may imply that hydrophobic interactions are not
important in the maintenance of the conformation of the
125
I-buserelin binding sites.
Retention of the high affinity, specific interaction between
125
I-buserelin and the solubilised binding site in the presence of
the solubilising solution was an important factor if affinity
chromatography was to be used for subsequent receptor protein
purification (Chapter 6). In the case of the anterior pituitary
125
membrane preparation, 63% of control specific I-buserelin
binding was detectable in the presence of 5mM CHAPS. Addition of
NaCl (0.2-1.5M) dramatically reduced this to around 30% (4.3.3.1).
That is, NaCl appeared to have a far greater deleterious effect on
125
I-buserelin specific binding than the detergent CHAPS. This
may be due to disruption, by the high ionic strength of the NaCl
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solution, of polar and ionic interactions important in maintaining
125
the active conformation of the I-buserelin binding site.
Experiments to investigate the effect of reducing the concentration
of detergent (CHAPS) and NaCl (when used in the solubilisation step)
after solubilisation were carried out to try to find conditions
125
suitable for both specific I-buserelin binding and the
retention of these binding sites in solution. It was found that
both for CHAPS alone and CHAPS/NaCl, at various reductions of the
solubilisation solution (either 5mM CHAPS or 5mM CHAPS/1.5NaCl)
concentrations, binding was significantly reduced in the presence of
the detergent, compared to that seen after removal of the detergent
by the inclusion of a PEG precipitation step (Fig. 4.6). Whilst the
% of available specific binding seen in the presence of the
detergent solution was consistently higher in the presence of CHAPS
alone, the initial low yield on solubilisation by 5mM CHAPS in the
absence of NaCl means that the actual amounts of specific binding
detected were less than for the equivalent reduced detergent
concentration sample solubilised in CHAPS/NaCl. The effect of the
reduction in concentration of the solubilisation solution on the
125
retention of the I-buserelin binding site in solution can be
seen in Fig. 4.7. For all the conditions it would appear that the
receptor can no longer effectively be held in solution. Again
whilst the % of available sites retained in solution by reduced
concentrations of CHAPS alone were higher than for the equivalent
reduction of CHAPS/NaCl concentrations, the actual numbers of
binding sites still found in the supernatant (in terms of specific
125
cpm of I-buserelin bound) were lower because of the reduced
efficiency of solubilisation. At 0.5rrM CHAPS, 0.15M NaCl (a
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ten-fold reduction of solubi1isation concentrations), where almost
50% of available specific binding sites could be seen in the
presence of the detergent solution, less than 20% of these
125
I-buserelin binding sites were found to remain in the
supernatant. Whilst the addition of 30% glycerol (Fig. 4.8) was
found to improve the retention in solution of the binding sites, it
also resulted in a dramatic reduction (to 6 ± 1% of available sites)
of the binding seen in presence of the detergent solution.
Reductions in the concentration of the solubilisation solution,
with or without the addition of glycerol seem unlikely to create
125
conditions under which the I-buserelin binding protein would be
both maintained in solution and retain its specific affinity for
128
I-buserelin.
The procedure described by Hazum, Schvartz, Waksman and Keinan
(1986) of anterior pituitary membrane solubilisation in 5mM CHAPS
followed by a 5-fold dilution with a glycerol solution to give
concentrations of ImM CHAPS, 10% glycerol for use in an affinity
chromatography method has also been investigated (4.3.5). The
initial solubilisation yields of the LHRH receptor were found to be
low, as expected, only 20 ± 1%. As a result of this the amount of
125
specific I-buserelin binding found to be retained in solution
by the CHAPS/glycerol was equivalent to only 10. ± 1% of the initial
membrane specific binding. Of this 55 ± 6% were detectable in the
presence of the CHAPS/glycerol solution. So in effect only ~5% of
the membrane LHRH receptors were detectable in the ImM CHAPS, 10%
glycerol solution. The protocol described by Hazum, Schwartz,
Waksman and Keinan (1986) would appear therefore to result in only a
125
very small % (~ 5%) of total membrane I-buserelin being
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available for interaction with specific ligands. The yield on
affinity chromatography of the sites might therefore be expected to
be very low.
Although none of the detergents screened for LHRH receptor
solubilisation showed an improvement over the solubilisation yields
obtained using 5mM CHAPS, 1.5M NaCl, some of them resulted in very
little denaturing of the receptor site (Table 4.1). The possibility
of replacing the LHRH receptors solubilised in 5mM CHAPS, 1.5M NaCl
into these non-denaturing detergents so enabling specific
125
I-buserelin binding to occur on the sites whilst solubilised,
125
was therefore investigated. Specific binding of I-buserelin
was monitored both in the supernatant (after a PEG precipitation
step) and the pellet, after the resuspended preparation had been
subjected to a centrifugation at 60,000 g, 4°C for 2 hrs. Controls
in the absence of detergent gave a recovery of ~76% of the
solubilised binding sites (Table 4.2). PEG precipitation had
previously been shown to have no deleterious effects on the binding
of LHRH analogues to either membrane bound or solubilised receptor
sites (2.4.1.3.). The loss in binding activity seen here was
unlikely to be a direct effect of the PEG precipitation, but may be
in part due to this. Another possibility would be the loss of the
binding protein as a result of absorption onto .the assay tubes. If
this was a contributory factor, the inclusion of 0.1% BSA in the
solutions may have reduced this loss. Whilst a small proportion of
these solubilised binding sites did appear in the supernatant (more
in the presence of 1.5M NaCl than without), the actual amounts were
very variable. Lauryl maltoside gave similar recoveries (total
amount of binding detectable in both the pellet and supernatant, 72%
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in the presence or absence of 1.5M NaCl) but none appeared to be
retained in solution. Replacement of the CHAPS/NaCl solubi1isation
solution would not appear to be a successful method for both
125
maintaining the I-buserelin binding site in solution and
125
retaining its specific affinity for I-buserelin.
The aims of experiments carried out in this Chapter had been two
fold:
1. the optimisation of conditions for solubi1isation of the LHRH
receptor.
2. to find conditions suitable for LHRH receptor affinity
chromatography, that is conditions allowing specific, high
affinity binding to the LHRH receptor in a solubilised state.
Throughout these investigations the LHRH receptor has been
125
assayed in terms of specific I-buserelin binding. Successful
solubilisation of this binding site was achieved using 5mM CHAPS and
1.5M NaCl, giving a yield of over 70% under optimal conditions. In
125
order to confirm that this I-buserelin binding site is in fact
the LHRH receptor further studies to characterise the solubilised
site would be required. These are described in Chapter 5.
Molecular characterisation (as described in 4.1) of the LHRH
receptor protein would be the ultimate aim of this study to try to
characterise the LHRH receptor. Solubilisation and purification of
the receptor protein are the initial steps of a strategy that has
been successfully used to characterise several membrane proteins
(Strosberg, 1987). Having optimised solubilisation conditions the
next step for the LHRH receptor protein would therefore be its
purification.
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The general method of choice for receptor purification is
affinity chromatography (Strosberg, 1984). Using an immobilised
ligand specific for the receptor^this method (by relying on unique
characteristics of the receptor protein) is highly selective.
Several receptor types have been purified using this technique,
including the GABA^ (Sigel and Barnard, 1984); muscarinic
acetylcholine receptor (Haga and Haga, 1985); glycine (Pfeiffer,
Graham and Betz, 1982); adrenergic (Homey, Rockson, Countaway
and Egan, 1983) and insulin (Cuatrecasas, 1972). The two criteria
found to be essential for receptor affinity purification are the
retention of the receptor in a solubilised state, together with the
retention of its affinity for the ligand utilised (Strosberg,
1984). Extensive surveying of different conditions has failed to
reveal any under which both criteria are fulfilled for the
125
solubilised I-buserelin binding site. Investigation of the
conditions used by Hazum, Schwartz, Waksman and Keinan (1986)
125
suggest that only approximately 5% of the total I-buserelin
binding sites in anterior pituitary membranes would be available for
affinity chromatography purification step. By examining the effect
of the detergent CHAPS and NaCl on the specific binding of
125
I-buserelin to membrane preparations it would appear that the
inhibition of binding is a direct effect of the-presence of CHAPS
and, to a greater extent, NaCl. This implies that the possibility
that the inhibition of specific binding is due to the removal of
essential elements (such as phospholipids or other proteins) from
the binding site is unlikely. This was further implied by the
finding (along with other groups, see 2.4.1.3) that full specific
binding activity returned after the removal of the CHAPS/NaCl
solution.
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From these results it can be concluded that an alternative
method to direct receptor affinity chromatography, would be
necessary to give an efficient purification of the solubilised
125
I-buserelin binding site. The selection of this method, its
development and application are the subject of Chapter 6.
Chapter 5
Characterisation of the solubilised receptor.
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5.1 Introduction
It has been suggested that integral membrane proteins
solubilised by mild detergents under optimal conditions are very
likely to retain their native confirmation (Tanford and Reynolds,
1986). One way of testing this directly would be to investigate the
spectral properties of the solubilised proteins, as the refractive
index and circular dichronism of proteins aredependent on the
a protein's
relative positions of^ amino-acid side chains (Tanford, Nozaki,
Reynolds and Makino, 1974). However, for detergent solubilised
3 S
proteins this is not always easily interpretabie ^the presence of
the amphipathic detergent molecules around the protein molecule may
mask these spectral changes (Tanford, Nozaki, Reynolds and Makino,
1974). Another way of determining whether a protein's native
conformation has been retained is to test for biological activity
(Tanford and Reynolds, 1976). For many solubilised membrane
receptors, such as the myocardial muscarinic acetylcholine receptor
(Berrie, Birdsall, Hulme, Keen and Stockton, 1984),the angiotensin
II receptor (Sen, Him and Softer, 1983), the atrial natriuretic
receptor (Kuno, Andersen, Kawisaki, Waldman, Chang, Saheki, Lertman,
Nakane and Murand, 1986; Hamade, Rondon, Frohlich and Cole, 1987),
the LH/hCG receptor (Wimalasena, Moore, Wiebe, Abel and Chen, 1985),
the prolactin receptor (Shiu and Friesen, 1974;. Church and Abner,
1982; Rae-Venter and Daod, 1983; Mitani and Dufau, 1986; Sakai, Ike,
Kohomoto and Johke, 1986; Ashkenazi, Mador and Gertler, 1987) and
the vasoactive intestinal peptide (VIP) receptor (Paul and Said,
1987)}this has been assayed for in terms of specific ligand binding,
although ligand activated enzymatic activity (such as the adenylate
cyclase activation by FSH-bound solubilised FSH receptors:
Dattatreyamurty, Figgs and Reichert, 1987) has also been used.
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Whereas in some cases, for example the atrial natriuretic factor
receptor (Kuno, Andresen, Kamisaki, Waldman, Chang, Saheki, Leitman,
Nakane and Murad, 1986; Hamada, Rondon, Frohlich and Cole, 1987) and
the LH/hCG receptor (Wimalasena, Moore, Wiebe, Abel and Chen, 1985)
the binding affinities have been found to be very similar in both
the solubilised and membrane preparations, others have been found to
exhibit specific binding in the solubilised state but of a different
affinity to that seen for the membrane bound receptor, for example
the angiotensin II receptor (Sen, Jim and Softer, 1983) and the
prolactin receptor (Shiu and Friesen, 1974; Rae-Venter and Daod,
1983; Ashkenazi, Madar and Gertler, 1987). In many cases the
susceptibility of high affinity specific binding to external
influences (such as guanine nucleotides; Berry, Birdsall, Hulme,
Keen and Stockton, 1984; Dattatreyamurty, Figgs and Reichert, 1987;
Paul and Said, 1987) has been demonstrated to exist in the
solubilised preparation in a similar manner to that found in the
membrane preparation. It would appear, from the literature, that
the determination of the binding characteristics of a solubilised
membrane receptor provides a convenient method of assaying for the
retention of native conformation. This method would also enable the
Solo jai -ho o~S
identity of thej(receptor site (if similar binding affinities and
profiles could be shown).
Further, physical characterisation of solubilised membrane
proteins has also been achieved. For example the finding that
guanine nucleotides regulate agonist binding to a solubilised
receptor, as found for the myocardial muscarinic acetylcholine
receptor (Berry, Birdsall, Hulme, Keen and Stockton, 1984), the
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cholecystokinin (CCK) receptor (Lambeert, Svoboda, Furnelle and
Christophe, 1985),the FSH receptor (Dattatreyamurty, Figgs and
Reichert, 1987) and the VIP receptor (Paul and Said, 1987),might
suggest that a G-protein and the receptor binding site have been
solubilised as one unit. In the case of the CCK receptor, the
G-proteins N.. (the G-protein coupled to adenylate cyclase
inhibition) and N$ (stimulates adenylate cyclase) have both been
found (after ADP-ribosylation using cholera toxin and pertussis
toxin respectively) to coelute from a gel filtration column with the
solubilised CCK binding sites, suggesting that the receptor exists
as a complex containing the CCK binding site and and N$
(Lambert, Svoboda, Furnelle and Christophe, 1985). Gel filtration
techniques have also been used to reveal the existence of other
receptor complexes. For example, the prolactin binding activity
solubilised from mammary tissue was found to appear in two peaks on
ion-exchange chromatography, the first peak of lower binding
affinity than the second (Sakai, Ike, Kohmoto and Johke, 1986). Gel
filtration in 7.5mM CHAPS of the lower affinity peak revealed an
apparent molecular weight of 37,000 whereas in 5mM CHAPS the
prolactin binding activity eluted as a volume suggesting a molecular
weight of 74,000. This was suggested to reveal the existence, under
condition of low detergent concentration, of either binding subunit
dimers or the existence of a complex between a binding subunit and
another similar molecular weight protein.
The presence of detergent during a gel filtration column
calibration with soluble proteins of known molecular weights has
been shown not to affect the calculated calibration curve (Fish,
Reynolds and Tanford, 1970). This suggests that the technique is
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valid to give estimates of molecular weights of detergent
solubilised proteins (subject to the usual limitations of the
technique, see 2.8). The ability to detect the presence of
solubilised membrane receptor proteins in the eluate from a gel
filtration column by the specific binding of radiolabelled ligands
has led to the wide use of gel filtration techniques to provide
estimates of their apparent molecular weights. For example the
somatostatin (Zeggari, Viguerie, Susini, Gamier, Esteve and Ribet,
1987), VIP (Paul and Said, 1987) and benzodiazepine (Ray, Mernoff,
Saugames-Warah and de Bias 1985) receptors' apparent molecular
weights have been estimated using calibrated gel filtration
columns. Strictly, gel filtration will give an apparent Stokes
radius value, not a molecular weight. The Stokes radius of a
molecule is a manifestation of its overall three-dimensional shape
(Tanford, Nazaki, Reynolds and Makino, 1974). A more accurate
determination of molecular weight requires the use of sedimentation
centrifugation techniques (Tanford, Nazaki, Reynolds and Makino,
1974). In combination with gel filtration techniques, sedimentation
centrifugation has been used to provide estimates of molecular
weight for the GABA/benzodiazepine receptor complex (Stephenson,
Watkins and Olsen, 1982), the platelet vasopressin receptor
(Thiobonnier, 1987),the prolactin receptor (Rae-Venter and Daod,
1983; Haldosen and Gustafsson, 1987),and the muscarinic
acetylcholine receptor from cardiac tissue (Peterson, Rosenbaum,
Broderick and Schimerlik, 1986) and brain tissue (Berrie, Birdsall,
Haga, Haga and Hulme, 1984) amongst others. Unlike gel filtration
however, the sedimentation centrifugation techniques require
relatively pure preparations of the solubilised proteins (Tanford,
Nazaki, Reynolds and Makino, 1974). When only unpurified
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solubilised preparations are avai1 able,the best method of obtaining
an estimate of an apparent molecular weight would appear to be gel
filtration.
For some solubilised membrane receptors, such as that for
insulin (Aiyer, 1983), LH/hCG (Wimalasena, Moore, Wiebe, Abel and
Chen, 1985) prolactin,(from ovarian tissue: Mitani and Fufai, 1986),
VIP (Paul and Said, 1987) and angiotensin II (Laribi, Allard,
Vincent and Simonnet, 1987), gel filtration reveals the existence of
specific binding to more than one molecular species. In these cases
and in some where only one peak of specific binding has been found
on gel filtration (for example the hepatic prolactin receptor:
Yamada and Donner, 1985), SDS PAGE may reveal lower molecular weight
species that make up the undenatured receptor complex. That is, the
polypeptide components of the receptor macromolecule can be
determined. By carrying out the SDS PAGE under both non-reducing
and reducing conditions the presence or absence of disulphide bonds
between the polypeptide components has been shown (with for example
:Mamada and Donner,1985). In the case of the hepatic lactogen receptor
the prolactin receptor ^identical results have been found under both
conditions, suggesting disulphide bonds are not involved in the
tertiary structure of the receptor complex (Haldosen and Gustafsson,
1987). One of the most convenient and widely used methods of
identifying the receptor proteins after SDS PAGE is to pre-label
them covalently with an iodinated ligand (as has been done with
angiotensin II receptors: Laribi, Allard, Vincent and Simonnet,
125
1987). For this reason the analysis of solubilised I-buserelin
binding sites by SDS PAGE was not attempted in this Thesis until a
method of covalently radiolabelling them was achieved (Chapter 6.)
Limited proteolysis is another technique that has been used to
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investigate the gross structure of proteins (Noelken, Nelson,
Buckley and Tanford, 1965; Lowry, Slayter, Weeds and Baker, 1969;
Spatz and Stittmatter, 1971). As in the case of the membrane
protein cytochrome b^, the presence of exposed or unstructured
links between two domains in the proteins tertiary structure can be
revealed (Robinson and Tanford, 1975). However, as for the
sedimentation centrifugation techniques, partial proteolysis appears
to require purified preparations of the solubilised protein. Prior
to developing an efficient purification technique for the
125
solubilised I-buserelin binding protein only crude, unpurified
solubilised preparations are available, making partial proteolysis
investigations unsuitable.
125
From the literature it would appear that the I-buserelin
binding site, solubilised with an optimum yield of 73 ± 5% from rat
anterior pituitary membranes, would be best characterised initially
using ligand binding techniques. This would also enable the
solubilised site to be positively identified as an LHRH receptor.
Further characterisation may be possible using gel filtration
techniques, to give an estimate of the apparent molecular weight of
the solubilised protein.
Unfortunately it was clear that the presence of the CHAPS/NaCl
solution,that uniquely provided high solubi1isation yields,severely
hampers ligand binding to the LHRH receptor site, both in situ in
the membrane preparation and once solubilised (4.3.3. and 4.3.4.).
Precipitation of solubilised proteins by PEG has previously been
shown to have no effect on LHRH binding site characteristics
(Perrin, Haas, Rivier and Vale, 1983; Winiger, Birabeau, Lang,
Capponi, Sizonenko and Aubert, 1983; and 2.4.1.3). So inclusion of
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a PEG precipitation step to remove the CHAPS/NaCl solution from the
solubilised proteins should allow the binding characteristics of the
125
formerly-solubilised I-buserelin binding site to be determined,
confirming whether or not these sites represent undamaged, high
affinity LHRH receptors.
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5.2 Materials and Methods
5.2.1 Materials
LHRH and its analogues [des pGlu^j-LHRH and [DpGlu"'",
O O £
DPhe , DTrp ' ]-LHRH were obtained from Sigma Chemical Company.
Sepharose 6B and high and low molecular weight calibration kits were
from Pharmacia Fine Chemicals.
5.2.2 Methods
5.2.2.1 Characterisation using ligand binding techniques of the
125
solubilised I-buserelin binding protein
Rat anterior pituitaries solubilised as in Chapter 4.2.2.1 using
20 volumes of 1.5M NaCI, 5mM CHAPS (in 25mM Tris-HCl pH 7.4 with
50mg/ml soybean trypsin inhibitor and 400KIU/ml approtinin, 4.2.2.1)
were used. Aliquots (50pl) of the supernatant were first subjected
to a PEG precipitation (Chapter 2,4.1.3) after increasing the volume
to 500y1 using 25mM Tris-HCl pH 7.4/0.1% BSA (Tris/BSA).
The resultant pellets were resuspended using Tris/BSA to a total
125
volume of 500pl containing ~50,000 cpm I-buserelin and
unlabel led LHRH analogue as appropriate. Non-specific binding was
determined in the presence of lyM LHRH (Chapter 2.4.1.2). After
incubation for 90 minutes at 4°C,equi1ibrium had been reached
lor
(Chapter 2.4.1.2) and bound and non-bound I-buserelin were
separated by a second PEG precipitation. Displacement of
125
I-buserelin by LHRH, buserelin (a superagonist), [des
pGlu^J-LHRH (a partial agonist) and [DpGlu^", DPhe^,
o r
DTrp ' ]-LHRH (antagonist) was determined. In all cases binding
datawere analysed according to the Eadie-Hofstee method (Chapter
2.5).
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5.2.2.2 Estimation of the apparent molecular weight of the
125
solubi1ised I-buserelin binding protein by gel
filtration.
SDS-PAGE techniques have been used previously to give estimates
of the molecular weight of an LHRH binding site protein. Values
obtained have been in the range of 60,000 (Hazum, 1981; Jansem de
Almeida Catanho, Berault, Theoleyre and Justisz, 1983; Edne,
Hendricks and Millar, 1985; Iwashita and Catt, 1985). These results
obtained under conditions of protein denaturation, contrast with the
estimate of a molecular weight of 135,000 for in situ LHRH receptors
(Conn and Venter, 1985). The matrix chosen here for gel filtration
125
of the solubilised I-buserelin binding site under mild
detergent conditions was therefore Sepharose 6B, with a molecular
weight fractionation range of 10,000-2,000,000. The column (see
2.7.1 for details) was calibrated using proteins from both the high
and low molecular weight calibration kits, to construct a
calibration curve covering the molecular weight range 13,700 to
235,000 (Fig. 2.9). Before every gel filtration of the solubilised
anterior pituitary preparation,the void volume (V ) of the column
was determined using dextran 2,000 (Pharmacia Fine Chemicals).
The density of the solubilised preparation was first increased
the preparation was
by the addition of sucrose (50mg/ml)>ithen applied to the column
(using a 5ml capacity sample applicator, Pharmacia Ltd). This
facilitated the entry of the sample onto the gel bed as a
well-defined band which would optimise the resolution of the sample
into its different molecular weight constituents. As described in
2.7.1, the sample was eluted using the 5mM CHAPS/1.5M NaCl
solubilisation buffer, at a flow rate of 19.5ml/hr. Fifteen minute
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fractions were collected and samples (1.3ml^subjected to a PEG
precipitation (2.4.1.3). This was scaled up appropriately to a
total volume of 35mls, and after standing on ice for 20 minutes the
precipitated proteins were separated by centrifugation for 30
minutes at 15,000g. Following resuspension into 1.8ml of 25mM
125
Tris-HCl pH 7.4, 300yl aliquots were used in I-buserelin
binding assays (as previously described, 2.4.1). A plot of specific
binding against elution volume enabled the elution volume (Vg) of
the peak(s) of specific binding to be
determined. This in turn could be used to calculate a Kav value -
Kav = Vt - Vo
Vt - Ve
where Vt is the total volumn volume.
The apparent molecular weight of the protein making up the




5.3.1 Analogue Binding to the Solubilised Preparation
125
I-Buserelin binding to the PEG precipitated solubilised
preparation under the conditions described was 52 ± 4% specific
compared to 69 ± 3% for an equivalent amount of rat anterior
pituitary membrane preparation (calculated from initial tissue
weight wet: ± SEM, n = 4 in both cases) and was displaced in a
concentration-dependent manner by all the LHRH-analogues tested
(Fig. 5.1). Hofstee analysis (Fig. 5.2) of the displacement data
dissociation
gave i constants very similar to those found on the anterior
pituitary membrane preparation (Table 5.1). The finding of similar
rank order of analogue affinity and actual values in both the
membrane and solubilised preparations would strongly suggest that
125
the solubilised I-buserelin binding protein represents
solubilised, functional LHRH receptors. This could be confirmed by
showing the same influences of cations and guanine nucleotides on
ligand binding to the solubilised LHRH receptor site as characterise
the in situ receptor (Chapter 3). However optimal solubilisation
requires the presence of 1.5M NaCl (4.3.1). The probability of a
single PEG precipitation step removing all NaCl might be expected to
be relatively low. Therefore the effect on ligand binding by the
addition of other cations could possibly be obscured. In the case
of the effect of guanine nucleotides on agonist binding to the LHRH
receptor in a soluble state, lengthy pretreatments and the presence
2+of Mg ions are required to reveal it in the membrane preparation
(3.3.3). Until improved antagonist radioligands are available (see




























Displacement of specific I-buserelin binding to the 5mM
CHAPS, 1.5M NaCl solubilised rat anterior pituitary gland
preparation by various LHRH analogues. Membranes were solubilised
in 20 volumes of solubilisation solution as described (4.2.2.1) and
the supernatant subjected to a PEG precipitation before ligand
binding. Binding assays were carried out as described (2.4.1.2)
125with 50,000cpm I-buserelin, supernatant aliquots equivalent to
one sixth of an anterior pituitary, and various concentrations of
unlabelled analogue in a total volume of 500pl 25mM Tris-HCl pH7.4,
0.1% BSA. Non-specific binding was determined using lpM LHRH.
( • ) LHRH
( ■ ) Buserelin
( ♦ ) [des-pGlu1]-LHRH
( A ) [DpGlu1,DPhe2,DTrp3,6]-LHRH
Each point is the mean ± SEM of 3-8 separate determinations.
Figure 5.2
Hofstee analysis of LHRH displacement of specific
1 ?5
I-buserelin binding to 5mM CHAPS, 1.5M NaCl-solubi1ised rat
anterior pituitary gland preparation after a PEG precipitation
step. Solubilisation and ligand binding were carried out as
described (4.2.2.1 and 2.4.1.2) and the displacement data analysed
by an error-weighted programme (2.5). = 2.91 ± 0.4nM.
Points are means of three separate determinations.
Figure5.2




















Dissociation constants of LHRH analogues for rat anterior pituitary
gland membranes and solubilised preparations. 125I-Buserel in
displacement data were analysed according to the Eadie-Hofstee method
by an error-weighted programme (2.5). Values are given as mean ±
SEM of 3-6 separate determinations.
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5.3.2 Gel filtration of the solubilised preparation
125
I-Buserelin binding to the PEG precipitated samples of
fractions eluted from the sepharose 6B column revealed a peak of
specific binding in fractions 45-48. This corresponds to an
apparent molecular weight of between 100,000 and 160,000 (Fig.
5.3). Four separate gel elutions (each assayed in duplicate)
consistently revealed the high molecular weight peak of specific
binding. A second much smaller peak was found in fractions 54-56,
corresponding to a molecular weight of 46,000 to 53,000. The
125
specific I-buserelin binding in the peak fractions represented
approximately 35% of the total binding, compared to 52 ± 4% for the
solubilised preparation before applying it to the gel filtration
column. Subjecting a sample of the solubilised preparation to a
large scale PEG precipitation^as described for the column eluate,
125
resulted in less specific I-buserelin binding being found than
after a small scale PEG precipitation (1494 ± 32 cpm compared to
2727 ± 123 cpm: ± SEM, n = 4). This was accompanied by a large
increase in non-specific binding (from 1787 ± 50 to 4108 ± 64),
which could also explain to some extent the lower % specific binding
seen in the eluted peak. Despite this reduction in detectable
specific binding, protein assay (2.10) on the peak tubes revealed an
increase in specific binding activity of seven fold over that in the
membrane preparation. The non-specific binding (and total in the
125
fractions which contained no specific I-buserelin binding) was
not constant for the entire elution. This presumably reflected the
different proteins, eluted according to size, at different volumes
from the column. The absence of specific binding in the void volume
(V ) fulfils another of the solubilisation criteria suggested by
Figure 5.3
Estimation of apparent molecular weight of the solubilised LHRH
receptors using gel chromatography. After solubilisation in 30
volumes of 5mM CHAPS, 1.5M NaCl, the supernatant fraction (with
50mg/ml sucrose added) was loaded onto a Sepharose-6B column using a
sample applicator (SA-5, Pharmacia Ltd). The column was
equilibrated, calibrated and eluted using the CHAPS (5mM)NaCl (1.5M)
solution.
3
The molecular weight standards and their weights (x 10 ) are
as indicated: Vo, Blue Dextran 2000; T 669, thyroglobulin; C 232,
catalase; Aid 158, aldolase; Alb 63, albumin; Ov 43, ovalbumin;
R 13.7, ribonuclease. Fractions of the eluate were PEG precipitated
125
and aliquots used in the I-buserelin binding assay for
duplicate determinations of specific and non-specific binding. The
specific binding in the peak fractions (45-48) represented
125
approximately 35% of total I-buserelin binding. Solubi1isation
of 30 pituitaries gave some 24,000cpm of specific binding in the
peak fraction of eluate, which when corrected for protein values
(assayed for as in 2.10) indicated at least a 7-fold purification of
the receptor over membrane values. The elution profile shows means
























125Razin (1972) and confirms that the I-buserelin binding protein




Displacement of I-buserelin from solubilised receptors by
the four LHRH-analogues (native LHRH, a super-agonist, a partial
agonist and an antagonist) has shown the solubilised receptor
protein to have very similar binding characteristics to that of the
in situ receptor. Any small difference in the calculated binding
constants may be due to the removal of the receptor from its
membrane environment and therefore the removal of the influence of
adjacent membrane constituents. For example, the solubilised and
membrane affinity constants for buserelin displacement of
125
I-buserelin were found to be 0.66 ± 0.3nM and 0.47 ± 0.14nM,and
were
those seen for the antagonist in the two preparations]^.11 ± 0.02nM
and 0.15 ± O.Olnt^respectively. Whilst the differences in affinity
constants seen for the two analogues are not significant,the trend
was for the antagonist to have a higher affinity for the solubilised
LHRH receptor,whereas buserelin (along with LHRH and the partial
agonist [DpGlu^j-LHRH) had a higher affinity for the membrane
preparation. This may indicate that membrane constituents mediating
the response to LHRH agonist binding are no longer present to exert
their influence on agonist affinity in the solubilised preparation.
As antagonist binding should be independent of receptor activation
any influence seen might be expected to smaller, or in some other
way different from that observed for agonists.
Hazum, Garritsen and Keinan (1982) have studied the effect of
membrane lipid hydrolysis on the binding of LHRH analogues to female
rat anterior pituitary membranes. They suggest that the reduction
in affinity observed, apparently more pronounced in the case of
agonists than antagonists, suggestsa role for membrane phospholipids
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in the interaction of LHRH and its receptor. These results are
apparently in agreement with those of this investigation and the
supposition of a role for membrane components in the binding of LHRH
analogues (in particular agonists) to the anterior pituitary LHRH
receptor. However further studies would be required to confirm
these findings. Possibly the re-addition of membrane phospholipids
to the solubilised receptor preparation would reverse the changes in
dissociation constants found . If this were found to be the case,then it
would strongly suggest a direct role for phospholipids in supporting
the LHRH-binding conformation of the receptor. Such experiments may
reveal different effects on adding different phospholipids.
Feasibly, but not necessarily, this may reflect the second messenger
system involved in LHRH receptor activation (e.g. a specific effect
of polyphosphoinositides may suggest the involvement of
phospholipase C activation and inositol trisphosphate production).
It would also be interesting to investigate the role of other
membrane proteins in LHRH receptor binding. For example, as shown
in Chapter 3, activation of G-proteins can exert an influence on
LHRH agonist binding. Addition of purified G-protein subunits to
the solubilised membrane preparation (or if possible purified,
solubilised LHRH receptors) may be found to affect LHRH analogue
binding.
Gel filtration of the solubilised preparation gave an estimate
of apparent molecular weight for the solubilised LHRH receptor of
100,000-160,000, or an approximate Stokes radius of 46 A (Tanford,
Nazaki, Reynolds and Makino, 1974). Determination of the molecular
weight and size by this method relies on a good correlation between
molecular radius and molecular weight (Ackers 1975). This may apply
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to proteins in a denatured state or the globular soluble proteins
used to calibrate the column but solubilised intrinsic membrane
proteins have not been shown to exist as compact globular molecules
(Tanford and Reynolds, 1976). This value must therefore be regarded
only as an estimated apparent molecular weight or size of the
solubilised LHRH receptor.
Despite this caveat the result is in good agreement for that of
the molecular weight of the in situ LHRH receptor (135,000, Conn and
Venter, 1985). The technique used by Conn & Venter to obtain the
estimate of the in situ molecular weight of the LHRH receptor was
radiation inactivation. This method depends on the relationship
between the dose of radiation required to inactivate a macromolecule
or multisubunit macromolecule and its molecular weight^and it has
been suggested that by calibrating the system with proteins of known
molecular weights that of an unknown protein can be found (Lo,
Barnard and Dolly, 1982). As the molecular weight determined is
that of any structure in a compact enough arrangement for
significant energy transfer to occur within all parts of it, the
technique in principle would be expected to detect any functional
complex that exists. The finding of an apparently high molecular
weight LHRH receptor by gel filtration and the binding data (showing
affinities very similar to those found in the membrane preparation)
suggest that the LHRH receptor solubilised by 5mM CHAPS/1.5M NaCl
is in very much the same state as the membrane bound molecule
detected by Conn and Venter (1985). The smaller peak of specific
125
I-buserelin binding eluting from the column at a volume
suggestive of a molecular weight of 46,000 - 53,000 (a Stokes radius
of ~30A (Tanford, Nazaki, Reynolds and Makino, 1974)) is more
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consistent with the molecular weight for LHRH receptors found under
the denaturing conditions of SDS PAGE (Hazum 1982; Jansen de Almeida
Catanho, Berault, Theoleyre and Justisz, 1983; Eidne, Hendricks and
Millar, 1985; Iwashita and Catt, 1985). Whereas an LHRH
immunoblotting technique visualised a single 60K band on SDS PAGE
corresponding to the adrenal cortex LHRH receptor (Eidne, Hendricks
and Millar, 1985),and photolabelled LHRH receptor sites from
placenta revealed a single 53,700 molecular weight band (Iwashita,
Evans and Catt, 1986),pituitary photolabelled LHRH binding sites
have been found (using SDS PAGE) to reveal two molecular weight
components (Iwashita and Catt, 1985) or a single 60,000 component
(Hazum, 1981(b)) Two protein bands (60,000 and 54,000) have also
been specifically photo-labelled with an LHRH agonist in ovarian
granulosa cells (Hazum and Nimrod, 1982). In the rat, the two
components specifically labelled in pituitary tissue appear to have
molecular weights of about 59,000 and 40,000, the larger molecular
weight component possibly being two (one of 63,000 and a smaller one
of 52,000: Iwashita and Catt, 1985). This may suggest that the
apparently high molecular weight species detected in this study
using gel filtration is in fact a dimer of two identical or possibly
non-identical binding subunits. Alternatively it may represent a
single binding subunit in a complex with non-binding protein.
The existence in situ of the LHRH receptor as a dimer could be
construed as consistent with evidence for a role of microaggregation
in LHRH agonist action. Conn, Rogers, Stewart, Niedel and Sheffield
(1982) demonstrated that an LHRH-antagonist could be converted into
an agonist using a divalent antibody, suggesting dimenisation of
LHRH binding sites as a requirement for activation. The solubilised
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preparation used in these gel filtration had not been exposed to
LHRH prior to membrane disruption. Following the agonist-induced
dimerisation hypothesis, therefore, the detection of large receptor
complexes here implied that at least part of the LHRH receptor
population exists normally in the dimerised form.
As mentioned above, an alternative explanation is that the LHRH
receptor has been solubilised as a complex of one binding site
component and other subunit(s) involved in modulation of LHRH
analogue binding or the mediation of the cells response to agonist
binding. The ratio of detergent to membrane protein used here in
the solubilisation step has been suggested to be sufficiently high
to greatly reduce the probability of artifactual protein adhesion
(Tanford and Reynolds, 1976). Any complex of molecules found should
therefore exist due to definite attractive forces. These may
however be disrupted by the major conformational changes associated
with denaturation of the proteins, explaining why a much smaller
apparent molecular weight of the receptor has been consistently
observed in SDS PAGE experiments.
Interestingly many receptor types whose responses are mediated
via a G-protein (Miller, 1988) have been solubilised both as
isolated receptor binding sites and in a complex with a G-protein,
both adenylate cyclase linked complexes (Limbird and Lefkowitz,
1978; Limbird, Gill and Lefkowitz, 1980; Smith and Limbird, 1981;
Kirkpatrick and Caron, 1983; Nissenson, Mann, Winer, Teitelbaum and
Arnaud, 1986; Couvineau, Amiranoff and Laburthe, 1986; Fitzgerald.
Uhing and Exton, 1986; Watanabe, Unegaki and Smith, 1986) and
phosphotidyl inositol linked receptors (Berri, Birdsall, Hulme, Keen
and Stockton, 1984; Bojanic and Fain, 1986). In many cases it was
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necessary to prelabel the membrane preparation with an agonist prior
to solubilisation in order to obtain the receptor-G-protein
complex. Agonists binding to the solubilised complex were then
susceptible to modulation by GTP analogues. The presence of the
G-protein resulted in an increase in apparent molecular weight of
about 100,000. This is similar to the size difference between the
denatured molecular weight of the LHRH receptor found on SDS PAGE
and that found under non-denaturing gel filtration conditions
(approximately 80,000).
Another possible explanation for the apparent high molecular
weight of the LHRH receptor seen here is the binding of detergent
and/or phospholipids to the protein. Binding of mild detergents to
solubilised intrinsic membrane proteins was first shown for
rhodopsin, where 180-200 molecules of digitonin can bind to one
rhodopsin molecule (Hubbard, 1954). Many other membrane proteins
have been shown to bind varying amounts of detergents from 20% of
the apparent molecular weight (Meunier, Olsen and Changeux, 1973;
Rubin and Tzagoloff, 1973) to over 50% (Sargent and Lampen, 1970;
Simons, Helenius and Garoff, 1973). As soluble, globular proteins
such as those used to calibrate the gel filtration column do not
tend to bind mild detergents in a similar way (Tanford and Reynolds
1976) no compensation for this is included in the column
calibration. Fish, Reynolds and Tanford (1970) showed that Kav
values for such soluble proteins are independent of the detergent
present. The binding of some detergents, such as triton X-100, to
the solubilised protein can be seen as a change in the expected
partial specific volume (calculated using centrifugation
sedimentation techniques). This has been done for triton X-405
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solubilised cardiac muscarinic receptors (Peterson, Rosenbaum,
Broderick and Schimerlik, 1986), where the difference between the
calculated partial specific volume and that measured gave an
estimate of l.Ollg of triton X-405 bound per g of receptor. For the
prolactin receptor solubilised from rat hepatic membranes using
triton X-100, 35 molecules of detergent have been estimated to be
bound to every receptor molecule (Rae-Venter and Daod, 1983).
However the partial specific volume of CHAPS is very similar to that
of proteins (0.81 (Hjelmand, Nevert and Osborne, 1983) compared to
0.71-0.76). Binding of CHAPS even in very large amounts would not
be expected to have a detectable effect on the measured partial
specific volume of the solubilised receptor. Therefore the amount
of detergent bound could not be measured using this technique.
Other methods, such as equilibrium dialysis (Steinhardt and
Reynolds, 1969) which require pure protein preparations, are
necessary. Before purification techniques have been developed for
the CHAPS/NaCl solubilised LHRH receptor,the measurement of
detergent binding could not easily be achieved.
The presence of phospholipid in detergent-solubilised membrane
proteins has also been shown (Awasthi, Chuang, Keenan and Crane,
1971; Chareau, Defau and Catt 1974). In these two examples
(cytochrome oxidase and the testis gonadotropin receptor) activity
of the protein is dependent on the presence of the phospholipid. In
some cases phospholipids have to be re-added to solubilised proteins
to restore activity (Cori, Garland and Chang, 1973). In the case of
the LHRH receptor it is possible that removal of the CHAPS/NaCl by
PEG precipitation allows for protein-phospholipid reaggregation in
order to restore binding affinity. However as PEG precipitation
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after gel filtration of the solubilised preparation also results in
a return of binding affinity, this is unlikely as phospholipids are
likely to be separated from proteins by gel filtration (Helenius and
Simons, 1975). The presence of tightly bound phospholipids in the
solubilised LHRH-receptor complex cannot however be ruled out,
although serotonin receptors solubilised by a similar CHAPS/NaCl
solution have been shown to be free of bound phospholipid (Wouters,
van Dun, Leysen and Laduron, 1985).
125 ^as
In conclusion the solubilised I-buserelin binding site^been
shown to have very similar binding characteristics to the in situ
LHRH receptor. This suggests that it is in fact the LHRH receptor
in solution. Estimates of the apparent molecular weight of the
solubilised LHRH receptor by gel filtration are of a major component
at 100-150,000 and a small amount at 46-53,000. Whilst the lower
molecular weight component is in good agreement with the LHRH
receptor molecular weight obtained using SDS PAGE techniques, the
higher is in agreement with estimates of the receptor size made
in situ by radiation inactivation techniques. This high molecular
weight receptor may represent a dimer of identical or non-identical
binding sites, a single binding site associated with accessory or
transducing elements (possibly a G-protein), or a binding site in a
complex with bound detergent and/or phospholipid. Present
techniques do not allow for these alternatives to be distinguished.
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The absence of any specific I-buserelin binding from the void
volume eluate confirms the truly solubilised state of the rat
anterior pituitary LHRH receptor protein.
Chapter 6
Strategies for LHRH receptor purification
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6.1 Introduction
Characterisation of the proteins making up receptor
macromolecules, as mentioned before (4.1) can be achieved at two
levels - characterisation of their secondary and tertiary structure
(that is physical characterisation - such as molecular weight,
subunit composition and so on) and the characterisation of their
primary structure or amino-acid sequence (or molecular
characterisation). The approach used in this Thesis has been
initially to solubilise the receptor protein using a mild detergent
(Chapter 4). Whilst this allows for the characterisation of the
LHRH receptor in the crude solubilised extract by ligand binding and
gel filtration techniques, further more detailed characterisation
requires that the receptor protein is purified. Purification of
solubilised receptor proteins has been a widely used as an initial
step in the strategy for their molecular characterisation
(Strosberg, 1987). Extensive purification is required prior to
attempting the amino-acid sequencing of any protein (Koningsberg and
Steinman, 1977). The more complex the protein, the more crucial the
purity of the sample is for precise sequencing, up to 97% purity has
been a suggested requirement (Koningsbert and Steinman, 1977). For
very large complex proteins such as receptors a common strategy is
to sequence highly purified portions (such as the ami no-terminal or
enzymatic proteolysis fragments) of the whole (Strosberg, 1987).
for
For example,jthe Electrophorus electricus sodium channel (Noda et
al., 1984), growth hormone receptor and serum binding protein
(Leung, Spencer, Cachlenes, Hammonds, Collins, Henzel, Barnard,
Waters and Wood, 1987)?and the dihydropyridine calcium antagonist
-187-
receptor (Tanabe, Takeshima, Mikami, Flockerzi, Takahashi, Kangawa,
Kojima, Matsuo, Hirase and Numa, 1987),primary structures were
determined by cloning and sequencing complementary DNA screened with
oligonucleotides prepared on the basis of partial amino-acid
sequences of the purified proteins.
Since the LHRH receptor (in common with other peptide hormone
receptors) occurs in only low abundance in anterior pituitary tissue
(90fmol per gland in male rat anterior pituitary tissue) a highly
selective method of purification is required. One such method is
affinity chromatography (Strosberg, 1984; Wilchek, Moron and Kohn,
1984). Purification is achieved by the specific interaction of the
protein of interest with immobilised ligands that are highly
selective for the protein. Unrelated proteins are removed by
washing through the affinity column to elute non-bound molecules.
Selective removal of the required protein can be achieved by the
addition of excess free ligand, alternatively by the use of
non-selective means such as the manipulation of pH, temperature or
ionic conditions (Strosberg, 1984; Wilchek, Miron and Kohn, 1984).
The method of affinity chromatography was first described for the
isolation of antibodies (Lerman, 1953) and with the introduction of
improved, inert gels for ligand immobilisation, has been adapted for
the purification of other proteins (Cuatrecasas., Wilchek and
Anfinsen, 1968). Many different membrane receptors have been
purified using the technique, for example the .insulin receptor
(Jacobs, Shechter, Bissell and Cuatrecasas, 1977), adrenergic
(Shorr, Lefkowitz and Caron, 1981; Shorr, Strohsacker, Lavin,
Lefkowitz and Caron, 1981), adrenergic (Graham, Hess and Homay,
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1982), glycine receptor (Pfeiffer, Graham and Betz, 1982),
adrenergic receptor (Homey, Rockson, Countoway and Egan, 1983),
GABA^-benzodiazepine receptor (Sigel and Barnard, 1984) and a
muscarinic acetylcholine receptor (Haga and Haga, 1985). In all
cases the receptor protein was first solubilised from a membrane
preparation, and the solubilised preparation applied to the ligand
affinity column. The retention of receptor protein affinity for the
ligand utilised in the presence of the detergent solution as used
for the affintiy chromatography step was therefore essential.
Unfortunately in the case of the LHRH receptor, extensive
investigations suggested that these two conditions - retention of
the protein in solution and retention of its affinity for LHRH
analogues - were mutually incompatible (Chapter 4). If the
principle of affinity chromatography was to be used for LHRH
receptor purification, some alternative strategy would be required.
A method of affinity chromatography based on the
biotin-avidin/streptavidin interaction has been described (Hofmann
and Finn, 1985; Kohanski and Lane, 1985). Incorporation of a biotin
molecule into a specific ligand for a receptor enables that receptor
to be purified on an avidin/streptavidin-gel. This method has been
used to purify insulin receptors (Kohanski and Lane, 1985(b)),growth
hormone receptors (Haruptle, Aubert, Djiane and Kraehenbuhl, 1983)
and parathyroid hormone receptors (Brennan and Levine, 1987).
Biotin analogues of.many specific receptor ligands have been
synthesised - including insulin (May, Williams and de Haen, 1978),
Leu -enkephalin (Koman and Terenius, 1980), glucagon (Flanders,
Hung Mar, Folz, England, Coolican, Harris, Floyd and Gurd, 1982),
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adrenocorticotropic hormone (Romovacek, Finn and Hofmann, 1983) and
6 nerve growth factor (Rosenbert, Hawrot and Breakefield, 1986).
[Biotinyl D-Lys^J-LHRH has been used to localise LHRH receptors on
anterior pituitary cell cultures using avidin and a biotin-1abelled
peroxidase to visualise the binding sites (Childs, Baor, Hazum,
Tibolt, Westland and Hancock, 1983). The same analogue has been
used in an attempt to purify LHRH receptors by affinity
chromatography utilising its interaction with an avidin affinity
column (Hazum, Schvartz, Waksman and Keinan, 1986). In that case
the initial solubilisation of LHRH receptors was carried out in 5mM
CHAPS, which has been found to give only 20% solubilisation of the
rat anterior pituitary LHRH receptor sites (Chapter 4). The
affinity chromatography step was performed in ImM CHAPS, 10%
glycerol, conditions which were found earlier (4.3.5) to result in
an apparent loss of 19% of solubilised binding sites, retention in
solution of only 67% of sites and detectable binding to only 55% of
the total sites available. Under these conditions, Hazum, Schvartz,
Waksman and Keinan estimate a recovery yield of 4-10% of the
solubilised receptor from the affinity chromatography step.
It has been suggested (Finn, Stehle and Hofmann, 1985) that the
1igand-biotin, avidin affinity chromatography method could be
adapted for receptor purification by covalently. labelling receptors
with the biotin analogue. Covalent labelling of a biotin-1igand to
the LHRH receptor site in the membrane preparation would by-pass the
problem of detergent suppression of LHRH analogue binding.
Covalent labelling of receptor proteins has been commonly
achieved in two ways -
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1) Photoaffinity labelling (Bayley and Knowles, 1977)
2) Affinity crosslinking (Pilch and Czech, 1984)
Both methods have been investigated here in conjunction with
various iodinated and biotinylated LHRH ligands to assess optimal
conditions for the covalent affinity labelling of LHRH receptors for
their subsequent purification.
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6.2 Materials and Methods
6.2.1 Materials
[DLys^]-LHRH was obtained from Peninsula Laboratories Europe
125
Ltd (Merseyside) and [ I]-Denny-Jaffe reagent
125
(N-[4-(p-az i do-m-[ I ] i odophenyl azo)-benzoyl ]-3-ami ndopropyl-N/ -
oxysuccinimide ester) from NEN Research Products (Du Pont (UK) Ltd,
3
Herts). The divalent crosslinkers BS (bis(sulphosuccinimidyl)
suberate), DSS (disuccinimidyl suberate), DST (disuccinidyl
tartarate), EGS (ethylene glycolbis(succinimidylsuccinate) and
sulpho-SANPAH (sulphosuccinimidyl 6-(4'-azido-2'-nitrophenylami no)
hexanoate) were purchased from Pierce and Warriner (UK) Ltd
(Chester). LHRH analogues PBL ([biotinyl-p-azidophenylalanyl-DLys^]-
LHRH),[DLys^, des Gly^]-LHRH ethylamide, PBAL ([biotinyl-p-azido
phenylalanyl-DLys®, des Gly^]-LHRH ethylamide) and XBAL
([biotinyl-aminoethylglycyl-DLys6, des Gly10]-LHRH ethylamide)
were synthesised by Dr C.M. Bladon (2.11 and Appendix III). All
other chemicals and peptides, unless otherwise stated, were obtained
from Sigma Chemical Company Ltd (Dorset).
6.2.2 Methods
6.2.2.1 Label transfer crosslinking of the LHRH-receptor site
125
using the [ I]-Denny-Jaffe reagent
125
The commercially available [ I]-Denny-Jaffe reagent is a
photoactivatable, cleavable crosslinking reagent. Its structure is
125
based on the N-[4-(p-azido-m-[ I] iodophenylazo)-benzoyl]- 3-
I
aminopropyl-N -oxysulphosuccinimide ester used by Denny and Blobel
(1984) in the affinity radiolabelling of human serum IgG. The
125
[ I]-Denny-Jaffe reagent is a heterobifunctional molecule with
both an N-hydroxysuccinimide ester group and a photoreactive aryl
-192-
azido group. This enables it to be linked first with a peptide via
an amino group and subsequently photoactivated to give rise to a
highly reactive aryl nitrene of non-selective reactivity (Ji,
1976). It should therefore be possible to react the reagent with a
specific ligand, equilibrate the derivatised ligand with its
specific receptor or binding site and, as a result of
photoactivating the reagent, covalently label the receptor or
125
binding site with the [ I]-Denny Jaffe reagent. Subsequent
cleavage of the reagent by dithionite splits the reagent molecule
between the iodinated portion crosslinked to the receptor site and
that derivatised with the specific ligand (Denny and Blobel, 1984)
raising the possibility of ligand dissociation and hypothetically
allowing for the subsequent binding of other specific ligands.
The LHRH-analogue chosen for conjugation with the
1
[ I]-Denny-Jaffe reagent was [DLys ]-LHRH which contains only
one free amino-group, on the DLys^ side chain. As the reagent is
supplied as a solution in benzene and the reaction with the peptide
was to occur in aqueous conditions, the benzene was first
evaporated, immediately prior to use, with dry nitrogen. Either an
excess of [DLys^]-LHRH (approximately 24,000 fold molar excess
125
over the [ I]-Denny-Oaffe reagent) or an equimolar amount of
[DLys^]-LHRH was added in a total of lOOyl phosphate buffer,
pH 8. After being left to react for an hour at room temperature,
excess (0.5ml of 0.2M) glycine was added to quench the reaction, and
the mixture was shaken and left at room temperature for a further 4
minutes. The reaction mixture was then diluted 1:10 into 25mM
Tris-HCl pH 7.4, 0.1% bovine serum albumin (Tris/BSA).
Binding of the conjugated [DLys^]-LHRH-["'"^^I]-Denny-Jaffe
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was investigated on anterior pituitary membranes. Rat anterior
pituitary membranes were prepared as previously described
(2.4.1.1). Two anterior pituitary gland membrane equivalents were
used in a total volume of 1ml of Tris/BSA with 10yl of the diluted
[DLys6]-LHRH-[^^I]-Denny Jaffe conjugate added. Non-specific
binding was determined in the presence of lyM LHRH. Binding was
allowed to reach equilibrium (90 minutes at 4°C as previously
described: 2.4.1.) before photoactivation of the reagent occurred.
All previous steps had been carried out under conditions of subdued
lighting to prevent the photoactivation of the reagent (Denny and
Blobel, 1984). Photolysis was carried out using a 12 watt Hg lamp
(366nm) at a distance of 5cm for 10 minutes (Jaffe, Lis and Sharon,
1980). Subsequent cleavage of the reagent [DLys^]-LHRH conjugate
(to leave specifically radioiodinated LHRH receptor sites) was
achieved by two successive additions of lOOyl sodium dithionite (2M,
pH 7.6 in 25mM Tris-HCl) followed by a 15 minute reaction period.
IOC
Separation of the [ 13—1abe1 led receptors from free
125
[ I]-reagent was carried out by diluting the reaction mixture
five-fold with Tris/BSA followed by centrifugation (l,600g for 20
minutes at 6°C). Specific labelling could be determined by
125
comparing total [ I]—binding with that carried out in the
presence of lpM LHRH. Bound radiolabel was counted using a
•y-counter.
6.2.2.2 Affinity labelling of the LHRH-receptor with biotinylated
LHRH-analogues.
Development of the method of receptor affinity chromatography by
biotin-avidin interaction (Hoffman and Finn, 1985; Kohanski and
Lane, 1985) for use with solubilised LHRH receptor proteins requires
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the crosslinking of a biotin molecule onto the receptor site. One
way of achieving this would be by covalently labelling the receptor
site with specific, biotinylated LHRH analogues (Finn, Stehle and
Hoffmann, 1985).
The problem of covalent binding of a biotinylated-LHRH analogue
was approached in two ways - using photoaffinity biotinyl-LHRH
analogues (6.2.2.2.1) and a non-photoreactive biotinyl-LHRH analogue
in conjunction with bifunctional chemical crosslinkers (6.2.2.2.3).
6.2.2.2.1 Use of photoreactive, biotinyl-LHRH analogues as affinity
ligands for the LHRH-receptor.
As previously described (2.9) the LHRH molecule is thought to be
in the form ofahairpin, with a 6 turn at position 6 forming the bend
(Momany, 1976(a)) and the two extremities of the amino-acid sequence
being included in receptor interaction (Momany, 1976(b)).
Substitutions at position 6, as long as they did not disrupt the
backbone shape of native LHRH, have been shown to have no
deleterious effects on its affinity for the receptor (Momany,
1976(b)). Positioning of the biotin and photoreactive groups on the
side chain of a suitable amino acid at position 6 therefore seemed
least likely to disrupt specific binding of the analogue to the LHRH
receptor site. The most suitable photoreactive group would appear
to be an aryl azide, a group said to be chemically inert in an
aqueous medium but with a low activation energy and being activated
at relatively long wavelengths (see 2.11.2.1).
Two photoreactive, biotinyl-LHRH analogues were synthesised
(2.9.4 and Appendix III), PBL and its des Gly^-ethylamide
derivative PBAL.
In order to confirm that these two analogues retained their
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specific affinity for the LHRH-receptor site the binding
characteristics on anterior pituitary membranes of PBL and the
amino-acid backbone of PBAL, (that is, [DLys^, des Gly^j-LHRH
ethylamide) were investigated. Insufficient PBAL was available to
allow similar ligand binding assays to be performed with it.
125
Displacement of I-buserelin from anterior pituitary membranes
by the unlabelled peptides was determined as previously described
(2.4.1) but under conditions of subdued light for PBL, and the data
dissociation
analysed to give ^ constants (2.5). Iodination of PBL and
PBAL by the chloramine-T method (2.3 and Appendix I) allowed the
specificity of their binding to be determined (non-specific binding
levels determined in the presence of lyM LHRH). Again ligand
binding incubations using the photoreactive analogues were carried
out in subdued light.
Photoactivation of PBL and PBAL was initiated on membrane
preparations that had reached binding equilibrium with the iodinated
analogues (as described previously: 2.4). For all the crosslinking
studies (photoaffinity and chemical crosslinkers) Hepes-KOH (25mM,
pH 7.4) replaced Tris/BSA in the ligand binding assay (as both Tris
and BSA contain primary amino groups which would compete for the
crosslinking reaction; Pilch and Czech, 1984). For photoreactive
analogues the assays were carried out in subduejd light.
Non-specific binding and crosslinking were determined in the presence
of lyM LHRH. Exposure to UV light (366nm) at a distance of 20cm
from a 12 watt Hg lamp for 0-10 minutes, on ice, was used to
activate the aryl azide moiety. The membrane preparation was then
centrifuged (45 minutes at l,600g, 6°C, subdued light) to remove
excess unbound label.
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A period of dissociation and displacement by lpM LHRH at room
temperature was used to assess the efficiency of the crosslinking
reaction. The photo-activated membrane preparations (total and
125 125
non-specific determinations of I-PBL and I-PBAL
photoaffinity labelling, in triplicate) were resuspended into 0.75ml
Tris/BSA (1.5 x equilibrium binding reaction volume) containing lpM
LHRH and the peptidase inhibitors soyabean trypsin inhibitor
(50pg/ml) and aprotinin (400KIU/ml). The peptidase inhibitors were
included to try to minimise any enzymatic degradation of both ligand
and receptor. Radioactivity present initially was determined by
Y-spectrometry whilst the preparations were left for 4 hours at room
temperature in the dark. After this time the membranes were again
125
centrifuged (to separate any dissociated I-ligand) and
recounted. Comparison of the difference between total and
non-specific binding-samples both before and after the period of
dissociation was used to estimate the fraction of the specific
binding that had been covalently attached.
6.2.2.2.2 Binding of a non-photoreactive biotinyl-LHRH ligand to
anterior pituitary membranes.
The non-photoaffinity biotinyl-LHRH analogue synthesised for use
with chemical crosslinkers was XBAL. The amino-acid backbone of the
ligand [DLys^, des 61y^]-LHRH ethylamide binds to the LHRH
receptor site with high affinity (6.3.2, Fig. 6) and would be
expected to have high specificity for the site (2.9.1). In addition
to the biotin molecule, the side chain contains a free amino group
with which N-hydroxysuccinimide ester containing bivalent chemical
crosslinkers can react (2.9.2.2).
XBAL binding to rat anterior pituitary membranes was
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125
investigated by its displacement of both I-buserelin and
125
I-XBAL from the membrane preparation. The peptides were
iodinated by the chloramine-T method (as described in 2.3 and
Appendix I) and the equilibrium binding assays were carried out as
in 2.4. Displacement data were analysed by a computer programme
dissociation
(Zivin and Waud 1982) to yield constants (Ki) as previously
described (2.5). For the self-displacement assay, washed membranes
in Tris/BSA (as used in ligand binding assays, 2.4) were incubated
125
with increasing concentrations of I-buserelin together with
125
50,000 cpm of I-buserelin. For each condition non-specific
binding was determined in the presence of lpM LHRH. After graphical
transformation of the data according to Scatchard (1949), it was
dissociation
analysed by linear regression to yield a / constant (Kn)A u
and a value for the total number of binding sites (Bm 1 forJ max
125
I-XBAL.
6.2.2.2.3 Optimisation of LHRH-receptor affinity labelling using
125
bifunctional chemical crosslinkers and I-XBAL
Two types of bifunctional chemical crosslinkers were used in
these studies, a heterobifunctional photoreactive,
N-hydroxysuccinimide ester (sulpho-SANPAH) and homobifunctional
N-hydroxysuccinimide esters (DSS, DST, BS^ and EGS). Of the
3
homobifunctional crosslinkers only BS was soluble in aqueous
solution, all the others required to be dissolved initially in an
organic solvent, DMSO (dimethysulphoxide). All of the chemicals
were kept desiccated and only dissolved immediately prior to use to
prevent the hydrolysis of the N-hydroxysuccinimide esters to free
acid (Pilch and Czech, 1984). ^I-XBAL iodinated by the
chloramine-T method and purified by HPLC (Appendix I) was used in
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these studies. This avoided the inclusion of additional protein (in
the form of BSA) in the binding and crosslinking steps of the
procedure.
The heterobifunctional sulpho-SANPAH was crosslinked with
125
I-XBAL before it was used in membrane equilibrium binding.
Excess sulpho-SANPAH (1.5mg) was left to react for 40 minutes with
1
~0.03pg I-XBAL in Hepes-KOH (200yl) at room temperature in the
dark. An equal volume (200yl) of 0.2M glycine was then added to
125
quench the reaction, and the I-XBAL-sulpho-SANPAH conjugate
diluted in Hepes-KOH for use in membrane equilibrium binding (2.4)
under subdued lighting conditions.
After binding equilibrium had been reached, the photo-reactive
125
I-XBAL-sulpho-SANPAH was photo-activated and the resulting
covalent specific labelling of the LHRH-receptor site was determined
as described for the photo-reactive analogues PBL and PBAL
(6.2.2.2.1).
125
For the homobifunctional crosslinkers, I-XBAL was first
allowed to come to equilibrium (total binding and non-specific
conditions) with anterior pituitary membranes (2.4, except that
Hepes-KOH replaced the Tris/BSA buffer). After dissolving the
crosslinkers into DMSO, or Hepes-KOH in the case of BS , they (or
vehicle) were added to the membrane preparation-at 1:100 dilutions.
These were then vortexed and left for 30 minutes either at room
temperature (BS^ and DST) or on ice (EGS and DSS), after which
excess glycine (to 67mM) was added to quench the reactions. Excess
125
unbound I-XBAL and crosslinker were then separated by
centrifugation (45 minutes at l,600g, 6°C) and the labelled
membranes resuspended into Tris/BSA, lyM LHRH, peptidase inhibitors
-199-
and assayed for specific LHRH-receptor site covalent labelling as
previous described (6.2.2.2.1).
6.2.2.3 Biotin affinity chromatography of the covalently labelled
and solubilised LHRH receptors.
Successful purification of biotin-1abelled LHRH-receptors using
biotin-streptavidin affinity chromatography is dependent on a number
of factors.
1. Retention of the biotin-streptavidin affinity under the
detergent conditions used,
2. Accessibility of the biotin molecule crosslinked to the LHRH
receptor for interaction with the streptavidin and vice-versa
3. The specificity of the biotin labelling of the LHRH-receptor.
Under the 5mM CHAPS/1.5M NaCl conditions used here to maintain
the LHRH-receptor in solution^it has been shown that the
•5
H-biotin-avidin-sepharose interaction is largely unchanged
(2.6). Optimisation of the specific crosslinking of biotinyl-LHRH
analogues to rat anterior pituitary membranes (6.2.2.2.1 and
6.2.2.2.3) would theoretically result in a suitable level of
specificity of biotin labelling of the LHRH receptors. The
remaining unknown factor is the accessibility of the biotin and
streptavidin molecules for each other. In order to increase the
probability of the two being accessible for interaction, carbon
spacers were used in linking the streptavidin to the agarose (a six
3
carbon spacer). PBL displacement of H-biotin from avidin-sepharose
in the presence of 5mM CHAPS/1.5M NaCl was assayed as previously
described (2.8.1) to determine whether or not the LHRH-backbone
interfered with the biotin-avidin interaction.
Rat anterior pituitary membranes were covalently labelled with
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either ^I-PBL or ^^I-XBAL and 0.5mM EGS as described above
(6.2.2.2.1 and 6.2.2.2.3; for both ligands total and non-specific
conditions were assayed in parallel). The labelled sites were then
solubilised using 5mM CHAPS/1.5M NaCl (4.2.1). The resultant
labelled supernatant was used for biotin affinity chromatography
(2.6). The eluate was collected (both before and in the presence of
2mM biotin) and counted by y-spectrometry to follow the progress of
125
the biotin- I-labelled components.
6.2.2.4 Estimation of the molecular weight of the covalently
labelled LHRH receptor using SDS PAGE
Previous studies using photoaffinity analogues of LHRH have
shown specific labelling of one or two proteins of ~ 60,000 mwt to
be revealed using SDS PAGE techniques (Hazum, 1981(b); Iwashita and
Catt, 1985). The same techniques (described in full in 2.8) have
been used here to try to identify the protein specifically labelled
125
by I-XBAL and EGS in rat anterior pituitary membranes.
6.2.2.5 The use of bovine anterior pituitary tissue for the
covalent labelling of LHRH receptors using biotinylated-LHRH
analogues.
Being far larger than rat anterior pituitaries, bovine anterior
pituitaries are potentially a better source of LHRH receptors for
large scale preparative purposes (see 3.3.7). Conditions for
optimal covalent labelling of LHRH-receptors using the biotinylated
LHRH ligand XBAL were therefore tested on bovine tissue.
125
Initial displacement assays of I-buserelin with XBAL on
bovine anterior pituitary membranes (as described in 2.4.2) were
carried out in order to confirm that XBAL bound to the bovine LHRH
125
receptor. The specificity of the I-XBAL binding sites, its
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displacement constant (Kp) and the number of binding sites
(Bmax) were determined by Scatchard analysis of self-displacement
data. This was carried out as described for rat anterior pituitary
membranes (6.2.2.2.2) except that bovine anterior pituitary
membranes were used in a Tris/BSA peptidase inhibitor medium
(2.4.2.1) and the samples were left at 4°C for 16 hours to come to
equilibrium (Jansem de Almeida Catanho, Berault, Theoleyre and
Justisz, 1983; 2.4.2).
125
Covalent crosslinking of I-XBAL on to bovine anterior
pituitary membranes was attempted using the bifunctional chemical
crosslinker EGS. This was carried out as described for rat anterior
pituitary membranes (6.2.2.2.3) except that peptidase inhibitors
(soybean trypsin inhibitor 50mg/ml and aprotinin 400KIU/ml) were
included in the equilibrium binding assay and the incubation period
was 16 hours at 4°C. Efficiency of the crosslinking step was




6.3.1 Label transfer cross!inking of the LHRH-receptor site using
the [^1 ]-Denny-Jaffe reagent
In order to try and optimise both the derivatisation of
[DLys^]-LHRH, and the specific binding of the conjugate
([^I]-Denny-Jaffe reagent - [DLys^J-LHRH) to membrane
preparations two concentrations of [DLys^]-LHRH were used in the
conjugation step. The presence of excess peptide in the reaction
125
with the [ I]-Denny-Jaffe reagent theoretically would result in
maximal derivatisation. On binding to the membrane preparation
however only low levels of radiolabel were found to be bound (1239 ±
76cpm, ± SEM, n = 5) probably due to the low specific activity of
the conjugate. Higher levels of bound radiolabel were found when
equimolar [DLys®]-LHRH was used in the derivation step (18405 ±
670cpm, ± SEM, n = 5, under similar conditions of membrane
concentration and total counts added). No specific binding was
detectable using either preparation. One possible reason for this
could be that the [DLys^]-LHRH peptide binds with only a low
specificity for the LHRH receptor site, as has been reported using
native LHRH as a ligand. In the light of further studies with LHRH
analogues altered at their C-terminal to desGly^ ethylamide,
better specific binding may have been seen using such analogues for
the Denny-Jaffe reagent conjugate. Another possibility is that the
1
presence of the [ I]-Denny-Jaffe reagent on the LHRH analogue
affects the shape of the peptide in such a way as to destroy its
specific binding to the LHRH receptor site. Unfortunately it was
not possible to test for this using the Denny-Jaffe conjugate.
Another possibility is that specific binding present before the
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photoactivation of the reagent was masked by the activation and
non-specific crosslinking of a relatively high concentration of free
reagent. The high concentration of free reagent was a result of the
low specific activity of the conjugate. This could have been
overcome in two ways - the inclusion of scavenger molecules (such as
BSA or Tris: Bayley and Knowles, 1977; Das and Fox, 1979) in the
photoactivation step to provide excess, non-membrane sites to react
with the excess reagent, or the inclusion of a wash step between the
equilibrium binding and photoactivation to remove excess reagent.
This second option may however have resulted in a re-equi1ibration
of bound peptide conjugate taking place, resulting in a reduction in
the number of LHRH receptor sites specifically bound. A third
possibility would have been to increase the specific activity of the
conjugate by separating it from unreacted peptide and reagent.
However, this and the inclusion of a wash step would have been
difficult without exposing the conjugate to some light. It was
therefore decided that some other means of specifically labelling
the LHRH receptor site should be attempted. Use of different LHRH
backbones may have resulted in increased specific binding, and other
methods would allow for the inclusion of a biotin molecule in the
LHRH.
6.3.2 Affinity labelling of the LHRH-receptor with biotinylated-
LHRH analogues
6.3.2.1 The use of photoreactive, biotinyl-LHRH analogues as
affinity ligands for the LHRH receptor
lor r
Displacement of I-buserelin by PBL and [DLys ,
desGly^]-LHRH ethylamide, the peptide backbone of PBAL, showed
that they both bound to the LHRH-receptor site with high affinity in
-204-
a concentration-dependent manner (Fig 6.1). Analysis of the data
dissociation
revealed ^ constants (K^) of 0.92nM ± 0.16 (± SEM, n = 4)
for PBL (Fig 6.2.a). This is similar to that reported for the
parent peptide [DLys^]-LHRH (Clayton and Catt, 1980) suggesting
that addition of the photo-biotin group in the DLys6 position does
not impede binding to the LHRH receptor. It is a reasonable
contention therefore that the presence of the same photo-biotin
6 10
group on the [DLys , desGly ]-LHRH ethylamide backbone will
have little effect on the binding of this analogue. Analysis of the
displacement by [DLys^, desGly^J-LHRH ethylamide of
125
I-buserelin showed it to have an apparent of 0.098nM ±
0.01 (± SEM, n = 3; Fig 6.2(b)).
Iodination of PBL and PBAL allowed for the specificity of their
binding on rat anterior pituitary membranes to be assessed.
12f-PBL binding (at a concentration of ~29pM) could only be
partially displaced by excess LHRH with 12% of the total binding
being specific for the LHRH receptor (compared to 50-60% of
125
I-buserelin binding under similar conditions). A similar level
125
(10%) of specific binding was seen with I-PBAL under the same
assay conditions. These results suggest that neither photoreactive
LHRH analogue binds with a high enough specificity for the LHRH
receptor site to make them suitable affinity ligands. Whereas the
alteration of the C-terminal of LHRH analogues to desGly^
ethylamide has previously been shown to enhance the specificity of
binding, (2.11), this does not appear to be the case for the
photoreactive analogues used here.
125
Photoactivation (0-10 minutes) of I-PBL at binding
equilibrium with the membrane preparation resulted in no detectable
Figure 6.1
125
Displacement of specific I-buserelin binding to rat
anterior pituitary gland membranes by [DLys^,desGly^]-LHRH
ethylamide and PBL. Binding assays were carried out as described
125
(2.4.1.2) with 50,000cpm I-buserelin and various concentrations
of unlabelled LHRH analogue. Non-specific binding was determined in























Hofstee analysis of a) PBL and b) [DLys6,desGly^J-LHRH
125
ethylamide displacement of specific I-buserelin binding to rat
anterior pituitary gland membranes. Binding assays were carried out
as described (2.4.1.2) and the displacement data analysed by an
error-weighted programme (2.5). PBL, = 0.92 ± 0.16nM (mean ±
SEM of four separate determinations). [DLys6,desGly*°]-LHRH
ethylamide, = 0.098 ± O.OlnM (mean ± SEM, of three separate
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specific labelling of the LHRH receptor site. That is the amount of
binding remaining, after 4 hours dissociation in the presence of lpM
1 25
LHRH, was no different in samples labelled with I-PBAL either
in the absence or presence of non-specific levels (lpM) of LHRH.
125
Photoactivation of I-PBAL resulted a small amount of specific
labelling being detected, reaching a maximum, after 2 minutes
activation, of 28% ± 5 (± SEM, n = 3) of the initial specific
binding (10% of total binding) (Fig 6.3). The method used to
analyse the efficiency of covalent labelling of the LHRH-receptor
site and the usefulness of the covalent labelling for receptor
purification is dependent on the specific binding of the iodinated
126 125
analogues used. In the case of both I-PBL and I-PBAL the
low specificity of binding and the low level of covalent labelling
meant that they were unlikely to be the ligands of choice for this
method.
6.3.2.2 Binding of a non-photoreactive biotinyl-LHRH ligand to
anterior pituitary membranes
The non-photoreactive biotinyl-LHRH ligand synthesised was XBAL,
based on [DLys6, desGly^]-LHRH ethylamide. This LHRH backbone
might be expected (from the literature) to have a high specific
125
binding (2.9),and displacement of I-buserelin from rat anterior
dissociation
pituitaries revealed a ^ constant of 0..098nM ± 0.01 (± SEM,
n = 3) (Fig 6.1 and 6.2(b)). Addition of the amino-biotinyl group
at position 6 (to form XBAL) did not seem to inhibit but apparently to
enhance binding affinity (K^ of 13.6pM ± 1.2; ± SEM, n = 6; Fig
126
6.4.a,b). Hofstee analysis of XBAL displacement of I-XBAL
binding (Fig 6.5) to the membrane preparation gave a of 57pM ±
14 (± SEM, n = 3) and Scatchard analysis using increasing
Figure 6.3
125
Photoaffinity labelling with I-PBAL. % of initial membrane
1 9K
specific I-PBAL binding covalently bound after exposure to UV
light (12 Watt Hg lamp, 366nm at 20cm) for various periods of time.
125
Initial specific I-PBAL binding was 10% of the total
125
I-PBAL bound. Amount of specific binding crosslinked was
125
determined by comparing I-PBAL binding remaining in total and
125
non-specifically bound I-PBAL membrane preparations (after
photoactivation) after a period of four hours displacement by lyM
LHRH at room temperature in subdued light. All points are mean ±










concentrations of I-XBAL gave a of 131pM ± 16 (± SEM, n =
3: Fig 6.6). The specific activity of the iodinated XBAL was
approximately assessed from the iodination data to be 2.65 x
5
10 cpm/pmol (Appendix IV). The apparent Bmax value for
125
I-XBAL binding on male rat anterior pituitary tissue was
63fmo 1 /g1 and, comparable to that for buserelin of 92fmo1/gland. The
125
specificity of I-XBAL binding under the conditions used
(~50,000cpm added in 500yl) was consistently 40-50%. The high
affinity of its binding and its relatively high specificity for the
125
LHRH receptor site indicate that I-XBAL was a suitable ligand
for the covalent labelling of this site.
6.3.2.3 Optimisation of LHRH-receptor affinity labelling using
125
bifunctional chemical crosslinkers and I-XBAL
In theory photoaffinity ligands might be expected to give a more
specific labelling of receptor sites than non-specific divalent
chemical crosslinkers. This is because covalent linking is
initiated at a molecule bound specifically to the receptor site.
For this reason the heterobifunctional crosslinker sulpho-SANPAH was
tested for covalent labelling of LHRH receptor sites using
125
I-XBAL. After reaction of the N-hydroxysuccimide ester moiety
1 ?5
of sulpho-SANPAH with the free amino side chain of I-XBAL the
1 25
conjugate, I-XBAL-sulpho-SANPAH, gave 15% specific binding to
rat anterior pituitaries. This is much less than that seen with
1 ?5
I-XBAL (6.3.2.2) and possibly could be the result of one, or a
combination of two, factors. Either addition of the sulpho-SANPAH
125
onto the bioti n-contaim ng side chain of I-XBAL reduces the
affinity of the analogue for the LHRH receptor site, or it confers





a. Displacement of specific I-buserelin binding to rat
anterior pituitary membranes by XBAL. Binding assays were carried
1
out as described (2.4.1.2) with ~50,000cpm I-buserelin, tissue
equivalent to one eighth anterior pituitary gland and various
concentrations of XBAL in a total volume of 500yl 25rrM Tris-HCl
pH7.4/0.1% BSA. Non-specific binding was determined in the presence
125
of IpM LHRH. Total I-buserelin binding was 6475 ± 58cpm, with
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Displacement of specific I-XBAL binding to rat anterior
pituitary gland membranes by unlabelled XBAL. Ligand binding was
carried out as previously described (2.4.1.2) with 50,000cpm
125
I-XBAL, tissue equivalent to one eighth of an anterior
pituitary gland and various concentrations of unlabelled XBAL in a
total volume of 500yl 25mM Tris-HCl pH7.4/0.1% BSA. Total binding
125
of I-XBAL was 5232 ± 89cpm with 43 ± 3% of total binding being
specific. Analysis of the data by an error-weighted programme
revealed a = 57 ± 14pM. All values and points are means ± SEM
for six separate determinations.
Figure 6.6
125
Scatchard analysis of I-XBAL binding to rat anterior
pituitary gland membranes. Ligand binding was carried out in 500yl
25mM Tris-HCl pH7.4 containing 50,000cpm plus various concentrations
125
of I-XBAL with tissue equivalent to one eighth of an anterior
pituitary gland. Non-specific binding was determined in the
presence of lpM LHRH. After graphical transformation of the binding
data^they uereanalysed by linear regression. = 131± 16pM, (mean
± SEM, n = 3) Bmax = 63fmo1/g1 and.
Figure6.6
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total binding of ^I-XBAL-sulpho-SANPAH was 6417 ± 115cpm
125
compared to 8470 ± 77cpm for I-XBAL under similar conditions,
whilst non-specific binding levels were relatively similar (5454 ±
125
104cpm for I-XBAL-sulpho-SANPAH compared to 5039 ± 57cpm for
126
I-XBAL; ± SEM, n = 4). These results suggest that it is the
sulpho-SANPAH moeity interfering with the affinity of the LHRH
analogue and reducing the level of specific binding seen, rather
than an increase in non-specific binding.
1 25
Photoactivation of the I-XBAL-sulpho-SANPAH (0-10 mins,
20cm from a 12 watt Hg lamp, 366nm) resulted in no detectable
specific labelling of the LHRH receptor site, assessed, as for PBL
and PBAL, by comparing the amount of binding remaining in total and
non-specifically labelled samples after a period of 4 hours
dissociation in the presence of lyM LHRH. As for the photoreactive
LHRH-analogues (PBL, PBAL and the [D-Lys^]-LHRH-Denny Jaffee
reagent conjugate) the level of specific labelling may have been
improved by the inclusion of a washing step to remove excess unbound
125 125
ligand (6.3.2.1). However, as with I-PBL and I-PBAL, the
low initial levels of specific binding seen here suggested that this
strategy did not merit further study. The results of the binding
with iodinated aryl-azido derivatives of LHRH suggest that this
group has a detrimental effect on specific binding to the LHRH
receptor site. For PBL, displacement studies (6.3.2.1) have shown
that the affinity for the LHRH receptor site is retained by this
analogue, but binding of the iodinated PBL revealed very high levels
of non-specific binding. Increasing the hydrophobicity of a peptide
can result in an increase in the portioning of the peptide in the
hydrophobic environment of the membrane, rather than the aqueous
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medium. This may be responsible for the increase in non-specific
1 26
binding of this ligand. However, for the I-XBAL-sulpho-SANPAH,
no similar increase in non-specific binding was observed, only a
reduction in total binding. This suggests that the affinity of the
XBAL was adversely affected by the addition of the sulpho-SANPAH
group.
The homobifunctional chemical cross!inkers that were tested had
125
the advantage of being added only after the I-XBAL binding had
come to equilibrium. This might mean that they have less
opportunity to affect the specificity of the ligand's binding than
the heterobifunctional sulpho-SANPAH. The results (effect of the
crosslinker on initial levels of specific binding and the percentage
of initial specific binding successfully crosslinked) of the
125
covalent crosslinking of I-XBAL to the LHRH receptor site are
presented in Table 6.1.
Despite not being present during equilibration of the
126 1
I-XBAL binding, both DSS and BS had detrimental effects on
the levels of initial specific binding seen. In the presence of
0.2mM DSS,values of specific binding were reduced to 58% of controls
(that is control samples in the absence of crosslinker), and to 55%
3
in the presece of 0.5mM BS . Whilst DST had less effect on
initial specific binding at low concentrations "(0.1 - 0.5mM) it,
like DSS, did not result in any specific labelling of the
LHRH-receptor site (again determined by comparing the amount of
binding left, after 4 hours dissociation in the presence of lyM
LHRH, in total and non-specifically labelled samples). Only at the
highest concentration tested (5mM) did EGS decrease initial specific
binding (to 79% of control levels). Concentrations of EGS above ImM
Table 6.1
1 p>c
Results of covalent crosslinking of specific I-XBAL binding
to rat anterior pituitary gland membranes with the chemical
crosslinkers. The effect of the crosslinkers on specific
125
I-XBAL binding was determined by comparing initial specific
125
I-XBAL binding in the presence and absence of various
concentrations of the crosslinkers. Specific binding crosslinked
125
was determined by ■ I-XBAL binding remaining in total and
125
non-specifically bound I-XBAL membrane preparations (after the
crosslinking reaction) subsequent to a period of 4 hrs displacement










binding as X of
control specific
binding




(n = 4 - 12 * SEM)
DSS 0.025 96 * 12 -6 ± 2
IX OMSO, 0.2 58 * 6 -3*2
30 minutes on ice 0.3 35 * 3 5*5
0.5 29 * 8 1 * 5
1 23 * 8 5 * 11
2 21 * 10 4*6
BS3 0.5 55 * 9 19 * 6
No OMSO 1 56 * 2 17 * 4
30 minutes at 2 33 * 1 24 * 4
room temperature 5 42 * 8 16 * 5
OST 0.1 78 * 9 -6*4
IX OMSO 0.2 78 * 13 -9*3
30 minutes at 0.5 72 * 14 17 * 10
room temperature 1 54 * 22 17 * 7
2 35 * 8 30 * 20
5 23 * 26 68 * 25
EGS 0.1 99 * 1 -1 * 1
IX OMSO 0.2 100 * 2 -2*2
30 minutes on ice 0.5 93 * 2 0*4
1 100 * 4 3*2
2 94 * 14 11*3
3 108 * 4 17 * 5
5 79 * Z 23 * 3
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125
were successful at crosslinking I-XBAL in an apparently
specific way (Fig 6.7). Up to 23% ± 3 (± SEM, n = 3) of the control
level of initial specific binding was covalently linked after
treatment with 5mM EGS. Whilst theoretical considerations suggest a
maximum of 40% specific labelling with these classes of crossl inkers
(Strosberg, 1984), a result of 23% seems an acceptable maximal value
in practice.
6.3.3 Biotin-affinity chromatography of the covalently labelled and
solubilised LHRH receptors
3
Displacement of H-biotin from avidin-sepharose by PBL in the
solubilisation solution (Fig 6.8) showed not only that the
biotinyl-LHRH analogue had an affinity similar to biotin for
avidin-sepharose, but also that this was not detrimentally affected
by the presence of 5mM CHAPS/1.5M NaCl. This suggests that LHRH
receptors labelled with our biotinylated ligands will bind to an
avidin-sepharose (or streptavidin-agarose) column under
solubilisation conditions. Of course, although the rest of the PBL
ligand did not affect the biotin interaction with the avidin-agarose,
it was not possible to be entirely certain that, on crosslinking the
ligand to the receptor site, this would still be possible.
125
Application of solubilised I-biotin labelled rat anterior
pituitary membranes to a streptavidin-agarose column, and subsequent
elution with 2mM biotin resulted in the appearance of a peak of
1 p c "i o r
I-activity. As expected in the case of I-PBL labelling,
the difference between parallel total and non-specifically labelled
samples was very small due to the low specificity of its binding
(Fig. 6.9). Affinity labelling with 0.5mM EGS treatment of
125
I-XBAL had rather more apparent specificity. As a result a
Figure 6.7
125
Efficiency of covalent linking of I-XBAL. % of initial
125
specific I-XBAL binding to rat anterior pituitary membrane
preparation covalently linked to the membrane preparation by various
concentrations of EGS. Crosslinking was carried out on membrane
125
preparations at equilibrium with I-XBAL (total and non-specific
binding samples, non-specific binding being determined on the
presence of lyM LHRH) for 30 minutes on ice. The reaction was then
quenched by the addition of excess glycine (6.2.2.2.3). Specific
125
binding crosslinked was determined by comparing I-XBAL binding
remaining in total and non-specifically bound samples (after
crosslinking) after a period Of 4 hrs displacement by lpM LHRH at










Displacement of H-biotin from avidin-sepharose CL-4B by PBL.
The binding assay was carried out as previously described (2.6.1) in
the 5mM CHAPS, 1.5M NaCl solubi1isation solution and revealed an
ICgQ of llpM for PBL as a biotin derivative under these
conditions. Points are means of triplicate samples.
Figure 6.9
125
I-PBL activity in aliquots of 2 min fractions eluted with
2mM biotin (in the 5mM CHAPS, 1.5M NaCl solubilisation solution)
from the avidin-Sepharose CL-4B affinity column after application
125
a solubilised, I-PBL-crosslinked rat anterior pituitary gland











greater difference between total and non-specifically labelled
preparations was seen, with 17% of the total radioactivity eluted by
biotin apparently being specific (Fig 6.10). The recovery of
radiolabel applied to the affinity column in the peak eluted by the
125
2mM biotin was 23% in the case of I-PBL but only 5% for the
1 26
EGS/ I-XBAL preparation (both values calculated from the total
binding conditions). One possibility is that different elution
conditions are required for the two affinity matrices used, with
which
those^used (2mM biotin) being more suitable for the avidin-agarose
than the streptavidin-sepharose. Another possibility is that whilst
126
the I-XBAL crosslinked with 0.5mM EGS results in a greater
amount of specific covalent labelling of the LHRH receptor site, a
smaller proportion of this is available for binding with the
streptavidin agarose. This may be a result of the non-selective
action of EGS on membrane constituents. Unlike photoreactive
affinity labels, homobifunctional chemical crosslinkers are capable
of non-specifically crosslinking any two free amino groups. This
may have resulted in protein crosslinking in the membranes that in
some way hindered the biotin (covalently attached to the LHRH
receptor site) from reacting with the streptavidin-agarose.
6.3.4 Estimation of the molecular weight of the specifically
labelled LHRH receptor using SDS PAGE
The anterior pituitary membrane preparations used in SDS PAGE
125
had been labelled using I-XBAL and 5mM EGS as previously
described (6.2.2.2.3). After exposure of the gel for four weeks,an
autoradiograph was obtained (see Appendix II for details). Using a
densitometer a standard curve was constructed of R(f) values against
molecular weights (Fig 2.10) and this was used to provide an
Figure 6.10
125
I-XBAL activity in aliquots of 2 min fractions eluted with
2mM biotin (in the 5mM CHAPS, 1.5M NaCl solubilisation solution)
from the streptavidin-agarose affinity column after application of a
125
solubilised I-XBAL-EGS-crosslinked rat anterior pituitary gland
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Figure 6.11
Densitometric traces of a representative SDS PAGE autoradiograph.
A 7% acrylamide gel, in combination with a 4.75% acrylamide stacking
gel was used (as described previously, 2.8.1).
14
Lane a) C-labelled molecular weight standards.
125
Lane b) I-XBAL-EGS crosslinked rat anterior pituitary gland
sample. (Total labelling).
125
Lane c) I-XBAL-EGS crosslinked rat anterior pituitary gland
1 oc
sample (Non-specific labelling), I-XBAL binding to
equilibrium and the covalent crosslinking reaction were
both carried out in the presence of lyM LHRH.
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estimate of the molecular weights of radioactive bands (proteins
125
covalently labelled with I-XBAL) in the sample lanes (Fig
IOC
6.11). The sample crosslinked with EGS and I-XBAL labelled
proteins at approximate molecular weights of 72,000 (a broad band of
between 60,000 and 82,000), 39,000 and 26,000. That labelled in the
presence of lpM LHRH (non-specifically labelled sample) showed a
125
protein labelled with I-XBAL of approximately 25,000 molecular
weight.
In addition to the labelled proteins entering the gel, both
total and non-specific samples had fairly large amounts of labelled
proteins that did not enter the stacking gel. This suggests that
either the proteins are of a very high molecular weight (over
500,000 to be excluded from the 7% stacking gel) or that the
membrane sample was not completely dissolved by the sample buffer.
Some aggregation of labelled proteins may be expected using 5mM EGS
(a relatively high concentration of crosslinker). If this is the
case, then more labelled protein may enter the gel if the amount of
SOS used to dissolve the sample buffer is increased. The optimal
ratio of SDSrprotein (w/w) has previously been found to be 3:1 for
complete protein solubilisation (Blackshear, 1984). Here a ratio of
approximately 2:1 was used. An increase to 3:1 may prove fruitful
in increasing the amount of labelled protein eatering the gel.
6.3.5 The use of bovine anterior pituitary tissue for the covalent
labelling of LHRH receptors using biotinylated LHRH analogues
125
Displacement of I-buserelin from bovine anterior pituitary
membranes by XBAL was concentration-dependent (Fig 6.12) and Hofstee
analysis revealed a of 0.096nM, of the same order of magnitude
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Displacement of specific I-buserelin from bovine anterior
pituitary gland membranes by unlabelled XBAL. Binding was carried
125
out as previously described (2.4.2) with 50,000cpm I-buserelin
and ~2.5mg of tissue in 500yl of 25mM Tris-HCl pH 7.4; 50yg/ml
soybean trypsin inhibitor; 400 Kill/ml aprotinin, reaching binding
equilibrium after 16hrs at 4°C. Analysis of the data by an
error-weighted programme revealed a of 0.096nM. All points are
means of triplicate determination.
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125
analysis of I-XBAL self-displacement data (Fig 6.13) gave a
Kp value of 0.122nM and a emax of 4.5fmol/mg initial tissue
weight, or approximately 3.6pmol/bovine anterior pituitary gland.
These results would suggest that the XBAL recognised the same site
125
as I-buserelin and was binding to a site of similar affinity to
that seen in the rat anterior pituitary membrane, which was
therefore likely to be the LHRH receptor site. The specific binding
125
of I-XBAL on the bovine anterior pituitary membrane preparation
was between 40-50%, similar to that seen on rat tissue (6.3.2.2).
Because of the long equilibration period required (16 hrs) for
LHRH-analogues binding to bovine anterior pituitary tissue (2.4.2),
it was considered necessary to include protease inhibitors to
prevent enzymatic degradation of both the LHRH analogue and the LHRH
receptor protein. These were included in the equilibrium binding
period prior to crosslinking, although non-selective crosslinking
may have been increased as a result. However, the Tris/BSA used in
equilibrium binding assays previously (2.4.2) was replaced by
Hepes-KOH. This had the effect of drastically increasing the amount
125
of non-specific binding of I-buserelin seen (from 7976 cpm to
14328 cpm, under otherwise similar conditions) and concomitantly
reducing the proportion of specific binding, to only 4 ± 9% (± SEM,
i
n = 4) of total binding. Not surprisingly, crosslinking of
195
I-XBAL binding with 0.5mM EGS to bovine anterior pituitary
tissue did not result in any detectable specific labelling of the
LHRH receptor site (assayed as previously described (6.2.2.2.1) by
comparing the amount of binding remaining after 4 hours dissociation
in the presence of lyM LHRH, in parallel total and non-specifically
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Figure 6.13
125
Scatchard analysis of I-XBAL binding to bovine anterior
pituitary gland membranes. Binding was carried out using 50,000cpm
125
and various concentrations of I-XBAL with tissue equivalent to
~2.5mg of initial tissue weight in a total volume of 500yl 25mM
Tris-HCl pH 7.4; 50yg/ml soybean trypsin inhibitor; 400 KlU/ml
aprotinin for 16 hrs at 4°C. Non-specific binding was determined in
the presence of lyM LHRH. After graphical transformation of the
binding data it was analysed by linear regression (2.5). Kp =
0.122nM, Bmax = 3.6pmol/g1 and. All values are means of triplicate
samples.
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for use in the affinity labelling of LHRH receptor sites under these




Covalent affinity labelling of membrane proteins was first
suggested to explain an irreversible blockade of adrenergic
receptors seen after treatment with dibenamine ligands (Nickerson
and Gump, 1949). The potential of such a technique for protein
biochemistry was not realised until the early 1960's when both
photoaffinity (Singh, Thornton and Westheimer, 1962) and chemical
affinity crosslinking (Baker, Lee, Tong and Ross, 1961; Lawson and
Schramm, 1962; Schowllmann and Shaw, 1962) were first used as tools
for enzyme active site studies.
Affinity labelling of membrane receptors has been regarded as
one way to provide positive identification of the protein after
membrane disruption as an alternative to the retesting of ligand
binding to show retention of receptor function (Zisapel and
Sokolovsky, 1977; Finn, 1977). The success of the method (for
protein identification, quantification and purification) is clearly
dependent on the specificity of the labelling (Zisapel and
Sokolovsky, 1977). Two steps are involved - the specific binding of
the ligand and the covalent bond formation.
Of the two strategies for affinity labelling tried, from the
literature photoaffinity labelling would appear to be the method of
choice. Incorporation of an arylazide in a ligand analogue allows
equilibrium binding conditions to be attained in an unreactive state
(Ji, 1979). Photolysis results in the generation of a highly
-4 -2
reactive species with a half-life in the order of 10 -10
seconds capable reacting with C-H bonds in the absence of more
reactive sidechains (Bailey and Knowles, 1977; Das and Fox, 1979;
Ji, 1979; Pilch and Czech, 1984). This would suggest that highly
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specific labelling of the receptor site could be achieved (dependent
on initial specificity of binding of the ligand).
Photoaffinity analogues of LHRH have previously been
synthesised, both by the reaction of [DLys^]-LHRH with the
heterobifunctional chemical crosslinker,N-hydroxysuccinimidyl-4-
azido-benzoate (Hazum, 1981(c); Iwashita and Catt, 1985),and by the
incorporation in the amino-acid backbone of photosensitive groups
(Mackiewicz, Belisle, Bellabarba, Gallo-Payet, Lehoux, Lagace and
Escher, 1987). In all cases the affinity of the analogue was
retained when the residues involved in incorporating the
photoreactive group were not those involved in binding, that is
usually residues 6 or 7 (see Chapter 3). The analogues used in
these studies all involved substitution of the photoreactive group
onto the amino-acid at position 6 (DLys^). Both PBL and PBAL
retained their affinity for the LHRH receptor site (as revealed by
125
displacement of I-buserelin), but in both cases the specificity
of their binding was very low (6.3.2.1). Similarly, low specific
binding was seen with the [DLys^]-LHRH conjugated with
125
I-Denny-Jaffe reagent (6.3.1). In the case of the
heterobifunctional crosslinker sulpho-SANPAH, the reduction in
125
specific I-XBAL binding seen appeared to be the result of a
126
reduction in affinity of the 1-XBAL-sulpho-S.ANPAH conjugate
rather than an increased level of non-specific binding (6.3.2.3).
Photo-activation of all the analogues and conjugates resulted in
very low levels of specific covalent labelling. This could have
been due to a number of factors, not least the low specificity of
the initial ligand binding seen. Possibly the positioning of the
photoreactive group at the part of the LHRH molecule not involved
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with binding resulted in exposure of the photoreactive group to the
bulk medium, or neighbouring macromolecules rather than the LHRH
receptor protein itself, a possibility suggested by Bayley and
Knowles (1977). It has also been suggested that ligand dissociation
before reaction of the activated aryl nitrene may be contributory to
low levels of photoaffinity labelling (Zisapel and Sokolovsky, 1977)
although this would seem to be unlikely here in the case of the LHRH
receptor. Dissociation of LHRH and its analogues at 4°C is slow
(Clayton and Catt, 1981) relative to the expected half-life of aryl
-4 *
nitrenes of ~10 seconds (Ji, 1979, Das and Fox, 1979). Another
possible explanation put forward for the low level of photoaffinity
labelling was that the electrophilic nature of the nitrenes results
in a preferential reaction with water or buffer (Das and Fox,
1979). The low yield of specific photoaffinity labelling of
membrane receptors is a result that has often been observed (Pilch
and Czech, 1984). Possibly the use of scavenger molecules (such as
Tris or p-amino benzoic acid, Bayley and Knowles, 1977; Das and Fox,
1979) to consume surplus photoactivated groups would have reduced
the non-specific labelling and so increased the specific labelling
seen, but concomitant reductions in yield may well occur.
The alternative strategy to photoaffinity labelling investigated
here was that of chemical crosslinking using bifunctional reagents,
the type chosen were the N-hydroxysuccinimide esters. These groups
are said to be relatively stable to hydrolysis in aqueous solution,
with the amide formation reaction proceeding at a higher rate at
physiological pH and a temperature of 0-20°C (Ji, 1979; Pilch and
Czech, 1984). Compared to photoaffinity labelling this method has
three apparent disadvantages. Firstly, it is necessary to have
-231-
specific groups (usually free amino groups) occurring on both the
ligand and receptor at an appropriate distance apart for
crosslinking (Ji, 1979; Pilch and Czech, 1984). Secondly, the
crosslinkers are likely to react with any suitably positioned free
amino group, not just those on the receptor or ligand, resulting in
considerably non-selective protein crosslinking (Ji, 1979; Pilch and
Czech, 1984). Thirdly, the relatively long reaction time - about 10
minutes for reactions to go to completion (Ji, 1979) allows more
time for receptor-1igand dissociation or the crosslinking of
adjacent membrane constituents as a result of putative random
collisions (Ji, 1979).
In order to overcome the first disadvantage,N-hydroxysuccinimide
esters of varying chain lengths, ranging from 0.6nm (DST, Smith,
Capaldi, Muchmore and Dahlquist, 1978) to 1.51nm (E6S, Baskin and
Yang, 1980),were used. These N-hydroxysuccinimide esters are highly
reactive for amide bond formation under mild conditions (Das and
Fox, 1979; Ji, 1979; Pilch and Czech, 1984) and,although primarily
they react with amino groups (and the crosslinking biotinyl-LHRH
analogue X-BAL was constructed with a free amino group available,
2.11),they can also react with the imidazole group of histidine (Ji,
19^
1979). (Possibly the apparent reduction in affinity of I-XBAL
seen after conjugation to excess sulpho-SANPAH -could have been the
result of substitution of the group onto the histidine, at residue
2, which is thought to be required for the biological activity of
LHRH analogues (2.9)). One assumption made was the occurrence on
the LHRH receptor of a suitable group for reaction with the esters.
This is probably a valid assumption, as hydrophilic residues, such
as lysine, which contains a free amino group on its side chain, tend
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to be situated on the external surface of many proteins (Matthews,
1977).
Whilst the length of the crosslinker has been generally regarded
as an important variable (Ji, 1979; Pilch and Czech, 1984)}with
those below 0.5nm being found to result in few or no crosslinks (Ji,
1979) and those over l.lnm to crosslink proteins regarded as
non-contiguous (Aizawa, Kurimoto and Yokono, 1977), in the case of
ligand crosslinking to the insulin receptor it was not found to be
an important variable (Pilch and Czech, 1984). The results we have
obtained here for the LHRH receptor show that the longest
crosslinker tried (EGS at 1.5nm) resulted in the highest level of
specific binding. This may imply that there are few free amino
groups at the receptor binding site, and those that do occur are at
125
least 1.5nm from the free amino group of the I-XBAL molecule as
it occupies the binding site.
The high level of non-specific crosslinking seen, particularly
with DSS (0.2-2mM) and the higher concentrations of BS^ (2 and
5mN), DST (5mM) and to a lesser extent 5mM EGS, may well be a result
125
of non-selective crosslinking of I-XBAL (either free or bound)
to membrane constituents - such as proteins or phospholipid head
groups. Higher concentrations of crosslinkers have been shown to
result in protein aggregation (Zysk, Cronin, Anderson and Thorner,
1986; Lewis and Williams, 1987). As a result, optimum affinity
crosslinking is said to occur using the lowest effective
concentration of crosslinker (Pilch and Czech, 1984) and a high
receptor/1igand ratio (Das and Fox, 1979).
To try to optimise crosslinking with the bifunctional esters,
125
reaction conditions were chosen to limit I-XBAL dissociation
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whilst (as far as possible) reproducing conditions under which
crosslinking with that particular reagent had previously been shown
to be effective. As such,EGS and OSS were left to react for 30
minutes on ice (Abdella, Smith and Royer, 1979. Massague, Guillete
and Czech, 1981) and DST and BS"^ for 30 minutes at room
temperature (Coggins, Hooper and Perham, 1976; Giedroc, Puett, Ling
and Starod, 1983). The concentration ranges used had also
previously been shown to give effective crosslinking of proteins
(Smith, Capaldi, Muchmore and Dahlquist, 1978; Abdella, Smith and
Royer, 1979; Massague, Guillette and Czech, 1981; Giedroc, Puett,
Ling and Straros, 1983; Staros and Kakkad, 1983). Within this
125
period of time, at pH7.4, I-XBAL binding would not be expected
to change significantly at 0°C, whilst at 30°C some re-equilibration
may occur, but as dissociation of similar LHRH analogues is slow
(Clayton and Catt, 1981), it would not be expected to have a large
125
effect on the level of specific binding seen. As I-XBAL is
expected to be a degradation-resistant LHRH analogue (2.9),
non-specific binding and affinity labelling,as a result of enzymatic
breakdown of the ligand (Das and Fox, 1979),are notexpected to be
significant factors over these time periods (Clayton and Catt, 1981).
Optimal affinity labelling of the LHRH receptor site was found
to occur using the bifunctional ester EGS (5mM-for 30 minutes on
125
ice) to crosslink I-XBAL binding at equilibrium with the
binding site. In attempts to purify the affinity-labelled receptor
by affinity chromatography, a lower concentration of EGS (0.5mM) was
used in an attempt to reduce non-selective protein crosslinking and
125
increase the specificity of the I-XBAL crosslinking (see
above). Initial experiments had shown that the biotin-avidin
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interaction was not supressed by the presence of 5mM CHAPS/1.5M
NaCI, and that attaching an LHRH analogue to the biotin molecule did
not affect its ability to bind to the avidin-agarose (2.6). The
affinity of biotin for the avidin-agarose is in the order of
-7 -15
10 M, much lower than that for free avidin (about 10 M;
Hoffman and Finn, 1985) making it easier to use specific elution of
biotin from the avidin sites and therefore more suitable for use as
an affinity chromatography method (Wilchek, Moron and Kohn, 1984).
This practically advantageous reduction in affinity as a result of
attaching a ligand to an inert gel has been seen for many different
ligands (Strosberg, 1984).
Using a photoaffinity labelled, solubilised, rat anterior
membrane preparation, the general strategy (of covalently attaching
biotin to a membrane protein via an LHRH ligand and purifying it by
use of an avidin-gel)was shown to be effective. However, the low
125
level of specific labelling seen using I-PBL meant that
purification of proteins achieved was not selective for the LHRH
receptor. The technique would be dependent on the specificity of
the covalent labelling achieved. Having optimised crosslinking
125
conditions for EGS and I-XBAL, membranes labelled in this way
were solubilised and applied to a streptavidin-agarose column. In
this case,whilst the yield of labelled proteins was much reduced,the
specificity (in terms of being blocked by the presence of excess
LHRH) was much higher (6.3.3). The low yield of labelled proteins
may be due to non-selective crosslinking of membrane constituents
resulting in steric hinderance of biotin-streptavidin binding. One
way to try to increase the yield would be to subject the solubilised
preparation to an enzymatic (or non-enzymatic) digestion (Kasper,
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1975). As long as the type of reaction chosen did not result in the
cleavage of the biotin-receptor crosslink, the biotin would still be
available as a "handle" with which to affinity purify the protein
fragment relating to the LHRH receptor binding site. In principle,
protein sequencing of such a fragment could in turn be used to
construct oligonucleotides for cDNA screening and so provide a route
to determining the amino-acid sequence of the LHRH receptor found
(6.1).
Using SDS PAGE the proteins specifically labelled using
1 ?5
I-XBAL and 5mM EGS were found to be approximately 72,000 and
39,000 molecular weight. Previously Iwashita and Catt (1985) found
pituitary LHRH binding proteins to have molecular weights of 59,000
and 40,000. As the binding to both these and those detected using
EGS crosslinked membranes is displaceable by non-specific levels of
LHRH (lpM), it is possible that the same proteins have been detected
in both studies. This is possible as although the mean size of the
higher molecular weight band was 72,000, it was a broad band
spanning the 60,000-82,000 range of molecular weights. Another
1 ?6
possibility is that the EGS has crosslinked the I-XBAL not onto
the LHRH receptor, but adjacent proteins. Whether or not this is
the case would only be assessable using purified preparations of the
LHRH receptor protein. However, the broad agre.ement with other
estimates of the LHRH binding protein molecular weight by the same
technique (see Chapter 5; Hazum, 1981(b); Iwashita and Catt, 1985;
Eidne, Hendricks and Millar, 1985) suggests that it is this which
has been specifically labelled by I-XBAL using EGS.
No high molecular weight protein band appeared to be labelled on
the SDS PAGE gel. This is in contrast to the estimate of the size
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of the CHAPS/NaCl solubilised LHRH receptor obtained from gel
filtration (5.3.2) of 100,000-160,000. Although as previously
mentioned in Chapter 5, there are several reasons why a protein on
gel filtration might artefactually appear to have a higher molecular
weight, it is also possible that this does represent the receptor as
it exists in the membrane. A dimer of binding proteins, or
association of other proteins with the binding protein may be
responsible for the higher molecular weight. It is interesting to
note that Couvinear, Amiranoff and Laburthe (1986) found that
125
crosslinking of I—VIP to a membrane preparation revealed a
50,000 molecular weight component (on SDS PAGE), whereas
crosslinking to a solubilised preparation revealed a 150,000
molecular weight protein. This might suggest that in situ covalent
labelling of a receptor site does not enable the crosslinking of the
binding protein to its adjacent proteins in the receptor complex.
After solubi1isation this would appear to become possible, so that
the receptor macromolecule as it exists in the membrane (and in
solution with mild detergents) is stabilised and can be detected on
125
SDS PAGE. Similarly, crosslinking of I-XBAL to CHAPS/NaCl
solubilised LHRH receptors (after removal of the detergent solution
by PEG precipitation) may provide confirmation of the existence of a
high molecular weight complex under these condi.tions by stabilising
it and allowing it to be detected using SDS PAGE. Although this had
not been attempted in this study, it might be an illuminating
experiment to carry out.
The total amount of LHRH receptor protein in rat anterior
pituitary tissue is low (only about 90fmol of binding sites per rat
anterior pituitary gland), therefore the intention was to transfer
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the optimised affinity labelling procedure to a more abundant source
of LHRH receptors. Such a source could possibly be bovine anterior
pituitary tissue (3.7). Although receptors exist in the bovine
gland at a rather lower density (10% of that found in male rat
tissue 3.3.7.1), the total number per gland is much higher than that
found in rats (about 3-4pmol). Unfortunately, removal of the
Tris/BSA binding medium and replacing it with the Hepes-KOH buffer
(which is free of primary amino-groups) resulted in a dramatic
increase in non-specific and decrease in specific binding. It was
clearly necessary to replace the Tris/BSA as this represented a
major source of free amino-groups for non-selective crosslinking and
may well have resulted in the sequestering of EGS activity.
(Glycine at 67mM is used to quench the reaction normally, 25mM
Tris/0.1% BSA may well have had a similar effect.) It is likely
that, rather than the replacement of the Tris-HCl buffer with
Hepes-KOH buffer?it was the removal of the BSA that resulted in the
increased non-specific binding seen. As optimal conditions for
125
specific I-XBAL binding to bovine anterior pituitary tissue
include the presence of BSA or a similar protein to reduce excessive
non-specific binding, it is possible that photoaffinity labelling
instead may be relatively more efficient and specific for this
tissue, although very high yields and specificity would not be
expected. Judging from most other photoaffinity labelling of
receptor sites, the overall yield of labelled receptors may be low;
a usual value given by Pilch and Czech (1984) is 4%, and judging
from the work with the rat receptor (6.3.1 and 6.3.2.1) only poor
levels of specificity would be predicted for the currently available
1igands.
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In conclusion, whilst conditions for the covalent labelling of
rat anterior pituitary receptors have been optimised to give 23%
specific labelling, these methods have not been found to be suitable
for use on the more abundant source of LHRH receptors, bovine
anterior pituitary tissue. Affinity chromatography of the
biotin-1abelled protein has been shown to be possible, but only low
recoveries have been attained. Better yields may be found if the
solubilised, crosslinked preparation is subjected to some method of
protein fragmentation prior to affinity chromatography in an attempt
to increase the accessibility of the biotin for the streptavidin-
sepharose. Further development of such a strategy could result in
the purification of a biotin labelled fragment of the LHRH receptor
protein suitable for amino-acid sequencing. This in turn could be
used to produce oligonucleotide probes to use in the determination
of the molecular characteristics (cDNA and amino-acid sequence) of
the LHRH receptor protein.
Chapter 7
Summary and General Discussion
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In this Thesis the approach of measuring 1igand-receptor
interactions has been used extensively to investigate a wide variety
of aspects of the LHRH receptor. Initial studies confirmed the
validity of the method used (described in 2.4) showing it to reveal
equilibrium binding to specific LHRH receptors that were
pharmacologically similar to those described in the literature
(Clayton and Catt, 1980). This approach proved useful in studies to
try to further investigate the transducing systems used by the LHRH
receptor of the pituitary gland and also in characterising the
integrity of solubilised receptors.
7.1 Studies on the membrane-bound LHRH receptor with reference to
LHRH action
In view of evidence that K+ channel closure may participate in
the mechanism of LHRH action and that agonist-activated G proteins
may interact rather directly with certain K+ channels (Chapter 3),
experiments were carried out to assess any allosteric effects of
K+ or of K+ channel blockers on LHRH receptor binding.
No support could be found for the hypothesis that potassium
channels, particularly A-type channels, are closely associated with
the LHRH receptor (Chapter 3). The pharmacology of potassium
channels is, however, very complex, with many similar but not
identical types having been identified (Cook, 1988). Recently the
cDNA clones of the Drosophilia Shaker locus have been sequenced
(Schwarz, Tempel, Papazian, Jan and Jan, 1988). This locus,absent
from the Shaker mutation,was thought to encode the A-type K+
channel (Salkoff and Wyman, 1981). It was found that by a mechanism
of alternative splicing of transcripts at least four different
proteins could be produced from the same locus (Schwarz, Tempel,
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Papazian, Jan and Jan, 1986). Two of these, expressed separately in
+
oocytes, resulted in functional K channels similar to A-channels
but each with slightly different kinetic properties (Timpe, Schwarz,
Tempel, Papazian, Jan and Jan, 1988). This led the group to suggest
that the multiplicity of K+ channels observed could be the result
of channel complexes (possibly each consisting of four gene
products) of varying subunit composition, each subunit type derived
from a differently spliced transcript. Possibly a similar mechanism
may also be responsible for the complexity of other types of K+
channels. This may in part explain the confusion existing in the
identification of K+ channels thought to be involved in LHRH
actions, most electrophysiological studies suggesting the
2+
involvement of M-type and Ca activated channels, but a minority
of electrophysioligical together with secretion studies indicating
the A-channel (see 3.3.4). It appears most likely that the
LHRH-induced K+ channel modulations observed by
electrophysiological techniques are indirect effects involving
diffusible second messengers and that the complexity of observations
on secretion may result both from the great heterogeneity of K+
channels and the simultaneous effects of LHRH on several different
types. This is likely to become clear as the primary transducing
systems of LHRH receptors are further elucidated.
Extensive investigations (under stringent conditions) revealed
that the LHRH-receptor is indeed likely to have a direct interaction
with a G-protein ~ as might be expected for receptors activating
phosphoinositide metabolism (Graziano and Gilman, 1987; Putney,
1987). Although it was not possible to consistently quantify the
reduction in affinity of LHRH in the presence of GTPyS (see 3.3.3)^
-241-
the present report would appear to be the first describing such an
effect. Alternative ligands (antagonists), in preparation, may
facilitate these investigations. As it appears likely from
molecular biological evidence that the sites of interaction of a
receptor and G-protein are similar for all types of G-protein
(Sullivan, Miller, Masters Beiderman, Heideman and Bourne, 1987)?it
is perhaps surprising that adenylate cyclase linked receptors appear
to show a more obvious allosteric influence on G-protein activation
(Blume, 1978; Glassman and Presek, 1979; Tsai and Lefkowitz, 1979;
Shane, Gammon and Bilezikian, 1981; Hulme, Berrie, Birdsall, Jameson
and Stockton, 1983). It may be that whilst all receptors that
interact with G-proteins do have some structural similarities (in
the same way as ion channels, both ligand and voltage gated, have
been identified to have several structural features in common;
Unwin, 1986; Stevens, 1987)?they also possess features uniquely
dependent on the type of G-protein they interact with. As such the
relationship between the ligand binding site and the site of
G-protein interaction in adenylate cyclase linked receptors may be
closer than those linked to phosphoinositide phosphodiesterase,in
the sense of displaying a greater allosteric interaction in ligand
binding experiments. Recognition of such features (common to one
type of receptor but not a related one) in cloned and sequenced
receptor proteins or the use of site directed mutagenesis and
expression vectors may help in assigning functional roles to the
tertiary and quaternary structures of proteins.
7.1.1 Investigations of some extra-pituitary LHRH receptors
Despite the finding by autoradiography of high levels of
specific LHRH binding sites in rat hippocampus (Reubi and Maurer,
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1984), ligand binding to hippocampai membranes was unable to confirm
this (3.3.5). Whilst it is possible that specific binding of
125
I-buserelin may be detectable using a purified plasma membrane
preparation, its absence from the crude, washed homogenate
preparation suggests that the level of specific binding may be very
low. Immunological and electrophysiological techniques have also
failed to reveal the presence of LHRH-like material in, or an action
of LHRH on, hippocampus (see 3.4.2) suggesting that the sites
detected by autoradiography may not be functional LHRH receptors.
Improved knowledge of the LHRH receptor site in the pituitary may
enable this putative hippocampai site to be clearly recognised as
perhaps a true receptor or possibly an enzyme degradation site for
an LHRH-like substance.
7.2 Studies on solubilisation and purification of the LHRH receptor
The series of experiments described in Chapters 4, 5 and 6 were
designed to solubilise from a membrane preparation (male rat
125
anterior pituitary) the I-buserelin binding site, characterise
it and so confirm its identity as the LHRH receptor and then to
further develop a strategy for its isolation.
Results in the literature suggested that there was no clear
pattern for predicting which detergent (or even which type of
detergent, such as nonionic, or zwitterionic) would be most
successful at solubilising a receptor protein in high yields without
denaturing it (see Chapter 4). However, it did appear that
increasing the ionic strength of a detergent solution may be
effective (4.1). Initial studies were carried out with the
zwitterionic detergent CHAPS - previously used in attempts to
solubilise the LHRH receptor (Perrin, Haas, Rivier and Vale, 1983;
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Capponi, Aubert and Clayton, 1984; Hazum, Schwartz, Waksman and
Keinan, 1986). The results showed that highest solubi1isation
yields were obtained using 5mM CHAPS and 1.5M NaCl (4.3.1). A range
of other detergents were also tested at concentrations approximately
equal to their critical micellar concentration, both with and
without the 1.5M NaCl found to be optimal with 5mM CHAPS. None of
the detergents tested were capable of solubilising the
125
I-buserelin binding sites as efficiently as the combined 5mM
CHAPS/1.5M NaCl (4.3.1.3). The other condition found to be
important for optimal solubilisation of the binding sites was the
ratio of detergent to protein, being optimal under the present
conditions at a value of 1.6 (w/w) (4.3.1.3). Addition of glycerol
(efficient at stabilising some other solubilised receptors; Dias,
Huston and Reichert, 1981; Ascoli, 1983; Iida, Amir and Ingbar,
1987) did not appear to have a beneficial effect on solubilised LHRH
receptors (4.3.1).
Although a high yielding solubilisation could be obtained using
5mM CHAPS/1.5M NaCl (over 70% of available sites under optimal
conditions), the subsequent presence of specific binding of
125
I-buserelin appeared to be conditional on the removal of the
CHAPS/NaCl solution by a PEG precipitation step. Binding to both
membrane and solubilised preparations in the presence of various
combinations of detergent, NaCl and glycerol suggeststhat whilst
each has some detrimental effect on the amount of specific
125
I-buserelin binding detectable, by far the greatest effect is
due to the presence of the high NaCl concentration (4.3.3; 4.3.4).
In turn, the high NaCl concentration was essential for the high
yielding solubilisation (4.3.1). The two conditions, high yielding
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solubi1isation and retention of specific I-buserelin under
solubilisation conditions did not appear to be compatible. Further
experiments, altering the composition of the solubilisation solution
after solubilisation had been achieved, were also unable to reveal
conditions which would allow both properties to be retained (4.3.5;
4.3.6).
125
Despite this, it was apparent that the I-buserelin binding
site solubilised by 5mM CHAPS/1.5M NaCl could be fully recovered by
subjecting the solubilised preparation to a PEG precipitation step.
In this way ligand binding assays were used to characterise the
125
I-buserelin binding site as an undenatured LHRH receptor
(Chapter 5). The binding affinities of native LHRH, a superagonist,
partial agonist and antagonist were all very similar for both the
solubilised and membrane bound site.
Having solubilised the LHRH receptor in an undenatured form, it
was possible to try to further characterise it in this state. The
apparent size of the LHRH receptor using SDS PAGE techniques has
been shown previously to be approximately 60,000, whereas estimates
obtained of the membrane bound receptor suggest a size of 135,000
(Conn and Venter, 1985). Gel filtration revealed that the
CHAPS/NaCl-solubi1ised LHRH receptor eluted mainly in a peak
corresponding to a molecular weight of between 100,000 and 160,000
(5.3.2). Whilst a number of factors, such as anomalous behaviour of
the protein in the gel column (due to a non-uniform shape and/or the
presence of carbohydrate moieties on the protein) or detergent or
lipid binding to the protein, may contribute to the high molecular
weight observed, it is possible that the solubilised form may be a
complex of the 60,000 LHRH binding protein detected by SDS PAGE,
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either as a dimer or associated with other non-binding subunits. In
order to determine if that is in fact the case, further purification
of the solubilised LHRH receptor would be necessary.
Initially, it was hoped that the solubilised receptor could be
purified using LHRH ligand affinity chromatography. The finding
that solubilisation and ligand binding conditions were incompatible
meant that some other approach was required. As the binding of
biotin to avidin (or streptavidin) is largely unaffected by the
presence of detergent solutions, and the affinity of biotin for
avidin-agarose is of suitable order for use in affinity
chromatography (ICgg of about lCT^M : 2.6),this interaction
seemed to provide a suitable method for receptor purification.
However, in order to be of any use in this case, the biotin had to
be covalently attached to the LHRH receptor in a highly specific
manner. To achieve this, several biotin-containing LHRH analogues
were designed (2.9) and their properties characterised (6.3.2).
These analogues were bound to the membrane preparation and either
photoaffinity or covalent crosslinkers were used to try to link them
to the receptor protein. Of those tried, the greatest values for
irreversible, specific binding were obtained with the LHRH analogue
XBAL and 5mM EGS; (6.3.2.3) up to 23% of the specific ^I-XBAL
binding being covalently linked of the LHRH receptor protein or
closely related structures.
Both the photoaffinity and covalent crosslinking methods of
biotin-1abel1ing the anterior pituitary membrane preparations were
used to test the feasability of the biotin-avidin affinity
chromatography step. The results suggested that the biotin-avidin
(or streptavidin) interaction retained its reversibility despite the
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bulky receptor-1igand complex being conjugated to the biotin. In
the case of the photoaffinity labelled preparation, using the ligand
PBL (6.3.3.1), the specificity of the receptor labelling was too low
to be of practical use. For the preparation labelled using covalent
crosslinkers, although much greater specificity and efficiency of
receptor labelling was seen, there appeared to be some steric
hindrance of the biotin-streptavidin interaction. Multiple
inter-protein links caused by the non-selective nature of the
crosslinkers may be responsible, so it may be possible to overcome
this problem by incorporating a partial protease degradation of the
biotin-1abelled membrane preparation prior to solubilisation. It
will be necessary to optimise this step before the full potential of
this method in the purification of the LHRH receptor (or a
sequenceable fragment) can be realised.
7.3 Future perspectives for studies of the LHRH receptor
Although these studies have largely been carried out on rat
anterior pituitary tissue, further studies on LHRH receptor
isolation and molecular characterisation would be greatly
facilitated by some more abundant source of LHRH receptors. With
this in mind, other possible sources of the receptor protein were
investigated (3.3.7), and the bovine anterior pituitary was found to
be the most promising. Unfortunately, largely due to differences in
the kinetics and specificity of LHRH binding to bovine and rat
anterior pituitaries, the methods of covalent labelling optimised on
rat tissue did not appear to be useful on bovine tissue. It would
be necessary to repeat the optimisation process in order to use this
larger supply of LHRH receptor sites in the biotin-avidin affinity
chromatography strategy devised here.
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An alternative, potentially more abundant source of LHRH
receptors, would be from a cell line. Unfortunately no present cell
line is known to express high affinity LHRH receptors. A recent
brief report of electrophysiological responses to LHRH in the GH^
rat somatomammotrophic cell line provides an interesting
possibility, but the specificity and reproducibiIty of these
observations remain unsubstantiated as yet (Rosenthal, Hescheler,
Hinsch, Spicher, Trautwein and Schultz, 1988). One method that has
been used to create novel neural cell lines has been by the
introduction of oncogenes into primary cells (Cepko, 1988). Using
retrovirus-mediated transduction this can produce stable cell lines
and such a technique may be useful in producing a gonadotrophic cell
line expressing high affinity LHRH receptors. Such a preparation
would greatly facilitate the study of the receptor, both
investigations of its mechanism of action and molecular
characterisation, by providing an abundant and uncontaminated source
of gonadotrophes.
The detergent solubi1isation and purification strategy for
molecular characterisation of receptor proteins is only one of
several that may be successful (Strosberg,1987). One that has
proved fruitful for the cloning of two low abundance
neurotransmitter receptors is that of functional expression of mRNA
(Levitan, 1988). Expression of both 5-HT^ receptor and substance
K receptor was determined electrophysiologically by their effects on
2+ _
Ca -activated CI channels. In order for this method to be of
use in the cloning of other receptor types, specific ligand binding
must result in the activation of a readily detectable ion channel
(either directly or indirectly via a second messenger). This is
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probably an appropriate route for investigating LHRH receptors (as
9+
ligand binding results in an elevation of cytosolic Ca levels
which may well be sufficient to activate the large conductance
chloride channels utilised in the 5-HTand substance K receptor
studies). Given the difficulties encountered by ourselves and other
groups with protein purification, such an approach may therefore
prove to be the strategy of choice in the cloning of the LHRH
receptor, provided that a suitable mRNA library containing the
message for functional LHRH receptors (in sufficient abundance) can
be produced.
If such a strategy were successful, it would be interesting to
compare the sequences of anterior pituitary LHRH receptors with the
low affinity receptors found elsewhere, such as the placenta, and
also with those responsible for the actions of LHRH in the CNS. It
is possible that, similar to other receptors such as the muscarinic
cholinergic receptor subtypes (Kerlavage, Fraser and Venter, 1987)
or the and adrenergic receptors (Frielle, Kobilka,
Lefkowitz and Caron, 1988), receptor proteins for the same
endogenous ligand but with different pharmacological characteristics
are in fact different gene products. Whether receptor heterogeneity
was the result of differential splicing (as seen for Drosophi1 a
A-channels; Timpe, Schwarz, Tempel, Papazian, Jan and Jan, 1988),
differential post-translation modification, or the existence of more
than one related gene could then be determined.
If the LHRH receptors present in the pituitary and other tissues
were found to be structurally different, then it may be possible to
develop selective drugs. Clinically these may be of use in
selectively modifying either the pituitary-gonadal axis, CNS aspects
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or other elements of LHRH action. For instance, LHRH agonists have
been found to be useful in the treatment of premenstrual syndrome, a
phenomenon that appears unlikely to be a direct effect of either
oestradiol or progesterone (Bancroft, Boyle and Fraser, 1986). One
aspect of the syndrome are the psychological symptoms, including
depression or irritability. Agonists selective for LHRH receptors
responsible for the beneficial effects in this syndrome (possibly
distinct from receptors in the anterior pituitary) may prove
effective in treating the syndrome in the absence of suppression of
pituitary gonadotroph release.
7.4 Conclusions
The experiments carried out in this Thesis have contributed to
the understanding of the properties of the LHRH receptor and its
transducing systems. Preliminary evidence (but the first of its
kind) supporting the hypothesis that the receptor interacts directly
with a G-protein is provided, whereas the involvement of K+
channels in LHRH action can neither be confirmed nor refuted. A
high yielding method of solubilization of the rat anterior pituitary
LHRH receptor was devised and multifunctional biotinylated covalent
ligands were designed, synthesised and used in a novel strategy for
receptor purification. Nevertheless, subsequent technical
difficulties and the lack of availability of abundant sources of
receptor protein, prevented purification of sufficient receptor
protein for partial sequencing. The results suggest that other
strategies for molecular characterisation of the LHRH receptor
protein may prove to be more productive.
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Appendices
(X)
Appendix I Iodination of LHRH Analogues
All LHRH analogues were iodinated by the chloramine T method
(Hunter and Greenwood, 1962) as described for LHRH and buserelin
(Nemann and Sandow, 1973; Sandow and Konig, 1979) with modifications.
Reagents














5yg/10yl MeOH, made up to 20yl with
0.01M acetic acid
5yg/10p1 PBS
Chloramine T 2.5mg/ml PBS
(N-Chloro-p-toluenesulphonamide-Na)
Sodium metabisulphite 2.5mg/ml PBS
Na^5I Amersham IMS 30: 3.7GBq/ml
0.5M Phosphate pH 7.5:
Protocol: i) 10yl (82yl for PBL) 0.5M phosphate buffer added to
peptide solution (volumes as above) in eppendorf.
ii) 10yl (5y1 for PBL) Na125I (37MBq) added.
iii) 20y1 chloramine T added, mix gently.
(xi)
iv) Leave to react for 20 seconds.
v) Add 50vil sodium metabisulphite, mix gently.
Separation of Iodinated Analogue
The iodinated analogue was usually separated from free iodine by
affinity chromatography using a G-25 fine sephadex column. For the
125
chemical crosslinking experiments I-XBAL was separated from
free Na^^I using HPLC.
1) Affinity Chromatographgy
Column: 1 x 15cm Sephadex G-25 fine.
Eluting solutions: 0.01M acetic acid.
0.01M acetic acid/3% bovine serum
albumin (for buserelin and PBL).
0.01M acetic acid/6% bovine serum
albumin (for PBAL, XBAL and
LHRH-antagonist).
Protocol: i) Iodination reaction mixture applied to column.
ii) Eppendorf rinsed with 0.8ml acetic acid/BSA
solution, this was also applied to the column.
IOC
iii) Free I peak eluted with 0.01M acetic
acid. 2ml fractions collected and counted.
iv) Iodinated peptide eluted with acetic acid/BSA
(3% or 6%) solution. 2ml fractions collected
and peak of activity tube retained.
v) Aliquot peak tube - lOOyl. Store at -70°C.
(xii)
2) HPLC
Apparatus - Two-channel minipump (Milton Roy Co., Riviera
Beach, FL)
Sample injection valve with 1ml loop (Rheodyne
Berkeley, CA)
Guard column holder (Brownlee MPLC cartridge
system: Brownlee Labs, Santa Clara, CA)
3cm x 0.46cm disposable column of cyanopropyl
silica (Spheri 5 cyano: Brownlee Labs)
Eluting Solvents: A 0.2% trifluoroacetic acid in
distilled H^O
_B 0.2% trif luoroacetic acid in MeOH.
Protocol: i) Prime pump and wash column with solvent B.
ii) Prime pump and wash column with solvent A.
iii) Increase iodination reaction mixture
volume by adding 0.9ml KI (lOmg/ml in A).
iv) Inject and load iodination reaction
mixture onto column.
v) Elute with stepwise gradient of B from 0%
to 100% (increments of 20%). Flow rate of
lml/minute, collect 1 minute fractions.
Six fractions at each, step of gradient.
1 oc
vi) Count fractions. Free I is eluted
first. Retain peak of labelled peptide
and store at -70°C.
Radiolabelled buserelin stored at -70°C was active for up to 12
weeks after iodination. Other iodinated analogues were used within
(xiii)
3 weeks of iodination.
In the case of the photo-sensitive analogues PBL and PBAL all
steps were carried out in subdued lighting or in the dark with a
safety light wherever practicable.
(x i v)
Appendix II SDS Polyacrylamide Gel Electrophoresis (SDS PAGE)
The method of SDS PAGE used was that first described by Laemmli
(1970).
Stock solutions
4 x separating Gel Buffer: 45.4g Tris/HCl (pH8.8)
l.Og sodium dodecyl sulphate
into 200mls distilled
4 x stacking Gel Buffer: 12.lg Tris/HCl (pH6.8)
0.8g sodium dodecyl sulphate
into 200mls distilled H^O
SDS Sample Buffer: lOg glycerol
5ml B-mercaptoethanol
2.3g sodium dodecyl sulphate
0.75g Tris/HCl (pH6.8)
made up to lOOmls with distilled H^O
30% Acrylamide: 29.2g acrylamide
0.8g bis-acrylamide
made up to lOOmls with distilled H^O
TEMED: N,N,N1,N'-Tetramethylethylenediamine.
These stock solutions were kept at 4°C (the acrylamide stock in the
dark).
10% Ammonium persulphate: w/v in distilled H£0
Made fresh for each experiment.
(XV)










Tank Buffer Tris 15.15g
glycine 77g
sodium dodecyl sulphate 5g




Preparation: 1) Polyacrylamide Gel.
a) Constituents of the separating gel (as above)
were mixed, the ammonium persulphate and TEMED
being added immediately before the gel was
poured.
b) The gel solution was poured into the prepared
(xvi)
gel plates. (Two 20 x 20cm glass plates
separated by a 0.7mm spacer. Edges sealed with
tape and 11 agarose.)
Overlay with butanol.
c) Leave to polymerise for an hour.
d) Mix stacking gel - adding ammonium persulphate
and TEMED immediately before pouring.
e) Decant butanol overlay and dry inside of plates.
f) Put well former (lOOyl wells) into place and
pour stacking gel.
g) Leave to polymerise for an hour.
h) Remove tape from bottom edge of gel plates and
well former from stacking gel.
2) Samples and molecular weight standards.
a) Samples were dissolved into lOOyl sample
buffer, add 5yl of It bromophenol blue.
b) Add 8yl of sample buffer and lyl 1% bromophenol
blue to 3yl ^C-molecular weight markers
(Amersham, 2,350-200,000MWT).
Running SDS PAGE: Apparatus: GE-214 LS vertical electrophoresis
apparatus (Pharmacia Fine Chemicals
Ltd)
LKB 2197 power supply
LKB 2219 Multitemp II thermostatic
circulator.
Protocol: i) Samples (80yl) and standards
(10pl) are applied to the wells
of the stacking gel.
(xvii)
ii) Gel placed in apparatus, with
the tank circulating, cooled to
10°C and the power supply on -
constant current 40mA. Run for
10-12 hr, (until dye front was
within 4cm of bottom of
separating gel.)
Fixing Gel and Autoradiography
i) Fixed (40% methanol, 7% acetic
acid) for at least 2 hrs.
ii) Dried under vacuum.
iii) Placed in Kodak X-Omatic
cassette (Rapid x 2) with
X-Omat S film, exposed for 4
weeks at -70°C.
iv) Developed using Kodak DX-80
developer, FX-40 X-ray liquid
fixer (Kodak Ltd, Glasgow).
(xviii)
Appendix III Synthesis of ligands PBL, PBAL and XBAL
(All peptide synthesis work was done by Dr C M Bladon)
The ligands (see fig. AIII.l: 1-3) were prepared by coupling
either of one of the two reagents (4,5) with one of the peptide
backbones (6,7).
1. Synthesis of reagents
Both reagents, biotinyl-p-azidophenylalanine N-hydroxy-
succinimide ester (4) and biotinyl-t-butoxycarbonylaminoethylglycine
N-hydroxysuccinimide ester (5) were prepared from biotin and either
L-p-nitrophenylalanine or L- 2,4-diaminobutyric acid as outlined in
schemes (1) and (2) respectively.
Note: the compounds are written in shorthand form, eg,
H2N"C^co2H
H
2. Synthesis of [D-Lys^, desGly^]-LHRH
This peptide was prepared by solid-phase synthesis using
Fmoc-t-butyl-polyamide chemistry (Eberle, Atherton, Dryland and
Sheppard, 1986). After purification by ion-exchange chromatography
the peptide was approximately 95% pure (by HPLC) and showed the
expected amino acid composition and
molecular weight (Glu-^ 1.02, His0.96, Ser^ 0.89, Tyr^ 0.97, D-Lys^
1.00, Leu^ 1.00^ Arg, 1.00^ Pro^ 0.95, FAB-MS: found MH+ 1225, calc.
CH2




















(7) [D-Lys^, desGly^]-LHRH ethylamide.
Figure A.II1.1
(XX)
3. Synthesis of conjugates
The conjugates PBL, PBAL and XBAL were all prepared by linking
the reagent via a peptide bond to the amino group of the D-lysine
residue at position 6. For example, PBL was synthesised by first
dissolving D-Lys^-LHRH (2mg, 1.6nmol) in freshly distilled DMF
containing triethylamine (2 drops). A 5-fold excess of the reagent
(4)(5mg, 9.45ymols) in DMF (1ml) was added and the resulting mixture
was left standing in the dark for 1 hour. The DMF was evaporated
under high vacuum and the residue was triturated with ethyl acetate
(3 x 2ml) to remove excess reagent. The crude product was purified
by semi-preparative HPLC to yield 1.84mg (69%) of pure (single peak
on analytical HPLC) conjugate. The amino acid compositions of the
three conjugates are given in the table.
Note
1. Reactions involving the p-azido reagent(4) were performed in the
dark and all handling of the p-azido conjugate was carried out in
subdued 1ighting.
2. The amino group of the second reagent (5) was protected with the
t-butoxy-carbonyl group during coupling to the peptide, and was
removed, with TFA, from the conjugate.
3. HPLC condition: semi-preparative Aquapore RP300 column; eluant
A, 0.1% aq TFA: B, 90% CH^CN 10% A. The column was eluted
isocratically for 2 min with 10% B and then with a linear gradient
of 10-70% B over 30 min, flow rate 3ml/min. Optical density was
monitored at 230nm. During purification of the azido conjugate









H-Phe(NHBoc)-OMeFmoc-Phe(NHBoc)-OMFmoc-Phe(NH2 e (vi) w(vii)(viii)x) biot-Phe(NHBoc)-OMe►tin-Phe(NH2)-OHbiot- (N3 0
(x)
ir biot-Phe(N3)-0NHS
Conditions:( )SOCl^-MeOH;iFm cCl-H CO^-I^O-dioxan;i)P^-S^Pd-C-AcOH;iv10% NaHCO^Boc^O-t^O-dioxan;(v)20%piperidineinDMF;biotpentaf1uorophenylester-HOBT-DMF; (vii)NaOH-P^O-MeOH;iqTFA;ixNa^-NaNg-lMHC1N-hydroxysuccinimide-DCC-dioxan.
Scheme2.
(i)iiiv)
H-Gly(CH2CH2NH2)-OH►H-Gly(CH2CH2NHBoc -0HFmoc-GlyC 2 2NHBoc)-O (L,-2,4-diaminobutyricacid)
(v)
(vii)f










made up to 20ml, distilled H^O
4g NaOH
20g NaHC03
made up to 200ml, distilled H^O
Alkaline copper reagent was prepared by mixing the above two
solutions together.
Folin-Ciocalteau reagent - 1:10 dilution in distilled H^O.
Protocol: i) Standards (0-20ug) of bovine serum albumin and
samples (5 - lOOpl) were made up to 200pl with
distilled H20 in LP3 tubes.
ii) 500pl alkaline copper reagent was added and mixed
well.
Tubes were left for 20 minutes.
iii) 1 vi 1 of diluted Folin-Ciocalteau reagent was added and
tubes rapidly mixed.
Tubes were left for 20 minutes.
iv) Absorbance read at 725nm in a spectrophotometer and a
standard curve constructed.
v) Samples were read off standard curve.
(xxiv)
Preparation of Samples
As buffers, such as Tris and Hepes, and detergents may interfere
with the colour formation in the protein assay (Thorne, 1978),
samples in such solutions were precipitated and resuspended prior to
protein assay. Where samples were in protein containing solutions
(such as the CHAPS/NaCl solubi1isation solution) standards were
prepared by dissolving bovine serum albumin into this solution.
Following precipitation and resuspension the standards were used as
above to prepare a standard curve.
Protocol: i) TCA (25%) was added to the sample aliquot (10-250yl)
to give a 5% solution.
ii) Samples left for 10 minutes.
iii) Centrifugation 15 minutes at l,600g, 4°C to separate
precipated proteins.
iv) Samples redissolved in 50pl 0.03M NaOH for use in
protein assay as above.
(xxv)
Appendix V Avidin-Sepharose CL-4B Coupling
The coupling of avidin to Sepharose CL-4B was carried out
according to the method of Beaty and Lane (1982) after activation of
the Sepharose CL-4B by the cyanogen-bromide method described by
March, Parikh and Cuatrecasas (1974).
Cyanogen bromide activation
Reagents
Sepharose CL-4B (Pharmacia Ltd, Bucks) preswollen
Na2C03 2M in distilled 1^0
CNBr 2mg/ml in CH^CN (dried and redistilled)
NaHC03 0.1M, pH 9.5
NaHC03 0.2M, pH 9.5
Protocol i) 25ml of Sepharose CL-4B - washed (with distilled
H30) on a coarse sintered glass funnel and
resuspended into 25ml distilled H^O.
ii) 50ml 2M Na3C03 added. Stirred to mix.
iii) 5ml CNBr/CH3CN solution added (on ice in fume
cupboard). Stirred vigorously for 2 minutes.
iv) Washed on coarse sintered glass funnel with 5-10
volumes of 0.1M NaHC03, distilled L^O, 0.2M
NaHC03.
v) Filtered to moist compact cake under vacuum.
Coupling of activated gel to avidin
Reagents
CNBr activated Sepharose CL-4B (see above).
Avidin (Sigma Chemical Company) - 10yg/ml in 0.01M Na/PO^ pH 7.
0.1M NaHC03 pH 8.5.
0.1M Na/P04 pH 7 - 30.5ml 0.2M NaHP04
19.5ml 0.2M NaH2P04
mixed and made up to 100ml in distilled II^O
(xxvi)
0.01M Na/P04 pH 7 - 1:10 dilution of 0.1M Na/P04 ph 7.
0.1M NH^C^H^H (Aldrich Chemical Company, Dorset) in 0.01M
Na/P04 pH 7.
Protocol i) 10ml activated gel washed by filtration with 2
volumes each 0.1M NaHCO^, pH 8.5, distilled H^O,
0.1M Na/P04 pH 7.
ii) Resuspended into 7.5ml 0.1M Na/P04 pH 7 in plastic
bottle.
iii) 2.5ml avidin solution added, agitated gently for
20-26 hours at 4°C.
iv) Washed (filtration) with 5 volumes of 0.01M Na/P04
pH 7.
v) Resuspended into 1 volume 0.1M NH2C2H40H
solution. Agitated gently for 24 hours at 4°C.
vi) Washed by filtration with 20 volumes of 0.01M
Na/P04 pH 7. Resuspended into 10ml 0.01M Na/Pty
pH 7 and stored at 4°C.
(xxvii)
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Appendix VI Determination of the specific activity of I-XBAL
A commonly used method to determine the specific activity of an
iodinated ligand is by radioimmunoassay. Such a method has
previously been used to determine the specific activity of iodinated
LHRH (Marshall and Odell, 1975) and it was this method that was
125
initially used to determine the specific activity of I-XBAL.
The antibody chosen was F86 (kindly provided by S Lynch, Birmingham
Hospital for Women) shown by Clayton, Shakespear, Duncan and
Marshal 1 (1979(a)) to bind to LHRH analogues with changes in
amino-acids in positions 7-10. This antibody was found to bind both
125
unlabel led XBAL and I-XBAL. However, construction of standard
125
curves for both XBAL and I-XBAL revealed that these were not
parallel, that is the antibody F86 did not bind to unlabelled and
iodinated XBAL in the same manner. A different method of
determining its specific activity was therefore required.
Another way of estimating specific activity is from the
iodination precedure data, a method commonly used by the MRC Brain
Metabolism Unit Radioimmunoassay group. Iodination data for
125
I-XBAL iodinated and separated by HPLC as described in
Appendix I used to give an estimate (to within 20%) of its specific
activity.
Data (representative)
Total XBAL used 5yg (3.2nmoles)
Total ^I-Na added 770,220 cplOsec
(1,000,000 cplOsec 37MBq)
Counts left in Eppendorf 106,400 cplOsec
Therefore total applied to HPLC 663,730 cplOsec




1 65,210 13 210 25 1,211
2 53,152 14 219 26 976
3 580 15 544 27 846
4 147 16 1,741 28 371
5 160 17 3,168 29 251
6 149 18 4,823 30 222
7 144 19 4,291 31 181
8 141 20 86,640 32 125
9 269 21 171,542 33 109
10 291 22 20,445 34 98
11 196 23 4,609 35 88
12 173 24 2,044 36 95
Estimation procedure cplOsecs
Free I-Na elute off column (fractions 1-3) 118,942
19C>
Total I- reacted with peptide (fractions 15-27) 302,880
plus counts left in eppendorf 106,490
[Efficiency of counting 200ul aliquots compared to
reaction volumes - 75% (average of 6 determinations).
Therefore correcting eluted values for efficiency
of counting:
Total 125I-XBAL (302,880 x 0.75) + 106,490] 510,330
125
Therefore specific activity of I-XBAL is:
510,330 cpl0secs/3.2nmoles
As 1,000,000 cplOsecs = 37MBq (for counter used)
Specific activity of ^I-XBAL = 18.9MBq/3.2nmols
or 5,896 GBq/nmol
(xxix)
Mean specific activity (from 4 separate iodinations):
6,489 (* 680) GBq/mmol
(y counter used for ligand binding assays, counting efficiency
125
75%, therefore specific activity of I-XBAL as detected on
5
y counter = 2.65 x 10 cpm/pmol.)
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A NOVEL STIMULATORY ACTION OF SOMATOSTATIN ON PROLACTIN SECRETION
R. Mitchell and S.-A. Ogier, MRC Brain Metabolism Unit, University Department of
Pharmacology, George Square, Edinburgh, EH8 9JZ
Several actions of somatostatin on the secretion of anterior pituitary hormones
have been described (Reichlin, 1983). Further to the classical inhibition of GH
secretion (Brazeau et al, 1973), inhibitory effects on basal - (or more
prominently, stimulus-induced) - secretion of TSH and ACTH have been reported.
Early experiments observed only weak and inconsistent effects oN prolactin
secretion (Vale et al, 1974), but employed long incubation periods, likely to
obscure the initial response.
We have investigated the effects of somatostatin analogues on secretion of
prolactin and GH, using a rapid superfusion technique which allows the
measurement of transient effects.
Anterior pituitary glands from male Wistar rats were chopped into 500pm prisms
and incubated for 1 hour at 37°C in oxygenated Krebs bicarbonate medium, pH
7-4 containing 0-1% BSA, 2 g/1 glucose and 30 pg/1 bacitracin. Tissue was
then superfused with medium at 0.5 ml/min. Fractions (2 min) were collected
serially and hormone concentrations were measured by radioimmunoassay.
After 90 min, a relatively steady baseline was reached and drugs were added.
Somatostatin-14 produced a marked increase in prolactin secretion in experiments
where GH secretion was concomitantly inhibited. The response gradually
diminished towards baseline over about 1 hour, even in the continued presence of
somatostatin. The effect was concentration-dependent from 20-250 nM but
declined at higher levels. Somatostatin-28 mimicked this response over a
similar concentration range with some 65± 10% increase at lOOnM. Neither
somatostatin-28^_12 (Benoit et al 1982) nor d-TrpB somatostatin-14 produced
any significant increase in prolactin secretion at concentrations up to 300nM.
The response to lOOnM somatostatin-28 was significantly attenuated to 16 ± 4%
increase by the putative somatostatin antagonist
cyclo [7-aminohepantanoyl- Phe-0Trp-Lys-Thr(Bzl)] (Fries et al, 1982) at 60nM.
These results demonstrate a novel stimulatory effect of somatostatin on
prolactin secretion, which contrasts with previously described effects on other
anterior ptiuitary hormones in that they are all inhibitory. Both
somatostatin-14 and somatostatin-28 but not the fragment somatostatin-28]_i2,
are active at this site and it is susceptible to the putative somatostatin
antagonist. The novel stimulatory influence exerted on lactotrophes suggests
that this somatostatin recognition site may have different properties from those
on other anterior pituitary cells.
Benoit, R. et al (1982) Proc. Natl. Acad. Sci. _79, 917.
Brazeau, P. et al (1973) Science, 179, 77.
Fries, J.L. et al (1982) Peptides, 3, 811.
Reichlin, S. (1983) In: "Brain Peptides", Ed: Krieger, Brownstein and Martin.
Vale, W. et al (1974) Endo. 95, 968.
[From the Proceedings of the Physiological Society, 19-20 December 1985
Journal of Physiology, 373, 75P, 1986]
Investigation of the mechanism of somatostatin action on growth hormone
secretion in rats
By R. Mitchell and S.-A. Ogier. M.R.C. Brain Metabolism Unit, University
Department of Pharmacology, 1 George Square, Edinburgh, EH8 9JZ
Studies on the mechanism of somatostatin (SS) action have yielded conflicting
results (see Hayasaki-Kimura & Takahashi, 1979). We have investigated this
problem using a rapid superfusion technique. Anterior pituitary glands from male
Wistar rats were sliced into 500 pva prisms and after preincubation were continuously
perfused with modified Krebs bicarbonate medium (Mitchell & Ogier, 1985). GH was
measured by radioimmunoassay.
Both SS-14 and SS-28 caused concentration-dependent inhibition of GH secretion,
in the range 0*2-300 nM, with SS-28 apparently being of much greater potency. The
effect was mimicked by the analogues D-Trp8 SS-14 and D-Trp8, D-Cys14 SS-14, unlike
the action of SS on prolactin secretion (Mitchell & Ogier, 1985) where these are
inactive. The K+ channel blockers TEA (10 mi) and quinine (200 pm) caused large
increases in GH secretion of around 5-fold and 2-fold respectively. However, they
caused no attenuation of the inhibitory effect of 10 nM SS-28 (control 62 + 6% ofprior
baseline; TEA 52 + 3%, quinine 41 ±2%, n = 4-6). Dibutyryl cyclic AMP (dbcAMP)
(1 mM) increased GH release by some 29 + 7%, but after exposure to 200 nM SS-14
(which had itself slightly reduced secretion) this was completely blocked ( — 9 + 6%,
n = 6).
It appears that K+ channels sensitive to TEA or quinine are not of major
importance in the action of SS on somatotrophes, in contrast to observations on
mouse pancreatic islet /? cells (Pace & Tarvin, 1981). The effect of SS on GH secretion
is reported to be attenuated by pertussis toxin (Cronin, Rogol, Myers & Hewlett, 1983)
suggesting an inhibitory coupling with adenylate cyclase. However, responses to
dbcAMP (which should by-pass any sites of adenylate cyclase regulation) are readily
inhibited by SS (see also Hayasaki-Kimura & Takahashi, 1979). Apparently, neither
activation of these K+ channels nor inhibition of adenylate cyclase can account for
the effects of SS on GH secretion.
references
Cronin, M. J., Rogol, A. D., Myers, G. A. & Hewlett, E. L. (1983). Endocrinol. 113, 209.
Hayasaki-Kimura, N. & Takahashi, L. (1979). Proc. Soc. Expl. Biol. Med. 161, 312.
Mitchell, R. & Ogier, S.-A. (1985). Brit. J. Pharmacol. (In the Press.)
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EVIDENCE FOR SEX DIFFERENCES IN GnRH RECEPTORS AND MECHANISM OF ACTION
R. Mitchell, S.-A. Ogier, M. Johnson, A. Cleland,
J. Bennie, G. Fink
MRC Brain Metabolism Unit
University Department of Pharmacology
1 George Square, Edinburgh EH8 9JZ
INTRODUCTION
Over recent years, a number of hypotheses have been proposed for
the biochemical mechanism of action of Gonadotropin-Releasing Hormone
(GnRH). Although adenosine 3',5'-monophosphate (cAMP) has been
implicated as a second messenger in GnRH action (Borgeat et al, 1972),
this has been refuted (Conn et al., 1979) and Cronin et al (1983) have
shown that changes in Luteinizing Hormone (LH) secretion are not
temporally coupled to changes in cAMP levels. An apparently direct
effect of cAMP derivatives on GnRH receptors (Smith et al, 1982) may
have contributed to some of these results.
In contrast, there is evidence that Ca2+ is necessary for the
post-receptor process coupling LH secretion to occupancy of GnRH
receptors. While most groups have described a strict dependence of
GnRH-stimulated LH release on extracellular Ca2+ concentration
(Marian and Conn, 1979; Pickering and Fink, 1979; Naor et al, 1980;
Bourne and Baldwin, 1980; Borges et al, 1983), it has been reported
that this is less marked than the Ca2+-dependence of
depolarisation-induced release (Hopkins and Walker, 1978). Radioactive
ion flux experiments have indicated that GnRH can mobilise Ca2+ from
extracellular-, but probably also intracellular sources (Williams,
1976; Hopkins and Walker, 1978; Conn et al, 1981). A number of studies
have reported marked inhibition of GnRH-stimulated LH secretion by
verapinoid calcium antagonists, although in many instances this appears
to be incomplete, even at very high antagonist concentrations (Hopkins
and Walker, 1978; Marian and Conn, 1979; Pickering and Fink, 1979; Naor
et al, 1980), again implying a component of intracellular Ca2+
mobilisation. An electrophysiological study on (trypsin-dispersed)
gonadotrophes of the ovine pars tuberalis, (Mason and Waring, 1985) has
reported membrane voltage fluctuations in response to GnRH which were
suggested to reflect the activation of a Ca2+ channel or a
Ca2 -dependent channel.
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Recent evidence suggests that inositol 1,4,5-trisphosphate (formed
in the metabolic turnover of inositol phospholipids) can act as a
second messenger signalling for Ca2+ mobilisation (Streb et al, 1984;
Berridge and Irvine, 1984), GnRH has been reported to stimulate
phospholipid metabolism in gonadotrophes, with increased turnover of
phosphatidyl inositol (Snyder and Bleasdale, 1982; Naor et al, 1984).
This response is likely to be multifunctional, in that diacylglycerol
(an activator of protein kinase C) is also formed (Nishizuka, 1984).
Both diacylglycerols and phorbol esters (which also activate protein
kinase C) can stimulate LH secretion (Smith and Vale, 1980; Catt et al,
1984; Conn et al, 1985). Arachidonic acid is also liberated in the
GnRH-induced turnover of inositol phospholipids and whilst the possible
involvement of prostaglandins in GnRH-induced LH secretion appears to
have been eliminated, a number of novel epoxygenated metabolites have
been recently implicated (Snyder et al, 1983). A synergistic
interaction between protein kinase C and elevated intracellular Ca2+
concentration as LH secretagogues has recently been suggested (Harris
et al, 1985).
Despite all this evidence implicating Ca2+ as a second messenger
in GnRH action, it is important to consider that mobilisation of Ca2+
is likely to be a ubiquitous requirement in secretory response
processes (Moriarty, 1978). Great caution is required therefore, in
attributing to this the role of the primary mechanism transducing the
signal of GnRH receptor occupancy by an agonist.
Extensive electrophysiological analysis of GnRH action at a
neuronal site has been carried out using the bullfrog sympathetic
ganglion. Although the GnRH-like peptide found there endogenously may
be teleost GnRH rather than the mammalian sequence (Eiden et al, 1982),
it-is clear that exogenous GnRH can mimic the synaptically-mediated
response of a late slow depolarisation of the principal cells of the
ganglion (Jan et al, 1980). Adams and Brown (1980) have reported that
the observed depolarisation is associated with inhibition of the
potassium M-current, which appears to show quite distinct electrical,
kinetic and pharmacological properties (Adams et al, 1982a,b). A
minority of GnRH-sensitive cells, either additionally or separately,
show conductance changes that cannot be accounted for by M-current
blockade (Katayama and Nishi, 1982).
Clearly therefore, there may be a number of membrane ion channels
involved in GnRH action, especially potassium M-currents, which have
not so far been investigated in gonadotrophes. It is not clear whether
any one ionic or chemical signal will prove to be the primary
co-ordinating event ensuing from GnRH receptor activation, but it now
seems likely that a number of components contribute to the overall
response observed.
Our approach was to attempt an assessment, by pharmacological
means, of the role of membrane K+- and Ca2+-channels in the
secretory response of gonadotrophes to GnRH. It is feasible that the
receptors could interact relatively directly with particular ion
channels within some membrane molecular complex, so we also sought any
allosteric effects of appropriate agents on ligand binding to receptor
sites. In relation to our other studies on the GnRH priming response,
we were interested to compare the mechanism of the basic LH secretory
response in male and female gonadotrophes with the premise that subtle




Rapid superfusion of anterior pituitary tissue in vitro
Adult Wistar rats were used for all studies; either males, or
females pooled in equal proportions from metoestrus and dioestrus days
of the 4 day cycles.
Animals were stunned, decapitated, and the pituitaries were
removed. The neurointermediate lobe was discarded and the anterior
lobe was mechanically chopped at 500ym intervals in two directions at
90°. Tissue was then incubated in Krebs Bicarbonate medium
(composition in mM: NaCl, 127; KC1, 3.83: CaCl2, 1.8; KH2PO4,
1.18; MgCl2, 1.18; NaHC03, 20; with 2gl-l glucose, 30mg 1~1
bacitracin and 0.1% BSA, pH 7.4) under 95%02/5% CO2 at 37°C. After
one hour of static incubation, tissue equivalent to one pituitary gland
transferred into a superfusion chamber, where it was supported on a
Millipore AP20 prefilter. Tissue was then superfused with oxygenated
medium at 0.5ml/min, at 37°C, and 2 minute fractions were collected.
After 60 min of superfusion, inlet lines were changed to medium
containing drugs or ions as appropriate. Subsequent challenges with
GnRH were carried out after some 45 min in the presence of the relevant
substances. Luteinizing Hormone was estimated by double antibody
radioimmunoassay.
Binding of [-^I] buserelin to GnRH receptors
[D-Ser(tBu)6] des Gly^-GnRH ethylamide (buserelin) was
iodinated using the Chloramine-T procedure and the product separated
from reactants according to Sandow and Konig (1979) with modifications.
Anterior pituitary glands were homogenised in 100 volumes of cold
Tris HC1 buffer (25mM), pH 7.6. Membrane fragments were washed once by
centrifugation (48,000g, 10 min) and resuspension in assay buffer,
(which additionally contained 0.1% BSA). Assays were carried out in
triplicate or duplicate in a total volume of 500ul, comprising:
~0.5-lmg tissue equivalent, [125j] buserelin to a final concentration
of ~25pM (-30,000-50,000 cpm), and drugs or ions as appropriate, with
300nM GnRH for determination of non-specific binding. After 90min at
4°C, bovine y-globulin (to 0.025%) and polyethylene glycol 8000 (to
15%) were added, tubes vortexed and left for 15 min at 4°C before
centrifugation and aspiration of the supernatant.
RESULTS AND DISCUSSION
GnRH-stimulated LH secretion
The superfusion protocol allowed a consistently steady baseline of
LH secretion to be reached, with basal levels of 2-4ng/ml from male and
female tissue. GnRH (l-1000yM) caused a prompt stimulation of LH
secretion, in a concentration-dependent manner, from both male and
female tissue. Near-maximal responses of around 80-100% increase were
obtained at a concentration of lOOOnM and a standard stimulus of 300nM
was used in all experiments here (Table 1).
Membrane Ca?+ channels and GnRH action
Verapinoid Ca2+ channel antagonists, but not 1,4 dihydropyridines
or diltiazem, have been previously reported to inhibit GnRH-evoked LH
secretion in female weanling rats (Conn et al., 1983). Ro5-4864
(4'-chlorodiazepam) belongs to a new class of putative Ca^+ channel
antagonist (Mestre et al., 1985). Surprisingly, both (±) verapamil and
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of mean control baseline)
male female
-4 99 ± 2 100 ± 1
-2 101 ± 2 98 ± 1
0 100 ± 2 99 ± 1
2 162 ± 8 170 ± 8
4 161 ± 9 174 ± 8
6 162 ± 8 178 ± 9
8 156 ± 8 177 ± 15
10 158 ± 8 180 ± 12
12 148 ± 6 188 ± 15
14 151 ± 6 187 ± 16
Mean ± S.E.M., n = 5 - 10 in all experiments.




% of control a








14 ± 7* ** 5i ± 7*
41 ± io* ** 112 ± 15
a values for 10 min after GnRH addition
* Significant inhibition of response
** significant difference between extent of inhibition
in male/female.
(P < 0.05, Mann-Whitney U test).
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Ro5-4864 were significantly more effective at blocking the GnRH
response in male rather than female gonadotrophes (Table 2), suggesting
that there may be a greater involvement of membrane Ca2+ channels in
the male response. Barium ions are reported to enhance the unitary
conductance through membrane Ca2+ channels* (Hagiwara and Byerly,
1981) and so might be expected to facilitate any response involving
them. A profound secretagogue action of Ba2+ is widely reported
(Douglas et al., 1983) which presumably also involves such a
mechanism. Male gonadotrophes are anomalous in that they fail to show
any secretagogue response to Ba2+ (Mitchell and Anderson, 1985),
although such a response is seen with female weanling gonadotrophes
(Conn et al., 1980). In the present experiments, Ba2+ released LH
from adult female but not male tissue (Table 3); a result apparently at
variance with the Ca2+ channel antagonist data.
Membrane K+ channels and GnRH action
One explanation of these apparently disparate results might be that
an action of Ba2+, not directly related to Ca2+ channels, is
involved. One such action is its powerful and selective blockade of
potassium M-currents (Adams et al., 1982b), equivalent to the proposed
mechanism of GnRH action in bullfrog sympathetic ganglion. Another
selective blocker of M-currents, uridine 5'-triphosphate (Adams et al.,
1982b) was also able to produce a small increase in LH secretion from
female but not male tissue. It may be therefore, that closure of
potassium M-currents (as mimicked by Ba2+) could account for a part
of the secretory response to GnRH in female but not male
gonadotrophes. This would be in accordance with a significant
proportion of the female gonadotrophe response being resistant to
Ca2 channel antagonists.
Table 3. Effects of some K+ channel antagonists
on basal LH secretion
LH secretion
drug (peak % of mean control baseline)
concentration
male female
Ba2+ 106 ±4 164 ± 7* **
(3mM)
4-AP 441 ± 25* 170 ± 7* **
(ImM)
* significant increase
** significant difference between extent of increase in
male/female.
(P < 0.05, Mann-Whitney U test)
* A recent report (Nilius et al., 1985) describes a novel class of
Ba2+-insensitive Ca2+ channel.
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When GnRH stimuli were applied to gonadotrophes that had been
previously exposed to Ba2+ or UTP, again a marked difference was seen
between responses of male and female tissue. The amplitude of stimulus
induced release was profoundly enhanced in female tissue but patently
unaffected in male (Table 4). If Ba2+, UTP and GnRH are all acting
on female but not male gonadotrophes to inhibit potassium M-currents,
then it implies that the huge potentiation seen here represents a
synergistic interaction of the modes by which GnRH and the other agents
influence M-currents. Alternatively, it is possible that M-currents
serve only as an inhibitory modulator rather than mediator of GnRH
action in female gonadotrophes. Detailed analysis of the interaction
will be required to resolve this.
Other k+ currents, such as the transient outward current (Ia)>
the delayed rectified (I|<) and Ca2+-activated currents (including
the classical Ig), (Thompson, 1977) could potentially be involved.
Preliminary experiments however, indicated no major effects of
tetraethylammonium or quinine on either basal or GnRH-stimulated LH
secretion, suggesting that currents of the latter two categories may
not be significantly involved. Nevertheless, the selective inhibitor
of A-currents, 4-aminopyridine (4-AP) (Thompson, 1977), caused both
prominent changes in baseline LH secretion and a modification of the
GnRH response. At a concentration of ImM, 4-AP caused a vast, but
transient increase in LH secretion from male gonadotrophes, with a much
more minor effect on female tissue (Table 3). This perhaps suggests
that more K+ A-current channels are normally present in an activated
state in the male gonadotrophe. After the baseline had recovered
(within 30 min), the response to GnRH of male but not female
gonadotrophes was significantly attenuated in the initial rapidly
Table 4. Effects of some K+ channel antagonists on
GnRH-stimulated LH secretion






Ba2+(3mM) a 89 ± 9 345 ± 51*
GnRH +
UTP(lOOpM) a 82 ± 9 226 ± 25*
GnRH +
4-AP (ImM) b 44 ± 4* 126 ± 15
a Values for 10 min. after GnRH addition
b Values for 2 min after GnRH addition
* significantly different from control response
(P < 0.05, Mann-Whitney U test.
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peaking phase of the response (Table 4). This is consistent with
closure of an ongoing A-current representing a component of the initial
response to GnRH of male but not female gonadotrophes. Although
experiments on bullfrog sympathetic ganglion failed to implicate
A-currents in GnRH action (Adams et al., 1982a), the A-current there is
unusual in being insensitive to 4-AP and other (as yet unidentified)
currents have been considered to contribute to the response (Jan et
al., 1980).
Effects of ions on GnRH receptors
Degradation-resistant analogues of GnRH bind almost entirely
to a single high affinity site in anterior pituitary membranes (Clayton
et al., 1979). A number of cations can substantially influence the
binding of [125j]_iabelled ligands (Marian and Conn, 1980; Hazum,
1981). In none of these experiments however, was a comparison made of
membranes from male and female anterior pituitaries. We addressed this
problem and found that while some cations (Na+, Ca2+) had identical
effects on [125i]bUSerelin binding, there appeared to be a
sex-related difference in the effect of K+ ions (Table 5). Under
these conditions, any allosteric influences from other membrane
components closely associated with GnRH receptors may be detectable.
The selective inhibitory effect of K+ on binding to the male GnRH
receptor parallels the selective inhibition by a potassium A-current
blocker of part of the male secretory response to GnRH. It may be
therefore, that in the male, the effect on [1^1] buserelin binding
represents an allosteric influence of an element of the ion channel
mediating A-currents on GnRH receptors, thereby reflecting the close
functional interaction of these sites.
Table 5. Effects of some cations on [125j] buserelin









a 72 ± 6* 74 ± 5*
94 ± 3 94 ± 4
56 ± 6* 85 ± 5
* significant inhibition of specific binding
(P < 0.05, Mann Whitney U-test)




Whilst it is clear that Ca^+ is involved in GnRH action, it is
now apparent that membrane K+ channels are also of major importance.
There is evidence for a role of potassium A- and M- currents both in
contributing to the basal membrane state of gonadotrophes and in either
mediating (or modulating) GnRH responses. At each of these levels,
there appears to be a quantitative or qualitative difference between
male and female gonadotrophes. While Ca?+ channel opening and
potassium A-current blockade appear to account for a large part of the
male response to GnRH, potassium M-current blockade and to a lesser
extent Ca2+ channel opening appear important in the female.
Experiments on properties of the receptors as labelled by [125j]
buserelin suggested an allosteric interaction between potassium
A-channels and GnRH receptors in the male but not female, and no
evidence of such close molecular interactions with Ca2+ channels. We
believe this sex difference in the ionic/biochemical mechanism of
action of what is empirically a single receptor, to be unprecedented.
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LHRH-induced 45Ca2+ influx into rat anterior pituitary tissue in vitro can be
reduced by activation of protein kinase C
By G. Fink, M. S. Johnson, N. J. Minaur, R. Mitchell and S.-A. Ogier. M.R.C.
Brain Metabolism Unit, 1 George Square, Edinburgh EH8 9JZ
The action of luteinizing hormone releasing hormone (LHRH) on LH secretion is
partly dependent on the presence of extracellular Ca2+ and its influx into gonado¬
trophs through verapamil-sensitive channels (Pickering & Fink, 1979; Hopkins &
Walker, 1978). LHRH effects are likely to be mediated by stimulation of phospho-
inositide hydrolysis (Schrey, 1985) which may lead to activation of protein kinase
C (PKC). We have investigated the role of PKC in the rapid stimulation of 45Ca2+
influx into anterior pituitary gland.
The animals used were adult Wistar rats of approximately 200 g body wt.,
maintained under controlled lighting (lights on 05.00-19.00 h) and temperature
(22 °C) and given free access to Diet 41B and tap water. Uptake of 45Ca2+ into 500 jam
prisms of anterior pituitary glands removed at 13.00 h was measured over 30 s at
37 °C in an oxygenated buffer containing NaCl 154 mi, KC1 5-4 mM, CaCl2 1-5 mM,
glucose 11-OmM, Hepes 6-0 mM, pH 7-4. Incubations were quenched with ice-cold
buffer which contaned 2 mM EGTA instead of CaCl2, filtered through cellulose
membrane and extensively washed with cold buffer.
In prisms from male rats and female rats in each day of the oestrous cycle, LHRH
(< 1-100 nM) elicited a concentration-dependent increase in 46Ca2+ uptake. The
LHRH-induced 45Ca2+ influx was greatly reduced at higher concentrations of LHRH
(> 100 nM) in dioestrous, pro-oestrous and male but not oestrous or metoestrous rats.
The inhibitory effects on 45Ca2+ influx of high LHRH concentrations were mimicked
by phorbol 12-myristate 13-acetate (100 nM) and 1-oleoyl 2-acetyl-rac-glycerol
(125 /lm) and were reversed by polymyxin B (10 /im), indicating the involvement of
PKC. The PKC-mediated restriction of LHRH effects on membrane Ca2+ channels,
which occurred at high agonist concentrations, is analogous to observations on the
control of cytosolic free calcium by the TRH receptor which is also linked to
phospho-inositide hydrolysis (Drummond, 1985).
These results show that LHRH can produce a biphasic influence on Ca2+ influx
and that this influence is likely to be hormone-dependent.
references
Drummond, A. H. (1985). Nature, Lond. 315, 752-755.
Hopkins, C. R. & Walker, A. M. (1978). Mol. Cell. Endocr. 12, 189-208.
Pickering, A. J.-M. C. & Fink, G. (1979). J. Endocr. 81, 223-234.
Schrey, M. P. (1985). Biochem. J. 226, 563-569.
[From the Proceedings of the Physiological Society, 19-20 September 1986
Journal of Physiology, 382, 31P, 1986]
Protein kinase C has inverse effects on LHRH- and depolarization-induced
45Ca2+ influx into rat anterior pituitary tissue in vitro
By G. Fink, M. S. Johnson, N. J. Minattr, R. Mitchell and S.-A. Ogier. M.R.C.
Brain Metabolism Unit, 1 George Square, Edinburgh EH8 9JZ
Luteinizing hormone releasing hormone (LHRH) may act by hydrolysis of
phospho-inositides. Subsequent Ca2+ mobilization from both intracellular and extra¬
cellular pools appears to be required for luteinizing hormone (LH) secretion. LHRH
rapidly elicits an influx of Ca2+ into anterior pituitary tissue (Fink, Johnson, Minaur,
Mitchell & Ogier, 1986), but the relationship between this and depolarization-induced
influx is unclear.
The measurement of 45Ca2+ influx has been described previously (Fink et al. 1986).
Briefly, 500 /cm prisms of male tissue were incubated at 37 °C in oxygenated
physiological buffer containing 45Ca2+ (2 /.cm), usually for 30 s. After quenching with
ice-cold EGTA-buffer the tissue was filtered and extensively washed. The influx of
45Ca2+ induced by LHRH (100 nM) was inhibited by phorbol 12-myristate 13-acetate
(PMA) (1-1000 nM), or by 1-oleoyl 2-acetyl-rac-glycerol (63/im) but not 4/?-phorbol
(10 /cm), indicating that protein kinase C (PKC) may inhibit the LHRH-induced
influx of 45Ca2+. In contrast, the influx of 45Ca2+ by K+ depolarization (60 mM-K+)
was greatly facilitated by these activators of PKC.
Inhibition of receptor responses by PKC has also been reported for other
pliospho-inositide linked receptors such as a, adrenoreceptors (Lynch, Charest,
Bocckino, Exton & Blackmore, 1985). Reduction in receptor numbers accounts for
many of these observations, but that is not the case here since we have shown using
[125I]buserelin binding that LHRH receptor numbers are not affected by exposure
to PMA. The facilitated voltage-activation of Ca2+ channels matches observations
in smooth muscle (Menkes, Baraban & Snyder, 1986), adrenal medulla (Wakade,
Malhotra & Wakade, 1986) and Aplysia neurones (De Riemer, Strong, Albert,
Greengard & Kaczmarek (1985), but contrasts with one report using GH3 cells
(Drummond, 1985). Our results indicate two sites of action of PKC with respect to
membrane Ca2+ channels: one related to voltage-sensitive Ca2+ channels and another
within the LHRH-activated transduction mechanism.
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High yield solubilization of undenatured luteinizing hormone-releasing hormone receptors from
rat anterior pituitary
SALLY-ANN OGIER, RORY MITCHELL and
GEORGE FINK
M.R.C. Brain Metabolism Unit, University Department of
Pharmacology, 1 George Square, Edinburgh EH8 9JZ,
U.K.
The solubilization of receptors in high yield is an important
initial step in their purification. In the case of the luteinizing
hormone-releasing hormone (LHRH) receptors, solubilization
has previously given low yields, such as 8% using 5mM-3-
[3(cholamidopropyl)dimethylammonio]-1 -propanesulphonic
acid (Chaps) (Perrin et al., 1983). Higher yields have been
reported (Winiger et al., 1983) but in that case the criteria
for authentic solubilization are questionable.
For the rat brain serotonin S2 receptor, significant increases
in solubilization yield were achieved by the addition of high
concentrations of NaCl to the detergent (Chaps) solution
(Wouters et al., 1985). Increasing Chaps concentration
above 5 mM, does not increase yields, and in some cases
seems to diminish them (Perrin et al., 1983: Winiger et al.,
1983; Wouters et al., 1985).
Studies on photoaffinity-labelled LHRH receptors using
SDS/polyacrylamide-gel electrophoresis have indicated an
apparent molecular weight of about 60 000 Da (Hazum,
1981). However, under these conditions receptors are
denatured. Radiation inactivation of the LHRH receptor
in situ indicates an apparent molecular mass of 136000Da
(Conn & Venter, 1985), suggesting the possibility of a
complex of subunits. Efficient solubilization of the LHRH
receptor using non-denaturing detergent conditions would
allow determination by gel filtration of the apparent mol¬
ecular mass of the isolated, undenatured receptor complex.
Anterior pituitaries from male Wistar rats were sonicated
in 100 vol. of 25 mM-Tris/HCl pH 7.4, centrifuged for 15 min
at 60 000g at 4°C and resuspended in either 20 vol. of 25 mM
Tris/HCl pH 7.4/0.1% bovine serum albumin for binding
assay or 20 vol. of the solubilization solution (25mM-Tris/
HC1 pH 7.4, 5mM-Chaps, 1.5M-NaCl, 50 pg of soyabean
trypsin inhibitor/ml, 400k.i.u. of trasylol/ml). For solu¬
bilization, samples were agitated for 90 min at 4°C then
centrifuged for 2h at 60000#, 4°C to separate solubilized
from membrane-retained material. The supernatant was
used in binding assay or applied to a calibrated Sepharose
6B gel column. Before ligand-binding assay, solubilized
proteins were precipitated from the detergent solution using
polyethylene glycol 8000 (PEG). PEG and bovine y-globulin
were added to 15% and 0.035% respectively followed by
incubation on ice for 20 min and centrifugation to collect the
precipitate.
Binding was carried out in 500 /tl containing 10-60/rg of
protein and approx. 25 pM-[125I]buserelin, iodinated by the
chloramine-T method (Mitchell et al., 1985). Non-specific
binding was determined in the presence of 100nM-LHRH.
Incubation, 90 min at 4°C, was followed by PEG precipi¬
tation as above to separate unbound ligand and the remain¬
ing pellet was counted.
The absence of Chaps and NaCl from the solubilization
solution resulted in the retention of all specific [l25I]buserelin
Abbreviations used: LHRH, luteinizing hormone-releasing hormone:
Chaps, 3-[(3-cholamidopropyl)dimethylammonio]-1 -propanesulphonic
acid; PEG, polyethylene glycol 8000.
binding in the pellet. Addition of 5 mM-Chaps caused the
solubilization of 14 + 1% of the specific binding, rising to
16 + 4% and 23 + 3% of 0.2 m- and 0.6M-NaCl respect¬
ively. 1.5 M-NaCl/5 mM-Chaps gave 73 + 10% of the specific
[l25I]busereIin binding in the supernatant. This was not
precipitated even on centrifugation for 60min at 263 000#
at 4°C, and was therefore considered to be truly solubilized.
In our hands, the solubilization procedure ofWiniger et al.
(1983) gave very low yields (22 + 3%) of authentically
solubilized receptor. Low-speed centrifugation of mem¬
brane fragments through 0.32M-sucrose/30% glucerol, as
employed by Winiger et al. (1983), produced a large artefact
of 20 ± 2% of binding apparently being retained in the
supernatant, presumably due to microdispersed fragments
of tissue.
The affinities of several LHRH analogues were determined
both on anterior pituitary membranes and the solubilized
receptor preparation. Affinity profiles were very similar in
both preparations although small relative changes were
observed.
The solubilized receptor showed decreased affinity for the
agonists, buserelin and LHRH, and increased affinity for
the antagonist, [D-pG]u',D-Phe2,D-Trp3,6]LHRH, with little
change for the partial agonist (des-pGlu1 JLHRH. Removal
of the receptor from its associated effector mechanism in
membranes may account for these changes.
Specific [12~I]buserelin binding indicated the presence of
the solubilized receptors in non-void fractions eluted from
the Sepharose 6B column using the same buffer as for
solubilization. The peak binding fraction corresponded
to an apparent molecular mass of 155-170 kDa. This is
similar to that found by radiation inactivation of receptors
in situ but somewhat more than twice that found by SDS/
polyacrylamide-gel electrophoresis. These observations,
together with evidence for two contiguous binding sites
being involved in LHRH receptor activation (Conn et al.,
1982), suggest that the LHRH receptor may exist in situ as
a dimer.
We are grateful to Hoechst for the gift of unlabelled buserelin. Our
thanks also to John Bennie, Dorothy Farrar and Graciela Sanchez-Watts
for their assistance with the binding assays. S.-A.O. is a Houldsworth
Scholar of the University of Edinburgh.
Conn, P. M. & Venter, C. J. (1985) Endocrinology 116, 1324 1326
Conn, P. M„ Rogers, D. C., Stewart, J. M., Niedel, J. & Sheffield, T.
(1982) Nature (London) 296, 653-655
Hazum, E. (1981) Endocrinology 109, 1281-1283
Mitchell, R., Ogier, S.-A., Johnson, M., Cleland, A., Bennie, J. &
Fink, G. (1985) in Neuroendocrine Molecular Biology (Fink, G.,
Harmar, A. J. & McKerns, K. W., eds.), pp. 91-100, Plenum
Publishing, New York
Perrin, M. H., Haas, M., Rivier, J. E. & Vale, W. W. (1983) Endo¬
crinology 112, 1538-1540
Winiger, B. P., Birabeau, M. A., Lang, U.,Capponi, A. M., Sizonenko,
P. & Aubert, M. L. (1983) Mol. Cell. Endocrin. 31, 77-91
Wouters, W., Vandum, J., Leysen, J. E. & Laduron, P. M. (1985) Eur.
J. Pharmacol. 115, 1-9
Received 27 August 1986
1987
619th MEETING, CAMBRIDGE 137
Dual effects of protein kinase C on gonadotropin secretion from rat anterior pituitary gland
MELAN1E S. JOHNSON, RORY MITCHELL and
GEORGE FINK
M.R.C. Brain Metabolism Unit, University Department of
Pharmacology, ! George Square, Edinburgh EH8 9JZ,
U.K.
Luteinizing hormone-releasing hormone (LHRH) acts
on pituitary gonadotrophs via its receptor to cause the
release of luteinizing hormone (LH) and follicle stimulatory
hormone (FSH). There is evidence that LHRH receptor
activation causes phosphoinositide hydrolysis giving rise to
inositol phosphates (Schrey, 1985) and presumably also
diacylglycerol (DAG). These breakdown products can act
as 'second messengers' in the cell, the inositol phosphates
involved in mobilizing intracellular Ca2+ stores (Berridge &
Irvine, 1984) while DAG activates the Ca2+/phospholipid-
dependent protein kinase C (PKC) (Nishizuka, 1984) lead¬
ing to protein phosphorylation.
Phorbol 12-myristate 13-acetate (PMA) also activates
PKC, and, while not altering cytosolic free Ca2+ levels in
pituitary cells (Drummond, 1985), does give rise to secretion
of LH (Smith & Vale, 1980). We have investigated the
potential regulatory control of PKC in gonadotropin
secretion using activators and inhibitors of this enzyme.
Pituitary glands from pro-oestrous COB'Wistar rats
removed and the anterior lobes were separated and bisected.
The hemipituitary glands (two/flask) were incubated in 2 ml
of Hepes-buffered minimal essential medium with Earles
salts, which had 1 mM-L-glutamine added, at 37°C in a
shaking water bath under 95% CL/5% C02. After a pre¬
incubation for 20min the medium was changed. The replace¬
ment medium had no additives or contained polymyxin B
(PMB), a selective inhibitor of PKC (Wooten & Wrenn,
1984), or 8-(WA'-diethyl amino)-octyl-3,4,5-trimethoxyben-
zoate (TMB-8) which has also been shown to inhibit phorbol
ester-evoked secretion (Simpson et al., 1984). After 5min a
sample of 200 pi ofmedium was taken and drugs were added
in the 200 /zl replacement medium to give the appropriate
final dilution. The flasks were then incubated for an hour
before repeating the procedure. Usually an hour of baseline
release was followed by successive hours with drugs. All
samples were frozen ( — 40° C) until assayed for LH or FSH
bv radioimmunoassay.
The PKC activators PMA and phospholipase C (PLC)
both effected a dose-dependent release of LH and FSH. The
response to PMA was delayed though, and secretion was
not significant until the pituitary glands had been in the
presence of PMA for at least 2h (PMA 100 nM, 1 pu, LH
P < 0.01, FSH P < 0.01). This was not the case for PLC
which, in addition, produced much greater secretion of both
LH and FSH (Table 1). The larger response to PLC may
reflect the presence of not only DAG, but also the Ca2+-
mobilizing inositol phosphates. The PKC inhibitor PMB
whilst not affecting baseline release of gonadotropins,
augmented the LHRH-induced release of LH and FSH
(Table 1). This was also a concentration-dependent effect
which was maximal at 10-100pM. TMB-8 caused a similar
increase in LHRH-induced gonadotropin release (Table 1)
(maximal 20 pM) but at higher concentrations (>20;im) it
increased basal release of LH but not FSH. At 100pM both
Abbreviations used: LHRH, luteinizing hormone-releasing hormone;
LH. luteinizing hormone; FSH, follicle stimulatory hormone; DAG
diacylglycerol; PKC, protein kinase C; PMA, phorbol 12-myristate
13-acetate; PMB, polymyxin B; PLC, phospholipase C. TMB-8,
8-(W,/V-diethylamino)-octyl-3,4,5-trimethoxybenzoate.
Table 1. Concentrations ofLH and FSH releasedfrom the pituit¬
ary gland in vitro with different inhibitors and activators of
protein kinase C
Results are means ±s.e.m. of n > 5. All values (except PMA
first hour), are significantly (P < 0.1) elevated from basal and/
or LHRH (0.85 nM) levels (Students t test).
Drug LH (ng/ml) FSH (ng/ml)
Basal 22.7 + 3.8 4.48 ± 0.15
LHRH 82.0 + 10.8 11.03 + 0.67
LI1RH -h PMB (10/(M) 220.4 + 13.6 18.95 ± 1.34
Basal 11.1 ± 0.96 6.61 + 0.18
LHRH 142.3 + 16.2 20.65 ± 0.61
LHRH Hh TMB-8 (10/im) 247.1 + 19.8 27.33 ± 1.74
Basal 10.1 ± 1.4 5.84 ± 0.72
PLC (0.25 unit/ml) 262.4 + 39.4 26.12 + 1.89
PMA (1 fiM) First hour 10.1 ± 0.5 7.66 + 0.83
Second hour 30.7 ± 5.0 15.25 ± 1.25
the release of LH and FSH decreased towards control levels
although LH levels were still significantly raised (P < 0.05).
At concentrations of 50pu, TMB-8 has been shown to
inhibit respiration in rat thymocytes (Brand & Felber, 1984)
and at higher concentrations still (> 500/tm), it may block
intracellular Ca2+ mobilization (Simpson et al., 1984).
These observations may explain the reversal of the aug¬
mented response at ioo/tm-tmb-8.
These results indicate that PKC activators can cause
gonadrotropin release, although PLC, which can increase
levels of inositol phosphates and hence raise intracellular
Ca2+ levels (Drummond, 1984), is more effective than PMA.
This is in accordance with the synergistic affects of PMA
and Ca2+ ionophores on LH release from gonadotrophs
(Naor & Eli, 1985). However, the antagonists of PKC
action, PMB and TMB-8, can greatly increase LHRH-
induced release of LH and FSH. This suggests that PKC has
a dual role in the control of gonadotropin secretion: PKC
may stimulate gonadotropin secretion by an unknown-
mechanism and yet also down-regulate secretion evoked by
LHRH receptor activation.
We thank Drs. G. D. Niswender, L. E. Reichert, Jr. and the Pituitary
1 tormone Distribution Agency of the NIADKK, Baltimore, Maryland,
U.S.A. for the gift of radioimmunoassay materials, and John Bennie.
Graciela Sanchez-Watts and Dorothy Farrar for assistance with the
radioimmunoassays.
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Luteinizing hormone-releasing hormone rapidly elicits an opening of membrane Ca2+ channels
which is suppressed by protein kinase C
RORY MITCHELL, NICOLA MINAUR,
MELANIE JOHNSON, SALLY-ANN OGIER and
GEORGE FINK
M.R.C. Brail? Metabolism Unit, University Department of
Pharmacology, I George Square, Edinburgh EH8 9JZ,
U.K.
Several groups have demonstrated that the stimulation by
luteinizing hormone-releasing hormone (LHRH) of lutein¬
izing hormone (LH) secretion from the anterior pituitary is
dependent on extracellular Ca2+ (Marian & Conn, 1979;
Pickering & Fink, 1979; Naor et al., 1980). Hopkins &
Walker (1978); Marian & Conn (1979) and Naor et al.
(1980) showed that La3+ inhibited LHRH-induced (but not
basal) LH secretion and organic Ca2+-channel blockers of
the verapinoid series are also effective (Marian & Conn,
1979; Naor et al., 1980). Therefore Ca2+ has been extensively
proposed as the second messenger mediating LHRH action
(Marian & Conn, 1979).
Nevertheless, LHRH-induced LH release appears rather
less sensitive to removal of extracellular Ca2+ than depolar¬
ization-induced release (Hopkins & Walker, 1978) and the
verapinoid inhibitors of release described were generally
only partial (Marian & Conn, 1979; Naor et al., 1980).
These findings suggest that LHRH can mobilize intracellular
as well as extracellular Ca2+. This is consistent with evidence
that LHRH can evoke phosphoinsitide hydrolysis (Schrey,
1985), thus generating both inositol phosphates, that may
mobilize intracellular Ca2+, and diacylglycerol, that may
activate protein kinase C (PKC).
It has been suggested that the mobilization by phospho-
inositide linked receptors of intra- and extra-cellular Ca2+ is
intimately linked (Putney, 1986). We therefore aimed to
assess whether elements of the phosphoinositide response,
particularly activation of PKC, participate in causing the
LHRH-induced influx of 45Ca2+, described briefly by
Hopkins & Walker (1978).
COB Wistar rats were maintained under controlled light¬
ing (light 05 : 00-19: OOh) and temperature (22°C) and given
free access to Diet 41B and tap water. Oestrous cycles were
assessed by daily vaginal smears. Anterior pituitaries were
chopped into 500 pm prisms and suspended in a pre-warmed
and pre-oxygenated Ca2+-uptake buffer with 0.1% bovine
serum albumin and 35% Percoll. The buffer contained
(concentrations in mm): NaCl 154, KC1 5.4, CaCl2 1.5,
glucose 11.0 and Hepes 6.0 [buffered to pH 7.4 with solid
Tris (hydroxymethyl)-aminomethane base]. Aliquots of tissue
suspension were added to equal volumes of buffer, then
preincubated at 37°C and gassed with 100% O, for approx.
20 min before initiation of the experiment. Pre-warmed buffer
containing 45Ca2+ to give a final concentration of 2 pM was
added and then after precise time intervals, 45Ca2+ uptake
was halted by quenching with 3 ml of an ice-cold wash. This
was uptake buffer containing 2mm-EGTA instead of Ca2+,
Abbreviations used: LHRH. luteinizing hormone-releasing hormone;
LH. luteinizing hormone; PKC, protein kinase C.
similar to those used by other workers to halt 45Ca2+ uptake
in smooth muscle. After quenching, the contents of each
tube were filtered and the tissue received another 3 ml of the
relevant wash immediately, as an acute wash. The filtering
was carried out on a Millipore filter block under vacuum,
using Millipore cellulose acetate filters supported on GF/B.
Three further 2 min washes followed. The 45Ca2+ uptake was
measured by liquid scintillation counting.
The amount of 45Ca2+ accumulated by unstimulated
tissue increased linearly in a time-dependent fashion, but the
excess uptake due to 100nm-LHRH or 60mm-K+ was
maximal within 30 s (the incubation time used for further
studies. LHRH increased 45Ca2+ influx in a concentration-
dependent fashion from 0.1 to 100nm. Maximal responses
to 100nm-LHRH (as percentage increase over controls)
varied with tissue from different stages of the oestrous cycle:
pro-oestrus, 99 + 14; oestrus, 124 + 15; met-oestrus,
74 + 10; di-oestrus, 35 ± 7; male, 40 + 9 (n = 6-8,
means + s.e.m.). Control unstimulated uptake was no dif¬
ferent in tissue from these various sources.
The activators of PKC, phorbol 12-myristate 13-acetate
(100nm) and 1-oleoyl 2-acetyl rac-glycerol (63 pM) (incu¬
bated with tissue for 10 min before uptake) drastically
inhibited the LHRH response with no effect on basal 45Ca2+
uptake. In oestrus tissue the response to 100nm-LHRH in
the presence of these activators was reduced to 30 + 10%
and —4 + 7% respectively (n = 5, means ± s.e.m.). Similar
effects were observed in male tissue where concentration-
dependent inhibition of the response to 100nm-LHRH by
phorbol 12-myristate 13-acetate was observed. This was
maximal by 100nm and was not mimicked by 10^m-4/J-
phorbol.
LHRH receptor properties in tissue subjected to these
PKC activators were investigated using equilibrium binding
of [l25I]buserelin (Mitchell et al., 1985). Neither affinity nor
number of sites were altered (male tissue), suggesting that
the locus of PKC action must be at some post-receptor site.
PKC activation clearly therefore does not act to mediate the
opening of membrane Ca2+ channels by LHRH but rather
acts as a regulatory inhibitor of this effect. Whether other
consequences of the phosphoinositide response, such as the
production of inositol phosphates, are responsible for Ca2+
channel opening, is not clear.
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Sandwich hybridization using immobilized DNA
PETER J. NICHOLLS, JANE A. LANGDALE and
ALAN D. B. MALCOLM
Department of Biochemistry, Charing Cross and
Westminster Medical School, Fulham Palace Road,
London W6 8RF, U.K.
The most common method currently used for the detection
of specific DNA sequences is the Southern blot (Southern,
1975). This technique is reliable and sensitive, but has the
disadvantages that it is not rapid and cannot be readily
automated. Clearly, an alternative eliminating these prob¬
lems should bring the diagnosis of genetic defects into the
realm of routine clinical medicine. We have developed such
an alternative, using DNA fragments chemically coupled to
resins and a sandwich hybridization assay. The major
advantage of this type of assay is that it does not require
the time-consuming immobilization of sample DNA. Our
technique uses two non-overlapping restriction fragments:
fragment A is attached covalently to a resin by a diazotization
reaction (Seed, 1982), and fragment B is radiolabelled to
108-10,c.p.m./jig of DNA by random priming with hexa-
deoxynucleotides (Feinberg & Vogelstein, 1983, 1984). A
and B will not cross hybridize, but since both hybridize with
the nucleic acid sequence we are searching for (the 'target'),
the resin becomes labelled. Digestion of target with the
enzyme DdeI, followed by hybdridization with A and B and
washing, allows us to discriminate between the 'normal' and
'sickle' genotypes (Langdale & Malcolm, 1985).
The sandwich hybridization assay has been used
previously to determine the presence or absence of specific
DNA sequences in non-homologous mixtures (Ranki et al.,
1983). The technique is suitable for probing variations
within a DNA sequence. The restriction fragment length
polymorphism associated with the single base substitution
causing sickle-cell anaemia was chosen as a model system.
Restriction fragments of the human /(-globin gene taken
from either side of. but not overlapping with, the mutation
site were used as A and B (Langdale & Malcolm. 1985).
In order to refine our method, we have to (i) identify the
most suitable fragments to use as A and B. (ii) find the most
suitable resin, and (iii) determine the sensitivity of the assay
with plasmid DNA and with human samples.
Suitable available fragments were of lengths 879, 341 and
Abbreviation used: bp, base pairs.
201 bp. It was found that fragment size is not an important
factor in diazotization reactions, and it does not affect
hybridization efficiency. The 341 bp fragment was chosen as
A and the 201 bp fragment as B (Langdale & Malcolm, 1985).
The diazotization reaction relies on the presence of free
hydroxyl groups on the surface of the supporting resin.
The hydroxyl groups first react with a di-epoxide linker
(2,4-butanediol diglycidyl ether), which subsequently reacts
itself with an aromatic amine (2-aminothiophenol). The
amine is diazotized with nitrous acid and the DNA coupled
via the bases. Of several suitable resins tested, including
Sephacryls S-500 and S-1000, Sepharose CL4B, Sephadex
G-50 and magnetic Dynospheres M450, Sephacryl S-1000
was found to be the most suitable, binding the most DNA
covalently. Approx. 75% of the coupled DNA was found to
be available for hybridization.
Our results clearly indicate that it is possible to repro-
ducibly detect as little as 20amol of /Tglobin DNA in a
complex mixture of non-homologous sequences (approxi¬
mately equivalent to the amount of single copy gene present
in 40 pg of human DNA). Normal, heterozygous and sickle
homozygous individuals can be readily distinguished, and
the technique is almost as sensitive as Southern blotting.
However, there is a significant improvement in the ease of
sample manipulation and time taken to achieve the result
(under 24 h).
The advantage of this technique should ensure that the
clinical processing of large numbers of samples will not
prove to be a problem. It is commonly accepted that DNA
probe technology will be based on the use of non-radioactive
detection methods. Our technique is adaptable for use with
such probes.
We would like to thank Cambridge Life Sciences for financial
support.
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Pyrrolidine-2-phosphonic acid: a new inhibitor of kidney prolidase
A. M. LACOSTE,* E. NEUZIL* and P. MASTALERZt
* Lahoratoire de Biochimie medicale,
Universite de Bordeaux II. 146, rue Leo-Saignat,
33076-Bordeaux Cedex, France, and
tInstitute of Organic and Physical Chemistry,
Technical University, Wybrzeze Wyspianskiego 27,
50 370 Wroclaw, Poland
Prolidase (iminodipeptidase, EC 3.4.13.9) hydrolyses dipep-
tides with a C-terminal proline or hydroxyproline residue,
characterized by a -CO-N < bond. Glycyl-l-proline and
l-alanyl-l-proline were shown to be the two main substrates
of the enzyme (Sjostrom, 1974; Hui & Lajtha, 1978).
Prolidase is a dimeric Mn2+-dependent enzyme with a
53 kDa subunit. This widespread cytoplasmic enzyme plays
Abbreviation used: Pro-P, pyrrolidine-2-phosphonic acid.
a role in collagen degradation (Bergmann & Fruton, 1937);
biological considerations and the properties of prolidase
were recently reviewed by Myara et al. (1984). The enzyme
is inhibited by proline, by divalent metal ions which com¬
pete with Mn"+ and by sulphydryl reagents (Davis & Smith,
1957).
A porcine kidney prolidase with a specific activity of
180 units/mg of protein (Sigma Chemical Co, St. Louis,
U.S.A.) was used in all experiments. Enzymic assays were
performed in 100mM-Tris/HCl buffer (pH 8) containing
5mM-MnCl2, 2-50 mM-Gly-Pro, 0-20 mM inhibitor and the
enzyme dilution in a final volume of 0.25 ml. To obtain its
full activity, the enzyme was preincubated in the buffer in
the presence of Mn2+ for 10minat37°C, before the addition
of the potential inhibitor; the substrate was added finally to
initiate the reaction. After an incubation of 8min at 37°C,
2m-HC1 (12.5p\) was added to stop the reaction. The
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Solubilization of a large molecular weight form of the rat
LHRH receptor
S.-A. Ogier, R. Mitchell and G. Fink
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ABSTRACT
The LHRH receptor has been solubilized from male
rat anterior pituitary glands, using the zwitterionic de¬
tergent 3-((3-cholamidopropyl)-dimethylammonio)-
1-propanesulphonate in the presence of a high con¬
centration of sodium chloride. This method gave high
yields (up to >70%) of the LHRH-binding site from
the membrane preparation. Ligand binding studies
using LHRH analogues were carried out to determine
dissociation constants for LHRH receptors both in
situ in the membrane preparation and for solubilized
LHRH receptors. For all the analogues the binding
characteristics were similar in both preparations,
suggesting that the solubilization procedure left the
LHRH receptor undenatured. Gel filtration revealed
an apparent molecular weight for the LHRH receptor
of 100 000-160 000, with the mean value being
approximately twice that found by others using
sodium dodecyl sulphate-polyacrylamide gel electro-
phoretic techniques. The results indicate that the
LHRH receptor probably exists in gonadotroph
membranes as a large complex of more than one
subunit.
J. Endocr. (1987) 115, 151-159
INTRODUCTION
The release of gonadotrophins from the pituitary is
mediated by the hypothalamic peptide luteinizing
hormone-releasing hormone (LHRH). This acts
through a cell-surface receptor on gonadotrophs to
cause the release of luteinizing hormone and follicle-
stimulating hormone, presumably by means of the
increased phosphoinositide turnover which occurs in
response to LHRH (Conn, Staley, Harris et al. 1986).
Purification and molecular characterization of the
LHRH receptor molecule would greatly facilitate the
understanding of its structure and those structural
elements involved in its mode of action.
An important initial step in the purification of any
receptor type is the effective solubilization of the
receptor from its phospholipid environment in cell
membranes. In the case of the LHRH receptor,
several previous attempts at solubilization have been
documented, although generally these have achieved
only low yields. For example, 8% of available sites
from bovine pituitaries (Perrin, Haas, Rivier & Vale,
1983) and 20% from rat ovaries (Capponi, Aubert
& Clayton, 1984) were solubilized with 3-((3-
cholamidopropyl) -dimethylammonio)-1 -propanesul-
phonate (CHAPS; 5 mmol/1). Where higher yields
have been reported (Winiger, Birabeau, Lang et al.
1983) the solubilization criteria may not have been
sufficiently stringent (Ogier, Mitchell & Fink, 1987).
In the case of the rat brain serotonin receptor a
75% increase in yield on solubilization was achieved
by the addition of NaCl (l-4mol/l) to the detergent
solution (Wouters, van Dun, Leysen & Laduron,
1985). Similar observations have recently been made
with the D2-dopamine receptor (Hooper, 1986). Salt
alone or higher concentrations of detergent alone
were less effective. In previous reports on the LHRH
receptor, increasing concentrations of CHAPS above
5 mmol/1 did not increase yields, but in some cases
appeared to diminish them (Perrin et al. 1983; Winiger
etal.m3).
The molecular weight of the LHRH-binding site
has been investigated by several groups using photo-
affinity labelling before gel electrophoresis under
denaturing conditions. The receptor from rat pitu¬
itary gland was demonstrated to display an apparent
molecular weight of 60 000 (Hazum, 1981), although
more recent studies (Iwashita & Catt, 1985) describe a
doublet at 63 000 and 52 000, the latter of which was
suggested to show greater specificity. A ligand immu-
noblotting technique under similar denaturing con¬
ditions also indicated a molecular weight of around
J. Endocr. (1987) 115, 151-159 © 1987 Journal of Endocrinology Ltd Printed in Great Britain
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60 000 (Eidne, Hendricks & Millar, 1985). The dena¬
turing/dissociating conditions of all of these studies,
however, would not reveal the existence of oligomeric
complexes, such as dimers, of a binding subunit or
association of the binding subunit with non-binding
accessory subunits. In order to assess the molecular
size of the native LHRH receptor complex we have
carried out gel filtration studies of the solubilized
receptor under non-denaturing conditions.
MATERIALS AND METHODS
Membrane preparation
Male Wistar rats (200-250 g) were stunned, decapi¬
tated and their anterior pituitary glands rapidly
removed. These were placed in 100 volumes ice-cold
Tris-HCl (25 mmol/1; pH 7-4) and sonicated, followed
by centrifugation at 60 000# for 15 min at 4°C. The
washed membranes were resuspended either as for
solubilization (see below) or in 20 volumes Tris-
HCl (25 mmol/1; pH 7-4) with 01% (w/v) bovine
serum albumin (BSA) (Tris/BSA; Sigma Chemical
Company Ltd, Poole, Dorset) for ligand binding
assay.
Receptor solubilization
Washed membranes were resuspended in 20 volumes
ice-cold solubilization solution (Tris-HCl; 25 mmol/1;
pH 7-4) containing CHAPS (5 mmol/1; Sigma), NaCl
(l-5mol/l), soybean trypsin inhibitor (50 pg/ml;
Sigma), aprotinin (400 KlU/ml; Sigma) or in this
solution with variations in the detergent and NaCl con¬
centrations as indicated. Samples were then agitated for
90 min at 4 °C, followed by centrifugation for 2 h at
60 000# at 4 °C to separate solubilized from non-solu-
bilized membrane constituents. Other detergents tested
for receptor solubilization were N,N-di-(propylamido-
(2,3,4,5,6-pentahydroxyhexanoyl)) cholamide (deoxy-
BIGCHAP; Pierce Chemical Co., Chester, Cheshire),
nonanoyl-N-methyl glucamide (MEGA-9; Cambridge
Research Biochemicals, Cambridge), (N-dodecyl)-
sulphobetaine (Zwittergent 3-12; Calbiochem Brand
Biochemicals, Cambridge), digitonin (Sigma), sodium
deoxycholate (Sigma), lauryl maltoside (Boehringer
Mannheim, Lewes, East Sussex), polyoxyethylene
sorbitan mono-oleate (Tween 80; Sigma) and (iso-
octyl phenoxy)deca-ethoxyethanol (Triton X-100;
Sigma). All detergents were used at concentrations
including those approximately equal to their pub¬
lished critical micellar concentrations. The super¬
natant (the solubilized preparation) was used either
for ligand binding assay to characterize the solubilized
LHRH-binding site or applied to the gel filtration
J. Endocr. (1987) 115, 151-159
column for determination of molecular weights. In
some cases the pellet was resuspended in 20 volumes
Tris/BSA for ligand binding.
Determination of apparent molecular weight of the
LHRH receptor
The apparent molecular weight of the LHRH receptor
was determined on a Sepharose 6B (Pharmacia Fine
Chemicals, Milton Keynes, Bucks) column (26 mm x
70 cm) run at 19-5 ml/h at 4 °C. The column was cali¬
brated using Pharmacia Calibration Kits for proteins
of high and low molecular weights. The eluting buffer
used was the same as the solubilization buffer. Sucrose
(50 mg/ml) was added to the solubilized preparation
before its application to the column to facilitate its
entry into the gel bed as a well-defined band. Frac¬
tions of the eluate were collected every 15 min, from
which 1-3 ml aliquots were taken and the proteins pre¬
cipitated from them before ligand binding. A poly¬
ethylene glycol (PEG) precipitation was used as in the
equilibrium binding assay (described below): 17-9 ml
30% (w/v) PEG 8000 (Sigma) in Tris-HCl (25 mmol/1;
pH 7-4) (15% in final solution), 5-1 ml 0-25% (w/v)
bovine y-globulin (Sigma) in Tris-HCl (25 mmol/1;
pH 7-4) (0-035% in final solution) and 11 -5 ml Tris/
BSA were added to the aliquots, after which the tubes
were vortexed and left for 20 min on ice. The precipi¬
tated proteins were then separated from the detergent
solution by centrifugation (30 min at 15 000#) fol¬
lowed by resuspension in 1 - 8 ml Tris-HCl (25 mmol/1;
pH 7-4). Aliquots of 300 pi were used in the sub¬
sequent ligand binding assays. The PEG precipitation
method of CHAPS-solubilized LHRH receptors has
been shown previously (Winiger et al. 1983; Ogier et
al. 1987) to permit recovery of fully functional
LHRH-binding sites from the solubilization solution.
Equilibrium binding assay
Standard equilibrium binding assays were carried out
with the protected LHRH analogue buserelin (d-
Ser(Bu')6 des Gly10 LHRH-ethylamide; a generous
gift from Hoechst A.G., Frankfurt, F.R.G.), which
was iodinated with 125I to a specific activity of about
1100 Ci/mmol by the chloramine T method (Mitchell,
Ogier, Johnson et al. 1985). Luteinizing hormone-
releasing hormone and its analogues [des pGlu1]-
LHRH and [d-pGlu1,d-Phe2,d-Trp3 6]-LHRH were
obtained from Sigma. Aliquots (50 pi) of the solubil¬
ized preparation for use in ligand binding assays were
first subjected to PEG precipitation of the proteins as
described above for the column fractions (but in a
final volume of 1 -4 ml). This was necessary as the pres¬
ence of the detergent-NaCl solution in the assay
caused marked suppression of 125I-labelled buserelin
binding.
LHRH receptor solubilization s.-a. ogier and others
Assays were carried out in a total volume of 500 pi
containing 10-60 pg protein, ~40000c.p.m. 125I-
labelled buserelin (~25pmol/l) and LHRH ana¬
logues, as appropriate, in Tris/BSA. Non-specific
binding was determined in the presence of 1 pmol
LHRH/1. Duplicate or, in some cases, triplicate deter¬
minations were carried out. Incubation for 90 min at
4 °C was followed by PEG precipitation as above
(final volume 1 -4 ml). The resulting pellet, contain¬
ing bound ligand, was counted by y-spectrometry.
Displacement of specific 125I-labelled buserelin bind¬
ing by LHRH and buserelin (agonists), [des pGlu1]-
LHRH (a partial agonist) and [d-pGlu^d-Phe2,
d-Trp3,6]-LHRH (antagonist) was determined. The
affinities of these analogues were compared in solubil-
ized and native (membrane) LHRH receptors.
Protein assay




The absence of NaCl and CHAPS from the solubiliz¬
ation solution resulted in the retention of all specific
125I-labelled buserelin binding in the pellet and none
in the supernatant of the solubilization preparation
(Fig 1). Addition of 5 mmol CHAPS/1 led to the
appearance of a small amount (14%) of the specific
binding in the supernatant. This was marginally
increased on addition of 0-2 and 0-6 mol NaCl/1 to the
5 mmol CHAPS/1. The combination of 5 mmol
CHAPS/1 and 1-5 mol NaCl/1, however, extracted
73 ±5% (s.e.m.) of the specific binding sites for 125I-
labelled buserelin into the supernatant. The sites were
retained in solution after 2 h of centrifugation at
60 000# and were regarded as truly solubilized. In
some experiments, centrifugation for 1 h at over
230 000# caused no further precipitation of the bind¬
ing sites in the supernatant, confirming their authentic
solubilization.
Although most previous studies on LHRH receptor
solubilization have described very low yields, Winiger
et al. (1983) reported efficient solubilization of LHRH
receptors from bovine pituitary glands using 10 mmol
CHAPS/1 in a sucrose (0-32 mol/1) and 30% glycerol
solution. Separation of solubilized from non-solubil-
ized specific binding sites was determined by centrifu¬
gation at 45 000# for 1 h. In our hands, using rat
tissue, this procedure gave an artifactual result of
20 ±2% of specific binding in the supernatant in the
absence of any detergent (Ogier et al. 1987). This was
presumably due to the retention of microdispersed
fragments of tissue in the dense solution. Yields of
Volumes of CHAPS/NaCl for solubilization
figure 1. (a) Effects of increasing concentrations ofNaCl on
solubilization of rat LHRH receptors from anterior pitu¬
itary membranes. Anterior pituitary membranes were
shaken with 30 volumes solubilization solution for 90 min at
4 °C. Detergent and salt concentrations were varied as indi¬
cated. Solubilized receptors were separated from residual
membrane sites by high-speed centrifugation. Using the
equivalent of approximately 0-25 anterior pituitary gland
per tube, specific binding to the 3-((3-cholamidopropyl)-
dimethylammonio)-1 -propanesulphonate (CHAPS;
5 mmol/l)/NaCl (1-5 mol/l)-solubilized supernatant was
around 6000 c.p.m., with some 50% of total binding being
specific. Values are means + s.e.m. for three separate deter¬
minations. (b) Effect ofdetergent/protein ratio on receptor
recovery and efficiency of solubilization. Receptor solubili¬
zation was carried out as in a using CHAPS (5 mmol/1)/
NaCl (1-5 mol/1), but at a varying ratio of volumes of
solubilizing solution to initial tissue volume (as indicated).
Solubilized and residual sites were again separated by centri¬
fugation before polyethylene glycol precipitation and 125I-
labelled buserelin binding. Squares indicate total recovery of
binding (values for supernatant plus pellet as a percentage
of initial membrane binding); circles indicate solubilized
binding (values for supernatant as a percentage of initial
membrane binding). Values are means ± s.e.m. for three
separate determinations.
authentically solubilized receptor were found to be
low (22 + 3%), similar to those reported by Capponi
et al. (1984) who used similar conditions but more
intensive centrifugation.
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Both the percentage recovery of viable binding sites
and the percentage of binding sites successfully solu-
bilized were dependent upon the detergent:protein
ratio during solubilization (Fig. 1 b). Optimal con¬
ditions for solubilization with 5 mmol CHAPS/1 plus
l-5mol NaCl/1 were found at a ratio of 30 volumes
solubilizing solution to tissue. Under these conditions
there was full recovery of binding sites and maximal
solubilization of around 70% of the sites. This corre¬
sponds to a detergent:protein ratio of approximately
1-6 (w/w), similar to the value of 2 recently reported
by Hazum, Schvartz, Waksman & Keinan (1986) to
be optimal for solubilization with CHAPS alone.
Various other detergents, in the presence and
absence of l-5mol NaCl/1, were screened for their
ability to solubilize the LHRH receptor whilst retain¬
ing its capacity to bind 125I-labelled buserelin after
PEG precipitation. The detergents tested included
examples of non-ionic detergents, bile salts and
zwitterionic sulphobetaines with alkyl and cholate
side groups (Table 1). Zwittergent 3-12 and sodium
deoxycholate were as efficient as CHAPS in protein
solubilization from the pituitary membrane prep¬
aration. However, no specific binding of 125I-labelled
buserelin was detectable in the supernatant, whilst
that in the pellet was much reduced (less than 10% of
that found in pellets not treated with detergent). This
suggests that the receptor is being denatured or the
binding site otherwise damaged. Similar effects on
specific binding of 125I-labelled buserelin were found
using digitonin, lauryl maltoside (1-8 mmol/1), Triton
X-100 (1%) or MEGA-9 (5%), with minimal recovery
of functional binding sites and only small fractions of
these being found in the supernatant. In other cases
(lauryl maltoside, 018 mmol/1; Triton X-100, 0-16%;
MEGA-9, 0-5%; Tween-80, 0-13 and 1-3%) there
were no deleterious effects on binding site recovery,
but also little solubilization of the binding sites. Only
CHAPS produced a marked solubilization together
with only modest losses in recovery. This efficiency of
solubilization was also seen with deoxy-BIGCHAP,
but recovery was further reduced. The addition of
l-5mol NaCl/1 to the detergents generally caused a
small increase in the amount of protein solubilized.
Percentage recovery of binding sites was generally less
than corresponding values without NaCl present.
Prominent reductions were seen with lauryl maltoside
(018 mmol/1), Triton X-100 (016%), digitonin,
sodium deoxycholate and MEGA-9 (0-5%). The
efficiency of binding site solubilization was generally
similar in the presence or absence ofNaCl. In the case
of CHAPS, however, the presence of NaCl effected a
two- to fourfold increase in solubilization of the
receptor.
Providing that solubilization had been carried out in
20-30 volumes detergent solution, PEG precipitation
gave full recovery of the CHAPS/NaCl-solubilized
receptor. Other detergents investigated (Table 1;
Winiger et al. 1983) were not compatible with signifi¬
cant recovery of solubilized receptor by PEG precipi¬
tation. There was marked suppression of binding of
125I-labelled buserelin if CHAPS or CHAPS/NaCl
was present during the binding assay (at concen¬
trations used for solubilization) (Fig. 2a). When the
concentrations of CHAPS and CHAPS/NaCl were
reduced in the binding assay, the amount of 125I-
labelled buserelin bound was increased. Values
reached only 50% of detergent/NaCl-free determin¬
ations, however, even when the CHAPS/NaCl levels
were reduced tenfold. Binding in the presence of
reduced concentrations of CHAPS was less impaired,
but CHAPS alone was so much less efficient as a solu-
bilizer that the overall yield of binding in the presence
of 0-5 mmol CHAPS/1, for example, was only 12+1%
of initial membrane binding. When receptor prep¬
aration solubilized in CHAPS (5 mmol/l)/NaCl
(l-5mol/l) was diluted to lower levels of detergent/
NaCl and then subjected to high-speed centrifugation
(Fig. 2b), it was clear that, at any concentration com¬
patible with efficient binding, little of the receptor was
retained in solution. Binding to the solubilized recep¬
tor was therefore not routinely measured in the pres¬
ence of even diluted solubilization solution, but,
instead, after the removal of detergent/NaCl by PEG
precipitation.
Characterization of the binding site solubilized by
CHAPS/NaCl
Comparison of the binding characteristics of the solu¬
bilized receptor with those of the receptor in situ in the
membrane preparation shows that the receptor was
essentially unaltered and clearly not denatured by the
procedure. Under the conditions described, binding
of 125I-labelled buserelin to both membrane-bound
and solubilized receptors was maximal within 90 min.
Displacement curves with agonist, partial agonist and
antagonist analogues were very similar in solubilized
and membrane preparations and dissociation con¬
stant (ATd) values derived by computer analysis were
essentially the same (Fig. 3). Since displacement of
125I-labelled buserelin by unlabelled buserelin was
essentially identical after solubilization, determin¬
ations at a single concentration of ligand could be
appropriately used to estimate the proportion of sites
solubilized.
Apparent molecular weight determination
Application of the solubilized LHRH receptor prep¬
aration to a Sepharose 6B column revealed that the
major peak of specific binding of 125I-labelled busere¬
lin in the eluate corresponded to a molecular weight of
J. Endocr. (1987) 115, 151-159
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figure 2. (a) Effects of detergent/NaCl on binding of1251-
labelled buserelin to solubilized rat LHRH receptor. After
solubilization in 20 volumes 3-((3-cholamidopropyl)-
dimethylammonio)-l-propanesulphonate (CHAPS;
5 mmol/1) (■) or CHAPS (5 mmol/1) plus NaCl (1-5 mol/1)
(•), and centrifugation, supernatant samples were assayed
for binding of 125I-labelled buserelin. Assays were adjusted
to the detergent and salt concentrations indicated and paral¬
lel determinations, after polyethylene glycol (PEG) precipi¬
tation, were always carried out. The binding detectable in
the presence of detergent/NaCl is expressed as percentage of
that detected after removal ofdetergent/NaCl by PEG pre¬
cipitation. Values are means + s.e.m. for three separate de¬
terminations. This experiment was carried out on solubilized
receptors rather than on a membrane receptor preparation,
in case their ability to bind ligand was affected differently by
the presence of detergent/NaCl. Very similar results were, in
fact, obtained with membrane receptor preparations. (b)
Ability of reduced detergent/NaCl concentrations to retain
solubilized receptors in solution. Receptors were solubilized
in CHAPS (5 mmol/1 (■) or CHAPS (5 mmol/1) plus NaCl
(1-5 mol/1) (•) as above. The supernatant fraction was
adjusted to the detergent/NaCl concentration indicated,
vortexed and then subjected to further high-speed centrifu¬
gation to pellet any proteins which had precipitated under
the new conditions. The binding in PEG precipitates of the
supernatant from such a second centrifugation is expressed
as a percentage of that in PEG precipitates of the first super¬
natant. This value indicates what proportion of the sites re¬
main in solution after dilution of the detergent/NaCl. Values
are means ± s.e.m. for three separate determinations.
100 000-160 000 (Fig. 4). There was notably minimal
specific binding in the molecular weight region of
60 000. The specific activity of the peak fraction for
125I-labelled buserelin binding (fmol specific binding/
pg protein) had increased approximately sevenfold
over that found in the crude membrane preparation
(7-76 fmol/mg protein in the membrane and 53-3 fmol/
mg protein in the gel column eluate; Fig. 4). Some
losses of specific binding were incurred in the large-
scale PEG precipitation of the column eluate (possibly
due to incomplete sedimentation of the precipitated
proteins under the conditions employed). The cal¬
culated factor of purification may therefore be
somewhat underestimated.
DISCUSSION
Using the zwitterionic detergent CHAPS in the pres¬
ence of high NaCl concentrations, conditions have
been achieved which resulted in the solubilization of
LHRH receptors from rat anterior pituitary mem¬
branes at a yield (>70%) far greater than that
achieved previously. The best yields previously
described were obtained with CHAPS (5 mmol/1), but
values as different as 8% (Perrin et al. 1983) and 40%
(Hazum et al. 1986) have been reported. It is a consis¬
tent finding (Perrin et al. 1983; Winiger et al. 1983;
Hazum et al. 1986) that increasing the CHAPS con¬
centration causes no improvement in the yield. The
combination of CHAPS (5 mmol/1) and NaCl
(1-5 mol/1) increased yields by two- to fourfold in the
present study. The addition of high NaCl concen¬
trations to the detergent solutions generally resulted
in a more efficient solubilization of membrane pro¬
teins, presumably by its influence on the effective criti¬
cal micellar concentrations of the detergents. In
several cases, however, this increased efficiency for
protein solubilization was associated with an
increased denaturing effect, seen as a reduction in the
total detectable specific binding of 125I-labelled
buserelin. For example, 91% of total control binding
was found in the pellet and supernatant treated with
Triton X-100 (016%) but only 18% in the presence of
1-5 mol NaCl/1. Similar results were found with
MEGA 9. Some of the detergents, such as digitonin,
sodium deoxycholate and Zwittergent 3-12, caused
profound loss of receptor viability both in the pres¬
ence and absence of NaCl. Other detergents, such as
Tween 80, had no deleterious effects on the LHRH
receptor, but (either with or without salt) failed to
solubilize the binding sites. Only CHAPS, in the pres¬
ence of salt, resulted in a high degree of receptor solu¬
bilization in combination with a low level of receptor
damage. The increased receptor solubilization due to
salt (in the order of two- to fourfold) seemed to be
J. Endocr. (1987) 115, 151-159
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figure 3. Comparison ofpharmacological profiles of solubilized and membrane LHRH receptors of the rat.
(a) Displacement of 125I-labelled buserelin binding to membrane receptors by a series of LHRH analogues:
[d-pGlu1 ,d-Phe2,d-Trp3,6]-LHRH (A), buserelin (■), LHRH (•) and [des pGhdJ-LHRH (♦). Values are
means ± s.e.m. for four to ten separate determinations. (b) Displacement of 125I-labelled buserelin binding to
solubilized receptors. Receptors in the supernatant fraction after solubilization in 3-((3-cholamidopropyl)-
dimethylammonio)-l-propanesulphonate (CHAPS; 5 mmol/1) plus NaCl (1-5 mol/1) were precipitated by
polyethylene glycol before the 125I-labelled buserelin binding assay. Analogues are as in a. Values are means
± s.e.m. for three to eight separate determinations, (c) Hofstee plot of examples of LHRH displacement of
125I-labelled buserelin binding in membrane (■) and solubilized (•) preparations. Results are typical of six
sets of observations. LHRH (0-1-100 nmol/1) displaced 125I-labelled buserelin from both preparations as a
single component from which the equilibrium dissociation constant (A!d) was determined by an error-weighted
computer programme (Zivin & Waud, 1982). Values formembrane and solubilized preparations were not
significantly different (2-20 + 0-72 and 2-91 +0-4 nmol/1 respectively). Values of K& for buserelin
(0-47 ±0-14 nmol/1), [d-pGlu1,d-Phe2,d-Trp3-6]-LHRH (0-15 + 0-01 nmol/1) and [d-pGlu']-LHRH
(1 -52 ± 0-26 pmol/1) on the membrane preparation were similar to those found on the solubilized preparation
(0-66 + 0-3 nmol/1,0-11 ±0-02 nmol/1 and 2-53 + 0-48 pmol/1 respectively). All values are means ± s.e.m. for
three to ten separate determinations.
rather selective for this protein, since it was accom¬
panied by only a minor increase in general protein
solubilization.
This high-yield solubilization technique (in which
the receptor is clearly not denatured) will greatly fa¬
cilitate subsequent purification of the LHRH receptor
protein, an important step in the elucidation of its
chemical and structural characteristics. The suitability
of the CHAPS/NaCl solubilization for preserving
LHRH receptor properties was confirmed by ligand
binding studies using the LHRH analogues which give
similar KA values for both the crude membrane
preparations and the solubilized LHRH receptors
(Fig. 3). Any minor differences in absolute values may
have been due to the removal of the receptor from its
membrane environment.
The apparent molecular weight of the LHRH
receptor, as revealed by the specific binding peak in
the gel column eluate, was 100 000-160 000. This is
the first time that a value in this range has been
described for the receptor in a solubilized form. Our
estimate agrees well with the molecular weight of
135 000 obtained by Conn & Venter (1985) using
target-size analysis of radiation-inactivated LHRH
J. Endocr. (1987) 115, 151-159
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figure 4. Estimation ofapparent molecular weight of solubilized rat LHRH recep¬
tors using gel chromatography. After solubilization in 3-((3-cholamidopropyl)-
dimethyammonio)-l-propanesulphonate (CHAPS; 5 mmol/l)/NaCl (1-5 mol/1),
the supernatant fraction was loaded onto a Sepharose-6B column using a sample
applicator (SA-5; Pharmacia Ltd). The column was equilibrated, calibrated and
eluted using the CHAPS (5 mmol/l)/NaCl (1-5 mol/1) solution. The molecular
weight standards and their weights ( x 1(C3; in parentheses) are as indicated: V0,
blue dextran; T, thyroglobulin; C , catalase; Aid, adolase; Alb, albumin; Ov,
ovalbumin; R, ribonuclease. Fractions of the eluate were precipitated with
polyethylene glycol and aliquots used in the 125I-labelled buserelin binding assay
for duplicate determinations of specific and non-specific binding. The specific
binding in the peak fractions (45-48) represented approximately 35% of total.
Solubilization of 30 pituitaries gave 24 000 c.p.m. of specific binding in the peak
fraction ofeluate, which when corrected for protein values indicated at least a
sevenfold purification of the receptor over membrane values. The elution profile
shows means ± s.e.m. of specific binding in aliquots of fractions from four separate
gel elutions.
receptors in situ. These two results contrast with those
obtained using sodium dodecyl sulphate-polyacryla-
mide gel electrophoretic molecular weights tech¬
niques, where values in the range of 60 000 are
obtained consistently (Hazum, 1981; Jansem de
Almeida Catanho, Berault, Theoleyre & Jutisz, 1983;
Eidne et al. 1985; Iwashita & Catt, 1985). This
suggests that our procedure succeeded in solubilizing
the LHRH receptor complex as it exists in situ, in an
undenatured form. A second much smaller peak of
specific binding was also found, corresponding to a
molecular weight of 46 000-53 000, similar to the
lower molecular weight unit of Iwashita & Catt
(1985). The native complex may contain a binding
subunit with a molecular weight of approximately
60 000 and an accessory subunit(s), or may feasibly
exist as a dimer of binding subunits. The latter sugges¬
tion could be construed as consistent with evidence
for a role of micro-dimerization of binding sites in
LHRH agonist action. Conn, Rogers, Stewart et al.
(1982) used a constructed ligand consisting of two
antagonist molecules joined through part of the struc¬
ture not required for binding. A monovalent antibody
could interact with one of the antagonist molecules in
the bridged analogue, leaving the other available for
receptor interaction, where it still displayed an antag¬
onist profile. However, a divalent antibody, which
was considered to present two antagonist molecules
(separated by ~15nm) for receptor interaction,
evoked an agonist-like response. Although it can be
inferred that LHRH agonist action requires receptor
dimerization, the large receptor complex in our study
had not been exposed to LHRH analogues before the
gonadotroph cell membranes were disrupted. It could
J. Endocr. (1987) 115, 151-159
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be that a proportion of the complexes already exists
in a dimerized form, perhaps on account of in-vivo
exposure to LHRH. It is possible then that the LHRH
receptor exists in situ at least in part as a dimer of two
60 000 molecular weight binding units presenting two
contiguous binding sites for occupancy by ligands.
Alternatively, it could be that the large native LHRH
receptor complex identified in the present study and
by Conn & Venter (1985) represents the monomeric
form of a receptor which consists of several subunits.
In-vitro exposure to agonists/antagonists before solu¬
bilization may help to resolve this question.
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PREPARATION AND USE OP A MULTIFUNCTIONAL COVALENT LIGAND FOR LHRH RECEPTOR
PURIFICATION.
R. MITCHELL, S.-A.OGIER and C.BLADON, MRC Brain Metabolism Unit, Department of
Pharmacology, 1 George Square, Edinburgh EH8 9JZ.
We have devised a strategy for purification of the LHRH receptor. A novel
photoaffinity biotinylated ligand ([biotinyl-p-azido-Phe- DLys^]- LHRH)(PBL)
was synthesised and utilised through avidin-affinity chromatography for
receptor purification. This ligand binds competitively to the LHRH receptor
site in the rat anterior pituitary, displacing [^5[] Buserelin with a Kq
of 1.55nM (not significantly different to that of DLys^ LHRH, 3nM) .
Exposure of the preparation to UV light 366nm for 2 min, resulted in the
binding of PBL to the receptor becoming irreversible, (no reduction in the
number of occupied sites over 24 hrs). PBL was iodinateo using the Chloramine
T method. Sepharose CL-4B, activated by cyanogen bromide, was coupled to
avidin. Biotin displacement of [^H] biotin bound to the avidin-sepharose in
the presence of 5mM CHAPS/1.5M NaCl showed that the matrix had umolar affinity
for biotin under these conditions. Anterior pituitary membranes prepared from
male rats were labelled with the [1251 ] pgL. After washing to remove
unbound ligand and UV activation (2 mins at 366nm) the membranes were shaken
in 5mM CHAPS / 1.5M NaCl at 4*C for 90 mins to solubilise membrane proteins.
The supernatant from centrifugation for 2hr at 60,000g was added to 1ml of the
aviain-sepharose matrix and left shaking gently for 12-18hrs at 4'C. The gel,
packed in a 1ml column, was washed using 20 volumes of CHAPS/NaCl solution.
Excess biotin (2mM) was used to elute PBL-labelled protein from thexolumn.
PBL- labelled sites were purified by =700 fold compared with those in native
mempranes.
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192 SYNTHESIS OF BIOTINYLATED REAGENTS AND THEIR USE IN LHRH RECEPTOR PURIFICATION
C.M. Bladon, R. Mitchell and S.-A. Ogier; MRC Brain Metabolism Unit, Department of
Pharmacology, 1 George Square, Edinburgh EH8 9JZ
In order to further our studies on the LHRH receptor we have prepared, and coupled to
LHRH analogues, two novel biotinylated reagents (1,2). We coupled our initial
photolabile compound (1) to DLys°-LHRH but the conjugate [biotinyl-p-azido-Phe-
DLys°]-LHRH lacked appreciable specific binding in rat anterior pituitary membranes.
To overcome this difficulty the peptide backbone was switched to DLys6,desGly10-
LHRH ethyl amide (synthesised by the FMOC/polyamide solid phase method) and the reactive
grouping to art amino moiety (reagent 2). This second conjugate [biotinyl-aminobutyl-
DLys", desGly10]-LHRH ethylamide showed approximately 50Z specific binding to rat








(1) R = CH2^^N3
(2) R = CHp-CHp-NHBOC
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231 REGULATION OF Ca2+ MOBILISATION IN GONADOTROPHES
R. Mitchell, M. Johnson, S.-A. Ogier & G. Fink, MRC Brain Metabolism Unit, University
Department of Pharmacology, 1 George Square, Edinburgh EH8 9JZ, Scotland,
The secretion of gonadotrophins induced by Luteinizing Hormone-Releasing Hormone (LHRH)
requires both extracellular and intracellular Ca2+. We have been investigating the
mechanisms through which activation of phospho-inositide metabolism in response to LHRH,
may lead to the different components of Ca2+ mobilisation. Experiments were designed
to investigate both influx of 45Qa2+ (through nimodipine-sensitive Ca2+ channels)
and the efflux of 45ca2+ (from endoplasmic reticulum stores) that occurred in rat
anterior pituitary slices in response to LHRH.
Activators of protein kinase C (PKC) such as phorbol 12-myristate, 13-acetate (10-300nM)
profoundly inhibited LHRH-induced 4uCa2+ influx but not efflux, in a manner
reversible by the PKC inhibitor H7(10vM). Biphasic concentration-response curves for
LHRH-induced 45Ca2+ influx suggested that PKC may exert feedback inhibition of
LHRH-induced mobilisation of extracellular Ca2+(1,2). In contrast, the priming effect
of LHRH involves a facilitated mobilisation of intracellular but not extracellular
Ca2+, with a parallel increase in inositol phosphate production. These data reveal
two quite different modes of regulation of LHRH-induced Ca2+ mobilisation.
1. Mitchell et al. (1986) Biochem. Soc. Trans. 115: 139.
2. Fink et al (1987) J. Physiol. 382: 31P.







can be used to estimate cellular Rbf fluxes with a time reso¬
lution of approximately 90 s.
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Fig. 1. S7Rb+ in perfused rat kidney
Single-pass perfusion of right kidneys from 350 g Wistar rats
was initiated with KHB. At time 0 min the perfusate was
switched to Rb-KHB. (a) Paired spectra (20 480 scans each,
duration 174 s, line broadening 150 Hz) during perfusion
with 1.18 mM-Rb+ and 4.72 mM-K + ; at 20 min the perfusate
K+ was reduced to 1.18 itim while maintaining the Rb+ con¬
centration constant. (b) Total renal Rb+ concentration
during perfusion with 2.36 mM-Rb+ and 2.36 itim-K+ (•); at
27 min the perfusate was switched back to Rb-free KHB.
Also shown in (£>) is the total renal Rb+ concentration during
perfusion of a glutaraldehyde-fixed kidney perfused at the
same flow rate and with the same concentration of Rb+ (o).
Regulation of receptor-operated Ca2 + influx by protein kinase C
RORY MITCHELL, MELANIE JOHNSON and
SALLY-ANN OGIER
M.R.C. Brain Metabolism Unit, University Department of
Pharmacology, 1 George Square, Edinburgh EH8 9JZ, U.K.
Activation of receptors for luteinizing hormone-releasing
hormone (LHRH) is accompanied by increased phospho-
inositide turnover and results in mobilization of Ca2+ from
both intracellular and extracellular stores (Naor et al., 1986).
We have been particularly interested in the mechanism
responsible for the receptor-operated Ca2+ influx com¬
ponent of this response. Although the involvement of a novel
inositol phosphate (Irvine & Moor, 1986) or of a kinetic
coupling between different calcium pools (Putney, 1986)
have been suggested, there is no firm evidence that they are
in fact responsible. We have investigated instead whether
protein kinase C (PKC) (which is also activated in response
to LHRH) might participate in the relevant signalling
mechanism (Mitchell et al., 1986; Fink et al., 1987). The
present experiments extend our analysis of the role of PKC,
Abbreviations used: LHRH, luteinizing hormone releasing
hormone; PKC, protein kinase C; PMA, phorbol 12-myristate 13-
acetate; H7, l-(5-isoquinolinesulphonyl)-2-methylpiperazine hydro¬
chloride.
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employing the 4:,Ca2 + influx protocol described in detail pre¬
viously (Mitchell etal., 1986).
Male COB Wistar rats were maintained under controlled
lighting (light 05.00-19.00 h) and temperature (22°C) and
given free access to Diet 41B and tap water. Anterior pitui-
taries were chopped into 0.5-1.0 mm prisms and suspended
in buffer with 0.05% (w/v) bovine serum albumin. The buffer
contained (him): NaCl, 154; KC1, 5.4; CaCL, 1.5; glucose,
11.0 and Hepes 6.0 (buffered to pH 7.4). Tissue was preincu-
bated at 37°C and gassed with 02 for approx. 20 min
before initiation of the experiment. Prewarmed buffer con¬
taining 45Ca2 + to give a final concentration of 2 pu was
added and then after 30 s, 45Ca2+ uptake was halted by
quenching with 3 ml of an ice-cold wash. This was uptake
buffer containing 2 mM-EGTA instead of Ca2 + . After
quenching, the contents of each tube were filtered and the
tissue received another 3ml of wash immediately. The filter¬
ing was carried out on a Millipore filter block under vacuum,
using Millipore cellulose acetate filters supported on What¬
man GF/B glass fibre filters. Three further 2 min washes fol¬
lowed. The 45Ca2+ uptake was measured by liquid
scintillation counting.
LHRH (100 ntvi) caused 69 ±8% increase over basal
45Ca2+ accumulation (n = 7, mean±s.e.m.), but the selective
activator of PKC, phorbol 12-myristate 13-acetate (PMA)
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was unable to cause any significant increase in 45Ca2 + influx
until concentrations in excess of 3 pw. At 30 pu, a 52 ± 10%
increase in 45Ca2 + influx was observed (n =5, mean ± s.e.m.),
but phorbol ester actions at such concentrations are grossly
non-specific. In contrast, low concentrations of PMA (3-300
nM) inhibited LHRH-induced 45Ca2+ influx in a manner
reversible by the PKC inhibitors H7 [l-(5-isoquinoline-
sulphonyl)-2-methyl piperazine hydrochloride] and poly¬
myxin B. LHRH-induced 45Ca2 + influx was reduced to
9± 10% increase over basal by 100 nM-PMA and in the
presence of H7 (10 pw) this was restored to 61 ± 8% (/; =5,
means ± s.e.m.). Additional experiments with diacylglycerols
and an inhibitor of diacylglycerol kinase further support the
idea that PKC is not the intracellular signal mediating
receptor-induced Ca2+ influx, but instead can act as a nega¬
tive regulator of this response.
To assess the route of 45Ca2 + influx here, experiments
were carried out with the dihydropyridine antagonist of
L-type Ca2 + channels, nimodipine (Nowycky et al., 1985) and
the inhibitor of the Na+/Ca2+ exchanger, amiloride
(Kaczorowski et al., 1984). LHRH-induced 45Ca2+ influx in
these experiments was inhibited by nimodipine with an IC50
(concentration required to inhibit by 50%) of 6 ± 1 nM (n =4,
mean ± s.e.m.). Amiloride, however, in the range 0.25-4 mm
(sufficient for blockade of the Na+/Ca2+ exchanger as well
as the Na + /H+ exchanger, Kaczorowski et al., 1984), did not
block, but enhanced LHRH-induced 45Ca2+ influx. In
contrast, it has been suggested that thrombin-induced Ca2 +
influx in platelets is inhibited by an amiloride analogue
(Siffert & Akkerman, 1987) and interestingly platelets are
reportedly devoid of dihydropyridine binding sites (Erne et
al., 1984). The mechanisms involved in receptor-operated
Ca2+ influx (and in its regulation) may therefore be quite
different in different cell types.
Erne, P., Burgisser, E., Buhler, F. R., Dubach, B„ Kuhnis. H„ Meier,
M. & Rogg, H. (1984) Biochem. Biophys. Res. Commun. 118,
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Effects of neomycin on K+ transport into inside-out erythrocyte membrane vesicles
CHARLES M. LAZENBY and ERNEST S. HARPUR
M.R.C. Mechanisms ofDrug Toxicity Research Group,
Pharmaceutical Sciences Institute, Aston University,
Birmingham B4 7ET, U.K.
Aminoglycoside antibiotics, such as neomycin, are ototoxic
and have been shown to reversibly inhibit receptor potentials
in vertebrate hair cells (Kroese & van den Bercken, 1980;
Hudspeth, 1982). Since Ca2 +-activated K+ conductance is
an important component of the transduction process in
cochlear hair cells (Ashmore & Meech, 1986) and since
neomycin and Ca2+ compete for binding sites in a wide
variety of tissues, we wished to examine what effect neo¬
mycin might have on Ca2 +-activated K+ transport.
The mammalian erythrocyte membrane is a readily acces¬
sible system for studying Ca2 +-activated K+ transport. We
prepared inside-out vesicles (IOVs) from human erythrocyte
membranes using the method of Lew et al. (1982) as modi¬
fied by Alvarez et al. (1984). K+ transport was assessed from
measurements of uptake of 86Rb + (Alvarez et al., 1984).
Incubations were performed at room temperature in a
medium containing 18 mM-KCl, 16.5 mM-Hepes and 0.04
niM-EGTA at pH 7.5. Ca2 + , neomycin, quinine or valino-
mycin were added to the incubation medium as required.
The uptake of 86Rb + in the presence of Ca2+ was rapid,
achieving equilibrium after 10 min. All subsequent measure¬
ments of uptake were done after 10 min incubation. 8ARb +
uptake was stimulated by Ca2+ with an EC50 of 4x 10"7 m
and a maximum response at 10"5 m. Initially it was difficult
to establish what effect, if any, neomycin had on this Ca2 + -
activated 86Rb+ uptake because neomycin alone stimulated
86Rb+ uptake and whereas the effect of Ca2+ was similar
when IOVs were prepared from erythrocytes from different
Abbreviations used: IOVs, inside-out erythrocyte membrane
vesicles; EC5„, concentration producing half-maximal activation.
donors (n= 5), the effect of neomycin was very variable
depending on the donor of the blood. Consequently, we
investigated this effect of neomycin on 86Rb+ uptake. In
IOVs prepared from one donor a dose-response to neo¬
mycin was established with an EC50 of 9x10~6m and a
maximum response at 10"4 m. In IOVs prepared from four of
five donors, the maximum response produced by 10"4 m-
neomycin averaged 41% (range 26-60%) of that produced
by 10"5 m-Ca2 + . However, in IOVs from the fifth donor
10 ~4 m-neomycin consistently stimulated an uptake of86Rb +
equivalent to that produced by 10 5 m-Ca2 + . Quinine
(10~3 m), had no effect on the neomycin-stimulated 8ARb +
uptake although it inhibited by 90% the uptake stimulated by
10"6 m-Ca2 + .
Neomycin(10"4 m), antagonized the effect of Ca2+ on
86Rb+ uptake, but this effect was partially masked by coexist¬
ing stimulation of 86Rb+ uptake by neomycin and was over¬
come at high concentrations of Ca2+ ( > 5 x 10~4 m). There
appeared to be little or no effect of neomycin on the rate of
Ca2 +-activated 86Rb+ uptake (half-time to equilibrium was
unchanged), but the amount of 8hRb+ associated with IOVs
at equilibrium (10 min) was reduced. The antagonism pro¬
duced by neomycin was more evident at high concentrations:
10 ~3 m-neomycin inhibited by 82% 8ARb + uptake stimulated
by 10~5 m-Ca2+ (P<0.01, paired /-test). However, in these
experiments neomycin alone produced little stimulation of
86Rb+ uptake, allowing the inhibitory effect on Ca2 + -
activated uptake to be clearly seen. In parallel experiments
we have examined the effect of furosemide on 8ARb + uptake
stimulated by another aminoglycoside antibiotic, gentamicin.
When furosemide (10~3 m), was incorporated into the IOVs
during vesiculation, a significant inhibition of gentamicin-
stimulated 86Rb+ uptake was achieved, whereas there was
little, or no effect of furosemide on Ca2 + -activated 86Rb +
uptake. As a consequence of this finding, the effect of
10 4 m-neomycin on Ca2+-activated 8ARb+ uptake was
1988
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191 USE OF DIVALENT CROSSLINKERS TO AFFINITY LABEL LHRH RECEPTORS.
S.-A. Ogier, R. Mitchell and C.M. Bladon. MRC Brain Metabolism Unit, University
Department of Pharmacology, 1 George Square, Edinburgh, EH8 9JZ, Scotland.
We have recently described a high yielding method of solubi1isation for the rat anterior
pituitary LHRH receptor (Ogier, Mitchell and Fink, 1987), the initial step in
purification and molecular characterisation of this receptor. The method of choice for
receptor purification is usually affinity chromatography. However for this approach to
be viable, detergent conditions must be used that allow the retention of the receptor in
a solubilised state and at the same time do not disrupt affinity for the ligand
utilised. In the case of the LHRH receptor, extensive experiments have failed to reveal
mutually compatible conditions. In comparison the biotin-avidin interaction is very
resilient to the presence of detergents. Hoffmann & Finn (1985) and Kohanski & Lane
(1985) describe the use of biotinylated insulin derivatives to purify insulin receptors
via avidin columns. As used, the method is still dependent on the retention of
substantial affinity for the analogue in the presence of detergent. In an attempt to
circumvent the problem and adapt the method for LHRH receptor purification, we have
covalently attached the biotinylated ligand to the receptor-. Several divalent
crosslinkers of varying length were used in order to obtain the highest efficiency of
covalently labelling the rat anterior pituitary LHRH receptor in situ with biotinylated
LHRH analogues.
Ogier, S.-A., Mitchell, R. and Fink, G. (1987) Solubilization of a large molecular
weight form of the rat LHRH receptor. J. Endocr. 115: 151-159.
Kohanski, R.A. and Lane, D.M. (1985) Receptor Affinity Chromatography. Annals N.Y.
Acad. Sci. 447: 373-385.
Hoffman, K. and Finn, F.M. (1985) Receptor Affinity Chromatography Based on the
Avidin-Biotin Interaction. Annals N.Y. Acad. Sci. 447: 359-372.
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Facilitated calcium mobilization and inositol phosphate
production in the priming effect of LH-releasing hormone
in the rat
R. Mitchell, M. Johnson, S.-A. Ogier and G. Fink
MRC Brain Metabolism Unit, University Department of Pharmacology, 1 George Square,
Edinburgh ehs 9jz
received 17 March 1988
ABSTRACT
The ability of LHRH to induce Ca2 + mobilization
and production of inositol phosphates in rat anterior
pituitary tissue in vitro was investigated in relation to
the self-priming effect of LHRH. Prior exposure to
LHRH (which caused a characteristic potentiation of
subsequent secretory responses) specifically enhanced
LHRH-induced inositol phosphate production and
mobilization of intracellular Ca2+ stores. LHRH-
induced influx of Ca2+ through dihydropyridine-
sensitive Ca2+ channels was unaltered, as was ligand
binding to LHRH receptors. These data suggest
that a novel facilitation of signalling may occur in
the phospho-inositide-Ca2+ mobilization response
mechanism during LHRH priming, and that this may
represent an important means of regulating cellular
responsiveness in gonadotrophs.
J. Endocr. (1988) 119, 293-301
INTRODUCTION
Luteinizing hormone-releasing hormone (LHRH) co¬
ordinates gonadotrophin secretion partly through a
unique self-priming effect on the anterior pituitary
gland whereby LHRH significantly increases the re¬
sponsiveness ofgonadotrophs to itself (Aiyer, Chiappa
& Fink, 1974). The priming effect of LHRH plays an
important role in the mechanism of the spontaneous
ovulatory surge of luteinizing hormone (LH) (Fink,
1979) and explains why in man and animals the LH
response to exogenously administered LHRH is corre¬
lated with the preinjection plasma LH concentrations
(Aiyer etal. 1974; Fink, 1979). The cellular mechanism
responsible is unknown, but is clearly quite distinct
from that of normal LHRH-induced gonadotrophin
secretion (Pickering & Fink, 1976a, 1979; Waring &
Turgeon, 1983). The magnitude of priming varies
throughout the oestrous cycle (Aiyer et al. 1974; Fink,
1979;Waring & Turgeon, 1980) and the effect is depen¬
dent both on protein synthesis and on the integrity of
microfilaments, but is independent of extracellular
Ca2+ (Pickering & Fink, 1976a, 1979). A significant
synthesis of LH does not seem to occur in the priming
effect, but instead there is synthesis of a novel protein
and probably post-translational modifications of
others (Pickering & Fink, 1979; Curtis, Lyons & Fink,
1985). The precise nature of the altered intracellular
signalling involved in the priming effect is not estab¬
lished, but the changes can only be evoked by LHRH,
not by any other secretagogue investigated (Pickering
& Fink, 1979).
Nevertheless, it is clear that calcium is required from
both extracellular and intracellular sources for LHRH-
induced gonadotrophin secretion (Pickering & Fink,
1979; Bourne & Baldwin, 1980; Bates & Conn, 1984;
Limor, Ayalon, Capponi et al. 1987). The cellular re¬
sponse to LHRH involves phospho-inositide hydroly¬
sis, and release of intracellular Ca2+ together with
activation of protein kinase C (PKC) (Hirota, Hirota,
Aguilera&Catt, 1985;Schrey, 1985; Limor etal. 1987).
Since in most cases the critical (though not exclusive)
signal for exocytotic secretion appears to be an increase
incytosolicfreeCa2+ levels (Baker& Knight, 1986) the
present series of experiments was carried out to exam¬
ine whether any modification of LHRH-induced Ca2+
mobilization occurs in priming. Our approach to this
was to measure LHRH-induced movements of 4:>Ca2+
rather than to use fluorescent indicators of cytosolic
free Ca2+ levels (Limor et al. 1987) since the priming
effect is impaired in isolated cells required for such
studies (Speight & Fink, 1981).
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MATERIALS AND METHODS
Standard laboratory chemicals were of Analar grade
obtained from BDH Chemicals Ltd, Dagenham,
Essex, U.K. All other compounds and drugs were
from Sigma Chemical Company Ltd, Poole, Dorset,
U.K., unless otherwise indicated. Ryanodine was pur¬
chased from Progressive Agri-Systems Inc., Wind
Gap, PA, U.S.A. Buserelin, nimodipine and dantro¬
lene were gifts from Hoechst UK, Hounslow, Middx,
U.K.; Bayer AG, Wuppertal, F.R.G. and Norwich-
Eaton Pharmaceuticals Inc., Norwich, NY, U.S.A.
LHRH priming
Female Wistar-COB rats (approximately 200 g)
purchased from Charles River UK Ltd, Margate,
Kent, U.K. were maintained under controlled lighting
(lights on from 05.00 to 19.00 h) and temperature
(22 °C) and allowed free access to diet 41B (Oxoid
Ltd, Basingstoke, Hants, U.K.) and tap water. The
rats had shown two consecutive 4-day oestrous cycles
immediately before use. Animals were anaesthetized
with sodium pentobarbitone (Sagatal; 30 mg/kg; May
& Baker Ltd, Dagenham, Essex, U.K.) at 13.30 h,
usually on the day of pro-oestrus (when the priming
effect is optimal). Hemisected anterior pituitary
glands were incubated in Hepes-buffered Minimal
Essential Medium with Earle's salts (and l-glutamine,
1 mmol/1) as described previously (Pickering & Fink,
1979). After 20 min preincubation and 1 h with
fresh medium, tissue was exposed to LHRH (0-85-
8-5 nmol/1) (Peninsula Labs Europe Ltd, St Helens,
Merseyside, U.K.) or control medium for one or two
more consecutive periods of an hour, designated I,
and I2 respectively. Parallel incubations were used for
determination of LH secretion using radioimmuno¬
assay procedures decribed in detail previously
(Pickering & Fink, 1979) or for 45Ca2+ flux and
[?H]inositol-labelling experiments. In order to enable
manipulation of the K+ concentration, some
incubations were carried out in a simplified Hepes-
buffered medium, normally of the following compo¬
sition (concentrations in mmol/1): NaCl, 135; KC1,
4-5; CaCl2, 1-5; MgCl„ 0-5; glucose, 5-6; Hepes, 10;
pH 7-4.
Influx of 45Ca2+
Procedures were based on those described previously
(Hopkins & Walker, 1978; Fink, Johnson, Minaur et
al. 1986). Following incubation in I, with or without
LHRH (8-5 nmol/1) hemipituitaries were washed three
times with 2 ml medium, quartered, and then rapidly
transferred to tubes containing 1 ml 'calcium-uptake
medium' of the following composition (Fink et al.
1986) (concentrations in mmol/1): NaCl, 154; KC1,
5-4; CaCl2, 1-5; glucose, 11; Hepes, 6; pH adjusted to
7-4 with Tris base and with the addition of 0-1% (w/v)
bovine serum albumin (BSA). After 20 min preincu¬
bation at 37 °C under 02, 1 ml medium containing
45Ca2+ (4pmol/l; ~3pCi per tube; Amersham
International pic, Amersham, Bucks, U.K.; specific
activity 17 mCi/mg) with or without LHRH was rap¬
idly added. After 30 s incubation, influx was quenched
with 3 ml ice-cold medium (2 mmol EGTA/1 replacing
Ca2+) (Meisheri, Palmer & Van Breemen, 1980) and
tissue was separated by filtration through Millipore
SCWP cellulose acetate/nitrate filters (8 pm pore size)
underlain by GF/B filters on Millipore 1225 Sampling
Manifolds (Millipore UK Ltd, Harrow, Middx,
U.K.). Samples were washed once immediately under
vacuum with 3 ml ice-cold EGTA medium and then a
further three times for 2 min each. Preliminary exper¬
iments revealed that these conditions gave the optimal
signal to noise ratio with LHRH or 60 mmol K+/l
medium. Stimulus-induced influx in excess of basal
controls was maximal within 30 s, suggesting that it
represented specific response-triggered flux rather
than adsorption or steady accumulation by storage
pools.
Unidirectional efflux of 45Ca2+
The protocol used for these experiments was based
on previous studies of pseudo-unidirectional 45Ca2+
efflux (Williams, 1976; Masters, Quinn & Brown,
1985), but here included EGTA (Meisheri et al.
1980) to minimize any exchange-induced efflux. Tissue
was not permeabilized in case this disrupted the
intracellular changes responsible for priming.
After incubation in I, with or without LHRH
(8-5 nmol/1) and extensive washing, pairs of hemipitui¬
taries were preincubated for 20 min in 0-5 ml 'calcium
uptake medium' with 0 05% BSA before addition of
1 ml medium containing 6pmol 45Ca2+/l (~4-5pCi/
tube). Samples were incubated for 1 h at 37 °C under
O, before the labelling solution was aspirated. Warm
oxygenated 'EGTA medium' (3 ml) was added and
the tissue captured by filtration through GF/B filters
on a Millipore 1225 Sampling Manifold. Following
five rapid 3 ml washes, the manifold was reassembled
with tubes to collect the filtrate, and 3 ml fresh
oxygenated 'EGTA' medium (37 °C) added for 2 min
before filtration. This process was repeated a further
nine times, with LHRH present when required from
the sixth fraction. Results were calculated in terms of
the fractional rate coefficient (FRC) of 45Ca2+ efflux
per fraction (i.e. d.p.m. per fraction divided by total
d.p.m. recovered).
Radioligand binding to LHRH receptors
Experiments were carried out to assess whether any
changes in the affinity or number of LHRH binding
sites occurred due to priming in vitro or due to
J. Endocr. (1988) 119, 293-301
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ovariectomy. After incubation with or without
LHRH (8-5 nmol/1) in period I,, anterior pituitary
glands were sonicated in ice-cold Tris-HCl buffer
(25 mmol/1, pH 7-6) containing 0-05 g soybean trypsin
inhibitor/1, 0 016 g trasylol/1 and 8-5 nmol LHRH/1,
before incubation for 90 min on ice to ensure equal
occupancy of LHRH receptors in control and primed
tissue. This was carried out to avoid any artefacts due
to residual occupancy of receptors by LHRH in
primed but not control tissue. Membranes were then
washed once by centrifugation at 48 000 g for 10 min
and resuspended in 1000 volumes fresh buffer before
allowing 12 h at 4 °C for dissociation of the majority of
bound LHRH. Then, after centrifugation and resus-
pension in fresh buffer (with 0-1 g BSA/1), equilibrium
binding of the LHRH analogue [l25I]buserelin ([d-
Ser(Bu')6desGlyl0]LHRH ethylamide) was determined
as described previously (Mitchell, Ogier, Johnson et
al. 1986). Approximately one-tenth of a pituitary
equivalent was used per tube with a label concen¬
tration of ~30pmol/l (specific activity — 1100 Ci/
mmol). Data was obtained from experiments with
duplicate determinations at ten unlabelled buserelin
concentrations in the range 0-05-5-nmol/l, and then
analysed by an error-weighted curve-fitting pro¬
gramme (Zivin & Waud, 1982) to yield values for
number of binding sites and affinity in each case.
Inositol phosphate production
Following incubation in period I,, with or without
LHRH (8-5 nmol/1), hemipituitaries were washed five
times with 2 ml of the Hepes-buffered medium (as
described for K+ depolarisation studies above) but
with 10 mmol glucose/1 and 01 g BSA/1 added and
then cut into quarters. Tissue was added to 100 pi of
the same medium in capped 1 -5 ml polypropylene
tubes at 37 °C underOr Then 10 pCi myo-[3H]inositol
(Amersham International pic; 80-120 Ci/mmol) was
added to each tube and incubation continued for 1 h.
Incorporation of label into inositol phosphates was
measured according to well-characterized procedures
(Berridge, Dawson, Downes et al. 1983; Batty,
Nahorski & Irvine, 1985; Schrey, 1985). Tissue was
washed twice with 1 ml fresh medium and resus¬
pended in 100 pi. An equal volume of medium con¬
taining 200nmol LHRH/1 and 20mmol LiCl/1 (or
LiCl alone) was added for 10 min (Schrey, 1985)
before stopping the incubation with 100 pi ice-cold
trichloracetic acid (22-5 g/1). After homogenization
and 15 min on ice, tubes were centrifuged (16 000g; 5
min) and an aliquot of the supernatant was removed.
This was washed five times with two volumes of
water-saturated diethyl ether and neutralized to pH
7-8 with solid NaHCO, (Batty et al. 1985). Samples
were loaded onto 0-5 ml columns of Dowex AG 1-X8
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figure 1. Effect of LHRH priming on LHRH-induced
45Ca2+ influx into anterior pituitary tissue of the rat in vitro.
Values are means+ s.e.m. from four to eight separate experi¬
ments. Accumulation of 45Ca2+ in the presence of 100 nmol
LHRH/1 was typically around 6000 d.p.m., ofwhich adsorp¬
tion to the filter was responsible for around 2000 d.p.m.
Basal 45Ca2+ accumulation by tissue in the absence of
LHRH was 1-45 + 0-21 (n= 12) and 1-43 + 0-27 (« = 8) pmol/
min per pituitary for control and primed tissue respectively.
The figure shows concentration-response data for LHRH-
induced 45Ca2+ accumulation following incubation with
medium (O) or 8-5 nmol LHRH/1 (•) for a 60-min period
(incubation I,) and extensive washing.
Ltd, Watford, Herts, U.K.) ion exchange columns
and eluted sequentially with buffers established by
other workers (Berridge et al. 1983; Batty et al. 1985)
to separate different inositol phosphates. Fractions
of eluate were collected (Batty et al. 1985) corre¬
sponding to glycerol inositol phosphate, inositol
monophosphate, inositol bisphosphate and inositol
trisphosphate.
RESULTS
45Ca2+ influx and LHRH primimg
A rapid influx of 45Ca2+ into anterior pituitary tissue
in vitro could be induced by LHRH (Fig. 1) or by
depolarising concentrations of extracellular K +
(Hopkins & Walker, 1978; Fink, Johnson, Minaur et
al. 1986, 1987). The 45Ca2+ influx induced by LHRH
(1 nmol/1) or K+ (30 mmol/1) was potently inhibited
by the l-type Ca2+-channel blocker, nimodipine
(Nowycky, Fox&Tsien, 1985), which caused 50% inhi¬
bition at nimodipine concentrations of 6 + 2 nmol/1
and 7+1 nmol/1 respectively (means + s.e.m.; n = 4).
However, exposure of tissue to LHRH in incubation
J. Endocr. (1988) 119, 293-301
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table 1. The priming effect of LHRH on LH secretion under different conditions in the
rat in vitro. Values are means ± s.e.m. and numbers of experiments are shown in
parentheses
Incubation Increments in LH
conditions during period (gg/1)
I. h I, L
Tissue
Pro-oestrous Medium LHRH(8) 6 + 3 127+13
LHRH LHRH(19) 144+15 335 + 57
Oestrous LHRH LHRH(8) 111 + 19 210 + 43*
Ovariectomized LHRH LHRH(10) 164+10 157 + 24*
Pro-oestrous LHRH LHRH(4) 96 + 24 313 + 15
(simplified medium)
Pro-oestrous LHRH LHRH(8) 125 + 15 449 ±58
LHRH + — (8) 65 + 17f —
nimodipine
LHRH LHRH + 136± 14 396 + 53
nimodipine(8)
Tissue was exposed to medium, lhrh (0-85 nmol/i) or nimodipine (300 nmol/1) as indicated in two successive
60-min incubation periods, i, and i2.
TcO-Ol compared with corresponding value for pro-oestrous tissue; f/><0 05 compared with corresponding
value for lhrh alone (Student's /-test).
I, (which caused priming of LH secretion in I2 (Table
1)) produced no detectable change in the concentra¬
tion-response curve for LHRH-induced 45Ca2+ influx
(Fig. 1). Since there is no increase in nimidopine-
sensitive 45Ca2 + influx under conditions of priming,
the excess secretory responsiveness of primed tissue
may be expected to be insensitive to nimodipine
(Mitchell, Johnson & Fink, 1987). Accordingly, whilst
a maximally effective concentration of nimodipine
(300 nmol/1) blocked approximately 50% of LHRH-
induced LH secretion in unprimed tissue, the
increased responses in primed tissue were inhibited
only marginally by nimodipine (Table 1).
4SCa2+ efflux and LHRH priming
Following an initial phase of rapid washout, the basal
efflux of 45Ca2+ declined slowly to an almost steady
rate, after which addition of lOOnmol LHRH/1
elicited a clear but transient increase in 45Ca2+ efflux
(Fig. 2). Efflux in the presence of LHRH was signifi¬
cantly greater than basal for the first two fractions
after LHRH addition (Fig. 2a). In tissue that had been
previously exposed to LHRH, the subsequent LHRH-
induced 45Ca~+ efflux was clearly facilitated, although
basal efflux was unaltered. The LHRH-induced
increment in FRC from such primed tissue was sig¬
nificantly greater than that from unprimed tissue in
the first three fractions after the addition of LHRH
(Fig. 2b). Concentration-response data (Fig. 2c)
showed that enhanced responsiveness was significant
at 10-100 nmol LHRH/1 with a similar trend at lower
concentrations.
The 45Ca2+ efflux response to LHRH (either with or
without previous exposure to LHRH) was inhibited
by 10 min prior exposure to dantrolene (10pmol/l),
caffeine (10mmol/l), ryanodine (100pmol/l) or by
45Ca2+-loading in the presence of lOpmol but not
1 pmol Ruthenium Red/1, whereas the 45Ca2+ efflux
induced by the mitochondrial poison carbonyl cya¬
nide m-chlorophenylhydrazone (5 pmol/1) was abol¬
ished by just 1 pmol Ruthenium Red/1 (R. Mitchell
& M. Johnson, unpublished observations). These
observations suggest (Kojima, Kojima, Kreutter &
Rasmussen, 1984; Biden, Wollheim & Schlegel, 1986;
Meissner, 1986; McBurney & Neering, 1987) that the
LHRH-induced 45Ca2+ efflux response here originates
from a non-mitochondrial pool which may be
endoplasmic reticulum.
The effect of priming on LHRH-induced 45Ca2+
efflux was further investigated under a variety of
conditions reported to influence the magnitude of the
secretory change in primed tissue (Table 1). In agree¬
ment with earlier observations (Fink, 1979; Pickering
& Fink, 1979; Waring & Turgeon, 1980) priming of
LH secretion was significantly less in oestrous than
in pro-oestrous rats (Table 1). Using tissue from
oestrous rats, incubation with LHRH during period I,
correspondingly caused no significant enhancement of
subsequent LHRH-induced 45Ca2+ efflux (Table 2).
Tissue from rats which had been ovariectomized 3
weeks previously showed high basal LH output and
no apparent priming (Table 1), as has also been
described previously (Aiyer, Sood & Brown-Grant,
1976). Basal 45Ca2+ efflux was unaltered in tissue from
ovariectomized rats and 45Ca2+ efflux responses to
LHRH were very much greater than in pro-oestrous
J. Endocr. (1988) 119, 293-301
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Fraction number LHRH concentration (nmol/l)
figure 2. Effect of LHRH priming on LHRH-induced unidirectional efflux of45Ca2+ from anterior pituitary tissue of the rat
in vitro. Efflux of 45Ca2+ expressed as the fractional rate coefficient (FRC) i.e. radioactivity per fraction divided by total
recovered radioactivity. Control basal efflux represented approximately 1500 d.p.m. at fraction 7. LHRH was present during
the period shown by the horizontal bars, (a) Basal efflux (□) and the response to 100 nmol LHRH/1 (O) in tissue previously
exposed to medium alone for a 60-min period (incubation I,); (b) basal efflux (■) and the response to 100 nmol LHRH/1 (•)
in tissue previously exposed to 8-5 nmol LHRH/1 in incubation I,. Values are means + s.e.m., n = l. *P<0 05, **R<0 01
compared with FRC for corresponding basal efflux (Student's t-test); fRcOOl compared with increment in FRC for tissue
not pre-exposed to LHRH (Student's /-test); (c) concentration-response data for the LHRH-induced increment in FRC,
calculated at fraction 7 ofexperiments like those shown in (a) and (b). Tissue had been previously exposed to medium (O) or
to 8-5 nmol LHRH/1 (•) in incubation I,. Values are means ± s.e.m., (« = 4—13). *P<005, **/><001 compared with in¬
crement in FRC for tissue not previously exposed to LHRH (Student's /-test).
rats (Table 2). However, incubation in I, with LHRH
rather than medium alone caused no significant
increase in the subsequent LHRH-induced 45Ca2+
efflux using tissue from ovariectomized rats (Table 2).
Blockade of protein synthesis with cycloheximide,
which prevents the priming effect of LHRH (Pickering
& Fink, 1979; Curtis et al. 1985; Turgeon & Waring,
1986), eliminated the increase in subsequent LHRH-
induced 45Ca2+ efflux from pro-oestrous tissue
exposed to LHRH rather than medium in I, (Table 2).
Depolarization with K+ in period I, fails to mimic
the priming effect caused by exposure to LHRH
(Pickering & Fink, 19766), and also failed here to
modify subsequent LHRH-induced 45Ca2+ efflux
(Table 2).
LHRH receptors and priming
Specific equilibrium binding of [l25I]buserelin was
determined in tissue from pro-oestrous rats that had
been exposed to either LHRH or medium in I, or
from ovariectomized rats. In each case, saturation
data showed excellent fit to a single component of
binding. Neither the affinity nor the number of sites in
pro-oestrous tissue were altered by exposure to
LHRH in period I,, equivalent to that which would
J. Endocr. (1988) 119, 293-301
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table 2. LHRH-induced unidirectional efflux of 45Ca2+ and binding of [125I]buserelin under



















































Tissue was exposed in a 60-min incubation period (I.) to medium, LHRH (8-5 nmol/1), high-K+ medium (30 mmol/1) or
cycloheximide (50 pmol/1) before 45Ca2+ efflux or [ I]buserelin binding experiments. For pro-oestrous tissue, incubation with
LHRH in Ij consistently caused priming of LHRH-induced LH secretion in a subsequent 60-min incubation period (I3) (see
Table 1). The values for 45Ca2+ efflux show the peak increment in fractional rate coefficient (FRC) (induced by 100 nmol
LHRH/1) over corresponding basal efflux curves (taken at fraction seven).
*/><0-01 compared with the increment in corresponding controls unexposed to LHRH in L: t/J < 0 01 compared with the
corresponding increment for pro-oestrous tissue exposed to LHRH in I,; + /' < 0 01 compared with the corresponding value for
pro-oestrous tissue (Student's (-test).
cause priming of LH secretion (Table 2). Ovari¬
ectomy, however, significantly increased the number
of available sites above pro-oestrous values (which are
normally the highest of the oestrous cycle (Marian,
Cooper & Conn, 1981) (Table 2).
Inositol phosphate production and LHRH priming
The incorporation of [3H]inositol into inositol phos¬
phates was measured in response to 100 nmol
LHRH/1 using pro-oestrous tissue that had been
exposed to medium or LHRH in period I, (Fig. 3).
Basal levels of incorporation were unaltered by the
previous exposure to LHRH. However, LHRH-
induced labelling of the inositol trisphosphate frac¬
tion was significantly increased by previous ex¬
posure to LHRH, and similar trends were seen in
the bisphosphate and monophosphate fractions.
Values for glycerol inositol monophosphate and
unincorporated inositol were unchanged. Under
the present experimental conditions, no signifi¬
cant levels of label could be detected that eluted
under the conditions described (Batty et al. 1985)
for inositol tetrakisphosphate, although other ex¬
perimental protocols and time-courses were not
investigated.
DISCUSSION
Under the present experimental conditions, either
LHRH-induced or depolarization-induced influx of
45Ca2+ was sensitive to concentrations of nimodipine
in the nmol/1 range. The functional importance of
such dihydropyridine-sensitive channels in LHRH
action is suggested by partial blockade of LHRH-
induced LH secretion by nitrendipine (Chang,
McCoy, Graeter et al. 1986) or nimodipine (Table 1).
However, it is clear that LHRH priming causes no
change in the LHRH-induced influx of 45Ca2+
through these channels (Fig. 1), and accordingly that
the excess LHRH-induced LH secretion from primed
gonadotrophs is insensitive to nimodipine (Table 1).
We therefore found no evidence here to suggest that
LHRH-induced influx of extracellular Ca2+ is pro¬
moted by priming. Nevertheless, other classes of
membrane Ca2+ channel (Nowycky et al. 1985),
cation exchanger (Kaczorowski, Costello, Dethmers
et al. 1984) or Ca2+ extrusion pump (Lotersztajn,
Hanoune & Pecker, 1981) could potentially by
influenced by priming, and their role may not be
detected by our particular experimental protocol.
In contrast, the LHRH-induced mobilization of
previously accumulated 45Ca2+ was markedly facili-
J. Endocr. (1988) 119, 293-301
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6-1
**
I, incubation I — 1 |lhrh| | — 1 [lhrh| 1 — | Ilhrh] | — | |lhrh|
GPI IP, IP2 IP3
figure 3. Effects of previous exposure to LHRH on LHRH-induced inositol
phosphate production in rat anterior pituitary tissue in vitro. Inositol phosphates
were separated, as described, into fractions corresponding to glycerol inositol phos¬
phate (GPI), inositol monophosphate (IP,), inositol bisphosphate (IP2) and inositol
trisphosphate (IP3). The figure shows the radioactivity recovered in each of these
fractions as mean + s.e.m. from seven experiments. Values obtained in the presence
oflO mmol LiCl/1 alone or 10 mmol LiCl/1 with 100 nmol LHRH/1 are shown by the
open or hatched columns respectively. The previous conditions in a 60-min incu¬
bation period (I,) are indicated beneath the columns. In I,, LHRH was present at a
concentration of 8-5 nmol/1. */><0 05, **P<001, ***P<0001 compared with LiCl
alone; tP<001 compared with response to LHRH in tissue not previously exposed
to LHRH during I, (Student's r-test).
tated by previous exposure to LHRH sufficient to
cause priming of LH secretion (Fig. 2). The 45Ca2+
efflux occurring in response to LHRH is transient,
suggesting that it originates from a finite cellular pool,
and the pharmacological properties of this pool
suggest that it relates to endoplasmic reticulum rather
than to mitochondria. It is possible that the increased
45Ca2+ efflux could result from changes in Ca2+
sequestration, extrusion or pool sizes (Lotersztajn et
al. 1981; Jy & Haynes, 1984; Adunyah & Dean, 1986)
although little is known about whether these can be
receptor-regulated under physiological conditions.
An alternative explanation is that the priming effect
of LHRH involves facilitating the efficacy with which
subsequent LHRH challenges can mobilize intracel¬
lular Ca2+ stores. Either receptor-induced production
of the second messenger inositol 1,4,5-trisphosphate
(IP3) or its action on endoplasmic reticulum Ca2+
stores might be enhanced. Two lines of evidence
strongly suggest that a facilitation of LHRH-induced
second messenger production is responsible for the
present observations. First, our data showing that
LHRH-induced labelling of inositol phosphates is
increased in tissue previously exposed to LHRH (Fig.
3) and secondly, the specific demonstration that
dantrolene (which blocks LHRH-induced 45Ca2+
efflux here) prevents IP3-induced Ca2+ mobilization in
permeabilized cells (Kojima et al. 1984).
The parallel increases in LHRH-induced inositol
phosphate production and intracellular Ca2+ mobili¬
zation could in principle be due to changes in affinity
or numbers of LHRH receptors. An up-regulation of
J. Endocr. (1988) 119, 293-301
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LHRH receptors may explain the increased LHRH-
induced 45Ca2+ efflux in tissue from ovariectomized
rats (Table 2). A quite different explanation is needed,
however, for the increased LHRH-induced 45Ca2+
efflux from pro-oestrous tissue previously exposed to
LHRH, as there is no corresponding change in recep¬
tor properties (Table 2). Our hypothesis is that a novel
phenomenon—a facilitated coupling of the LHRH
receptor to its effector (phospho-inositidase C)—may
be responsible for the changes observed. Changes in
the activity of inositol lipid kinases or of the enzymes
involved in inositol phosphate metabolism could be
alternative explanations, but the specific changes in
LHRH-induced, rather than basal, inositol phosphate
production suggest that they are less likely. However
the altered signalling is brought about, it is clear that
its importance extends to a functional alteration of
receptor-induced Ca2+ mobilization in gonadotrophs.
The degree to which changes in LHRH-induced
intracellular Ca2+ mobilization may directly account
for the enhanced stimulus-secretion coupling in the
priming effect is difficult to establish. Nevertheless, a
close correlation exists between factors influencing the
priming of LH secretion and those affecting the
enhancement of LHRH-induced 45Ca2+ efflux in
tissue previously exposed to LHRH (Tables 1 and 2).
Furthermore, it is clear that significant priming of
gonadotrophs to LHRH still occurs in conditions
where only intracellular and not extracellular Ca2+
mobilization can be enlisted (Pickering & Fink, 1979).
Whilst facilitated mobilization of intracellular Ca2+
may be crucial for primed responses to the natural
secretagogue LHRH, other changes may occur in
the secretory apparatus of primed gonadotrophs
(Lewis, Morris & Fink, 1985). These may be respon¬
sible for the enhancement of responses to non-specific
secretagogues such as K+ or Ca2+ ionophores seen
after LHRH priming (Pickering & Fink, 1979;
Turgeon & Waring, 1986). Recent experiments have
revealed that LHRH priming causes a significantly
greater degree of enhancement of subsequent
responses to LHRH rather than to K+ or iono-
mycin (R. Mitchell & M. Johnson, unpublished data).
Kinetic analysis of these data indicates that the
greater degree of enhancement of LHRH responses
involves two distinct components, one ofwhich is also
apparent with non-specific secretagogues and the
other which is specifically receptor-related (like the
changes described here).
If enhanced activation of phospho-inositidase C
were occurring in primed tissue it may well lead to
increased activity of PKC as well as to changes in
Ca2+ mobilization. Secretion of LH is slowly
increased by phorbol esters (which activate PKC)
(Smith & Vale, 1981; Turgeon & Waring, 1986;
Johnson, Mitchell & Fink, 1988) in a manner which is
synergistic with raised cytosolic Ca2+ levels (Harris,
Staley & Conn, 1985). Responses to LHRH can also
be facilitated by phorbol esters (Turgeon & Waring,
1986), although our studies with inhibitors as well as
activators of PKC (Johnson et al. 1988) reveal that
PKC plays no apparent role in the priming effect. Our
evidence therefore suggests that one element of the
priming effect of LHRH is a quite novel facilitation
of receptor-induced inositol phosphate production
and intracellular Ca2+ mobilization, whilst any con¬
comitant increase that may occur in PKC activity
does not play an important role in the enhanced re¬
sponsiveness of gonadotrophs.
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PREPARATION AND USE OF BIOTINYLATED LIGANDS FOR LHRH RECEPTOR PURIFICATION.
Christine M. Bladon*, Rory Mitchell, and Sally-Ann Ogier
MRC Brain Metabolism Unit, 1 George Square, Edinburgh EH8 9JZ, Scotland.
Summary: The synthesis of biotinylated analogues of LHRH is described in which the peptides
simultaneously combine biotin and either a photolabile or an amino substituent. In rat
anterior pituitary membranes the conjugate [biotinyl-aminoethylglycyl-D-Lys®, des GlylO]-
LHRH ethylamide showed approximately 50% specific binding and could be covalently crosslinked
to the LHRH receptor site with ethylene glycolbis(succinimidylsuccinate).
Photoaffinity labelling has developed into a regular technique for the investigation of
neuropeptide-receptor interactions. In this procedure a ligand containing a photolabile
species, normally an azido group, is activated by photolysis and the resulting nitrene
f 0
covalently binds to the receptor ' . This technique combined with affinity chromatography
3-5based on the biotin-avidin/streptavidin interaction provides a method for the
identification, localisation and purification of hormone-receptor complexes®. We have
adopted and extended this approach for the purification of the luteinizing hormone releasing
hormone (LHRH) receptor. In addition to investigating the photoaffinity approach to receptor
labelling we have developed an alternative method in which an amino group can be covalently
attached to the receptor with bifunctional crosslinkers^. LHRH(l), a hypothalamic
decapeptide, plays a key role in the mammalian reproductive cycle and knowledge of the
structure of the receptor binding site would further our understanding of the mechanism of
cellular response. In this report we describe the synthesis of two novel biotinylated
reagents, their conjugation to LHRH analogues and preliminary biological studies of the
peptide derivatives in rat anterior pituitary membranes.
Two active LHRH analogues, D-Lys®-LHRH(2) and [D-Lys®, des Gly^j-LHRH
ethylamide(3) were selected for this study. The e-amino moiety of the D-Lys® residue
provides a convenient group on which to couple reagents. The latter peptide was chosen as
O
previous reports indicate that better specific:non-specific binding ratios are observed
with the des Gly^-ethylamide C-terminus. D-Lys®-LHRH was obtained commercially
(Peninsula) and [D-Lys®, des Gly^j-LHRH ethylamide was synthesised by the solid-phase
g
method using Sheppard's Fmoc-t-butyl-polyamide chemistry . After purification by
ion-exchange chromatography this peptide showed the expected amino acid composition and
molecular weight (Glu^ 1.02, His^ 0.96, Ser1 0.89, Tyr^ 0.97, D-LySj 1.00, Leu^ 1.00,
Argx 1.00, Pro1 0.95; FAB MS: found MH+ 1225, calc. MH+ CggHggN^O^ 1225).
(1) pGlu-Hi s-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2
(2) pGl u-Hi s-Trp-Ser-Tyr-D-Lys-Leu-Arg-Pro-Gly-NHg
(3) pGl u-Hi s-Trp-Ser-Tyr-D-Lys-Leu-Arg-Pro-NHEt
1401
1402
The reagents biotinyl-p-azidophenylalanine (4) and biotinyl-t-butoxycarbonylamino-
ethylglycine^)^ were prepared from L-p-nitrophenylalanine and L-2,4-diaminobutyric acid
respectively and the syntheses are outlined in schemes 1 and 2. Both reagents were converted
to their N-hydroxysuccinimide esters for coupling to the peptide backbone1*.
Scheme 1, Synthesis of biotinyl-p-azidophenylalanine (4)
H-Phe(N02)-0H 1
(L-4.-n i tropheny 1 alanine)
H-Phe(N02)-0Me — Fmoc-Phe(N02)-0Me
111
H-Phe(NHBoc)-OMe —- Fmoc-Phe(NHBoc)-OMe—— Fmoc-Phe(NH9)-OMe
biot-Phe(NHBoc)-OMe vn, vin biot-Phe(NH2)-0H biot-Phe(N2)-0H
(4)
Conditions: i, SOCl2-MeOH; ii, FmocCl-K2C03-H20-dioxan; iii, H2-5%Pd-C-Ac0H;
iv, 10%NaHC03-(Boc)20-H20-dioxan; v, 20% piperidine in DMF; vi, biotin-pentafluoro-
phenyl ester-HOBT-DMF; vii, Na0H-H20-Me0H; viii, aq TFA; ix, Naf^-NaN^-lMHCl.
Scheme 2, Synthesis of. biotinyl-t-butoxycarbonylaminoethylglycine (5)







Conditions: i, CuC03.Cu(0H)2-H2O; ii, Mg0-(Boc)20-MeoH; iii, H^-HgO-NH^OH;
iv, FmocCl-KgCO^-HgO-dioxan, v, CHgNg-EtgO; vi, 20% piperidine in DMF;
vii, biotin-pentafluorophenyl ester-HOBT-DMF; viii, Na0H-H20-Me0H
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Three conjugates were prepared, [biotinyl-p-azidophenylalanyl-D-Lys®]-LHRH (6)
[biotinyl-p-azidophenylalanyl-D-Lys^, des Gly^]-LHRH ethylamide (7) and
[biotinyl-aminoethylglycyl-D-Lys®, des Gly^]-LHRH ethylamide (8), and the coupling
procedure was similar in each case. For example, D-Lys^-LHRH (2mg, 1.6pmol) was dissolved
in freshly distilled DMF (2ml) and triethylamine (2 drops) was added. Biotinyl-p-azido-
phenylalanine-N-hydroxysuccinimide ester (5mg, 9.45vmols) in DMF (1ml) was added and the
12
resulting mixture was left standing in the dark for 1 h. The DMF was evaporated under
high vacuum and the residue was triturated with ethyl acetate (3 x 2ml) to remove excess
13
reagent. The crude product was purified by semi-preparative reverse-phase hplc to yield
1.84mg (69%)"^ of pure (single peak on analytical hplc) conjugate. The amino acid
compositions of the three conjugates are given in Table 1.







Table 1, Amino acid analysis of LHRH conjugates
No. PGlu His Ser Tyr D-Lys Leu Arg Pro Gly Phe(N3)* Gly(CH2CH2NH2)
6 1.07 1.00 0.81 1.07 1.01 1 1.00 0.96 1.04 0.30 -
7 1.05 0.96 0.83 0.95 1.02 1 0.89 0.91 0.20 -
8 1.09 1.01 0.91 1.01 1.07 1 0.96 0.99 - - 0.94
* largely decomposed on hydrolysis
Of the three ligands prepared, two contain a photolabile moiety (6,7) whilst the third
(8) contains an amino substituent suitable for reaction with bifunctional chemical
crosslinkers. The ligands were iodinated and the specificity of their binding to anterior
pituitary membranes of male rats was examined by displacement with lyM LHRH (see Table 2).
Their affinity and maximal number of specific binding sites were determined (where
appropriate) by saturation analysis and affinity values for the uniodinated forms were
confirmed to be similar by displacement of iodinated buserelin ([D-Ser(Bu^)®, des Gly^]-
LHRH ethylamide). A proportion of the specific binding was rendered resistant to
dissociation (4 hrs, 23°C in the presence of excess LHRH) either by illumination for 10 min
on ice using a 4 Watt Hg lamp (ligands 6, 7) or by incubation for 30 min on ice with 5mM
ethylene glyco1bis(succinimidylsuccinate) in the case of ligand (8). Preliminary experiments
have shown that membrane protein covalently labelled with (8) will subsequently bind to
streptavidin-agarose columns and can be efficiently eluted with 2mM biotin.
1404
Table 2, Biological experiments with iodinated ligands16




as % of affinity (Kg) number of sites
total binding pM (Bmax)
fmol/pituitary
as % of initial overall yield






78 ± 4(8) 280 ± 20 92 ± 3
12 ± 4(4)
10 ± 3(3)
44 ± 6(3) 131 ± 16 63 ± 5
< 4(4) < 0.5
28 ± 5(3) 3 ± 1
18 ± 3(5) 8 ± 1
values are means ± SEM; numbers of experiments in parentheses
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Novel ligands for the affinity labelling of luteinizing hormone
releasing hormone receptors
H Sally-Ann OGIER, Rory MITCHELL* and Christine M. BLADON
MRC Brain Metabolism Unit, 1 George Square, Edinburgh EH8 9JZ, Scotland
A number of novel luteinizing hormone releasing hormone (LHRH) analogues incorporating biotin together
with potential covalent attachment sites have been synthesized. Those based on the des-Gly10-[d-Lys6]-
LHRH ethylamide peptide backbone resulted in the most useful characteristics of binding to the LHRH
receptor in rat anterior pituitary gland membranes. Of these, des-GlyI0-[biotinyl-aminoethylglycyl-d-Lys6]-
LHRH ethylamide (XBAL) gave the best specific: non-specific binding ratio, with 44 + 6% ( + s.e.m.) of
total binding being specific with a Aj, of 131 +16 pM (+ s.e.m., n = 4) as determined by Scatchard analysis.
Two methods have been used to covalently crosslink these analogues with the LHRH receptor; photoaffinity
labelling and the use of homobifunctional A-hydroxysuccinimide ester crosslinkers. The photoaffinity
analogues gave poor specific:non-specific binding ratios. Of the chemical crosslinkers tested, ethylene
glycolbis(succinimidylsuccinate) (EGS) was found to be the most efficient at covalently linking the 125I-
XBAL bound to the LHRH receptor site. At an EGS concentration of 5 mm, 23±3% ( + s.e.m.) of the
specific binding of 126I-XBAL was covalently crosslinked.
INTRODUCTION
Luteinizing hormone releasing hormone (LHRH)
causes release of gonadotrophins from the anterior
pituitary gland by a mechanism involving interaction
with a membrane-bound receptor (Clayton & Catt, 1981)
and a subsequent increase in the turnover of membrane
phosphoinositides (Conn et al., 1986). Information on
the structure of the binding site and signal transduction
domains of the LHRH receptor may facilitate our
understanding of the signalling events occurring. We
have recently described a high-yielding method of solubi¬
lization for the rat anterior pituitary LHRH receptor
(Ogier et al., 1987), the initial step in purification and
molecular characterization of this receptor. Several
receptor types have been successfully purified using the
technique of ligand affinity chromatography (Strosberg,
1984), including the GABAa (Sigel & Barnard, 1984),
muscarinic cholinergic (Haga & Haga, 1985), glycine
(Pfeiffer et al., 1982), ^-adrenergic (Homey et al., 1983)
and insulin receptors (Cuatrecasas, 1972). This approach
requires conditions to be found which retain the receptor
in a solubilized state without denaturing the protein or
greatly reducing its affinity for the ligand utilized. In the
case of the LHRH receptor, an extensive survey of
different detergents failed to find conditions compatible
with these criteria (Ogier et al., 1987). Although deter¬
gent/salt conditions were found to successfully solubilize
the receptor, ligand binding could only be observed
subsequently by removal of the solubilizing agents (and
consequent precipitation of the receptor protein). A
novel method for purification of the solubilized LHRH
receptor was therefore required.
Hofmann & Finn (1985) and Kohanski & Lane (1985)
described a method of receptor affinity chromatography
based on the interaction of immobilized avidin/strept-
avidin with biotin incorporated into specific receptor
ligands. A similar biotinylated (but still reversible) ligand
for LHRH receptors has also been described (Hazum
et al., 1986). As described, this approach is strictly depen¬
dent on the ligand-receptor interaction being viable in
the presence of the detergent (the biotin/avidin inter¬
action appears to be much more resistant to disruption
by detergents; Hofmann & Finn, 1985; Kohanski &
Lane, 1985). To further develop this approach for
LHRH receptor purification we adopted the strategy of
covalently linking biotinylated ligands to the LHRH
receptor, thereby overcoming the problem of detergent
suppression of reversible ligand binding.
The present study describes the design of several
LHRH analogues incorporating a biotin molecule. These
have been used in conjunction with the two methods of
covalent labelling (photoaffinity labelling or affinity cross-
linking; Pilch & Czech, 1984) to assess the optimal
conditions required for the covalent affinity labelling of
LHRH receptors by biotinylated LHRH analogues.
EXPERIMENTAL
Materials
The divalent crosslinkers bis(sulphosuccinimidyl)-
suberate (BSSS), disuccinimidyl suberate (DSS), di-
succinimidyl tartarate (DST), ethylene glycolbis(succin-
imidylsuccinate) (EGS) and sulphosuccinimidyl 6-(4'-
azido-2'-nitrophenylamino)hexanoate (sulpho-SANPAH)
Abbreviations used: LHRH, luteinizing hormone releasing hormone; buserelin, des-Gly1"-[i>Ser(But)6]LHRH ethylamide; PBL, [biotinyl-p-
azidophcnylalanyl-D-Lys6]LHRH, PBAL, des-Gly"'-[biotinyl-/7-azidophenylalanyl-D-Lys6]LHRH ethylamide; XBAL, des-Glylu-[biotinyl-amino-
ethylglycyl-D-Lys6]LHRH ethylamide; sulpho-SANPAH, sulphosuccinimidyl 6-(4'-azido-2'-nitrophenylamino)hexanoate; EGS, ethylene glycolbis-
(succinimidylsuccinate); DSS, disuccinimidyl suberate; DST, disuccinimidyl tartarate; BSSS, bis(sulphosuccinimidyl)suberate; Boc, r-butoxy-
carbonyl; Fmoc, 9-fiuorenylmethoxycarbonyl; chloramine-T: iv-chloro-/)-toluene sulphonamide, sodium salt; PEG. poly(ethylene glycol)8000.
* To whom correspondence should be addressed.
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were purchased from Pierce and Warriner (U.K.) Ltd.,
Chester, U.K. The LHRH analogue buserelin (des-
Gly10-[D-Ser(Bu')6]LHRH ethylamide) was a generous
gift from Hoechst A. G., Frankfurt, F.R.G. [d-Lys6]-
LHRH was purchased from Peninsula Laboratories
Europe Ltd., St. Helens, U.K. Other LHRH analogues
were synthesized as described below. All other chemicals
and peptides, unless otherwise stated, were obtained
from Sigma Chemical Company Ltd., Poole, Dorset,
U.K.
Synthesis and derivatization of peptide analogues
[des-Gly10, D-Lys6]LHRH ethylamide was synthesized
by the solid-phase method using Sheppard's Fmoc-t-
butyl-polyamide chemistry (Eberle et al.., 1986). After
purification, the peptide had the expected amino acid
composition (Glu15 1.02; HiSj, 0.96; Ser^ 0.89; Tyrt,
0.97; Lys1; 1.00; Leu;, 1.00; Arg1? 1.05; Pro15 0.95) and
fast atom bombardment mass spectrum (MH+, 1225;
calc. for C59H85N17Oia, 1224).
The biotinylated reagents (Fig. 1, 1 and 2) were
prepared in several steps from biotin and either p-
nitrophenylalanine or 2,4-diaminobutyric acid, and were




































Fig. 1. Biotinyl-LHRH analogue structures
Structures of the novel biotin ligands (1) and (2) and





coupling to the e-amino group of the d-Lys6 of the
peptide backbone (Bladon et al., 1988).
The synthesis of reagent 2, (Fig. 1) (biotinyl-/-butoxy-
carbonylaminoethylglycine), required the selective protec-
tion/deprotection of the two amino groups of l-2,4-
diaminobutyric acid. The y-amino function was protected
with the acid-labile /-butoxycarbonyl group (Boc) in a
two-step process (Schwyzer & Rittel, 1961) which first
involved the formation of a copper complex with the oc-
amino and carboxyl groups. Only the y-amino function
was then left available to react wih di-r-butyl dicarbonate
to yield the protected derivative in 40 % yield. The copper
complex was then destroyed by treatment with H2S. The
a-amino function was protected with the base-labile 9-
fluorenylmethoxycarbonyl (Fmoc) group using the stand¬
ard procedure (Carpino & Han, 1972), and the carboxylic
acid was esterified with diazomethane. The Fmoc group
was cleaved by piperidine and then the free amino
derivative was treated with biotin pentafluorophenyl
ester to yield biotinyl-r-butoxycarbonylaminothylglycine
methyl ester in 66 % yield for the two-step process. The
methyl ester was hydrolysed to yield reagent 2 (Fig. 1).
To facilitate coupling to the peptide, the carboxylic acid
was converted to its A-hydroxysuccinimide ester. Also,
the Boc-protecting group on the y-amino function was
left in position until after the reagent was conjugated to
the peptide backbone and the production purified. The




D-LysB]LHRH ethylamide (PBAL) and des-Gly10-
[biotinyl-aminoethylglycyl-d-LysB]LHRH ethylamide
(XBAL) were all synthesized in a similar manner. For
example, PBL was synthesized by first dissolving d-Lys6-
LHRH (2 mg, 1.6 //mol) in freshly distilled dimethyl-
formamide (2 ml) containing triethylamine (2 drops),
and then an excess of biotinyl-/?-azido-phenylalanine-A-
hydroxysuccinimide ester (reagent 1, Fig. 1) (5 mg,
9.45 //mol) was added. The resulting mixture was left in
the dark for 1 h and then the dimethylformamide was
evaporated. The residue was triturated with ethyl acetate
(3x2 ml) to remove excess reagent and then the crude
product was purified by semi-preparative reverse-phase
h.p.l.c. (Column: Aquapore RP300; eluents: A, 0.1%
aqueous trifluoroacetic acid; B, 90% acetonitrile: 10%
A; the product was eluted with a linear gradient of
10-70% B over 30 min). Reactions utilizing the azido
ligand were carried out in subdued lighting, and during
purification the u.v. detector was switched off whilst the
peak was collected. Amino acid compositions of the
derivatives are shown in Table 1.
Membrane preparation
Male Wistar rats (approx. 250 g) were stunned, decapi¬
tated and their anterior pituitary glands rapidly removed.
These were placed in 100 vol. of ice-cold Hepes/KOH
(25 mm, pH 7.4) and sonicated, followed by centrifu-
gation at 60000# for 15 min at 4 °C. The resulting
washed membranes were resuspended in the Hepes/
KOH buffer.
Equilibrium binding studies
The binding characteristics of the LHRH analogues
were determined by equilibrium displacement assays on
anterior pituitary membranes. Iodination ofall analogues
1989
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Table 1. Amino acid analysis of affinity analogues
Results of amino-acid analysis of the three biotinyl-LHRH analogues PBL, PBAL and XBAL.
883
Amino acid
Analogue pGlu His Ser Tyr d-Lys PheN3* But Leu Arg Pro Gly
PBL 1.07 1.00 0.81 1.07 1.01 0.30 1.00 1.00 0.96 1.04
PBAL 1.05 0.96 0.83 0.95 1.02 0.20 - 1.00 0.89 0.91 -
XBAL 1.09 1.01 0.91 1.01 1.07 - 0.94 1.00 0.96 0.99 -
* Largely decomposed on hydrolysis.
was by the chloramine-T method (Mitchell et al., 1985)
to a specific activity of approx. llOOCi/mmol. Assays
were usually carried out in triplicate, in a volume of 500 fi\
containing 10-60 fig of protein, unlabelled analogue as
appropriate and 50000 c.p.m. of iodinated analogue in
25 mM-Tris/HCl, pH 7.4, containing 0.1 % bovine serum
albumin. Non-specific binding was determined in the
presence of 1 /rM-LHRH. After incubation for 90 min at
4 °C, equilibrium had been reached and the membrane
preparation was subjected to a poly(ethylene glycol)
8000 (PEG) precipitation as previously described (Ogier
et al., 1987). Briefly, PEG was added to a final concen¬
tration of 15% and bovine y-globulin to 0.035% in a
volume of 1.5 ml. After 20 min on ice, samples were
centrifuged at 1600#, 6 °C for 15 min. Precipitated
(bound) label was then counted by y spectrometry.
Under these conditions, total binding of the iodinated
analogue 125I-labelled buserelin was typically 21 + 1 %
(+ s.e.m., n = 8) of the total radioligand added, with non¬
specific binding representing 28 + 3% (± s.e.m., n = 8)
of this value. These values are similar to those previously
reported for the binding of iodinated LHRH analogues
(Marshall & Odell, 1975). For photoreactive analogues,
all procedures were carried out in subdued light, using
a safety light as necessary. Equilibrium binding for
chemical crosslinking studies was carried out as above
but in Hepes/KOH instead of Tris/HCl/bovine serum
albumin. Saturation and displacement data were analysed
by an error-weighted programme (Zivin & Waud, 1982).
Covalent labelling of the LHRH receptor
In all cases, covalent labelling was initiated on mem¬
brane preparations which were at binding equilibrium
with an iodinated LHRH analogue. For photoaffinity
labelling studies, the photoreactive conjugates were pre¬
pared prior to iodination, with the exception of 125I-
labelled-XBAL-sulpho-SANPAH. After an excess of the
heterobifunctional reagent sulpho-SANPAH (1.5 mg)
had been allowed to react for 40 min with t25I-XBAL
(approx. 0.03 fig in Hepes/KOH), at room temperature
in the dark (total volume 200 //.I), 200 /tl of 0.2 M-glycine
was added for 10 min to quench the reaction. The 125I-
XBAL-sulpho-SANPAH was then diluted in Hepes/
KOH for use in membrane equilibrium binding. When
binding equilibrium had been attained, the photoreactive
analogue 125I-XBAL-sulpho-SANPAH (or in other
experiments 125I-PBL or 125I-PBAL) was activated by
exposure to u.v. light (366 nm) at 20 cm from a 4 W
mercury lamp for 0-10 min (on ice).
In the divalent chemical crosslinker studies, DSS, DST
and EGS were dissolved into dimethyl sulphoxide imme¬
diately before use. In the case of BSSS, the crosslinker
was dissolved directly into Hepes/KOH. Crosslinkers
were routinely added at 1:100 dilutions and left to react
for 30 min either on ice or at room temperature, before
quenching with 0.25 ml of 0.2 m-glycine.
After photoaffinity or chemical crosslinking, the mem¬
brane preparation was centrifuged (45 min at 1 600 g,
6 °C) to remove excess unbound label and crosslinker,
and the membrane-bound radioactivity was determined
by y spectrometry. Photoreactive preparations were kept
in subdued lighting.
Assay of crosslinking efficiency
Efficiency of the covalent crosslinking reaction was
monitored by comparing the amount of bound ligand in
the same samples both at the time ofcrosslinking and then
subsequently after a period of 4 h at room temperature in
the presence of 1 /tm-LHRH (sufficient to cause disso¬
ciation of at least 95 % of the ligand reversibly bound to
the receptor). The crosslinked membrane preparation (or
crosslinker-free controls) were resuspended into 0.75 ml
of Tris/HCl (25 mM, pH 7.4) containing 1 ^m-LHRH,
0.1 % bovine serum albumin, soyabean trypsin inhibitor
(50 fig/m\) and aprotinin (400 KlU/ml). The radio¬
activity present was counted. After 4 h at room tempera¬
ture the membranes were again centrifuged (45 min at
1 600 g, 6 °C) and recounted. As before, photoreactive
preparations were used in subdued light.
Samples for total and non-specific binding were carried
through all procedures in parallel. Since the excess
amount ofmembrane binding in the total samples (above
that in non-specific samples) initially represented occu¬
pancy of the LHRH receptor (being displaceable by
LHRH), the effect of crosslinking these samples will
most likely include attachment of some of this
specifically-bound ligand to part of the receptor protein.
Crosslinking the non-specific samples should control for
the same level of spurious labelling of non-receptor
proteins as occurs additionally to the specific binding in
the total samples. After crosslinking, the excess specific
covalent labelling in the total samples should be reflected
by the value for non-dissociable binding in total samples
less that in non-specific samples. The efficiency of
receptor-specific crosslinking can then be expressed in
terms of the fraction by which reversible specific
binding is rendered irreversible after incubation with
crosslinker rather than its vehicle control (that is, specific
irreversible binding).
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RESULTS
Characterization of LHRH analogue binding properties
The affinities of non-radioactive analogues for the
LHRH receptor were assessed by the displacement of
125I-buserelin as described previously (Mitchell et al.,
1985; Ogier et al., 1987). Displacement of 125I-buserelin
from rat anterior pituitary membranes revealed a At of
0.92 nM±0.16 (+ s.e.m., n = 4) for PBL (Fig. 2). This is
similar to that reported for the parent peptide [D-Lys6]-
LHRH (Clayton & Catt, 1980) suggesting that the
addition of the photo-biotin group in the i>Lysfi position
does not impede binding to the LHRH receptor. Binding
with the iodinated derivative 125I-PBL could be partially
displaced by excess LHRH but only a low ratio of
specific to non-specific binding could be observed
(Mitchell et al., 1987). Previous reports of binding using
iodinated LHRH analogues have suggested that better
specific: non-specific ratios are seen using analogues
altered at their C-terminal to des-Gly10-ethylamide
(Perrin et al., 1983). The analogue des-Gly10-[d-Lys6]-
LHRH ethylamide was constructed. Again, displacement
of l25I-buserelin (Fig. 2) showed it to bind specifically to
the LHRH receptor site, with a At of98± 10 pM ( +s.e.m.,
n = 3). Addition of the biotin-containing group at d-
Lys6 (to form the analogue XBAL) apparently enhanced
binding affinity [At of 14+ 1 pM ( + s.e.M., n = 6)] (Fig. 2).
Hofstee analysis of self-displacement (Hofstee, 1952)
gave a At value of 57±14pm ( +s.e.m., n = 3) and
Scatchard analysis of saturation (Scatchard, 1949) gave
a At(I of 131±16pm (+ s.e.m., n = 3) (Fig. 3). The
apparent receptor number (5max) value for 125I-XBAL
binding on male rat anterior pituitary tissue was
63 fmol/anterior pituitary, comparable to that for buse-
relin of 92 fmol/anterior pituitary. Under the conditions
used, specific binding of 125I-XBAL was 11 + 1 %
(± s.e.m., n = 4) of total radioligand added and repre¬
sented 44 + 6% ( +s.e.m., n = 4) of total binding. The
specific binding of 125I-XBAL was displaced by buserelin
with a K, value of 0.22 + 0.07 nM ( +s.e.m., n = 4),
similar to the value of 0.47 + 0.14 nm ( + s.e.m., n = 6)
for displacement of 125I-buserelin by buserelin.
Photoaffinity labelling
The receptor specificity of photolabelling will be deter¬
mined in the first instance by the degree of specific binding
of the iodinated ligand prior to photoactivation. In the
Fig. 2. Binding characteristics of the LHRH analogues
(a) Displacement of 125I-buserelin by the photoaffinity
analogue PBL (■), the LHRH analogue des-Gly10-[D-
Lys6]LHRH ethylamide (♦) and the biotinyl-LHRH
analogue XBAL (A), from male rat anterior pituitary
membrane preparations. Specific binding was 66 + 5%
(± s.e.m., n = 8) of total binding; non-specific binding was
determined in the presence of 1 //m-LHRH. Values are the
means + S.e.m., n = 4-8. (b) Hofstee plot of PBL displace¬
ment of 125I-buserelin from rat anterior pituitary mem¬
brane preparation. At(1 = 0.92 + 0.16 nM ( +s.e.m., n = 4).
(c) Hofstee plot of des-Gly10-[D-Lys°]LHRH ethylamide
displacement of 125I-buserelin from rat anterior membrane
preparation. Kd = 0.098±0.01 nM (±s.e.m., n = 3). (d)
Hofstee plot of XBAL displacement of 125I-buserelin
from rat anterior pituitary membrane preparation.
Ka = 13.6+1.2 pM ( +s.e.m., n = 6).
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Fig. 3. Scatchard analysis of 125I-XBAL binding
125I-XBAL binding to rat anterior pituitary preparation is
shown. All determinations were made in duplicate through
the range of 5000 to 500000 counts of 125I-XBAL added
per assay tube. Non-specific binding was determined
in the presence of I^m-LHRH; specific binding was
30-60% of total. Ka = 131 ± 16 pM (±s.e.m., n = 3),
63.2 + 5 fmol/anterior pituitary ( + s.e.m., n = 3).
Fig. 4. Photoaffinity labelling of the LHRH receptor
The graph shows the percentage of the initial specific
binding of 125I-PBAL which had failed to dissociate after
a period of4 h at room temperature in the presence of 1 /<m-
LHRH (that is, the irreversible specific binding) plotted
against exposure time to u.v. light. In samples unexposed
to u.v. light, some 95 ± 12% of initial specific 125I-PBAL
binding dissociated under these conditions. Initial specific
binding was 10 + 3 % of total binding; non-specific binding
was determined in the presence of 1 //m-LHRH. Values are
means + s.e.m., n — 3.
case of 125I-PBL, the binding displaceable by 1 /m-
LHRH (specific binding) was only 12 + 4% (± s.e.m.,
n = 4) of total binding [2+1 % (±s.e.m., n = 4) of total
added ligand)]. The photoaffinity analogue of des-Gly10-
[D-Lys^LHRH ethylamide, that is 125I-PBAL, gave
specific binding of only 10 + 3 % ( + s.e.m., n = 3) of total
binding [3+ 1 % (± s.e.m., n = 3) of total added ligand]
and 125I-XBAL-sulpho-SANPAH gave specific binding
of only 15+4% (± s.e.m., n = 4) of total binding
[2+1% (+ s.e.m., n = 4) of total added ligand]. These
values for ligands containing aryl azido photoreactive
groups were all much lower than for the other ligands
such as buserelin and XBAL. After activation (0-10 min)
with u.v. light (366 nm), only minimal levels of specific
irreversible labelling could be detected for either 125I-
PBL or 125I-XBAL-sulpho-SANPAH. (Specific irrevers¬
ible binding was defined as above as the excess binding
in total above non-specific samples that was resistant to
4 h dissociation in the presence of excess LHRH.) 125I-
PBAL showed a small amount of labelling, reaching a
maximum, after 2 min activation, of 28 + 5% (±s.e.m.,
n = 3) of initial specific binding (Fig. 4). Since however
the initial specificity of 125I-PBAL binding was low
(10%), the specific irreversible binding represented only
some 3 % of initial total binding and with a poor
specific: non-specific binding ratio.
Homobifunctional chemical crosslinkers
The success of specific chemical crosslinking was
dependent on two factors: firstly, on the ability of the
reagents to allow specific ligand binding to the receptor
without detrimental effects, and secondly, on their effi¬
ciency at rendering specific binding irreversible (Table 2).
Of the reagents used, both DSS and BSSS had detrimental
effects on the initial level of specific binding; that is,
measured immediately after the 30 min crosslinking
incubation, they reduced the difference in bound counts
between total and non-specific samples. Control values
of specific binding were reduced to 58 % in he presence
of 0.2 mM-DSS, and to 55 % in the presence of 0.5 mM-
BSSS. Whilst DST had less effect on initial specific
binding at low concentrations (0.1-0.5 mM), it too had
profound inhibitory effects on specific binding at higher
concentrations. However, in contrast, EGS had no
significant effect on specific binding until the highest
concentration tested, 5 mM, at which there was a small
reduction in initial specific binding, to 79% (Table 2).
Concentrations above 1 mm-EGS were successful at
crosslinking a proportion of the specific binding of 125I-
XBAL and rendering it resistant to dissociation. Concen¬
tration-dependent increases in irreversible specific bind¬
ing were observed (Fig. 5) with a maximum of 23 + 3%
(± s.e.m., n = 3) of the control level of initial specific
binding being rendered irreversible after treatment with
5 mM-EGS. Both BSSS and DST also rendered significant
proportions of specific binding irreversible but only at
concentrations with profound inhibitory effects on
specific binding. Under the present conditions, DSS
appeared to be ineffective at crosslinking specific binding
of XBAL to the LHRH receptor. The levels of non¬
specific irreversible binding were slightly increased (1.5-
2-fold) by the highest concentrations of BSSS, DST and
EGS, whereas DSS at concentrations of 1-3 mM caused
large increases of greater than 10-fold. It appears there¬
fore that all the reagents were active in these experi¬
ments, but that only EGS showed the required ability
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Table 2. Crosslinking of l25I-XBAL to rat anterior pituitary membranes using homobifunctional covalent crosslinkers
The effects of the crosslinking reagents DSS, BSSS, DST and EGS on the initial specific binding of 125I-XBAL and their ability
to irreversibly crosslink this specifically-bound ligand are shown at various concentrations. Rat anterior pituitary membrane
preparations were equilibrated with 125I-XBAL (90 min at 4 °C) prior to exposure to the crosslinkers or relevant solvent alone
in the controls. The crosslinking reaction was quenched by the addition of excess glycine (67 mm). After centrifugation the
membranes were resuspended into buffer containing 1 //m-LHRH in the presence of peptidase inhibitors and left at room
temperature for 4 h. Meanwhile the initial specific binding (a) was determined as the difference between membrane counts in
samples with or without 1 /tm-LHRH present during the earlier equilibration with 125I-XBAL and the crosslinking incubation.
Results in (a) are expressed as percentages of control specific binding determined in the absence of any crosslinker (means ± s.e.m.,
n = 4-12). After 4 h dissociation of reversibly bound ligand, the same membrane samples were again centrifuged and the amount
of specific binding remaining was determined. This irreversible specific binding (b) was expressed as a percentage of the previously
measured (initial) specific binding in the presence ofcrosslinker which was resistant to dissociation (means ± s.e.m., n = 4-12). The
irreversible specific binding gives an estimate of the amount of specific crosslinking ot 125I-XBAL to the LHRH receptor site
achieved. In control sets of samples, routinely over 95% of the initial specifically-bound ligand had dissociated during the
4 h incubation. In the case of DSS, DST and EGS, their control experiments were carried out in the presence of 1 % dimethyl
sulphoxide (DMSO). The solvent had no deleterious effect on the initial specific binding, values in the presence of 1 % dimethyl
sulphoxide being 104 + 6% (±s.e.m., n = 12) of solvent-free controls. The overall yield of specifically bound ligand crosslinked
to receptor is dependent on both (a) and (b). In the case of 5 mm-EGS, this was 18 + 3% (± s.e.m., n = 5), since there was
23±3% (+ s.e.m., n = 5) crosslinking of specifically bound ligand (b), and the available specific binding (a) was reduced to
79±2% (+ s.e.m., n = 5) by the disruptive effect of crosslinker on ligand binding. Since binding of 125I-XBAL under these
conditions was 44 + 6% (± s.e.m., n = 4) specific, these figures represent specific crosslinking to the receptor of some 8% of the
total binding and since specific binding was 22+ 1 % ( + s.e.m., n = 4) of total added label, specific crosslinking of around 2%
of total added label.
(a) (by
Crosslinker and Concentration of Initial specific Irreversible specific
reaction conditions crosslinker (mm) binding (%) binding (%)
DSS 0.025 96+12 -6 + 2
1 % DMSO 0.2 58 + 6 -3 + 2
30 min on ice 0.3 35 + 3 5 + 5
0.5 29 + 8 1 +5
1 23 + 8 5+11
2 21 + 10 4±6
BSSS 0.5 55 + 9 19 + 6
No DMSO 1 56 + 2 17 + 4
30 min at 2 33 + 1 24 + 4
room temperature 5 42 + 8 16 + 5
DST 0.1 78 + 9 -6 + 4
1 % DMSO 0.2 78+13 -9 + 3
30 min at 0.5 72+14 17+10
room temperature 1 54 + 22 17 + 7
2 35 + 8 30 + 20
5 23 ±26 68 ±25
EGS 0.1 99+1 -1 + 1
1 % DMSO 0.2 100 + 2 -2 + 2
30 min on ice 0.5 93 + 2 0 + 4
1 100 + 4 3 + 2
2 94+14 11+3
3 108 + 4 17 + 5
5 79 + 2 23 + 3
to crosslink ligand bound specifically to the LHRH
without disrupting the ligand-receptor interaction.
DISCUSSION
The present study describes the development of a
novel approach for receptor purification. LHRH
analogues incorporating biotin together with a covalent
attachment site have been designed and synthesized, and
methods for their covalent crosslinking to the LHRH
receptor have been optimized.
Photoaffinity ligands may be expected to give a more
specific labelling of receptor sites than the addition of
non-specific bivalent crosslinkers, since the linking group
is already localized to the ligand. Activation of the
photoreactive aryl azido group gives rise to a transient
aryl nitrene with a non-selective reactivity (Ji, 1976), and
so receptor labelling will not be dependent on the local
presence of a particular chemical group. In contrast,
chemical crosslinking is dependent both on the presence
of suitable functional groups on both ligand and receptor
and on their appropriate spatial separation (Pilch &
Czech, 1984), but generally occurs in higher yield (Stros-
berg, 1984). The present experiments employed a series of
homobifunctional A'-hydroxysuccinimide ester cross-
linkers with selective reactivity for amino groups. Since
the separation between the side-chain free amino group
of 125I-XBAL and hypothetical amino groups around the
receptor binding site is unknown, we used four cross-
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Fig. 5. EGS crosslinking of specific binding of 125I-XBAL to
anterior pituitary membranes
The graph shows the percentage of the initial specific
binding of 125I-XBAL which had failed to dissociate after
a period of 4 h at room temperature in the presence of
LHRH (that is, the irreversible specific binding) plotted
against concentrations of the bivalent crosslinker EGS
used. Initial specific binding was 44 + 6% ( + s.e.m., n = 4)
of total binding; non-specific binding was determined in
the presence ofl /im-LHRH. Values are the means+ s.e.m.,
n = 4—12.
showed sufficient specificity for further use in receptor
purification.
Of the bivalent crosslinkers used, EGS was the most
successful in covalently crosslinking the ligand 125I-XBAL
to the receptor site. This is the longest of the crosslinking
reagents tested, at 1.5 nm bridge length. Some 23% of
the specific binding of 125I-XBAL was rendered irrevers¬
ible at the highest concentration of EGS tested, 5 mm.
Both the appearance of an inhibitory effect on the
ligand-receptor interaction and solubility problems pre¬
vented higher concentrations from being tested. This
figure represents some 8 % of the total binding (and 2 %
of added ligand) being specifically covalently attached to
the receptor; sufficient to develop the strategy further for
receptor purification.
Preliminary experiments examining displacement
of [:!H]-biotin from avidin-sepharose showed that our
biotinylated ligands retained a significant proportion of
the potency of biotin even in the presence of detergent-
salt solutions required for receptor solubilization (Ogier
et al., 1987). For example, PBL retained 45 + 5%
(+ s.e.m., n = 3) of the potency of native biotin. Using
solubilized membranes previously labelled with 125I-
PBL, we have further shown that labelled membrane
proteins do bind to an avidin-Sepharose column and can
be displaced by elution with 2 mM-biotin (Mitchell et al.,
1987). This procedure resulted in an approx. 700-fold
increase in the specific activity of labelled proteins
compared with the initial membrane preparation. How¬
ever, the low specificity of 125f-PBL binding made it
unsuitable for receptor purification. Preliminary experi¬
ments showed that membrane proteins specifically
labelled with 125I-XBAL and then crosslinked with EGS
can be similarly purified by affinity chromatography on
streptavidin-agarose. The higher level of intrinsic speci¬
ficity in 125f-XBAL binding means that its use with
covalent crosslinkers such as EGS should facilitate
extensive purification of the LHRH receptor.
Many thanks to J. Bcnnie for help with all the iodination
procedures. Also to Hoechst A. G., Frankfurt, F. R. G. for the
generous gift of buserelin. S.-A. O. was a Houldsworth Scholar
of the University of Edinburgh.
linkers of various bridge lengths. These range from
DST at 0.5 nm (Smith et al., 1978) to EGS at 1.51 nm
(Baskin & Chung, 1980).
Initially, [d-Lys6]LHRH was chosen as the parent
LHRH ligand for the analogues. Attaching a biotin-
photoreactive aryl azido group via the free amine on
d-Lys6 gave the PBL derivative which retained a high
affinity for the LHRH receptor site, but a poor specific:
non-specific binding ratio. As in previous reports (Perrin
et al., 1983), alteration of the analogue at the C-terminal
to des-Gly10-ethylamide gave better specific binding.
However, the photoaffinity ligands 125I-PBAL and 125I-
XBAL-sulpho-SANPAH gave much higher non-specific
binding than the biotin-free amine derivative 125I-XBAL.
The presence of the aryl azido group seemed to increase
the non-specific binding of the analogue - perhaps due to
low-level activation of the photoreactive group outwith
the u.v. illumination. Although care was taken to protect
the analogues from exposure to light, low levels were
necessary for safe handling of the iodinated compounds.
None of the photoaffinity analogues tested therefore
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